department of internal medicine annual report 2008-2009 pope l ...

Table of ContentsKey Departmental Accomplishments and Significant Events ............................................ 1-7Office of Clinical Affairs ...................................................................................................... 8-26Office of Education & Training ......................................................................................... 27-37Office of Research ............................................................................................................... 38-62Faculty .................................................................................................................................. 63-71Housestaff ............................................................................................................................ 72-77Division of Cardiology ........................................................................................................ 79-86Division of Endocrinology .................................................................................................. 87-94Division of Epidemiology & Preventive Medicine ......................................................... 95-106Division of Gastroenterology & Hepatology ................................................................. 107-121Division of General Internal Medicine (UH)/Integrative Medicine Section .............. 122-133Division of General Internal Medicine (NMVHCS) .................................................... 134-137Division of Geriatrics/Palliative Care Section .............................................................. 138-144Division of Hematology/Oncology ................................................................................. 145-172Division of Infectious Diseases ....................................................................................... 173-189Division of Nephrology ................................................................................................... 190-196Division of Pulmonary, Critical Care, Sleep Center .................................................... 197-218Division of Rheumatology .............................................................................................. 219-222Center for Occupational and Environmental Health Promotion (COEHP)............. 223-227Allergy Services .............................................................................................................. 228-2311

KEY DEPARTMENTAL ACCOMPLISHMENTSThe Department has created a new financial management culture, enhancing the DivisionsChiefs’ role in the financial success of his/her Division, with the establishment of acomprehensive revenue distribution model focusing on output and not historical allocations. Themost important element of this change has been to align responsibility with authority at thedivisional level, mimicking the relationship of Dean to Chair, at the departmental level betweenChair and Chief. None of this would be possible without the improvement of the currentfinancial systems and reporting. The Department has gone through an extensive financialreporting redesign, engaging and achieving buy-in at all levels of the institution, which hasdramatically reduced the complexity of the financial analyses and reporting for the Departmentand Divisions, separating operating activities from programmatic activities. These financialphilosophies are a direct result of some of our improved clinical and research metrics.Mid-year (December 2008) the Department begun work on our inpatient clinical charge captureprocess, resulting in a dramatic change in the way we view and manage our inpatient clinicalbilling. Clinical collections for the Department improved 18% overall, from the prior year and14% increase per clinical FTE, demonstrating the strong improvement of our inpatient chargecapture initiative. When we isolate our first 6 months of clinical inpatient work RVUs ascompared to the second 6 months of clinical inpatient work RVUs our improvements becomemore visible increasing 124%. We expect continued improvements, as we have not fullyreviewed all of our inpatient services.Our research total awards have consistently topped $30 million for the last 4 years (includesextramural awards received by DoIM Faculty in the UNM Cancer Center and UNM Center forInfectious Diseases). Also, our Facilities & Administration revenues (indirect cost on grants andcontracts) have continued to increase 11% over the prior year, and despite a slight reduction inthe Department’s overall research FTE of 1%, faculty salaries on extramural sources grew 8%from the prior year, without institutional-wide salary increases.All of this has resulted in the first year, in the recent past, which we have achieved a positiveoperating margin.The new UNM Cardiac Catheterization Laboratory Suite represents an important step in theexpansion of the UNM Heart and Vascular Center’s mission to provide outstandingcardiovascular services to UNM patients and their physicians. The UNM Heart and VascularCenter represents the end-result of many individuals’ vision for modern, efficient and proficientdelivery of cardiovascular care to the citizens of New Mexico. The commitment of UNM to theNew Mexico community is nowhere more evident than in this sparkling new facility.- Already recognized by national organizations such as the American Heart Association forthe Center’s outstanding quality of care in patients with heart failure and myocardial infarction,this new facility, along with additional developments in the near feature, will enable us tomaintain our current high level of care for the patient with an acute, life-threateningcardiovascular condition. Dedicated full-time faculty and support staff- the life blood of the2

Heart and Vascular Center- are committed to the “24/7” level of care that such situationsdemand. The opportunity to care for patients in such spectacular new surroundings with the mostadvanced cardiovascular imaging facilities in the state of New Mexico will translate into a morepatientcentric, patient-friendly and professionally rewarding experience.- In addition to the noted accomplishments of the UNM cardiovascular program to date,these new facilities will provide for the capability to participate in truly front-line cardiovascularcare. In collaboration with faculty in the division of Pediatric Cardiology, our adult cardiologistshave initiated a Structural Heart Disease program in which high quality imaging is absolutelyessential for procedural success. Advances in the invasive treatment of disturbances in the heart’srhythm are now possible with this expanded facility and will become an important aspect ofcardiac care to the aging population of New Mexico.- The teams responsible for the vision, financing, building and operating of such a programare to be recognized for their commitment and professionalism. All members of the UNM HealthSciences Center should be justifiably proud of this accomplishment and those to come. Thereality that it is- a world-class facility in which world class faculty can perform their life-savingprocedures.- The most recent data ranks UNM the best in New Mexico for so-called “door-to-balloon”times and top 5% in the country.The UNM Center of Life, UNM's new Integrative Medicine Specialty Clinic held its GrandOpening Friday, August 15, 2009 with a free Public Forum from 1:30-2:30 p.m. and an OpenHouse Celebration from 3-5:00 p.m. at 4700 Jefferson Blvd. NE, just north of MontgomeryBlvd.- Dr. Arti Prasad, Director of the Center for Life rejects the label of alternative medicine.Instead, she prefers to call what the center offers “complementary medicine” augmenting modernmedicine with practices and treatments that may go back thousands of years in other cultures.The philosophy has its basis in preventing disease, what Dr. Prasad decribes as “keeping thebody in balance, staying healthy, exercising, eating healthy and doing good things in your life.”- The uniqueness of the program is that we not only embrace Eastern andWesernphilosophies, but we try to integrate the traditions of New Mexico including Native Americanhealers and Hispanic curanderas who are invited to work with patients at the clinic.- Also, the UNM Center of Life is excited to now offer Reiki. Reiki is a subtle, specifictype of energy work that gently balances a person's energies to aid health and well-being. It is ahealing modality performed by the flow of universal energy through the practitioner's hands tothe patient. This energy work is a simple and non-invasive therapy used for stress reduction andrelaxation, which can enhance the body's natural healing abilities.Professor of Internal Medicine Wilmer L. Sibbitt, Jr., M.D., recently was selected as one of thetop 100 people of note in the medical device industry. Medical Device & Diagnostic Industry(MD&DI) Magazine listed Dr. Sibbitt as one in an exclusive group who “make amazingadvances in medical science and technology, and ensure that medical devices can treat patientssafely and effectively.” The list included inventors, executives, constultants, engineers,academics and regulators. Dr. Sibbitt, one of only 4 M.D.’s on the list, was recognized for hisinnovative work in developing products for procedural medicine and drug-delivery, newinterventional cardiology products, and imaging contrast agents that improve pictures of organsin the human body.3

Edgar Boedeker, M.D., Professor of Medicine (Gastroenterology) has received AmericanRecovery and Reinvestment Act (ARRA) funding for his research entitled “An Attenuated E.coli Vaccine for Enterotoxigenic E. Coli” (ETEC). His goal is to create a licensed vaccine totreat this disease which is among the primary causes of infantile and traveler’s diarrhea. Despitethe number and severity of ETEC infections worldwide, at present, no licensed vaccine isavailable for at-risk individuals. ETEC is the leading cause of diarrhea in developing countriesand a major cause of morbidity and mortality in children in high risk areas. Annually, ETECcauses an estimated 650 million cases of diarrhea in children less than 5 years of age and over100 million diarrheal episodes in children between 5-14 years. An estimated 800,000 childrenunder 5 years of age die each year from ETEC induced diarrhea. The ARRA funding willprovide for an additional Post-Doctoral Fellowship.Robert Hromas, M.D., Professor and Chief, Hematology-Oncology, Deputy Director for ClinicalAffairs has been awarded an ARRA grant “Transposases in Etoposide Resistance.” The purposeof the grant is to explore alternative uses for Entoposide, a widely used anti-neoplastic drug thathas been used with remarkable results in many types of cancer. There are some long-termconsequences of utilizing Etoposide for cancer treatment because the patient can develop adverseside effects. Dr. Hromas’s research team has isolated a human transposase protein, Metnase,which from earlier tests, shows potential to make Etoposide a more effective drug in treatingsmall cell lung cancer, ovarian cancer, testis cancer, leukemia and lymphoma. It is anticipatedthat the grant will create three new jobs. In addition, it is possible that experimental informationobtained through the performance of this grant could be leveraged to assist New Mexico Biotechventures that have the capability to create more jobs, since the grant supports investigation intonew cancer therapies.The UNM Health Sciences Center’s Project ECHO received a national award in the“Transforming Care Delivery at the Point of Care” category as part of the eHealth Initiative FifthAnnual Conference and Awards Dinner on December 3rd in Washington, DC. Project ECHOhas proven to be a new and innovative model for treating complex chronic diseases in rural andunderserved areas of New Mexico. Project ECHO is a partnership between the Department ofHealth, the UNM Health Sciences Center, the New Mexico Corrections Department, and theNew Mexico Primary Care Association. It began in 2003 and provides medical providers acrossthe state with expert advice through telehealth sessions on treating their patients.The UNM School of Medicine has named 2008 recipient of the prestigious Spencer ForemanAward for Outstanding Community Service by the Association of American Medical Colleges(AAMC). The award cited several innovative programs that support UNM’s mission of servingthe state’s communities through direct patient care, training and exploring the relevant causes ofboth health and disease, including the UNM Health Extension Rural Offices (HERO) program,the Health Commons initiative and Project Extension for Community Healthcare Outcomes(ECHO).The Office of Academic Affairs at the School of Medicine is pleased to announce theappointment of Bronwyn Wilson, M.D., Professor of Internal Medicine, as Assistant Dean of4

Faculty Development beginning October 1, 2008. Her primary responsibilities will be facultyworkshops, Promotion and Tenure, and the Academic Affairs Advisory Council.Dr. Sanjeev Arora was elected as outstanding Faculty Physician for Alpha Omega Alpha (AOA),the honorary medical society. This honor is bestowed on individuals who have excelled in theareas of scholarship, personal integrity, and leadership qualities.Dr. Ravi Durvasula was selected as a member of the American Society for Clinical Investigation.Dr. Akshay Sood received the University of New Mexico School of Medicine Department ofInternal Medicine William R. Hardy Teaching Physician of the year award for 2008-09.Dr. Arti Prasad, Professor of Medicine, Section Chief of Integrative Medicine, and the ExecutiveMedical Director of the UNM Center for Life, has been chosen as the UNM representative anddelegate for the United States Pharmacopeia (USP) convention to be held in Washington, DCfrom April 21-24, 2010. Dr. Prasad has been nominated by Dr. Ellen Cosgrove to serve as anexpert on the Dietary Supplements sub-committee.Science Technology Corporation (STC) held its 6 th Annual Creative Awards Reception on April13, 2009. Among the award recipients were: Sanjeev Arora, M.D., Terry W. DuClos, M.D.,Ph.D., and Phillip L. Wagner, M.D. Patents and copyright awarded to UNM researcher represent22 technologies ranging from software program for disease management hydrophobic coatings toa spatial approach to mass spectroscopy. Several technologies have formed around start-upswhile others have been licensed to companies or are being actively marketed, making a strongcontribution to New Mexico’s economy.Thirteen employees of the Department of Internal Medicine were recognized at this year’sService Award Ceremony:35 Years of ServiceArthur D. Bankhurst, M.D.25 Years of ServiceCarolyn KingAroop Mangalik, M.D.Gregory Mertz, M.D.Mary S. MontoyaMaryhelen E. Pridham20 Years of ServiceChristine A. Stidley, M.D.15 Years of ServiceSanjeev Arora, M.D.Julie S. Broyles, M.D.Mark R. Burge, M.D.5

- Shmuel Inbar, M.D., Associate Professor/Cardiology- J. Rush Pierce, M.D., Associate Professor/General Internal Medicine- Ambreen Gul, M.D., Visiting Assistant Professor/Neprology- Jason Cohen, M.D., Assistant Professor/General Internal Medicine- Montaser Shaheen, M.D., Assistant Professor/Hematolgy-OncologyCENTRAL ADMINISTRATION ACCOMPLISHMENTS- The Department reorganized its upper Staff Management. Shannon Griego, formerlyDirector of the Department's Office of Human Resources was promoted to ChiefOperations Officer of the Department Richard Nuttall joined the Department as ChiefFinanical Officer. Mr. Nuttall was formerly the financial systems manager for theSchool of Medicine of the University of Medicine and Dentistry of New Jersey and theDepartment Administrator for the Department of Pediatrics.DoIM’s STAFF AWARDEESDepartment Chair Administrative Staff Category- Awardee: Maryhelen PridhamDivisional Administrative Staff Category- Awardee: Patricia Esquibel- Awardee: Lisa Finley- Awardee: Enedina Estrada- Nominee: Jennifer Montoya- Nominee: Ysela Gonzales- Nominee: Karen LutteckeDivisional Professional Staff Category- Awardee: Wesley pak- Awardee: Deborah Anaya- Nominee: John Brown- Nominee: Joseph Shealy- Nominee: Venita Wolfe- Nominee: Donna Pham- Nominee: Carolyn King- Nominee: Daphne TritleDepartment Chair Professional Staff- Awardee: Shannon Griego- Awardee: Mike Maes- Awardee: Denise OsborneProfession Research Staff- Awardee: Denise DionTeam Award CategoryFinance Team7

Instruction d’assemblage Kit Twinstar II # 21 4210Familiarisez-vous avec le kit d’assemblage!Les kits d’assemblages MULTIPLEX sont soumis pendant la production à des contrôles réguliers du matériel. Nous espérons quele contenu du kit répond à vos espérances. Nous vous prions de vérifier le contenu (suivant la liste des pièces) du kit avantl’assemblage, car les pièces utilisées ne sont pas échangées. Dans le cas où une pièce ne serait pas conforme, nous sommesdisposé à la rectifier ou à l’échanger après contrôle. Veuillez retourner la pièce à notre unité de production sans omettre de joindrele coupon de caisse ainsi qu’une petite description du défaut.Nous essayons toujours de faire progresser technologiquement nos modèles. Nous nous réservons le droit de modifications de laforme, dimensions, technologie, matériel et contenu sans préavis. De ce fait, nous ne prenons donc pas en compte toutesréclamations au sujet des images ou de données ne correspondants pas au contenu du manuel.Attention!Les modèles radiocommandés, surtout volants, ne sont pas des jouets au sens propre du terme. Leur assemblage etutilisation demande des connaissances technologiques, un minimum de dextérité manuelle, de rigueur, de discipline et derespect de la sécurité. Les erreurs et négligences, lors de la construction ou de l’utilisation, peuvent conduire à des dégâtscorporels ou matériels. Du fait que le producteur du kit n’a plus aucune influence sur l’assemblage, la réparation etl’utilisation correcte, nous déclinons toute responsabilité concernant ces dangers.Compléments nécessaires au modèle Twinstar II:Colle et activateur correspondantColle rapide d’une viscosité moyenne (Colle Cyanoacrylate = colle CA) à utiliser avec l’activateur correspondant – n’utilisez pas decolle rapide pour polystyrène ! Les colles Epoxy ne donnent qu’un joint de tenue moyenne, car celui-ci casse lorsqu’il subit descharges un peu plus importantes et les pièces ne tiennent plus. Le joint n’est que superficiel.Vous pouvez utiliser de la colle à chaud comme alternatif !Eléments de radiocommande du modèleRécepteur Micro IPD UNI 35 MHz par ex. Bande A Nr. Com. 5 5971alternative 40 MHz Nr. Com. 5 5972Servo Tiny-S UNI (besoin 4x) prof. / 2x ailerons / direction Nr. Com. 6 5121Câble de rallonge 300mm UNI 2x pour servo d’aileron Nr. Com. 8 5031ou câble de filtrage 200mm UNI 2x pour servo d’aileron Nr. Com. 8 5035Chargeur :MULTIcharger 5008 DC 1-8 éléments NiCd/NiMH Nr. Com. 9 2525(courant de charge entre 100mA et 5A)pour connecter à un accu de voitureMULTIcont M-32 UNI régulateur Nr. Com. 7 2279Accu de propulsion MPX Permabatt NiMH 7 / 3000 mAh Nr. Com. 15 6026ou Accu de propulsion MPX Permabatt NiMH 8 / 3000 mAh Nr. Com. 15 6027Outils :Ciseaux, cutter, pince coupante, tournevis plat de 8mm, fer à souderRemarque : détachez les deux pages du milieu des instructions de montage.Données techniques : TWIN STAR IIEnvergureLongueurSurface alaire env.Poids env.Charge alaire (FAI)PropulsionAlimentation du récepteurFonctions RC1420 mm1085 mm43 dm²1500g35 g/dm²2x Permax 400 6VBECProfondeur, ailerons, direction, moteur électriqueInformation importanteCe modèle n’est pas en polystyrène!De ce fait, n’utilisez pas de colle blanche ou époxy. N’utilisez que des collescyanoacrylate (colle rapide), de préférence avec ajout d’activateur (Kicker). Pour tous les joints de colle, utilisez une collecyanoacrylate avec une viscosité moyenne. Pour les pièces en Elapor®, vaporisez toujours l’activateur (Kicker) sur une despièces à coller, laissez aérer pendant 2 minutes, et enduisez l’autre pièce avec de la colle cyanoacrylate. Assemblez les pièceset amenez-les de suite en bonne position.10

SANJEEV ARORA, M.D., DIRECTOR OF THE OFFICE OF CLINICAL AFFAIRSAND EXECUTIVE VICE CHAIRMAN, DEPARTMENT OF INTERNAL MEDICINEMembers: Sanjeev Arora, M.D., Lee Brown, M.D., Julie Broyles, M.D., Lenny Noronha,M.D., Joseph Scaletti, Ph.D., Claudia Scherer, RN, Kristine Garcia, BA, Laura Marsh, RN -MSN-MBA, Connie Fassler, RN, Terrance Holmes, RN-BA, Yolanda Hubbard, Denise Dion,Ph.D, Wesley Pak, MBA, Kathleen Moseley, RN-MS, Camille Chapman, John Brown, MA,Amy Hunter Baird, BS, Lisa Finley, Adrian Rodriguez, Karen Luttecke, BA, Erika Harding,MA, David Porter, MBA, Sandra Cordaro, Ronselle Harrison, Andrea Bradford, MSc, JeanneBoyle, RN-BSN, Brian Swager, BS, Julie Rosen, Candida Pullen, Miranda Haynes, Ana Moriel,MA, Tom Burke, Anna Knackstedt, Michael Han, Bonnie Kraybill, BN-BCGoals of the Office of Clinical Affairs- Continuously Improve Patient Care- Continuously Improve the Practice Environment Collaboratively with UNMH- Enhance Reimbursement for Clinical Activities- Expand Scope of Project ECHO Telemedicine ClinicsA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARLEE K BROWN, M.D.Allergy- Westside faculty practice for adult allergy, located at the UNMH Westside clinic, remainssuccessful and profitable. Professional revenue has continued to cover faculty salaryattributable to the practice and facility revenue has provided significant profit to UNMH.Endocrinology- Planning was initiated for a Diabetes Center of Excellence. The Center will be located at1101 Medical Arts Avenue Building 4 with occupancy occurring after the departure ofThe Digestive Disease Center to their new building. Approval has been obtained fromUNMH to fund a mid-level practitioner and 0.5 FTE Endocrinology fellow to staff theCenter. A business plan is being developed to justify creation of a clinician-educatorfaculty position.- Training in ultrasound was completed for faculty and the equipment is in regular use forthyroid biopsies. Training in ultrasound has been incorporated into the fellowshipcurriculum.Gastroenterology- Planning completed, and a building purchased, for the Digestive Disease Center. This willbe located on Martin Luther King Jr. Drive and will include both endoscopy and clinicspace. Renovation of the building was begun.Outpatient Treatment Center- Planning completed for Saturday and Sunday hours, and evening hours initiated. Staffrecruitment for weekend sessions initiated.- Renovation funding request again failed to gain approval from UNMH.Pulmonary Disease10

- Approval was obtained from UNMH to fund a demonstration project that wouldreorganize the pulmonary, asthma, and adult cystic fibrosis clinics into a self-containedspecialty clinic with dedicated staff, emulating a single-specialty group practice. A seriesof planning meetings were held, delineating the current state of affairs and constructingthe new model. A staffing plan was developed and planning of the workflow model wasbegun. However, the loss of significant provider clinical time resulted in suspension ofplanning until additional faculty and mid-level providers could be identified. The lossesconsisted of the following:Betty Chang, M.D. appointed as Program Director for the DOIM graduate medicaleducation.Gary Iwamoto, M.D. appointed as Chief Medical Information Officer, UNMH.Michelle Harkins, M.D. appointed as Medical Director, Medical Intensive Care Unit.Karen Lynn Fiato FNP-C transferred from Asthma Clinic to Medical Intensive Care Unit- A business plan is now being developed to recruit additional clinician-educator faculty tothe Division to bring the pulmonary clinics back to the level of staffing necessary tojustify the demonstration project. In addition, at least one mid-level will be recruited toreplace Ms. Fiato.- Plan developed for a pulmonary vascular disease program. Helen (Kitty) Busby, M.D.transferred from the Albuquerque VA Medical Center to UNMH to initiate this outpatientprogram.- Michelle Harkins, M.D. initiated development of a telemedicine asthma outreachprogram through Project ECHO.Rheumatology- Business plan developed for recruiting clinician-educator faculty member to improveclinic access.- Mid-level practitioner fully trained and scope of practice expanded as appropriate.- Rheumatology telemedicine outreach conducted through Project ECHO.Senior Health/Geriatrics- Productivity of Senior Health Clinic providers analyzed and improvement plancompleted.Inpatient Palliative Care Service initiated.Sleep Medicine- A business plan was presented to senior leadership of the UNMMG for a Westside SleepDisorders Center. Approval was not obtained due to the adverse financial analysis, aresult of the requirement for global professional, rather than facility-based, billing. Ameeting was subsequently held with UNMH senior leadership to consider collaborationbetween UNMMG and UNMH so that facility-based billing could be employed. UNMHsenior leadership indicated they would consider the plan. Planning is now underway toadd sleep laboratory bedrooms to the UNMMG Sandoval Regional Medical Center inorder to support a proposed bariatric surgery program.- A business plan was initiated for expansion of the current sleep laboratory into a UNM-SOM owned building near the current sleep disorders center, but discarded in favor ofeventual expansion into 1101 Medical Arts Avenue, Building 5 when the Orthopedicsfaculty clinic moves to a new site in ~3 years.11

- A business plan was initiated for expansion of the sleep laboratory and clinic operationsinto the OmniSleep location near the current sleep disorders center, when this privateoperation vacates.- Negotiations continue with the Albuquerque VA Medical Center with respect toassuming the sleep disorders care of their patients. Agreement has been reached on aninterim fee-based contract and a long term contract based on funding a 1.0 FTE facultymember and a 1.0 FTE sleep medicine fellow as well as fee-based sleep laboratoryservices. However, stringent information systems security requirements on the part ofVA administration at the federal level have delayed final execution of these contracts.Several work-arounds have been proposed to the VA but no decision has been received asof yet from VA leadership.- The primary care advanced access process continues with weekly reports on access.Advance Beneficiary Notice committee- Recommendations have been forwarded to UNMH senior management, including arequest to fund a software module that would enable implementation of best practice inthis arena.An alternative, web-based service is under active evaluation through a pilot project at the UNMHSleep Disorders Center. Multiple problems with this approach have been identified, andevaluation continues. Final steps of having patients sign the notice and billing for non-coveredservices have been suspended for the time being. An ICD-9 to CPT crosswalk was developedand implemented via a discharge form in order to aid in obtaining Medicare coverage for orderedlaboratory services.Planning for DOIM components of the Sandoval Regional Medical Center have been initiated.DOIM representation on the UNMMG Physician Advisory Group initiated.Participation in search committees for Executive Director, Ambulatory Specialties; UnitDirector, 5-ACC Clinics; and Senior Director, Patient Support Services.Plan developed for improving the registration process on 5-ACC including creation ofregistration kiosks with “full-court press” approach to registering the first patients for morningand afternoon clinic sessions utilizing MA’s to register, since they are not yet triaging patients.Received 2009 Outstanding Clinician Award from the New Mexico Thoracic Society.JULIE BROYLES, M.D.Patient Safety OfficerMedical Director for Credentialing- Credentialing and recredentialing for all privileged members of the Department ofInternal Medicine- Member, Credentialing and Privileging Committee of the UNM Health Sciences Center- Chaired a planning group for merging Ongoing Professional Practice Evaluations datawith two year recredentialing cycle- Goal July 2009 through June 2010; Continue to work with the Office of Clinical Affairsand the credentialing office as the new database is employed and the institutiontransitions to the new core privilege model; work with each division to modify,streamline and update privilege lists12

Medical Director for Compliance- Member, Compliance Committee of the University of New Mexico Medical Group;continuous work with UNM Medical Group leadership monitoring the institution workplan to maintain the excellent compliance of the Department of Internal MedicineFaculty. This position will be managed by Dr. Lenny Noronha.Medical Director for Quality Improvement- Involved in multiple projects with the Ambulatory Quality Committee, the AdultInpatient Medicine Committee, the Inpatient Glycemic Control committee, the DiabetesLeadership Group, the Diabetes Center of Excellence working group, the SepsisMortality Improvement Team, the palliative care consulting service, the UniversityHospitals Mortality Committee, and the Quality Outcomes Department;- Started the New Mexico Chapter of the Institute for Healthcare Improvement OpenSchool; a multidisciplinary educational program on Quality Improvement- Achieved 100% mortality review for the Department of Internal Medicine- Goals 2009-2010 continue to improve the mortality review process for the department,improve the electronic review process, develop meaningful data to bring to the QualityImprovement mission of the Department, continue to work on identification of processesfor improvement; hand washing initiative, handoff communication for dischargedpatients with outpatient providersMedical Director for Vulnerability Management- Department of Internal Medicine; Standing meetings with University HospitalsVulnerability Management, root cause analysis and development of process improvementas indicatedOther- Facilitated the Academy Clinic Risk Reduction Clinic, a collaborative effort with theCollege of Pharmacy to see high risk patients with endocrine and endovascular disorders- Member, Diabetes Disease Management Team and Diabetes Leadership Group:Participated in efforts toward improvement in delivery of diabetes care and education forthe University Hospital Inpatient Service and Ambulatory Clinics. Coordinated diabetesdisease management for the UNM Family Health Academy Clinic- Goal July 2009 through June 2010; assist in coordinating the inpatient and outpatientDiabetes care programs- Quality improvement advisor to the UNM Family Health Academy Clinic; continuedsupport of excellence in patient care delivery to patients with Diabetes Mellitus andassociated co-morbidities using a registry and the Chronic Care Model; support of thedevelopment of the ‘nurse run diabetes clinic’ model- Coordinator Adult Inpatient Medicine Committee; coordination of agenda and facilitationof action plans, networking; presentation and dissemination of information; collaborationfor process improvement- Goal July 2008 through June 2009; further work on process improvement andcoordination- University Hospitals Ambulatory Quality Committee Member; assisted the ExecutiveDirector for Ambulatory Care and the Hospital Administration in forming a vision forchronic care delivery and the medical home13

- Goal July 2009 through June 2010; continue to assist the executive leadership in carryingout their goals of implementing patient care registry functions to improve care delivery tothe outpatient population- University Hospital Pharmacy and Therapeutics Committee; attending monthly meetings- Goal July 2009 through June 2010; continued work with the committee andsubcommittees as needed by leadership- University Hospitals Inpatient Glycemic Control Process Improvement;- Goal July 2009 through June 2010; assist in disseminating data collected through thisprocess and coordinating continued process improvement as needed to improve patientcare- Support role for the BOOST (Better Outcomes for Older adults through Safe Transitions)project with the hospitalist section- Quality Outcomes Department of University Hospitals; regular collaboration with thisdepartment will continue during the next academic year.LENNY NORONHA, M.D.- Joined GIM Hospitalist Section July 1, 2008- Coordinated section “Best Practices” lecture series- Joined Clinical Affairs to improve billing and collections May 1, 2009- Collaborated with CFO, UNMMG to analyze and redesign DoIM charge capture process- Created educational presentations for hospitalist faculty and specialty division fellowsand faculty- Presented new record for Department charge capture to medical executive committeeSANJEEV ARORA, M.D.- “Computerworld Honors Program Award: Honoring Those Who Use InformationTechnology to Benefit Society,” Computerworld Information Technology AwardsFoundation, Massach usetts, 2008.- “Transforming Care Delivery at the Point of Care through Health InformationTechnology.” Award presented by The Foundation for eHealth Initiative, Washington,DC, December 2008.- “Outstanding Leadership by an Individual in the Field of Distance Learning.” Awardpresented by the United States Distance Learning Association, Boston, MA, 2009.- Alpha Omega Alpha, Medical Society membership awarded to Dr. Sanjeev Arora.Alpha Omega Alpha is a national honor society founded in 1902 for medical students,residents, scientists and physicians in the United States and Canada. April 2009.- Ashoka Fellowship awarded to Dr. Sanjeev Arora. The Ashoka Fellowship Programrecognizes leading social entrepreneurs who have innovative solutions to social problemsand the potential to change patterns across society. Arlington, VA, June 2009.- Project ECHO Telehealth Clinics for the period 7/1/2008 – 6/31/2009:- Community Hepatitis C Clinics held: 49- Corrections Hepatitis C Clinics held: 48- Number of HCV patients presented in Clinic: 337- Number of HCV patients presented in Corrections HCV Clinic: 174- Average number of patients on peg-interferon/ribavirin therapy:- Total number of participants in Community HCV Clinic: 129414

- Total number of participants in Corrections HCV Clinic: 379- Total number of patients starting HCV treatment for this period: 253- Cardiovascular Risk Reduction Clinics held: 47- Rheumatology Clinics held: 49- Integrated Addiction and Psychiatry Clinics held: 44- Average number of patients receiving buprenorphine treatment, per month, under ProjectECHO co-management: 300.- Chronic Pain Clinics held: 51- Asthma & Pulmonary Care Clinics held: 22- Pediatric Obesity Clinics held:- Occupational Medicine Clinics held: 3- Medical Ethics Clinics held: 6- High Risk Pregnancy Clinics held: 17- Child & Adolescent Psychiatry Clinics held: 12- Psychotherapy Clinics held: 34- HIV Clinics held: 12- Specialists supporting the ECHO Hepatitis C Provider Team which has allowedCommunity providers to give more comprehensive care/management for their HCVpatients:- Psychiatry: Davin Quinn, MD, Department of Psychiatry- Psychology/Motivational Interviewing: Keri Bolton-Oetzel, PhD, Envision New Mexico.- Substance Use: Dr. Miriam Komaromy, Former Medical Director, AlbuquerqueHealthcare for the Homeless.- Infectious Disease: Dr. Karla Thornton, HIV/HCV Co-infected specialist, Truman St.Clinic.- Chronic pain: Dr. Joanna Katzman, Department of Neurology- Pharmacy: Paulina Deming, PhamD, School of Pharmacy (HCV clinic now includesparticipation of Pharmacy Residents program).- CME / CEU credits issued in the period 7/1/08-6/30/09:- Continuing Medical Education (CME): 4925- Continuing Education Units (NM Counseling and Therapy Practice Board; for counselorsand social workers): 159- Continuing Education Units (issued internally by Project ECHO, typically for medicalassistants, community health workers): 813Travel and outreach activities by Project ECHO:Clinic Location DatesCRRC Las Cruces, NM 07/15/08-07/16/08HCV Taos, NM 08/06/08-08/08/08Technology Atlanta, GA 08/11/08-08/15/08HCV Taos, NM 08/08/08-08/10/08CRRC Taos, NM 08/08/08-08/10/0815

Replication Lima, Peru 08/19/08-08/25/08Pulmonary/Asthma Santa Fe, NM 07/16/08-07/16/08Technology Carlsbad, NM 09/08/08-09/11/08Technology Santa Fe, NM 08/29/08-08/29/09Chronic Pain Espanola, NM 09/10/08-09/10/08Technology Espanola, NM 10/07/08-10/07/08HCV Grants, NM 10/02/08-10/03/08Replication Washington, DC 09/07/08-09/09/08HCV Ruidoso, NM 10/15/08-10/16/08HCV San Francisco, CA 10/30/08-11/04/08HCV Las Vegas, NM 11/04/08-11/04/08HCV Portales, NM 10/15/08-10/16/08Pulmonary/Asthma Hobbs, NM 11/06/08-11/07/08Technology Santa Fe, NM 10/17/08-10/17/08Technology Farmington, NM 11/17/08-11/18/08Technology Las Cruces, NM 11/26/08-11/26/08Technology Washington, DC 12/03/08-12/06/08Recruitment Clovis, NM 7/16/2008-07/17/08Recruitment Las Cruces, NM 01/14/09-01/14/09HCV Santa Fe, NM 02/05/09-02/05/09Pulmonary/Asthma Las Cruces, NM 02/19/09-02/20/09Peer Education Amarillo, TX 01/21/09-01/22/09HCV Roswell, NM 02/25/09-02/27/09Recruitment Santa Fe, NM 02/02/09-02/02/09Recruitment Santa Fe, NM 03/06/09-03/06/09IAP/HCV Roswell, NM 02/25/09-02/27/0916

Ethics Gallup, NM 02/19/09-02/20/09IAP Las Cruces, NM 03/12/09-03/13/09Recruitment Farmington, NM 03/17/09-03/18/09IAP Las Cruces, NM 03/13/09-03/14/09Pulmonary/Asthma Carlsbad, NM 04/11/09-04/13/09Pulmonary/Asthma Gallup, NM 04/16/09-04/16/09Recruitment Los Lunas, NM 04/03/09-04/03/09CRRCCRRCSanta Domingo Pueblo,NMSanta Domingo Pueblo,NM02/18/09-02/18/0903/11/09-03/11/09CRRC El Rito, NM 03/16/09-03/16/09Recruitment Santa Fe, NM 04/20/09-04/20/09IAP Las Cruces, NM 03/12/09-03/13/09Technology Las Vegas, NV 04/24/09-04/29/09IAP Santa Fe, NM 04/30/09-04/30/09CHW Santa Fe, NM 04/30/09-04/30/09Rheumatology Gallup, NM 05/13/09-05/13/09HCV Taos, NM 05/14/09-05/15/09Recruitment Las Cruces, NM 05/11/09-05/12/09IAP Las Vegas, NM 05/19/09-05/20/09Peer Education Amarillo, TX 01/21/09-01/22/09Recruitment St. Louis, MO 04/28/09-05/02-09Replication Oklahoma City, OK 03/23/09-03/24/09HCV Espanola, NM 05/19/09-05/19/09HCV Las Vegas, NM 03/14/09-03/14/09IAP Las Vegas, NM 02/10/09-02/10/0917

HCV Santa Fe, NM 01/29/09-01/29/09CRRC Abiquiu, NM 05/20/09-05/22/09High Risk Pregnancy Santa Fe, NM 05/20/09-05/20/09HCV Chicago, IL 05/29/09-06/03/09CRRC Carlsbad, NM 05/26/09-05/26/09IAP Leslie Hayes 04/29/09-05/03/09Recruitment Las Cruces, NM 06/16/09-06/17/09Recruitment Isleta, NM 06/17/09-06/17/09HCV Las Cruces, NM 06/07/09-06/08/09Evaluation Atlanta, GA 06/14/09-06/17/09Peer Education Dayton, TX 06/15/09-06/18/09Chronic Pain Farmington, NM 06/23/09-06/24/09CRRC Belen, NM 06/26/09-06/26/09Recruitment Las Cruces, NM 05/11/09-05/12/09Recruitment Carlsbad, NM 06/23/09-06/24/09Recruitment Taos, NM 06/26/09-06/27/09Chronic Pain Cuba, NM 06/23/09-06/24/09Chronic Pain Shiprock, NM 06/23/09-06/24/09Chronic Pain Santa Fe, NM 05/12/09-05/12/09CHW Las Cruces, NM 06/16/09-06/17/09Other projects/accomplishments:- Prison Peer Education Program developed and launched, June ’09, with first trainingcohort of prison health educators at Central New Mexico Correctional Facility.- Diabetes Community Health Worker curriculum developed (first training launched July’09).- Community Health Worker Core Curriculum proposal presented to and accepted by theDepartment of Health Community Health Worker Advisory Council.- Collaborative Agreement University of Washington, to replicate Project ECHO HCVClinic model through UW Harborview Medical Center.18

- Advanced discussions to replicate Project ECHO model with University of ChicagoDepartment of Pediatrics.- Advanced discussions to replicate Project ECHO model with Oklahoma Indian HealthServices.- Advanced discussions to expand Project ECHO model to Veteran’s Administration ruralclinics.- Have received extended visits from representatives the following internationalinstitutions to examine the ECHO model:- Cairo University Medical School, Cairo, Egypt.- Maulana Azad Medical College, New Delhi, India.- Provided training and DEA certification to approximately 50 physicians in New Mexicoto increase the number of physicians certified to prescribe buprenorphine.- Provided access to telehealth infrastructure and support to Department of Health forStatewide Community Planning and Action Group, composed of health educators,outreach experts and harm reduction experts, in order to facilitate Statewidecommunication and coordination.- Conducted two retreats with New Mexico Secretary of Health in order to plan strategycongruence- Partial FTE support to other faculty members provided through Project ECHO:Alverson, DaleBankhurst, ArthurBennahum, DavidBerwick, MarianneBolton Oetzel, KeriCaldera, ElizabethColleran, KatherineCuret, Luis BenDeming, PaulinaDion, DeniseEpstein, JaneGraeber, DavidHarkins, Michelle S.Jenkusky, SteveKalishman, SummersKatzman, Joanna GKipp, BillieParish, BrookeQuinn, DavinScaletti, JosephSimpson, AnneThornton, KarlaB. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURELEE K. BROWN, M.D.Endocrinology- Complete business plan for clinician-educator faculty member and initiate recruitment.19

- Recruit mid-level provider.- Define the administrative structure for the Diabetes Center of Excellence.- Initiate the Diabetes Center of Excellence at 1101 Medical Arts Avenue, Building 4.Gastroenterology: Move Digestive Disease Center to renovated site on Martin Luther King Jr.Drive.- Outpatient Treatment Center:. Pursue approval of renovation request.. Initiate weekend sessions.Pulmonary: Recruit additional clinic providers and re-start demonstration project.Senior Health/Geriatrics: Expand Palliative Care Service.Sleep Medicine:- Continued development and implementation of expansion plans for the sleep disorderscenter on the Eastside.- Continued development of a sleep laboratory component at the Sandoval RegionalMedical Center.- Conclude agreements with the Albuquerque VA Medical Center.- Pursue UNMH/UNMMG funding of additional primary care faculty positions forEastside locations.If staffing level allows, pilot afternoon/evening reminder calls to patients one day in advance oftheir appointments for 5-ACC specialty clinics.Pursue renovation of 5-ACC lobby area for registration kiosks.LENNY NORONHA, M.D.- Redesign off-site service patient registration process- Audit and redesign billing process for outpatient procedures by division- Represent DoIM on UNMMG Compliance Committee- Revise inpatient documentation templates- Create new outpatient visit documentation templates- Create provider billing feedback process with UNMMG- Plan for new Senior Faculty Practice Manage to further analyze DoIM revenueopportunities- SEAC grant application for faculty behavior change studyC. APPOINTMENTS TO FACULTY/STAFFFacultyLenny Noronha, M.D. – Associate Medical Director, Clinical Affairs – May 1, 2009Appointments to StaffJohn Brown, MA-LMHC – Project ECHO, Program Operations Manager – July 1, 2008Amy Hunter Baird, BS – Project ECHO, Accountant III – July 10, 2008Lisa Finley – Project ECHO – Coordinator, Community Education – July 21, 2008Adrian Rodriguez – Project ECHO – User Support Analyst 3 – September 15, 2008Karen Luttecke, BA – Project ECHO – Administrative Assitant 3 – October 1, 2008Erika Harding, MA – Project ECHO – Program Coordinator – November 17, 2008David Porter, MBA – Project ECHO – Database Administrator – November 25, 2008Sandra Cordaro – Project ECHO – User Support Analyst 3 – December 4, 200820

Ronselle Harrison – Project ECHO – User Support Analyst 3 – December 5, 2008Andrea Bradford, MSc – Admin Asst to the Executive Director – February 2, 2009Jeanne Boyle, RN-BSN – Project ECHO – Nurse Manager – May 11, 2009Brian Swager, BS – Project ECHO – Coordinator – Data Entry – May 26, 2009Julie Rosen – Project ECHO – Education and Outreach Manager – May 27, 2009Miranda Haynes – Project ECHO – Administ rative Assistant 3 – June 1, 2009Ana Moriel, Ma – Project ECHO – Administrative Assistant 3 – June 1, 2009Tom Burke – Project ECHO – Database Administrator – June 1, 2009Anna Knackstedt, BA – Project ECHO – Coordinator, Training – June 1, 2009Michael Han – Project ECHO – Data Manager – June 8, 2009Candida Pullen – Project ECHO – Administrative Assistant 3 – June 22, 2009Bonnie Kraybill, BN-BC – Project ECHO – Nurse Manager – June 22, 2009D. SEPARATIONS OF FACULTY/STAFFFacultyNoneStaffJustin Goodman – Project ECHO – Coordinator, Community Education – August 15, 2008Sylvia Law – Project ECHO – Program Coordinator – September 26, 2008Thomas Peterson – Project ECHO – Data Analyst – December 31, 2008E. PUBLICATIONSLEE K. BROWN, M.D.Casey KR, Brown LK. Sleep-Disordered Breathing and Renal Failure: A Search forFundamental Mechanisms. Sleep Med 2009; 10:15-18.Brown LK. Physicians and Sleep Deprivation [editorial]. Curr Opin Pulm Med 2008; 14:507-511.Brown LK. The Harvard Medical School’s Guide to a Good Night’s Sleep. [book review] JClin Sleep Med 2008; 4:381-2.Brown LK. President’s Column: Of this and that…. [editorial] GAMA Reports 2008; 30(October): 1,7.Brown LK. President’s Column: GAMA Annual Membership Fee Could Increase. [editorial]GAMA Reports 2008; 30 (November): 1-2.Brown LK. President’s Column: Caley, We Hardly Knew Ye. [editorial] GAMA Reports 2008;30 (December): 1,3.Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, Parthasarathy S, Quan SF,Rowley JA. Response to Marcus CL. Letter to the Editor: Concerns regarding the pediatriccomponent of the AASM clinical guidelines for the manual titration of positive airway pressurein patients with obstructive sleep apnea. J Clin Sleep Med 2008; 4:607.Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, Parthasarathy S, Quan SF,Rowley JA. Response to Johnson K, Johnson D. Letter to the Editor: In reference to clinicalguidelines for the manual titration of positive airway pressure in patients with obstructive sleepapnea. J Clin Sleep Med 2008; 4:610.21

Brown LK, Lee-chiong T. Hypoventilation Syndromes [preface]. Semin Respir Crit Care Med2009; 30:249-251.SANJEEV ARORA, M.D.PublicationYu S, Douglass JM, Qualls C, Arora S, Dunkelburg JC. “Response to Therapy with PegylatedInterferon and Ribavirin for Chronic Hepatitis C In Hispanics Compared to Non-HispanicWhites,” American Journal of Gastroentrology. 2009 Jul;104(7):1686-92.Berkley, EM, Leslie, KK, Arora, S, Qualls, C, Dunkelberg, JC. “Chronic Hepatitis C inPregnancy,” Obstet Gynecol. 2008 Aug;112(2 Pt 1):304-10.PosterArora, S, Alverson D, Stewart R, Pak W, Fassler C, Brown J. “Project ECHO KnowledgeNetworks Expand Access for Rural Areas/Prisons” American Telehealth Association (ATA)Annual Meeting, Las Vegas. 2009 April 26-28, 2009.Invited LecturesHoly Cross Hospital, Toas, NM, Grand Rounds, “Project ECHO”, June 27, 2009.Decentralized HCV Care Models Advisory Board, Denver, CO, ”Extending Hepatitis CTreatment to Rural Areas and Prisons” , June 26, 2009.Carlsbad Haspital, Carlsbad, NM, Grand Rounds, “Project ECHO”, June, 24, 2009.La Clinica de Familia, Las Cruses, NM, Grand Rounds, “CHW’s and Project ECHO”, June 17,2009.Integrating Hepatitis C Care and Treatment into Primary Care: Exploring Strategies for Maine,Albuquerque, NM, “Project ECHO – A Model to Learn From”, June 11, 2009.University of New Mexico, Department of Internal Medicine, Albuquerque, NM, Grand Rounds,“Project ECHO Update”, May 28, 2009.Community Clinic, Project ECHO Telemedicine Clinic, Albuquerque, NM, "Hemochromatosis",May 27, 2009.Mid-Atlantic Association of Community Health Centers (MACHC), Albuquerque, NM, “ProjectECHO”, May 21, 2009.Interview with KOAT, Hepatitis Awareness Month, “Cause and Treatment Options forHepatisis”, Albuquerque, NM, May 20, 2009.Community Clinic, Project ECHO Telemedicine Clinic, Albuquerque, NM, “Interpreting IronStudies in Liver Disease”, May 20, 2009.New Mexico Health Resources Annual Provider Retreat, Taos, NM, “Hepatitis C and ProjectECHO”, May 15, 2009.Miner Colfax Medical Center, Dinner Program, Raton, NM, “ Project ECHO”, May 14, 2009.Mimbres Memorial Hospital, Deming, NM, Grand Rounds, “Project ECHO”, May 12, 2009.La Clinica de Familia, Las Crues, NM, Grand Rounds, “Project ECHO”, May 11, 2009.32 nd Annual Rural Health Conference, NRHA, Miami, FL, Keynote Speech, “Project ECHO”,May 6, 2009.Western Group on Educational Affairs, WEGA Panel, Santa Fe, NM, “Project ECHO”, April 20,2009.Alpha Omega Alpha, Induction Dinner, Albuquerque, NM, “Big Vision”, April 16, 2009.22

San Juan Regional Medical Center, Farmington, NM, Grand Rounds, “Project ECHO”, March18, 2009.Northern Navajo Medical Center, Shiprock, NM, Grand Rounds, “Project ECHO”, March 18,2009.Vietnamese Baptist Church, Vietnamese Community, Albuquerque, NM, “Hepatitis A, B, andC”, March 15, 2009.COCHS Annual Meeting, Washington, DC, Panelist, “Continuity of Care for Inmates BattlingAddition”, March 10, 2009.Hepatitis Coordinators’ Meeting, CDC, Atlanta, GA, Workshop, “Developing Rapport withPhysicians to Promote Viral Hepatitis Prevention”, March 3, 2009.CTSC/ECHO Clinical Investigators Dinner Meeting, Albuquerque, NM, “Project ECHO” ,February 17, 2009.University of New Mexico Update and Review of Internal Medicine 2008, Santa Fe, NM,“Hepatitis B Update and Project ECHO,” October 19, 2008.University of New Mexico Update and Review of Internal Medicine 2008, Santa Fe, NM,“Gastroenterology Q&A,” October 19, 2008.University of New Mexico Gastroenterology Division, Albuquerque, NM, Faculty Didactic,“Treatment of Hepatitis B,” August 14, 2008.National Rural Health Association 2008 Quality/Clinical Conference, San Diego, CA, KeynoteSpeaker, “Extension for Community Healthcare Outcomes: Project ECHO,” July 15, 2008.University of New Mexico Gastroenterology Division, Albuquerque, NM, Faculty Didactic,“Project ECHO,” July 10, 2008.Indian Health Services, Gallup, NM, Grand Rounds, “Project ECHO,” July 1, 2008.F. OUTSIDE PROFESSIONAL ACTIVITIESAd Hoc Reviewer for:CHESTClinical Pulmonary MedicineSLEEPClinical Sleep MedicineAmerican Journal of MedicineRespirationNephronMayo Clinic ProceedingsClinical Infectious DiseaseMetabolismAmerican Thoracic Society, Health Policy Committee (2004-present; Chair, 2006-2009)New Mexico Thoracic Society, Planning Committee, 29 th - 37 th Annual New Mexico ThoracicSociety Lung Disease Symposia (2000-present)American College of Chest Physicians:Sleep Issues in Healthcare Workers Task Force (2008 – present)CHEST Editorial Board (2001-present)Abstract Reviewer for Annual Scientific Assemblies (1995 - 2009).American Academy of Sleep Medicine (formerly, American Sleep Disorders Association):Board of Directors (2006 – 2009)23

Chair, Ad Hoc Guidelines Task Force (2008 – 2009)Documents Committee (2009 – present)Ad Hoc NPPV Titration Protocol Task Force (2008 – present)Ad Hoc Institute of Medicine Task Force (2009)Ad Hoc ACGME Sleep Fellowship Task Force (2007 – 2009)Ad Hoc PAP Titration Protocol Task Force (2007 – 2009)Ad Hoc Course Review Task Force (2008 – 2009)Associate Editor, Journal of Clinical Sleep Medicine (2006-present)Book Review Editor, Journal of Clinical Sleep Medicine (2006-present)American Sleep Medicine Foundation, Board of Directors (2006-2009)American Board of Sleep Medicine, Board of Directors (2006-2009)Associated Professional Sleep Societies LLC, Board of Directors (2007 – 2009)Greater Albuquerque Medical Association:Immediate Past President and Member, Board of Trustees (2009)President and Member, Board of Trustees (2008)Physician Recruitment and Retention Committee (2002-2003, 2009-present)Delegate to the New Mexico Medical Society Annual Meeting (2000-2009)New Mexico Medical Society, Liaison Committee to the UNM School of Medicine (2001-present)State of New Mexico Medical Board, Polysomnographic Practice Advisory Committee (2008-present; Chair, 2009-present)Editor, Sleep and Respiratory Neurobiology Section, Current Opinion in Pulmonary Medicine,2007 – 2009).Brown LK, Lee-chiong T. Guest Editors, Seminars in Respiratory and CriticalCare Medicine, Hypoventilation Syndromes Issue (2009)LecturesBrown LK. Sleep Disorders. Interdisciplinary Geriatric Certificate Program, New MexicoGeriatric Education Center, University of New Mexico Health Sciences Center, Albuquerque,NM, July 12, 2008.Brown LK. Miles to Go Before I Sleep: Sleep/Wake Issues in the Medical Workplace. 12 thAnnual Update and Review of Internal Medicine 2008, Santa Fe, NM, October 19-24, 2008.Brown LK. Sleep Apnea Update. 24 th Annual Advances in Respiratory Care Conference,American Lung Association in Nevada, Las Vegas, NV, April 27-28, 2009.Brown LK. Sleep Medicine. Clinical Expert, Clinicians ’ Center, 2009 InternationalConference, American Thoracic Society, San Diego, CA, May 15 – 20, 2009.Sessions ModeratedModerator, “Periodic Limb Movements of Sleep: Clinical Disorder or Incidental Finding?”Annual Scientific Assembly, American College of Chest Physicians, Philadelphia, PA, October25-30, 2008.Workshop Vice Chair, “Pediatric Sleep-Disordered Breathing: An Unrecognized Public HealthProblem.” Held in conjunction with the International Conference, American Thoracic Society,San Diego, CA, May 16, 2009.LENNY NORONHA, M.D.24

Hospitalist section consultation committeeNutrition committeeSANJEEV ARORA, M.D.Medical Executive CommitteeClinical Operations Group of UNMHSCUncompensated Care Task ForcePatient & Referring Physician Satisfaction Committee, UNMHMember, American Gastroenterology AssociationFellow, American College of Physicians-American Society of Internal MedicineMember, American Association for the Advancement of SciencesFellow, American College of GastroenterologyAmerican society of Gastrointestinal Endoscopy (ASGE)Practice Management Committee of ASGEGreater Albuquerque Medical AssociationProgram Chairman (Dr. Arora)Course Director, Update and Review of Internal Medicine, Annual conference October 19-24,2008G. OUTSIDE SPONSORED RESEARCHLEE K. BROWN, M.D.Research Allocation Committee: $13,600. “Can Open Lung Ventilation with SpontaneousBreathing Lead to Better Sleep Patterns: A Pilot Study” P.I.: Jonathan Marinaro, MD and Lee K.Brown MD.SANJEEV ARORA, M.D.A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa 2a(Pegasys®) and Ribavirin (Copegus®) in Treatment Naïve Subjects with Genotype 1 ChronicHepatitis C VX950-108. $165,643.00Vx-950-TiDP24-C216 "A Randomized, Double blind, Placebo-controlled, Phase III Trial of 2Regimens of Telaprevir (with and without delayed start) Combined with Pegylated Interferonalfa-2a (Pegtasys) and Ribavirin (Copegus) in Subjects with Chronic Genotype 1 Hepatitis CInfection who Failed Prior Pegylated Interferon Plus Ribavirin Treatment.MV21371/A (Roche) A Randomized, Open-Label, Multicenter Study Examining the Effects of24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD)plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with ChronicHepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response.VX08-950-111 (Vertex) A Randomized Study of Stopping Treatment at 24 Weeks orContinuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 ChronicHepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While ReceivingTelaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®).A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a(Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) ofStudy VX06-950-106 Who do not Achieve or Maintain an Undetectable HCV RNA LevelThrough Sustained Viral Response, $150,000.25

INPATIENTInpatient Admissions 39,893Patient Days:MI/CICU 6,930MS/SAC 6,738General Medicine 9,097Medicine 11,0807 South 6,04827

OFFICE OF EDUCATION AND TRAININGOFFICE OF EDUCATIONANNUAL REPORT: JULY 1, 2008 – JUNE 30, 2009BETTY CHANG, M.D.C.M., Ph.D., DIRECTOR OFRESIDENCY TRAINING PROGRAMBRONWYN WILSON, M.D.28

DIRECTOR OF UNDERGRADUATE MEDICAL EDUCATIONGRADUATE MEDICAL EDUCATIONFACULTY AND STAFFGraduate Medical EducationBetty Chang, M.D.C.M., PhD, Associate Professor and Residency Program DirectorGregory Fotieo, M.D., Professor and Associate Director of Residency Program at the VeteransAdministration Medical CenterJennifer Jernigan, M.D., Associate Professor and Associate Director of Residency Program atUniversity HospitalDana Fotieo, M.D., Associate Professor and Assistant Director of Residency ProgramMichelle Harkins, M.D., Associate Professor and Assistant Director of Residency ProgramLinda Simmons, Residency Office Administrator and Senior Medical Residency CoordinatorDenise Kelly, Medical Residency CoordinatorA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARGraduate Medical Education- The University of New Mexico’s Department of Internal Medicine Residency Program had asuccessful recruiting season and match. Ten preliminary positions were filled with eight fromthe University of New Mexico and 1 from US schools. One Neurology preliminary position wasfilled from India. Twenty-one categorical positions (4 from UNM, 8 from US schools, and 9International) were filled. The wide diversity of schools represented includes the Mid-West (UCincinnati COM, Michigan State U Osteopathic, Oklahoma State U College of OsteopathicMed), the Southeast (UT at San Antonio); the East (Temple Univ SOM), the Southwest (U UtahSOM, Oregon HSU SOM, Touro U Osteopathic, Arizona College of Osteopathic Med).International medical schools represented are in China, India, Jordan, Pakistan and thePhilippines. The wide range of medical schools that supply residents to us continues to enrichthe diversity of our program.- Of the 2008-09 graduating class, 5 are slated to practice general internal medicine (4 in NewMexico), 2 are our own Chief Medical Residents, 1 is our Primary Care Chief Resident, and 14will pursue subspecialty training in various medical subspecialties, 9 at UNM. The subspecialtyprograms chosen by our departing residents include Allergy-Immunology (Denver Jewish),Critical Care (UNM), Endocrinology (UNM and Baylor), Gastroenterology (UNM),Hematology-Oncology (UNM and U Oklahoma), Nephrology (UNM and UC Davis),Rheumatology (UNM and Case Western). Both of the chief residents plan to pursue fellowships.- Our graduates have a cumulative pass rate of 87% for the ABIM certifying exam for 2004through 2007.- Awards were presented at the annual Spring Party to the following residents and faculty. Allrecipients were chosen by ballot by the residents.Intern of the YearLeonardo Macias, M.D.Resident of the YearJon Blaschke, M.D.Laurent T. Visconti29

Teaching Fellow of the YearWilliam R. HardyTeaching Physician of the YearHouman Fekrazad, M.D.Akshay Sood, M.D.- The House Officer Research Award for 2008-09 was given to two residents, Joseph Mizzell,MD and Wen-Huan Steve Ho, M.D.- International electives, both clinical and research rotations were provided for five residents inIndia, Pakistan, Israel, Mexico, and China.- An annual survey of all residents was again conducted. The information gathered will be usedto improve the program. Of particular concern are the reported deterioration of call room/workroom conditions at both UNMH and the VA Hospital. The UNMH call room renovation wascompleted in June; the VA call rooms are slated to be refurbished in the coming academic year.- Duty hour entry program was changed to www.tsheets.com with the housestaff text messagingtheir duty hours or entering them via web browser. Duty hour entry compliance is over 99%.- The Office of Education continues to track compliance on a daily basis and follow up on thecauses of any suspected violations. Weekly duty hour reports are being sent to the GME officeand to Dr. Moseley for review.- With the assistance of the hospitalists at both institutions the program was able to eliminate 30hour duty hour violations by the end of the academic year.- Wards at UNMH changes based on resident feedback:1) a second as needed non-resident service was enacted to cover the increase in patient census soas not to affect the housestaff duty hours.2) the team cap was decreased to 183) The morning overflow was taken by the non-resident service.- Wards at VA changes based on resident feedback: the team cap was decreased to 20- MICU – VA changes based on resident feedback:1) residents were moved to night coverage only under a night float system2) day coverage was provided by interns, fellows, and attending3) step down patients were taken by the hospitalist/cardiology services- Cardiology at UNM changes based on resident feedback:1) the admission cap/24 hours was set at 72) after 7 admissions fellows would be paid to do subsequent admissions- Cardiology at VA changes based on resident feedback:1) call was taken by interns or residents in a q4/5 frequency2) critical care admissions after 7pm were covered by the VA-MICU team.- Didactic teaching was successfully moved to the Thursday School format. The residents wereprovided protected time from clinical duties to attend. The resident attendance at didactics hasdramatically improved as has satisfaction with didactic sessions.- A weekly board review conference was conducted for the third year residents to assist in theirboard preparation. This conference was proctored by the Program Director, the AssociateProgram Directors and many of the subspecialty fellows.- Journal Club has successfully been altered to a small group format in which there is a residentdiscussion leader and a faculty mentor present in each small group.- The House Officer Scholarly Activity Committee continued to be successful under thedirection of chair Michelle Harkins, MD. Potential mentors and research projects were30

identified. Assistance was provided to residents in connecting with a suitable mentor for theirinterests.- House officers continued to be productive in their research and scholarly activities.- Resident Portfolios have been created which are maintained in the Office of Education andprovide a road map of the resident’s residency experience.- Evaluations of residents by faculty has been closely monitored and the completion rate hasimproved to greater than 95%.- To gain more resident input into the quality of the residency program, Resident Voice wascreated in which residents and the program director could discuss issues related to the residency.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTUREPostgraduate Medical Education1. The didactic Thursday School will be augmented to focus on board preparation in thefollowing manner:- Thursday school topics will be based on an internal medicine text which ensures that topicsrequired for the boards are covered- Thursday school curriculum will be an 18 month cycle to allow all residents to have 2opportunities to hear each topic before the end of residency.- Quizes based on board review questions will be conducted at the beginning of each Thursdayschool based on the topics presented that day- Assigned reading from an Internal Medicine text will be assigned each week based on thetopics presented that day2. In ongoing efforts to improve the ratio of service to education, the department anticipates thefollowing changes:- Cardiology non-resident service at UNMH to start July 2009.- VA Hospital: non-resident medicine service to start July 2009.- UNM Wards: a new wards system based on 6 resident teams and 1-2 non-resident teams.- UNM Wards: a second seasonal non-resident service to start October 2009 through March2010.- VA MICU: will no longer be an internal medicine staffed teaching service- UNM Hematology/Oncology: will rotate the resident two weeks on each service to providethem with a clinical experience in both fields.3. Recommendations for future changes which will improve the educational experience of theinternal medicine housestaff are:- Nocturnal faculty presence in both the wards and ICU experiences will provide more educationfor the residents as well as supervision- Increasing utilization of non-resident services with a goal of decreasing dependence onresidents for service.4. The Office of Education will continue its scrutiny of service obligations at both UNMH andVAMC with the goal of bringing about the most favorable service vs education ratio forresidents.5. The Program Director and Chief Residents will maintain surveillance of on-call facilities atthe VA as renovations proceed in order to insure that RRC requirements are met.31

6. The website for the residency office will again be upgraded under the direction of the chiefresidents, with input from the residents, in order to provide an optimal recruiting tool for theprogram.7. Begin preparations for the ACGME site visit scheduled for the 2009-2010 academic year.8. Resident evaluation of faculty completion rate will be focused upon to ensure that faculty hasfeedback on their teaching and role modeling. These evaluations will be summated and given toDivision Chairs on a semi-annual basis.9. The program and the hospitalists will create an Internal Medicine Wards Council which willformally review changes to the policies and procedures involved with inpatient wards medicineat UNM.10. The program will conduct the first faculty annual evaluation of the residency program andutilize the results of that survey to improve the residency program.11. The program will review the curriculum to ensure it continues to be a timely, up to datedocument that guides the education of our residents.12. The program will begin to conduct resident practice based learning and improvementprojects in the outpatient clinics. The goal is to teach the residents how to inquire on the qualityof their own medical practice and systematically improve upon it.C. APPOINTMENTS TO FACULTY/STAFFFaculty- Betty Chang, MDCM, PhD, was appointed Program Director on March 1, 2009.- Dana Fotieo, MD, will become an Assistant Program Director on July 1, 2009.- Michelle Harkins, MD, will become an Assistant Program Director on July 1, 2009.- Joseph (Jay) Mizzell, MD (UNM) and Jon Blaschke, MD (VAMC) to begin one-yearappointments as Chief Medical Residents in July 2009.Staff- Denise Kelly, Administrative Assistant III, began work in January 2009.- Denise Kelly was competitively promoted to Medical Residency Coordinator in June 2009.D. SEPARATIONS OF FACULTY/STAFFFaculty- Ann Gateley, MD, stepped down as Program Director on March 1, 2009. She will continueworking with GIM full-time or part-time in the future.- Pejvak Salehi, MD, and Rema Hanna, MD, completed one year service as Chief Residents atUH and VAMC in June 2009.Staff- Veronica Steimle, Administrative Assistant III, left the department in November 2008.- Melinda Franklin, Medical Residency Coordinator, left the department in May 2009.E. PUBLICATIONS AND OTHER SCHOLARLY ACTIVITY OF THE DIVISION32

Ann Gateley, M.D.- Gateley A, Stern N and Barrett J. Practice Experiences of Women Physicians in Primary CareSports Medicine. 17 th Annual American Medical Society for Sports Medicine Meeting, LasVegas, Nevada, 2008.Betty Chang, MDCM, Ph.D.ACGME Annual Educational Conference, March 2009 Promoting Good Learning and Safe,Effective Care: A Five-Year Review of the ACGME's Common Duty HourStandards Panel Discussion – Panel Member.House Officer Presentations and Publications:January 2009 Carmel Western Regional Meeting1. Feasibility of a Walking School Bus Program to Prevent Obesity in Hispanic ElementarySchool Children. C. Conklin, N. Burks, C. Roldan, A. Kong: UNM SOM, Albuquerque, NM.2. Anorectal Ulcerations: A Rare Presentation of Miliary Tuberculosis. N.B. Vachhani1, W.S.Ho: University of New Mexico Health Sciences Center, Albuquerque, NM.Other Meetings – 2008-091. Interactive VTE Prophylaxis Form. Keith McClung M.D. and Kendall Rogers M.D.Presented at Society of Hospital Medicine, April 2008, San Diego.2. Dermatology Education. Alex Eshaghian M.D.. Abstract presented at American Academyof Dermatology meeting, San Francisco, CA, March 2009.Clinical Vignettes Presented at New Mexico ACP Meeting, November 20081. Acute Myelogenous Leukemia Associated with Breast Chloromas and SystemicMastocytosis. Sharon Ing M.D., M.Houman Fekrazad M.D., Sujana Movva MD, Han ShefflerPAC, Kristin Hunt MD, Ian Rabinowitz MD2. Sexual Transmission of Q Fever. Andrea Veryser M.D.3. HyperInsulinemia/ Euglycemia as Treatment of Hypotension in Patients with DiltiazemOverdose. Chris Gallagher M.D. and Shozab Ahmed M.D.4. Hemorrhagic Colitis Secondary to Elemental Mercury Vapor Inhalation in a 46 year-oldMale. Jennifer R. Vigil M.D., Laura A. Heise, Brant M. WagenerPosters Presented at New Mexico ACP Meeting, October 20081. Acute Retroviral Syndrome with pancytopenia. Darren Young M.D.2. Q fever in New Mexico. Greg Brown M.D.3. End-Stage Renal Disease secondary to lower urinary tract obstruction in men. Jesse PicenoM.D., Lawrence J. Gibel M.,.D Yijuan Sun M.D., Karen S. Servilla M.D., Michael F. HartshorneMD, and Antonios H. Tzamaloukas MD FACP4. Association Between Exposure to Hydrocarbon Fumes and Goodpasture's Syndrome. NirupaPaulraj M.D.5. Young Male with Liver Abscess. John Khuu MD, Erik Kraai MD6. Vancomycin-Intermediate Staphylococcus aureus has Arrived in New Mexico: Implicationsfor Health Care. Theresa White M.D. MPH, Susan Kellie MD MPH33

7. A Rare Case of Acute Renal Failure Secondary to Inflammatory Abdominal Aortic AbdominalAortic Aneurysm. Carlos Reyes M.D.8. Hepatic Hydrothorax in Alcohol-Induced End-Stage Liver Disease: A Case Report. SuzanneL. DeLea M.D.9. Acquired Factor VIII Inhibitor: A Case Study. Maya A Mehta M.D., Edward N Libby MDand M. Houman Fekrazad M.D.10. A Patient with Acute Pericardial Tamponade Secondary to Non-Small Cell Lung Cancer.Maya Mehta MD and George Comerci M.D.11. Ovarian Cancer: An Old Story Revisited. WenHuan Steve Ho M.D., Glen Murata M.D.12. An acute febrile neutrophilic dermatosis case: Sweet's Syndrome. Natalia Chavez ChiangM.D, Kendall Rogers M.D.13. Chest Pain and Shingles: To Heparinize or Not. Wen-Huan Steve Ho MD, Greg Fotieo MDResearch Presented at Thursday School – Residents as Scholars Day:1. Chart-Based Case-Based Learning. Scott Helberg M.D.2. Brugada syndrome in an 85 year old male: Literature and case review. Jon Blaschke M.D.3. Diabetes attitudes among healthcare providers. Christina Lovato M.D.4. Exhaled Breath Condensates. Joseph Mizzell, MD.5. A case of pneumococcal necrotizing fasciitis in a patient with lupus. Christopher Quintana,MD.6. Medicine Hispana, the Medical Interview: a medical interview course in Spanish. CesarRamos, M.D.7. The comparison of personal attitude and use of integrative medicine among primary careprofessionals between Tiangmen City Central Hospital, China, and UNMH. Sarah Wu, D.Publications by Internal Medicine Residents – 2008-091. Cheney P, Haddock T, Sanchez L , Ernst A, Weiss S: Safety and compliance with anemergency medical service direct psychiatric center transport protocol. Amer J Emergency Med(2008) 26, 750-756.2. S.Z. Wang, Y.X Bao, Z.J Jie, X.J. Guo, J.A. Wilder, E.G. Barrett, M.F. Lipscomb, K.S.Harrod: Respiratory Syncytial Virus Alters Dendritic Cell-Mediated Lymphocyte Production ofIFN-ÿ. Submitted to European Respiratory Journal, Spring 2009.UNDERGRADUATE MEDICAL EDUCATIONFACULTY AND STAFFBronwyn Wilson, M.D., Professor, Director of Undergraduate Medical Education and Directorof Phase III Comprehensive Ambulatory MedicineEd Fancovic, M.D., Associate Professor and Phase II Clerkship DirectorDeepti Rao, M.D., Assistant Professor and Associate Phase II Clerkship DirectorYvonne Dalton-Etheridge, M.D., Assistant Professor and Assistant Phase II Clerkship Directorof at VAMCErnestina Gomez, Sr. Medical Student Educational CoordinatorMelissa Cordero, Administrative Assistant III34

A. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARPhase I:59 DoIM Faculty were tutors in Phase 1 tutorials8 DoIM Faculty were preceptors in Foundations of Clinical PracticePhase II Internal Medicine Clerkship:Curriculum Updates- Phase 2 tutorials hours reduced from two hours to one hour to incorporate study time formedical students to prepare for the required NBME shelf board exam at the end of therotation and students are offered the opportunity to expand their approach and knowledgebase.- Phase 2 practical exam was introduced to allow students the opportunity to demonstratetheir competency in general Internal Medicine clinical knowledge during a practical casebasedexamination at the end of the rotation. The examination tests students on theirabilities to interpret laboratory and imaging data, and to formulate differential diagnosesbased on their interpretation. The criteria component for evaluation of the practicalexamination is 10% of final grade.- The clerkship provides a didactic lecture series covering general Internal Medicine topics.These lectures take place every Tuesday afternoon for one hour.- Students continue to use the various in-patient teaching modules available on the website. The modules include topics as UTI - Pyelonephritis module, Thyroid Storm Module,Thrombocytopenia Module, and Syncope Module.- The clerkship offers students direct observation by an expert faculty member as theyconduct a typical inpatient encounter. Afterwards, the faculty member provides thestudent with formative feedback.- Students round with a palliative care and/or medical ethics expert and discuss issuespertaining to death and dying. This is a unique opportunity for students to explore andreflect on end of life care.- Students are expected to maintain a strong commitment to professionalism throughout theclerkship. As a result, a small percentage of their final grade is affected by their generalprofessionalism. Professionalism issues that arise during the clerkship may result indeductions from the students’ final grade.Evaluation Updates- The Internal Medicine Clerkship assures that students receive formal feedback in a timelyfashion. Currently, the Internal Medicine Clerkship is divided into 2 4-week inpatientblocks at each of the 2 inpatient sites (University Hospital and the VAMC). TheClerkship director(s) meet with each of the ward teams midway during each of the 4-week inpatient blocks and conduct a PRIME evaluation session. The clerkship director(s)then meet individually with each student to discuss the evaluation, and to design alearning plan to improve the student’s performance. Thus the students receive mid-blockassessment for each 4-week period with the opportunity to build on their competencies aswell as to improve their summative evaluations.35

- The clerkship director reviews the PRIME evaluations for each student at the end of theclerkship and assigns a grade based on a standardized grading scale utilized by all theclerkships. The tutorial leaders grade the students based on a standardized protocol. Theshelf board is graded based on a scale that correlates the student’s percentage to anumerical grade designation. The practical exam and professionalism is alsoincorporated into the final grade.- Phase 2 work hour violations are documented electronically on STROLS by medicalstudents during weeks 2 and 6 of the rotation. The clerkship director promptly reviewsany work-hour violations. The clerkship director subsequently contacts the students andtheir ward teams directly to see if the violations are the result of the ward teams thenthese issues are addressed directly with them. If the violations are the result of neglect bythe students then this results in a deduction from their professionalism grade.Phase III Students:Curriculum Updates:- Dr. Wilson assumed role as DoIM Director of the Phase 3 Comprehensive AmbulatoryMedicine rotation- The MICU rotation at the VAMC was discontinued due to staffing changes.- PRIME sessions have been added for the Phase 3 students in order to provide feedbackmidway through their rotation.- Advising and Mentoring:- Annual Residency Advisement party for students interested in pursuing internal medicineas a career, hosted by Dr. Chang in June 2009.- Mentoring/advisement sessions are held with students interested in pursuing a career ininternal medicine by Clerkship and Residency director(s).- Clerkship director(s) will meet with medical students interested in Internal Medicinecategorical positions to write Departmental Letters in August 2009.- Dr. Betty Chang will interview medical students interested in Internal Medicine positionsand provide career advisement and encourage program selection in October 2009.Career choice of students:Match Year Number of graduating students choosing IM residencies2006 172007 122008 112009 11(Data reported by Dr. Eve Espey)- 12 UNM graduating medical students chose to begin their residency training in internalmedicine. Four are categorical and eight are preliminary year residents at UNM.Faculty Development initiatives:36

New Hospitalist orientation- The first Hospitalist orientation was piloted by three new faculty members on May 8,2009. The orientation included an overview of hospital history and organizationalstructure, clinical and educational expectations, a tour, and computer training. Theorientation was an all day event with brunch and lunch provided for participants.- A GroupWise shared folder was created with various types of information ranging fromCity of Albuquerque Rapid Ride schedules, UNM PopeJoy Hall ticket information, UNMLobo Card cash deposit handout, and much more. Due to popular demand, allHospitalists will be given access to the shared folder.- A Faculty Member’s Individual Record of Achievement binder was distributed, using thePromotion & Tenure checklist Dr. Wilson created, for each participant.- A resource handbook and faculty needs assessment survey was also designed. The needsassessment has been converted to an electronic format in an Opino secure database.- All Hospitalists have been given a Faculty Member’s Individual Record of Achievementbinder during the August 18, 2009 presentation on career development.- All Hospitalists have been given access to the New Faculty Resource InformationGroupWise shared folder.B. SIGNIFICANT PLANS FOR RECOMMENDATIONS FOR THE NEAR FUTUREUndergraduate Medical EducationPhase I:- New and improved initiative to track Educational Teaching Efforts for Phase I – II wasimplemented ensuring that the required departmental allocation of 306 weeks of serviceis met.Phase II Clerkship:- Transition to new leadership. Drs. Edward Fancovic and Deepti Rao replace Dr. ParsaShahinpoor in July 2009. Two positions were created from the Clerkship Directorposition: Clerkship Director and Associate Clerkship Director. Dr. Yvonne Dalton-Etheridge continues to be the VA Assistant Clerkship Director.- Post-discharge rounds – a new collaboration with Pharmacy to give students theopportunity to follow an inpatient back into the community.- Continue collaboration with other Phase II Clerkship Directors to improvestandardization across clerkships.- On-going evaluation of clerkship curriculum and orientation session for Phase II students.- Continue electronic monitoring of numbers and types of patients seen by students, andcontinue to develop a plan to ensure that all students meet the minimum clerkshipexpectations.- Continue to identify opportunities for direct observation of students, and provide facultytraining for this effort.Phase III:SUB-Internship37

- Dr. Deepti Rao will institute a new curriculum as a part of her Medical EducationScholars ES requirement by February 2010. The curriculum will include Bat Caveinteractive simulation teaching experiences including hands on procedural instruction, aswell as lectures on common topics and communication issues.Faculty Development Mentorship Program:- Hospitalist resource pocket book will be created and distributed by the next facultyorientation in October 2009.- New Faculty Nuts & Bolts Lecture Series to include teaching skills development andopportunities, research skills development and opportunities, planning for promotion, andMentorship. Develop a new Faculty Development web site.- The electronic needs assessment will be used to collect data for faculty development.C. APPOINTMENTS TO FACULTY/STAFFFaculty- Edward Fancovic, M.D., Phase II Clerkship Director as of July 09.- Deepti Rao, M.D., Associate Phase II Clerkship Director as of July 09.- Bronwyn Wilson, M.D., Assistant Dean o f Academic Affairs- Bronwyn Wilson, M.D., Director of required Phase III Comprehensive AmbulatoryMedicine rotationStaff- NoneD. SEPARATIONS OF FACULTY/STAFFFaculty- Parsa Shahinpoor, M.D.Staff- NoneE. PUBLICATIONS AND OTHER SCHOLARLY ACTIVITY OF THE DIVISIONBronwyn Wilson, M.D., Peggy Beeley, M.D., Ernestina Gomez, and Jennifer MontoyaAbstract poster presentation at the 2009 AAMC Group on Faculty Affairs ProfessionalDevelopment Conference in San Francisco, CA from August 7-9, 2009 on “Laying theGroundwork for Academic Success: A Pilot Faculty Development Program for New AcademicHospitalists ”.38

OFFICE OF RESEARCHOFFICE OF RESEARCHJULY 1, 2008 – JUNE 30, 200939

DAVID S. SCHADE, M.D., PROFESSOR AND DIRECTOR OF RESEARCHCHRISTINE PACHECO, SR. CONTRACT AND GRANT ADMINISTRATORA. SIGNIFICANT ACCOMPLISHMENTS AND DEVELOPMENTSThe Office of Research continues to support and encourage research by faculty of theDepartment of Internal Medicine (DoIM). The office also provides administrative support to theClinical and Translational Science Center (CTSC) formerly known as the General ClinicalResearch Center (GCRC). In addition, the Office of Research provides support to theDepartment Chair and the Departmental Administrators, especially in areas related to research.Key accomplishments and developments during the year follow:- NIH reports that total funding for the University of New Mexico Health Sciences Centerwas $51,715,084 in FY09, and the total funding for Internal Medicine was $20,385,157.Department of Internal Medicine had the highest percentage of funding from NIH forUNM at nearly 40%.- There were 59 faculty members that submitted 136 proposals, through the department,requesting almost $23 million of extramural funding.- There were 23 faculty members with appointments in the department that submitted 110roposals through the department, requesting over $26 million of extramural funding.- There were 35 different faculty members serving as Principal Investigators who received97 department awards totaling over $18 million made for projects submitted throughthdepartment.- There were 19 faculty members serving as Principal Investigators who received 61awards totaling over $13 million made for projects submitted through other departmentswithin the School of Medicine, including the Cancer, Research & Treatment Center, theCenter for Infectious Disease & Immunity, and the New Mexico Tumor Registry.- There were 11 faculty members’ servings as Principal Investigators, with appointments inthe Department, who applied for federal stimulus package funding through the AmericanRecovery and Reinvestment Act (ARRA). Total funding requested was $10,440,466. Todate, three of the faculty have received funding totaling $633,724. Drs. Edgar Boedekerreceived $187,500, Robert Hromas received $311,249, and D.J. Perkins received$134,975.- The Office of Research maintained the database of contract and grant applicationssubmitted and awards made, and produced needed reports as required.- There were four junior faculty members that successfully completed the CTSC/ECHOClinical Investigators’ Program during this fiscal year. The scholars that completed theprogram were Husam Abed, MD, from Obstetrics & Gynecology, Vlad Dinu Ianus, MD,from the Department of Pediatrics, Jennifer Taylor-Cousar, MD, from the Department ofInternal Medicine, and Tola B. Omotosho, MD, from the Department of Obstetrics &Gynecology. Unfortunately, there was one junior faculty member that had to drop due topersonal reasons.- Three new junior faculty members from two departments – Obstetrics & Gynecology (2)and Anesthesiology (1) – were recruited to fill vacancies in the CTSC/ECHO ClinicalInvestigators’ Program.40

- The CTSC/ECHO Clinical Investigators’ Program, under the auspices of the Office ofResearch, awarded a $10,000 grant to CTSC scholar, Julia Whitefield, MD, Departmentof Emergency Medicine, for her work on the ‘Predictability of Abnormal ECGs in thePediatric Population’.- The Office of Research provided $6,991 to support travel by five fellows and fiveresidents presenting ten abstracts at national and regional meetings including sixpresentations at the AFMR Western Division meetings at Carmel, CA in January 2009.- The Office of Research maintained the department’s inventory of (wet and dry)laboratory space and provided information for requests for lab space for new facultymembers.- The Office of Research provided financial incentives to the department’s members of theHuman Research Review Committee to attend a total of 47 meetings of this IRB.- A total of 97 awards, submitted through the department, were made to 35 facultymembers of the department as Principal Investigators of record. The distribution of thenumbers of proposals submitted and awards received by funding agency is shown inFigure 1 below.50Figure 1Proposals Submitted and Awards Receivedby Type of Funding Agency45403530ProposalsAwards2520151050Pharmaceutical & IndustrySponsorsNIHSubawards, Usually of NIHFundsOther Federal AgenciesState & Local GovernmentAgenciesFoundations & ProfessionalAssociations- A total of 110 proposals and 61 awards, submitted through the School of Medicine in theCancer, Research & Treatment Center, the Center for Infectious Disease & Immunity, orthe New Mexico Tumor Registry were made to 19 faculty members who have anappointment in the department and served as the Principal Investigator of record. SeeFigure 2 below.41

50Figure 2Proposals Submitted & Awards ReceivedThrough Other Departmentsby Faculty w/Appointments in DOIM454035ProposalsAwards302520151050Pharmaceutical & IndustrySponsorsNIHSubawards, Usually of NIHFundsOther Federal AgenciesState & Local GovernmentAgenciesFoundations & ProfessionalAssociations- As is evident, federal funding continues to be the principal source of extramural fundingfor the Department of Internal Medicine. Of the 136 proposals submitted in 2008-09, 54proposals (40%) directly requested federal funds totaling $14,815,638, almost 63% of allfunds requested. The bulk of these federal funds were requested from the NationalInstitutes of Health (NIH) — 44 proposals (32%) requested $11,974,587 (51% of allfunds requested). In addition, requests directly to NIH and other federal agencies facultyin the department submitted 32 proposals (24%) requesting $2,139,127 (9%) in the formof sub-awards. The agencies offering these sub-awards are generally themselves fundedby NIH or other federal agencies. Thus, requests for federal funds most likely account for63% of all funds requested and 52% of all funds received for projects with facultymembers of the Department of Internal Medicine as the Principal Investigator for theproject.- The primary sources of funding continues to be federal sources accounting forapproximately 81% of the funds received for projects with Principal Investigators whoare faculty members in the Department of Internal Medicine. The distribution by the typeof funding agency of the amounts requested in proposals and the amounts received inawards is shown in Figure 3 for faculty submitting through the department and Figure 4for department faculty who submitted through other School of Medicine departments.42

$14,000,000Figure 3Funds Requested & Awards Receivedby Type of Funding Agency$12,000,000$10,000,000ProposalsAwards$8,000,000$6,000,000$4,000,000$2,000,000$-Pharmaceutical &Industry SponsorsNIHSubawards, Usuallyof NIH FundsOther FederalAgenciesState & LocalGovernmentAgenciesFoundations &ProfessionalAssociations$25,000,000Figure 4Funds Requested & Awards ReceivedThrough Other Departmentsby Faculty w/Appointments in DOIM$20,000,000$15,000,000ProposalsAwards$10,000,000$5,000,000$-Pharmaceutical &Industry SponsorsNIHSubawards, Usually ofNIH FundsOther Federal AgenciesState & LocalGovernment AgenciesFoundations &ProfessionalAssociations- Of the 246 proposals submitted by faculty members of the department 136 proposalswith 59 faculty members as principal investigators were submitted through the43

Department of Internal Medicine. Of the remaining 110 proposals 90 were submittedthrough the Cancer Research and Treatment Center (CRTC); 9, through the Centerfor Infectious Disease and Immunity (CIDI); and 11, through the New Mexico TumorRegistry (NMTR). With the recent creation of the Center for Infectious Disease andImmunity (CIDI) the department’s single most prolific researcher in terms of bothproposals submitted and awards received began submitting proposals and receivingawards through CIDI rather than DoIM.- Of the 136 proposals submitted through the Department of Internal Medicine about98% were processed through the Office of Research. Figure 5 shows the number ofproposals processed through the Office of Research since the fiscal year 1999-2000(FY00). As can be seen, proposals processed through the Office of Research sincethat period has increased by 43%. The effect of the creation of the Center forInfectious Disease and Immunity (CIDI) is also evident. This alternative path forsubmission reduced proposals submitted through the Office of Research by about16%.200Figure 5Proposals Submitted Through theOffice of Research180160Number of Proposals140120100806040200FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009Fiscal YearThe Biomedical and Research Institute of New Mexico (BRINM) reported that DOIMfaculty did not receive grant funding for FY09. The Veterans Affairs Medical Center(VAMC) reports that there were four VA Merit Review Grants awarded to DOIM faculty thisyear, totaling $450,341. Faculty receiving funding included: Drs. Edgar Boedeker -$159,132, Samuel Lee - $150,000, Henry Lin - $90,000, and Richard Hoffman - $51,209.- Proposals processed by the Office of Research are reviewed to verify compliancewith the policies and procedures of UNM/HSC as well as those of the sponsoringagency. Principal Investigators are notified of errors and omissions and instructed torectify them before the proposal is forwarded to the HSC PreAward Office in theFinancial Services Division for final review prior to submission.44

- In FY09, Christine Pacheco provided substantial assistance to the department facultysubmitting proposals for funding including the faculty who successfully submittedelectronic proposals through Grants.gov. This assistance included preparation ofinternal and agency budgets and forms, liaison with the funding agency and proposedsub awardees of UNM, assistance with cost-share budgets, forms and approvals,preparation of Memoranda of Understanding, and other facets of applicationpreparation as appropriate.- To support its efforts to assist faculty members seeking and administering externalfunds the Office of Research keeps current on appropriate internal and externalopportunities, policies, and procedures. Toward this end, Ms. Pacheco, attendedmonthly meetings of the Research Administrator’s Network and the FinancialServices LEARN group, teleconferences conducted by the National Council ofUniversity Research Administrators, and attended the regional and national meetingsof the National Council of University Research Administrators (NCURA). She copresenteda welcome session to new members, co-presented a workshop on conflictresolution, and moderated a session at the NCURA Region VI/VII regional meetingin Santa Fe and attended the NCURA National Meeting in Washington, DC. Ms.Pacheco was one of ten participants nationally that participated in and graduated fromthe NCURA’s Leadership Development Institute. She has also contributed an articleto the February/March edition of the NCURA Magazine entitled, “Leadership Tips:Creating a Richer Life.” In addition, she was selected and is currently serving as theVolunteer Coordinator for NCURA’s Region VII.- Peer reviewed research proposals and awards play a significant role in thedepartment. In the year past, 33 faculty members of the department served asPrincipal Investigators on projects that received 8 peer-reviewed awards totaling$24,422,756.Awards with Peer-Reviewed Selection Received in FY09 withInternal Medicine Faculty Members as the Principal InvestigatorPI LastNamePI FirstNameSponsorAwarded toAssociatedDepartmentProject TitleAwardArora Sanjeev Robert WoodJohnson FoundationArora Sanjeev DHHS/Agency forHealthcare Researchand QualityInternalMedicineInternalMedicineA RobustParadigm toExpand BestPractice forVulnerablePopulations(ECHO)Expansion ofRural HealthCare ResearchInfrastructurethrough theECHO Model$4,996,512.00$500,000.0045

Bauman Julie New Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase II$40,625.00Bauman Julie New Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase II$16,660.00BerwickBerwickBoedekerBoedekerBoedekerBoedekerMarianne NIH/NationalCancer InstituteMarianne NIH/NationalCancer InstituteEdgarEdgarEdgarEdgarNIH/NationalInstitutes of HealthNIH/NationalInstitutes of HealthVeteransAdministrationMedical CenterVeteransAdministrationMedical CenterCrowell Richard VeteransAdministrationMedical CenterDurvasulaRaviNIH/NationalInstitutes of HealthCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineSolarExposure andMelanomaSurvivalSolarExposure andMelanomaSurvivalARRA - AnAttenuatedE.coliVaccine forEnterotoxigenic E.coli(ETEC)InterventionStrategies ofHemorrhagicColitis andHUSIPA - ErinOKeefeIPA - ErinOKeefeIPA -ChristopherZimaT. CruziMolecularTargets forVectorParatransgenesis$324,896.00$41,313.00$187,500.00$111,801.00$5,344.00$90,769.00$38,603.00$332,974.0046

DurvasulaRaviNIH/NationalInstitute of Allergyand InfectiousDiseasesFlores Kristina NIH/NationalCancer InstituteFlores Kristina NIH/NationalCancer InstituteGarcia David New Mexico CancerCare AllianceInternalMedicineCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCT.CruziMolecularTargets forVectorParatransgenesisFolateMetabolism &Methylationin LungCancerFolateMetabolism &Methylationin LungCancerClinical TrialPhase II$36,996.00$136,894.00$136,894.00$75,746.00Garcia David New Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase III$39,800.00Gonzales MelissaSociety forMelanoma ResearchCancerResearchTreatmentCtr CRTCAdministrative Support$12,648.00Gonzales Melissa NIH/NationalInstitute ofEnvironmentalHealth SciencesHoffman Richard New MexicoMedical SocietyInternalMedicineCancerResearchTreatmentCtr CRTCGeneenvironmentCancer Risksin MelanomaColorectalCancerScreeningSurvey$120,232.00$7,000.00Hoffman Richard Foundation forInformed MedicalDecision MakingInternalMedicineMedicalEditor$23,655.00Hromas Robert NIH/National Heart,Lung, and BloodInstituteCancerResearchTreatmentCtr CRTCTheTransposaseProteinMetnase in$375,000.0047

LeukemicDecatenationHromas Robert NIH/NationalInstitutes of HealthHromas Robert NIH/National Heart,Lung, and BloodInstituteHromas Robert NIH/NationalCancer InstituteJones Dennie New Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCInternalMedicineCancerResearchTreatmentCtr CRTCARRATransposaseProteinMetnase inEtoposideResistanceTransposaseProteinMetnase inLeukemicDecatenationThe Role ofMetnase inReplicationStressClinical TrialPhase II$311,249.00$375,000.00$26,839.00$74,223.00Kesler Denece HRSA-HealthResources andServicesAdministrationKesler Denece HRSA-HealthResources andServicesAdministrationLee Fa-Chyi New Mexico CancerCare AllianceInternalMedicineInternalMedicineCancerResearchTreatmentCtr CRTCRadiationExposureScreening andEducationProgram(RESEP)RadiationExposureScreening andEducationProgram(RESEP)Clinical TrialPhase I$198,000.00$4,900.00$28,756.00Libby Edward National MarrowDonor ProgramCancerResearchTreatmentCtr CRTCStem CellTherapeuticOutcomes$45,516.0048

Libby Edward New Mexico CancerCare AllianceLyons Clifford NIH/NationalInstitutes of HealthLyons Clifford NIH/NationalInstitute of Allergyand InfectiousDiseasesMa Thomas NIH/NationalInstitute of Diabetesand Digestive andKidney DiseasesMertz Gregory NIH/NationalInstitutes of HealthMertz Gregory NIH/NationalInstitutes of HealthMertz Gregory NIH/NationalInstitutes of HealthMunk Robert J. NIH/NationalLibrary of MedicineCancerResearchTreatmentCtr CRTCCenter forInfectiousDisease andImmunityCenter forInfectiousDisease andImmunityInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineClinical TrialPhase III$105,783.00Pulmonary $2,769,297.00Responses toBioweaponCategory APathogensPulmonary $2,848,174.00Responses toBioweaponCategory APathogensInterleukin-1 $360,000.00BetaModulation ofIntestinalTight JunctionBarrierTraining in $17,866.00HantavirusEcology,Virology &ClinicalInvestigationin theAmericasTraining in $123,856.00HantavirusEcology,Virology, andClinicalInvestigationin theAmericasHantavirus $951,433.00Ecology andDisease inChile andPanamaAIDS InfoNet $57,046.0049

Myers Orrin Vaccine-AssociatedFeline SarcomaTask ForceInternalMedicineVallesCalderaStatisticalSupport$15,395.00Myers Orrin VeteransAdministrationMedical CenterPatt Yehuda New Mexico CancerCare AllianceInternalMedicineCancerResearchTreatmentCtr CRTCIPA/OrrinMyersClinical TrialPhase II$3,492.00$27,704.00Perkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthPerkins Douglas NIH/NationalInstitutes of HealthInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineTraining andResearch onSevereMalarialAnemiaGenetic Basisof SevereMalarialAnemiaARRA -UNMFrameworkProgram inGlobal HealthTraining andResearch onSeveralMalarialAnemiaTraining andResearch onSevereMalarialAnemiaGenetic Basisof SevereMalarialAnemiaGenetic Basisof SevereMalarialAnemia$129,342.00$579,613.00$134,975.00$12,375.00$129,342.00$495,677.00$81,908.0050

Perkins Douglas NIH/NationalInstitutes of HealthRaizada Veena The Mind ResearchNetworkInternalMedicineInternalMedicineTraining and $86,929.00Research onSevereMalarialAnemiaEKG Reading $3,300.00Raj Dominic Satellite Research InternalMedicineRaj Dominic NIH/NationalInstitutes of HealthRavindranathanMeeraNew Mexico CancerCare AllianceRoldan Carlos NIH/NationalInstitutes of HealthRoyce Melanie American CancerSocietyRoyce Melanie New Mexico CancerCare AllianceRoyce Melanie New Mexico CancerCare AllianceInternalMedicineCancerResearchTreatmentCtr CRTCInternalMedicineCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCCancerResearchTreatmentCtr CRTCCytokinesActivationand ProteinCatabolism inESRDCytokineGenePolymorphism in CRICClinical TrialPhase IIILibman-SacksEndocarditisAppointReminders forBreast CancerPatients inDiverse,UnderservedAreas of NewMexicoClinical TrialPhase IIClinical TrialPhase III$50,000.00$407,244.00$11,112.00$518,903.00$10,000.00$46,950.00$8,800.0051

Schade David American DiabetesAssociation IncSchade David NIH/NationalInstitute of Diabetesand Digestive andKidney DiseasesServilla Karen VeteransAdministrationMedical CenterTaylor-CousarTaylor-CousarJenniferJenniferCystic FibrosisFoundationCystic FibrosisFoundationInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineTheImportance ofInsulinTiming inType IDiabetesDiabetesPreventionProgramOutcomesStudy(DPPOS)IPA - CharlesMcQuadeTherapeuticDevelopmentNetwork(TDN)ExpansionCF CareCenter$200,000.00$523,500.00$45,328.00$64,800.00$28,915.00Taylor-CousarJenniferCystic FibrosisFoundationInternalMedicineClinicalResearchFacilitationAward$5,400.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase III$9,979.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase I$25,825.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase I$81,549.0052

VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase I & II$98,074.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase II$113,983.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase III$91,330.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase I$26,678.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase III$82,825.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase II$25,958.00VerschraegenClaireNew Mexico CancerCare AllianceCancerResearchTreatmentCtr CRTCClinical TrialPhase II$53,676.00VerschraegenClaireNIH/NationalCancer InstituteWiggins Charles NIH/NationalCancer InstituteCancerResearchTreatmentCtr CRTCCRTC NewMexicoTumorRegistryNMTRNew MexicoMinority-BasedCommunityClinicalOncologyProgramAlaska/Cherokee NationSupplement toSEER$100,001.00$19,223.0053

Wiggins Charles NIH/NationalCancer InstituteWiggins Charles NIH/NationalCancer InstituteWiggins Charles NIH/NationalCancer InstituteWiggins Charles NIH/NationalCancer InstituteWiggins Charles DHHS-IndianHealth ServiceWiggins Charles Department ofJusticeWilliams S BruceWilliams S BruceHRSA-HealthResources andServicesAdministrationHRSA-HealthResources andServicesAdministrationCRTC NewMexicoTumorRegistryNMTRCRTC NewMexicoTumorRegistryNMTRCRTC NewMexicoTumorRegistryNMTRCRTC NewMexicoTumorRegistryNMTRCRTC NewMexicoTumorRegistryNMTRCRTC NewMexicoTumorRegistryNMTRInternalMedicineInternalMedicineSEER Health,Eating,Activity andLifestyleStudy(HEAL)SEERPatterns ofCare,DiagnosisYear 2007Surveillance,Epidemiologyand EndResults -CORESurveillance,Epidemiologyand EndResults –COREAssociationBetweenDiabetesMellitus andColorectalCancerRadiationExposureCompensationProgramRyan WhiteTitle IV:CoordinatedHIV Servicesfor Women &FamiliesOngoingExpansionFunds forCurrent PartD and Part DYouth ServiceInitiativeGrantees$88,382.00$25,252.00$1,520,251.00$1,300,000.00$102,986.00$2,000.00$333,817.00$34,666.0054

Williams S BruceWilliams S BruceHRSA-HealthResources andServicesAdministrationHRSA-HIV-AIDSBureauInternalMedicineInternalMedicineRyan White $349,778.00Program PartC: HIV EarlyInterventionServicesRyan White $365,719.00Part C:OutpatientEIS ProgramTotal $24,422,756.00- In addition, 13 faculty members of the Department of Internal Medicine serve asPrincipal Investigators of the following 27 sub-awards that received funding totaling$2,140,335 from institutions that received primary awards as a result of a peer-reviewapplication process. These primary awards are most likely awards from the NIH.Sub-Awards Received in FY09 from Primary Awardees Funded through Peer-ReviewedApplications with Internal Medicine Faculty Members as the Principal InvestigatorPI LastNamePI FirstNameSponsorAwarded toAssociatedDepartmentProject TitleAwardBerwick Marianne University ofMinnesotaBerwick Marianne Penrose-St.Francis HealthServicesCrowell Richard LovelaceRespiratoryResearchInstituteFlores Kristina AlbuquerqueArea IndianHealth Board,Inc.Hill Deirdre MassachusettsGeneralHospitalCancerResearchTreatment CtrCRTCCancerResearchTreatment CtrCRTCInternalMedicineCancerResearchTreatment CtrCRTCCancerResearchTreatment CtrCRTCIndoor TanningUse, DNARepair and Riskof MelanomaNM Partnershipwith RockyMountain CISRisk Factors forEpigeneticSilencing ofLung CancerGenesTribalCommunityCancer ControlProjectCancer GeneticsNetwork$138,411.00$122,354.00$268,171.00$107,876.00$76,782.0055

Hoffman Richard University ofSouthernCaliforniaKing Irena FredHutchinsonCancerResearch CenterKing Irena FredHutchinsonCancerResearch CenterKing Irena FredHutchinsonCancerResearch CenterKing Irena FredHutchinsonCancerResearch CenterKing Irena FredHutchinsonCancerResearch CenterKing Irena University ofWashingtonLyons Clifford University ofTexas HSCHoustonLyons Clifford University ofNevada at RenoCancerResearchTreatment CtrCRTCInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineInternalMedicineCenter forInfectiousDisease andImmunityCenter forInfectiousDisease andProstateSpecificAntigenPractices andOutcomes in theElderlyMechanisms ofEnergy Balanceand CancerPrevention(TREC project5)EnhancingLong-Term 5-a-Day BehaviorChange inWorksitesA ProspectiveStudy onSelenium,Genetics ofSlenoenymes,and ColorectalCancerReducingObesity at theWorkplace: ARandomizedTrialTRECCoordinationCenterHuman GeneticVariations inFatty AcidMetabolism andSudden CardiacArrestAnthraxVirulanceFactorsB. Anthracis:PassiveImmunization$82,336.00$8,252.00$11,232.00$12,479.00$11,232.00$20,702.00$80,348.00$61,601.00$160,979.0056

Lyons Clifford ColeyPharmaceuticalGroupLyons Clifford LovelaceBiomedical &EnvironmentalResearchInstituteLyons Clifford University ofTexas HSCHoustonPerkins Douglas University ofCalifornia,IrvineSchade David Case WesternReserveUniversitySchade David University ofSouth FloridaImmunityCenter forInfectiousDisease andImmunityCenter forInfectiousDisease andImmunityCenter forInfectiousDisease andImmunityInternalMedicineInternalMedicineInternalMedicinewithAnticapsularAntibodiesDiscovery andDevelopment ofNovel TLR 7and TLR 9Feasibility ofToxinNeutralizingAgents,Vaccines, andAntibioticsAnthraxVirulanceFactorsEcology ofAfricanHighlandMalariaEpidemiologyof DiabetesIntervention andComplications(EDIC)Type 1 DiabetesTrialNet$209,467.00$159,212.00$61,600.00$7,365.00$142,394.00$10,000.00Stidley Christine LovelaceBiomedical &EnvironmentalResearchInstituteStidley Christine LovelaceRespiratoryResearchInstituteStidley Christine LovelaceRespiratoryResearchInstituteInternalMedicineInternalMedicineInternalMedicineGenetic andEpigeneticBiomarkers ofSquamous CellCarcinoma ofthe LungValidation ofPan-SpeciesELISAs toDetectAntibodies toF1 and VAntigensStatisticalSupport forLung CancerPrograms$17,432.00$31,240.00$41,701.0057

Thomas Elaine University ofColoradoHealth SciencesCenterThomas Elaine University ofColoradoHealth SciencesCenterThornton Karla AlbuquerqueHealthcare forthe HomelessIncWiggins Charles University ofLouisvilleInternalMedicineInternalMedicineInternalMedicineCRTC NewMexico TumorRegistry NMTRNew MexicoAIDSEducation andTraining CenterNM AIDSEducation andTraining Center$220,618.00$6,000.00Evaluation $69,876.00Services andTreatment forthe HomelessEthnicity,$675.00Breast CancerRecurrence &Long-TermQuality of LifeTotal $2,140,335.00- During FY09, the largest source of extramural funding for Investigators in theDepartment of Internal Medicine consisted of awards from the National Institutes ofHealth. NIH made 37 awards totaling $15,798,177 for projects with department facultymembers as the Principal Investigator or Project Director. These awards were 23% of theawards received and provided 50% of the extramural funds supporting projects withmembers in the department as the Principal Investigator or Project Director.- The second largest source of support in FY09 was from pharmaceutical companies andother industry sources. Thirty-eight industry sponsors provided a total of $2,613,148 inextramural support. These contracts provided 24% of the awards and 8% of the fundssupporting projects with department faculty members as the Principal Investigator orProject Director.- During FY09, contracts with state and local government agencies provided faculty, withappointments in the department, the third largest source of extramural funding. Eightcontracts with state and local agencies provided a total of $2,269,470, which constituted7.2% of extramural support.- The fourth largest source of support was from subawards. Twenty-seven subawardsprovide a total of $2,130,335 in extramural support. These subawards provided 17% ofthe awards and 6.8% of the funds supporting projects with department faculty membersand the Principal Investigator or Project Director. Subawards to the department arealmost invariably made by institution with a primary award from NIH or another federalagency such as HRSA or AHRQ.- Other federal agencies include HRSA and AHRQ. In FY09, department faculty wereawarded a total of 14 awards that provided a total of $2,075,402 in extramural support.This funding provided 9% of the awards and 6.6% of the funds supporting projects forfaculty with assignments in the department.- On the assumption that subawards pass through federal funds combining NIH awards,subawards, and direct awards of other federal funds shows that 49% of the awards and58

64% of the support for projects in the Department of Internal Medicine are federal inorigin.- As shown in Figure 6, both the requested and awarded F&A for proposals applied for byfaculty through the department appears to be on the rise in FY09. With an 18% increasefrom last year in requested F&A and a 30% increase from last year in awarded F&Adollars.$8,000,000Figure 6Facilities & Administrative Costs (F&A)Requested/Awarded to DOIM$7,000,000$6,000,000Requested DOIMAwarded DOIM$5,000,000$4,000,000$3,000,000$2,000,000$1,000,000$0FY04 FY05 FY06 FY07 FY08 FY09- The Office of Research maintained its database of contract and grant applicationssubmitted by, and awards made to, faculty members of the department. Reports ofactivity were periodically provided to the department’s Chair, Administrator, andDivision Chiefs. Other reports were provided as requested by the department’s Chair,Administrator, or faculty members.- The Office of Research’s Contract and Grant Administrator, Ms. Pacheco monitoreddata posted by NIH. NIH’s posting of awards made was periodically checked againstinstitutional data to ensure the accuracy of the data reported by NIH. As any errorswere detected, corrections were sent to NIH and the data monitored to ensure thatthese corrections were properly entered.- The CTSC/ECHO Clinical Investigators’ Program, under the auspices of the Office ofResearch, has recently made available a Large Grant for Research of up to $10,000 tofaculty investigators. These grants can be used to jump-start research projects forjunior faculty who are participating in the CTSC/ECHO Clinical Investigators’59

Program. The award can be utilized for grant writing expenses; expenses associatedwith research projects conducted by the faculty member, a resident, or a student, or toenhance the research infrastructure of the department. During the past fiscal year,$10,000 was awarded to Dr. Julia Whitefield, from the Department of EmergencyMedicine, to offset her research project in the area of ‘Predictability of AbnormalECGs in the Pediatric Population’.- During FY09, the Office of Research provided partial support for five fellows andfive residents to present ten abstracts at regional or national meetings. Travel grantsof up to $1,000 were made to these fellows and residents. The fellows were Drs. LinaE. Aguirre (Endocrinology), Stephen M. Mitchell (Endocrinology), David Podolsky(Endocrinology), Frank Ralls (Pulmonary/Critical Care), and Zhi Qiao(Endocrinology). The resident awards were made to Dr. Shadi Imra Battah(Pulmonary/Critical Care), Alex Eshaghian (Internal Medicine), Kye Park(Immunology and Rheumatology), Nitesh B. Vachhani (Gastroenterology), AudreyGail Wells (Pulmonary/Sleep Disorder Center). Fellows presented four abstracts andresidents presented three abstracts at the AFMR Western Division Meetings inCarmel, CA. The residents awarded presented three abstracts at the AmericanThoracic Society conference in San Diego, the American Academy of Dermatologyin San Francisco, and the Annual Scientific Meeting of the American GeriatricsSociety in Chicago. The Office of Research provided a total of $6,991 to supporttravel to these meetings.- The Office of Research cooperates with the Clinical Trials Center in providingclinical trials service for the faculty of the Department of Internal Medicine. Duringthe past year, usage by the department’s faculty accounted for 95% of the ClinicalTrials Center’s activity. In FY09, there were eleven faculty that utilized the Center.- The Office of Research supports the Clinical and Translational Science Center(CTSC)—formerly known as the General Clinical Research Center (GCRC) byproviding administrative support to the CTSC and conducts the CTSC ClinicalInvestigators’ Program—formerly known as the GCRC Scholars’ Program. Duringthis year, the Office of Research’s Sr. Contract and Grant Administrator, ChristinePacheco, recorded the minutes of the monthly meetings of the CTSC AdvisoryCommittee. Drafts of the minutes were distributed to members of the committee forcomment and the amended draft was presented for formal approval at the nextmeeting of the CTSC Advisory Committee.- The Office of Research conducts the CTSC/ECHO Clinical Investigators’ Program—formerly known as the GCRC Scholar’s Program—that continues to provide excellentopportunities for scholars to enhance their clinical research skills under the directionof experienced clinical researchers and staff expert in areas related to conductingresearch and presenting the findings. During FY09, 12 scholars were active in theCTSC/ECHO Clinical Investigators’ Program. These junior researchers were drawnfrom a broad range of departments of the Health Sciences Center—Department ofAnesthesiology, Department of Emergency Medicine, Department of InternalMedicine, Department of Obstetrics and Gynecology, Department of Pediatrics,Department of Surgery, the Library and Informatics Center. The Office of Researchadministratively supports the program by scheduling monthly meetings, processing60

eimbursements to the participating mentors, and managing the grant selectionprocess.- During FY09, four investigators successfully completed the program and oneparticipant withdrew because of other commitments. Two junior faculty memberswere recruited to fill the vacancies in the program. These new investigators camefrom the departments of Obstetrics and Gynecology and the Library and InformaticsCenter. At the end of FY09, 8 scholars were active in the program.- The value of the CTSC/ECHO Clinical Investigators’ Program is evidenced by thefact that since entering the program, participating young investigators have succeededin securing funding to support their projects and in publishing their results. Dr.Jennifer Taylor-Cousar, a recent graduate of the program in the Department ofInternal Medicine, recently received the 2009 Cystic Fibrosis Research, Inc. (CFRI)Professional of the Year Award. The award recognizes her dedication in providingand directing a Cystic Fibrosis (CF) Center at UNMH, the only CF center in the state.During the past fiscal year, 2 active scholars and graduates of the program received10 awards of extramural funds totaling $119,118 to support their projects. Thisbrings the total amount of extramural funding received, by 59 total fundedparticipants in the program, to just over $17 million since the program began elevenyears ago.- Both the number of scholars with publications and the average number ofpublications per scholar increased dramatically after the scholars entered the CTSCClinical Investigators’ Program. Though 2006—the last year for which data isavailable—prior to entering the program, 19 of the participants had a total of 86publications; 59 scholars had no publications. After beginning the program, 47 of the78 scholars have published a total of 362 publications. The number of publishedscholars more than doubled and the average number of publications per publishedscholar increased from 4.5 to 10.6.- The above information on the funding and publications of participants in theCTSC/ECHO Clinical Investigators’ Program provides clear evidence of theprogram’s success. However, that information only includes information on theprogram participants who have remained at the University of New Mexico. It doesnot include information on the 29 graduates who left the University for positionselsewhere. Many of whom took research oriented positions at other universities. Thetrue impact of the program is likely much greater.- Dr. David S. Schade, Director of the Office of Research, developed and oversees theCTSC/ECHO Clinical Investigators’ Program. Mentors in the program provide directone-on-one consultation for the junior investigators as they develop and refine theirskills as clinical researchers. Mentors currently active in the program are Mark R.Burge, M.D., Philip Kroth, M.D, Robin Ohls, M.D., Rebecca Rogers, M.D, David S.Schade, M.D., and Mark R. Schuyler, M.D. Support for the monthly dinner meetingsof the CTSC/ECHO Clinical Investigators’ Program is provided by the Dean of theSchool of Medicine. Support for other program expenses for each scholar is providedby the scholar’s department, college, or school.- Beginning in June 2000, the department started providing financial incentives to itsrepresentatives on the Human Research Review Committee to attend these committeemeetings to review protocols involving research on human subjects. During this year,61

the Office of Research monitored attendance by the department’s representatives andrequested reimbursement when the faculty member had attended at least fivemeetings of this IRB. During FY09, five faculty members received incentives forattending a total of 47 HRRC meetings.- Through the use of bulletin boards and e-mail notices, the Office of Research keepsfaculty and staff apprised of new developments in the Office of Research, the Pre-Award Office, other HSC offices, and NIH and other funding agencies. The officealso disseminates information on new opportunities to obtain funds from sourcesoutside the University of New Mexico. Faculty members are encouraged to discussany difficulties or obstacles they face when conducting research activities. Thisallows the Office to act as a liaison between the HSC Pre-Award Office, the FinancialServices Division, other faculty, and staff to facilitate the progress of thedepartment’s research activity.B. PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURE- Continue to assist faculty and administrative staff with federal electronicsubmission via Grants.gov.- Keep current with University and agency policies and procedures affectingresearch and funding by attending meetings of the Research AdministratorsNetwork, the National Council of University Research Administrators, and theNational Institutes of Health.- Inform departmental faculty and staff of changes in policies and proceduresaffecting both conducting research and securing funds to support it.- Monitor research activities—contract and grant proposals and awards— bydivision and -report the results to the department’s chair, administrator, anddivision chiefs.C. APPOINTMENTS TO FACULTY AND STAFF- NONED. SEPARATIONS FROM FACULTY AND STAFF- NONEE. PUBLICATIONS- Not applicableF. OUTSIDE PROFESSIONAL ACTIVITIES OF STAFF MEMBERS- Christine Pacheco graduated from the National Council of Research Administrators –Leadership Development Institute in November of 2008. Ms. Pacheco was one of 10national participants selected to this year’s class.- Ms. Pacheco contributed to the February/March 2009 edition of the NCURAMagazine with an article entitled, “Leadership Tips: Creating a Richer Life.”- Ms. Pacheco attended the NCURA National Meeting in Washington, DC.- Ms. Pacheco was also selected as the NCURA Region VII’s Volunteer Coordinator.62

- Ms. Pacheco attended and co-presented a welcome session to new members to theorganization, co-presented a workshop on conflict resolution and moderated adiscussion group at the NCURA Region VI/VII annual meeting in Santa Fe.G. OUTSIDE SPONSORED RESEARCH- Not applicable63

FACULTY LIST2008-200964

INTERNAL MEDICINE FACULTY ROSTER FOR FY 2008-09Last Name First Name Degree Rank DivisionAbeyta William M.D. Associate Professor General MedicineAbrams Jonathan M.D. Professor Emeritus CardiologyAdolphe Allen M.D., PhD. Professor General MedicineAlexander Warren M.D. Assistant Professor Hematology/OncologyAnthony Paul M.D. Associate Professor Hematology/OncologyArndell Cynthia M.D. Assistant Professor General MedicineArora Madhu M.D. Assistant Professor General MedicineArora Sanjeev M.D. Professor GastroenterologyBankhurst Arthur M.D. Professor RheumatologyBarakat Jehad M.D. Assistant Professor GastroenterologyBarnett Peter M.D. Assistant Professor General MedicineBauman Julie M.D. Assistant Professor Hematology/OncologyBeck Amanda M.D., Ph.D. Associate Professor GerontologyBeeley Peggy M.D. Associate Professor General MedicineBennahum David M.D. Professor Emeritus GerontologyBerle Lisa M.D. Assistant Professor Hematology/OncologyBerwick Marianne Ph.D. Professor EpidemiologyBigney Jessica M.D. Professor General MedicineBlanchard Janet M.D. Assistant Professor General MedicineBoedeker Edgar M.D. Professor GastroenterologyBoivin Michel M.D. Assistant Professor Pulmonary/CCBoyle Patrick M.D. Professor General MedicineBrown Lee M.D. Professor Pulmonary/CCBroyles Julie M.D. Associate Professor General Medicine65

Buchwald David M.D. Visiting AssistantProfessorNephrologyBurge Mark M.D. Professor EndocrinologyBurgos Marcos M.D. Assistant Professor Infectious DiseaseBusby Helen M.D. Associate Professor Pulmonary/CCByrd, III Thomas M.D. Professor Infectious DiseaseCasey Kenneth M.D., MPH Associate Professor Pulmonary/CCChadha Amandeep M.D. Assistant Professor General MedicineChang Betty M.D. Associate Professor Pulmonary/CCCharlton Gerald M.D. Associate Professor CardiologyCohen Jason M.D. Assistant Professor General MedicineColleran Kathleen M.D. Associate Professor EndocrinologyComerci George M.D. Associate Professor General MedicineCook Linda Ph.D. Associate Professor EpidemiologyCosgrove Ellen M.D. Professor General MedicineCrowell Richard M.D. Professor Pulmonary/CCDahl Richard Ph.D. Research AssistantProfessorHematology/OncologyDalton-E. Yvonne M.D. Assistant Professor General MedicineDavis Dana M.D. Associate Professor General MedicineDayao Zoneddy M.D. Assistant Professor Hematology/OncologyDokladny Karol Ph.D. Research AssistantProfessorGastroenterologyDorin Richard M.D. Professor EndocrinologyDuclos Terry M.D., Ph.D. Professor RheumatologyDunkelberg Jeffrey M.D. Associate Professor GastroenterologyDurvasula Ravi M.D. Associate Professor Infectious DiseaseEaton Phillip M.D. Professor Emeritus Endocrinology66

Edwards Kevin M.D. Associate Professor General MedicineEmil Nicole M.D. Assistant Professor General MedicineFancovic Edward M.D. Associate Professor General MedicineFleming Holly M.D. Assistant Professor General MedicineFlores Kristina Ph.D. Research AssistantProfessorEpidemiologyFotieo Dana M.D. Associate Professor General MedicineFotieo Gregory M.D. Professor General MedicineFritch Robert M.D. Assistant Professor General MedicineGarcia David M.D. Associate Professor General MedicineGateley Ann M.D. Professor General MedicineGerety Meghan M.D. Professor Infectious DiseasesGerstein Wendy M.D. Assistant Professor General MedicineGibb James M.D. Visiting Asst Professor NephrologyGoade Diane M.D. Associate Professor Infectious DiseaseGonzales Melissa Ph.D. Associate Professor EpidemiologyGonzales David M.D. Professor General MedicineGul Ambreen M.D. Assistant Professor NephrologyHarford Antonia M.D. Professor NephrologyHarji Farzana M.D. Assistant Professor General MedicineHarkins Michelle M.D. Associate Professor Pulmonary/CCHashimoto Frederick M.D. Professor Emeritus General MedicineHerman Carla M.D., MPH Professor GerontologyHill Deirdre Ph.D. Assistant Professor EpidemiologyHoffman Richard M.D., MPH Professor EpidemiologyHorowitz Bruce M.D. Professor General MedicineHromas Robert M.D. Professor Hematology/Oncology67

Iandiorio Michelle M.D. Assistant Professor Infectious DiseaseIcenogle Milton M.D. Associate Professor CardiologyInbar Shmuel M.D. Associate Professor CardiologyIwamoto Gary M.D. Professor Pulmonary/CCJernigan Jennifer M.D. Associate Professor General MedicineJing Tong M.D. Assistant Professor GastroenterologyJones, Jr Dennie M.D. Associate Professor Hematology/OncologyJutila Charlotte M.D. Assistant Professor CardiologyKang Huining Ph.D. Research AssistantProfessorEpidemiologyKapsner Curtis M.D. Professor General MedicineKapsner Patricia M.D. Associate Professor EndocrinologyKellie Susan M.D. Associate Professor Infectious DiseaseKesler Denece M.D., MPH Associate Professor EpidemiologyKhan Mirkutub M.D. Professor Hematology/OncologyKing Irena Ph.D. Research Professor EpidemiologyKistin Martin M.D. Associate Professor GastroenterologyKitzes Judith M.D., MPH Research AssociateProfessorGerontologyKlepper Diane M.D. Professor Emeritus Pulmonary/CCKnoefel Janice M.D., MPH Professor GerontologyKonstantinov Konstantin M.D. Associate Professor RheumatologyKonstantinova Teodora M.D. Assistant Professor General MedicineKraai Erik M.D. Assistant Professor General MedicineKrokos Irene M.D. Assistant Professor General MedicineLaskey Warren M.D. Professor CardiologyLauer Richard M.D. Professor Hematology/OncologyLee Fa-Chyi M.D. Associate Professor Hematology/Oncology68

Lee Samuel M.D. Assistant Professor Infectious DiseasesLee Sang-Joon Ph.D. Assistant Professor EpidemiologyLeverence Robert M.D. Associate Professor General MedicineLibby Edward M.D. Associate Professor Hematology/OncologyLieberman Margaret M.D. Assistant Professor General MedicineLin Henry M.D. Professor GastroenterologyLindeman Robert M.D. Professor Emeritus GerontologyLovchik Julie Ph.D. Research AssistantProfessorHematology/OncologyLyons Clifford R. M.D. Professor Hematology/OncologyMa Thomas M.D., Ph.D. Professor GastroenterologyMacias Carlos M.D. Assistant Professor General MedicineMangalik Aroop M.D. Professor Hematology/OncologyMarr Lisa M.D. Associate Professor GerontologyMartinez Melissa M.D. Associate Professor General MedicineMcCarthy Denis M.D. Professor GastroenterologyMcGuire Elizabeth M.D. Associate Professor Hematology/OncologyMertz Gregory M.D. Professor Infectious DiseaseMontgomery Lorene M.D. Assistant Professor General MedicineMorrison Ann M.D. Associate Professor General MedicineMoseley Pope M.D. Professor Pulmonary/CCMunk Robert Ph.D. Research AssistantProfessorInfectious DiseaseMurata Glen M.D. Professor EpidemiologyMyers Orrin Ph.D. Research AssistantProfessorEpidemiologyNeale Devon M.D. Assistant Professor GerontologyNoronha Leonard M.D. Assistant Professor General Medicine69

Olson, Jr. David M.D. Assistant Professor General MedicineOnime Aideloje M.D. Assistant Professor NephrologyOsborn Larry M.D. Professor CardiologyOsman Farid M.D. Assistant Professor NephrologyParasher Gulshan M.D. Assistant Professor GastroenterologyParker Donna Jean M.D. Assistant Professor GerontologyPatt Yehuda M.D. Professor Hematology/OncologyPentecost Percy M.D. Assistant Professor General MedicinePerkins Douglas Ph.D. Associate Professor Infectious DiseasesPetersen Emily M.D. Assistant Professor General MedicinePierce Ruch M.D. Associate Professor General MedicinePrasad Arti M.D. Professor General MedicineQaseem Sandra M.D. Assistant Professor GerontologyRabinowitz Ian M.D. Associate Professor Hematology/OncologyRaizada Veena M.D. Professor CardiologyRaj Dominic M.D. Associate Professor NephrologyRao Deepti M.D. Assistant Professor General MedicineRasila Kanwaldeep M.D. Assistant Professor Hematology/OncologyRatliff D. Michelle M.D. Assistant Professor CardiologyRavindranathan Meera M.D. Assistant Professor Hematology/OncologyRicciardi Mark M.D. Associate Professor CardiologyRogers Kendall M.D. Assistant Professor General MedicineRohrscheib Mark M.D. Assistant Professor NephrologyRoldan Carlos M.D. Professor CardiologyRoyce Melanie M.D., Ph.D. Associate Professor Hematology/OncologyRushton John Ph.D. Research AssistantProfessorHematology/Oncology70

Saiki John M.D. Professor Emeritus Hematology/OncologySalehi Pejvak M.D. Visiting AssistantProfessorGeneral MedicineScaletti Joseph Ph.D. Professor Emeritus Infectious DiseaseSchade David M.D. Professor EndocrinologySchroeder Thomas M.D. Assistant Professor Hematology/OncologySchuyler Mark M.D. Professor Pulmonary/CCServilla Karen M.D. Associate Professor NephrologyShaheen Montaser M.D. Assistant Professor Hematology/OncologyShahinpoor Parsa M.D. Assistant Professor General MedicineSheldon Mark M.D. Assistant Professor CardiologySibbitt Wilmer M.D. Professor RheumatologySiddiqui Mohammad M.D. Assistant Professor GeriatricsSierra Julie M.D. Assistant Professor General MedicineSimpson Anne M.D. Associate Professor GerontologySimson J. Mitchell M.D. Assistant Professor General MedicineSood Akshay M.D., MPH Associate Professor Pulmonary/CCSpalding Charles M.D. Visiting Professor NephrologySpector Monroe M.D. Professor Emeritus GastroenterologyStidley Christine Ph.D. Associate Professor EpidemiologyStone Eric M.D. Assistant Professor GastroenterologyStrickland Robert M.D. Professor Emeritus GastroenterologySun Yijuan M.D. Assistant Professor NephrologyTancik Corey M.D. Professor Infectious DiseaseTarnower Amy M.D. Associate Professor Hematology/OncologyTaylor Robert M.D. Associate Professor CardiologyTaylor-Cousar Jennifer M.D. Assistant Professor Pulmonary/CC71

Thomas Elaine M.D. Professor Infectious DiseaseThompson William M.D. Associate Professor Hematology/OncologyThornton Karla M.D., MPH Associate Professor Infectious DiseaseTimm T. M.D. Professor CardiologyTzamaloukas Antonios M.D. Professor NephrologyUpson Dona M.D. Associate Professor Pulmonary/CCVerschraegen Claire M.D. Professor Hematology/OncologyVoss Carolyn M.D. Professor General MedicineWagner Phillip M.D. Assistant Professor EpidemiologyWharton Walker Ph.D. Research AssociateProfessorPulmonary/CriticalCareWiggins Charles Ph.D. Assistant Professor EpidemiologyWilliams S. Bruce M.D., MPH Professor Infectious DiseaseWilliamson Elizabeth Ph.D. Research Asst Professor Hematology/OncologyWilson Bronwyn M.D., MPH Professor General MedicineWong Gene M.D. Professor Hematology/OncologyWu Terry Ph.D. Research AssistantProfessorYe Dongmei Ph.D. Research AssistantProfessorHematology/OncologyGastroenterologyYee Ellen M.D., MPH Associate Professor General MedicineZager Philip M.D. Professor NephrologyZwahlen-MintonDenise M.D. Assistant Professor Geriatrics72

HOUSESTAFF2008-200973

INTERNAL MEDICINE RESIDENTSHOUSE OFFICERS – JULY 1, 2008- JUNE 30, 2009Internal Medicine Housestaff – 2008-2009PGY-IAl-Mansour, ZeinaAlomari, Ihab*Anderson, RyanAngeli, EvaAzarkh, MichaelBansal, DhruvCastillo, Juanita (Janie)*Eshaghian, AlexGonzalez, ZorisaddayHawkins, Lakisha*Hickox, John**Kawano Castillo, JorgeLangsjoen, Jens*Laughlin, Mary*Lee, Christina*Legler, AllisonMacias, Leonardo*Maestas, Adrian*Marcial, JorgeMartinez, Milagros (Millie)Matthews, JesseMills, DavidUniversity of JordanUniversity of JordanDuke University School of MedicineUniversity of New Mexico SOMFlinders University of South AustraliaSmt. N.H.L. Municipal Medical College, IndiaTexas A & M University HSC College of Medicine.Vanderbilt University School of MedicineTexas Tech University School of MedicineUniversity of Nevada School of MedicineTexas Tech University School of MedicineUniversidad Peruana Cayetano Heredia, PeruUniversity of Texas Medical Branch - GalvestonUniversity of New Mexico SOMUniversity of Texas Med School at San AntonioUniversity of New Mexico SOMUniv Autonoma de Baja California, MexicoUniversity of New Mexico SOMUniversidad Central Del Caribe, Puerto RicoUniversity of Texas Medical Branch - GalvestonSaint Louis University School of MedicineUniversity of New Mexico SOM74

Nguyen, Hung*Ornelas, ChristopherParada, Alisha*Pham, VincentRitch de Herrera, T. DavidSchevchuck, Oleksandr (Alex)Shirley, MichaelWest, JaredYaqub, SabeenYoussef, MoustafaR. Franklin University/Chicago Medical SchoolUniversity of New Mexico SOMUniversity of New Mexico SOMWayne State University School of MedicineJefferson Medical CollegeTernopol Medical Institute, UkraineOhio State University College of MedicinePonce School of Medicine, Puerto RicoFatima Jinnah Medical College, PakistanUniversity of Mansoura, Egypt*Preliminary Year Intern**Neurology Preliminary Year InternPGY-IIAhmed, ShozabArriens, CristinaClark, DanicaCourmier, FrankGarcia, PabloHelberg, ScottHo, Wen-Huan (Steve)Ing, SharonKhuu, JohnMenon, RishiModi, SheilaNorton, HillaryPrevost, MeridethPunjab Medical College, PakistanU Texas Southwestern Med Center – DallasOregon Health Sciences UniversityUniversity of Texas Medical School – San AntonioUniversity of Illinois College of MedicineSanford SOM U of South DakotaUniversity College Dublin, IrelandFlinders University of South AustraliaMedical University of OhioUniversity of Missouri-Kansas City SOMUniversity of Texas Medical Branch – GalvestonUniversity of New Mexico SOMUniversity of New Mexico SOM75

Reyes, CarlosSadler, CorinnSilvey, KirstenStephenson, LukeVeryser, AndreaWinters, JohnWong, DanielYoung, DarrenU niversity of Iowa Roy J. & Lucille A. Carver COMUniversity of New Mexico SOMUniversity of New Mexico SOMUniversity of South Florida COMWayne State University SOMUniversity of OK COM – Oklahoma CityTemple University School of MedicineOregon Health Sciences UniversityPGY-IIIAvitia, JoseBlaschke, JonBouchonville, MatthewBrown, GregoryCandelaria, DulcineaChavez Chiang, NataliaDeLea, SuzanneGabaldon, DarleneGallagher, ChrisGutierrez, AbsalonJoseph, CharleslyKaza, ArchanaLovato, ChristinaMcClung, KeithMehta, MayaMizzell, JosephPaulraj, NirupaPiceno, JesseUniversity of Illinois College of MedicineUniversity of Oklahoma College of MedicineEastern Virginia Medical SchoolU of Texas Medical School at San AntonioUniversity of New Mexico SOMUniversidad San Martin de Porres, PeruUniversity of New Mexico SOMUniversity of New Mexico SOMUniversity of New Mexico SOMUniversity of New Mexico SOMBrown Medical SchoolJawaharlal Inst, IndiaUniversity of New Mexico SOMUniversity of New Mexico SOMU of Chicago Pritzker School of MedicineUniv of South Carolina School of MedicineUniversity of The West Indies, TrinidadUniversity of Illinois College of Medicine76

Quintana, ChristopherRamos, CesarRao, AnshulSanchez-Goettler, LeslieVigil, JenniferWang, SamWhite, TheresaYoung, JoshuaUniversity of New Mexico SOMUniversity of Illinois College of MedicineMedical University of OhioUniversity of New Mexico SOMUniversity of New Mexico SOM2nd Military Medical Univ. of ChinaUniversity of New Mexico SOMUniversity of Texas Medical School at Houston77

INTERNAL MEDICINE FELLOWSJULY 1, 2008- JUNE 30, 2009CARDIOLOGYHEMATOLOGY/ONCOLOGYAwad, KhaledMoualla, HayanBoyer, NathanMovva, SujanaGabaldon, JudePacheco, AlonsoHamirani,Yasmine Quintana, Dulcinea (thur 08/09/09)Issac, TimJoson, JosephINFECTIOUS DISEASEMacias, Carlos Abu Ali Al-Muntaser (thru 08/09/09)Martinez, JuanBrett, MeghanNoonan, DanielCalvo, KatyaOberton, Brent SelbyKlein, NicoleRandhawa, TejpalKu NeilSiddiqi, Ahmad SaadiNEPHROLOGYENDOCRINOLOGYAlas, EduardoAguirre LinaElia, GabrielBouchonville, Matthew IIGabaldon, DarleneGarimella, MadhaviHorowitz, BruceJoseph, CharleslyKannaeganti, PrasadGASTROENTEROLOGYOwen, JonathanAl-Khatib, KhaldunSingh, PoojaAshok, AshwinGilles, MichaelPULMONARY/CC/SLEEPKasen, WesleyAbouhouli, HassanKaza, ArchanaBattah, ShadiKolendich, KevinMelendres, LanaMougey, AdamTaneja, DeepakOthman, MohamedVerma, KaninikaPatel, Yatin White, Theresa (Teri) (thru 09/09/09)Villas-Adams, AngelinaLee, CalVorlop, ErichSaeed, AliCooperman, SharonGERIATRICSStanley, JeffreyHemphill, David (thru 8/31/09)Metzler, EricRHEUMATOLOGYParker, Donna (thru 8/31/09) Chavez-Chiang, Natalia (thru 08/09/09)DeLea, SuzannePark, Kye78

DIVISION OF CARDIOLOGY79

DIVISION OF CARDIOLOGYANNUAL REPORT: JULY 1, 2008-JUNE 30, 2008WARREN LASKEY, M.D., S, FLINN PROFESSOR OF MEDICINEAND DIVISION CHIEF OF CARDIOLGYA. SIGNIFICANT DEVELEOPMENTS DURING THE ACADEMIC YEAR- The “CV Product Line” exhibited substantial growth in patient visits and proceduralvolumes over the year prior. Such growth could not have been possible without thededicated efforts of our full-time faculty. Ceaseless efforts to transform the division into a“can-do” program have resulted in the following:- 14% growth in overall volumes throughout the Heart and Vascular Center- 23% increase in procedural volumes within the Heart Station (echos, ECGs, treadmills,etc.). With our digitally-enabled echo lab, enhanced efficiency in generating andinterpreting these studies has contributed to the increase in volume.- 17% increase in procedural volumes in the cath lab. This represents growth in bothinvasive angiographic electrophysiologic procedures. “Project AMI”, (door to balloontime under 90 minutes), the latter is now viewed nationally as a metric of the quality ofprimary PCI programs. Special recognition goes to Drs. Mark Ricciardi, Larry Osbornand Mark Sheldon for their expertise as well as to our colleagues in the emergencydepartment who are integrally involved in this effort.- The arrival of our electrophysiologist, Dr. Shmuel Inbar, in January, 2009 has had adramatic effect on diagnostic and therapeutic procedural volumes. In comparison to yearprior, invasive EP procedural volumes have increased by 50%l- In May, 2009, the long-awaited renovation of the UNMH cath center was completed andthe first case was performed in the new suite on the 3 rd floor of UNMH. These three stateof the art fully digital labs now provide for not only increased and more efficientactivities but also new programs. Among the latter are the invasive EP program with stateof the art complex mapping and new treatment modalities, the pediatric invasivecardiology program and the Structural Heart Disease Program. The latter, a collaborativeeffort between adult and pediatric cardiology, is the only such one in the state of NewMexico and offers innovative alternatives to the surgical management of acquired andcongenital heart disease in children and adults.- 10% growth in non-invasive vascular lab procedures. In addition, the vascular lab hasreceived its national accreditation and remains the only vascular lab in the state of NMwith such distinction.- 18% increase in cardiology outpatient visits. This represents growth at both the UNMHclinic site on 5 ACC as well as at the off-site Medical Arts Building.As a consequence of such sustained (11 consecutive quarters) growth, professional and technicalrevenues have continued to increase--the first such sustained increase in over a decade and anastonishing accomplishment in the present economy (see Figure).80

Heart and Vascular Center VolumeJan. - Dec 2006 Jan - Dec 2007 Jan - Dec 2008 Jan - Mar 2009 (numberannualized)Cath Lab 2103 2761 3278 3996Heart Station 55552 66908 75296 88704Cardiology5108 5848 6507 5568ClinicCardiacRehab5022 5180 5878 6060B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURE- The division continues to recruit additional faculty in the areas of general/preventivecardiology and cardiovascular imaging.- Plans are underway for the construction of a new multi-modality out-patient facility onthe side of the present cancer center; this facility will house all divisional out-patientactivities including heart failure, cardiac rehab, state-of-the-art cardiac echo, peripheralvascular disease diagnosis and management, and nuclear cardiologic testing.- The division’s commitment to cardiovascular outcomes will continue with obtainingTJC/AHA certification in heart failure in early 2010.- The structural heart disease program will be expected to grow with addition of Dr. JohnLove, pediatric interventionalist, to the on-going collaboration between the divisions ofadult pediatric cardiology.C. EDUCATION/TEACHINGFellowship Programa. Graduating Fellows- Abinash Achrekar, MD- Employment: Assistant Professor of Medicine, Division of Cardiology UNMSOM- Matthew Fraley, MD- Employment: clinical cardiologist, St. Louis, MO.- Eric Haas, MD- Employment: clinical cardiologist, Everett, WA.- Jeremy Lum, MD- Employment: electrophysiology fellowship, Providence RI.81

- Mel Peralta, MD- Employment: Assistant Professor of Medicine, Division of Cardiology UNMSOMb. Incoming Fellows- Nathan Boyer, MD- Residency: Oregon Health and Science University- Yasmin S. Hamirani, MD- Residency: St. Agnes Hospital- Carlos Macias, MD- Residency: University of New Mexico Health Science Center- Selby Oberton, MD- Residency: Baylor College of Medicine- Saadi Siddiqi, MD- Residency: University Hospital at Stony Brookc. ABIM Certification- From the class of 2008, one out of two has passed their ABIM-certification exam incardiovascular disease (Evan O. Mokwe, MD).d. Program developments and updates- The fellowship program continues with its expanded training opportunities. The adultcongenital heart disease in tandem the pediatric congenital heart disease programprovides a unique opportunity to observe the continuum of disease in this enlargingpatient group. This same rotation also includes exposure to new modalities for CVimaging, e.g., CT and MR, particularly as they relate to structural heart disease. Thededicated EP rotation at UNMH provides for one-on-one interactions, on a structuredbasis, with a geographic full-time faculty person. With invasive EP services nowavailable at UNMH, fellows are expected to participate in the decision-making andconduct of these procedures.- The fellowship program has been reviewed by the RRC. The CardiologyTraining Program has been given “Continued Accreditation” status, with a cyclelength of 3 years by the ACGME. Congratulations to all involved!- Finally, sincere appreciation and recognition for a job superbly done goes to ourfellowship program training direction, Dr Gerald Charlton. Dr Charlton now devotes 50%of his overall effort in the division to the increasing demands of the training program.D. APPOINTMENTS TO FACULTY; APPOINTMENTS TO STAFF- Dr. Shmuel Inbar joined the division in January 2009 as full-time faculty and is theDirector of Electrophysiology.82

- Drs. Abinash Achrekar and Mel Peralta completed their fellowship with UNMCardiology and are now full time faculty members.- Dr. Loren Montgomery will be working part time in the division in her capacityoverseeing cardiovascular health promotion in women.- The division welcomes Chris Gallegos and Charlotte Surveyor as members of thedivision’s administrative staff. Chris will assist in the daily tasks of looking afterdivisional needs and will assist Dr. Charlton with the fellowship. Charlotte will assist inthe daily tasks and will help update and maintain the website.- Patricia Esquibel has been promoted from an Administrative II position to anAdministrative III position; she will be supervising the other staff and is now Dr.Laskey’s Administrative Assistant. Patricia received 1 st place at the 2009 DivisionalAdministrative Staff Recognition Award Ceremony.E. SEPARATIONS OF FACULTY AND STAFFStaff- Pauline Vicenti retired on 4/30/2009.- January 2009, Glenda Harris took another position with UNM.F. PUBLICATIONS OF THE DIVISION/UNIT; AND PUBLICATIONS OFINDIVIDUAL FACULTY/STAFFLaskey, Warren K.- Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, LaskeyWK, Williams DO, Smith C, Anderson WD, Lee JS, Srinivas V, Kelsey SF, Kip KE.Impact of drug-eluting stents among insulin-treated diabetic patients: A report from theNational Heart, Lung and Blood Institute Dynamic Registry. J Am Coll Cardiol Intv. 1:139-147, 2008- Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronaryflow reserve and ST-segment resolution during percutaneous coronary intervention foracute myocardial infarction. Cathet Cardiovasc Int 72: 212-20; 2008- Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF for the VALOR TrialInvestigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidneydisease: the VALOR trial. Am Heart J 156: 776-782, 2008- Klein LW, Miller DL, Balter S, Laskey W, Naito N, Haines D, Ross A, Mauro MA,Goldstein JA. Occupational health hazards in the interventional laboratory: time for asafer environment. J Vasc Interv Radiol. 20:147-52,2009- The BARI 2D Study Group. Baseline characteristics of patients with diabetes andcoronary artery disease enrolled in the Bypass Angioplasty RevascularizationInvestigation 2 Diabetes (BARI 2D) Trial.. Am Heart J. 156: 528-36, 2008- Glaser R, Naidu SS, Selzer F, Jacobs AK, Laskey WK, Srinivas VS, Slater JN, WilenskyRL. Factors associated with poor prognosis for patients undergoing primarypercutaneous coronary intervention during off-hours. J Am Coll Cardiol Intv. 1:681-8,200883

- Ficaro EP, Zanzonico P, Stabin MG, Raff GL, Thompson RC, Einstein AJ, HenzlovaMJ, Budoff MJ, Dilsizian V, Laskey WK, Lima J, Roti Roti JL, Bateman TM. ASNCAnnouncement. J Nucl Cardiol 16: 161, 2009- Laskey WK, Kussmaul WG, Noordergraaf A. Systemic arterial response to exercise inpatients with aortic valve stenosis. Circulation. 119: 996-1004, 2009- BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF,MacGregor JM, Orchard TJ, Chaitman RR, Genuth SM, Goldberg SH, Hlatkey MA,Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapiesfor type 2 diabetes and coronary artery disease. N Engl J Med. 360: 2503-15, 2009Abstracts- Rana JS, Venkitachalam L, Mukutula S, Marroquin O, Selzer F, Laskey W, Holper E,Srinivas VS, Kelsey S, Nesto RW, Kip K. Outcomes of percutaneous coronaryintervention across angioplasty, bare metal stents and drug eluting stents in patients withdiabetes. Circulation 118(Suppl II) II: 739, 2008- Parikh SV, Enriquez JR, Selzer F, Slater JN, Laskey WK, Wilensky RL, Marroquin OC,Holper E. Association of a unique cardiovascular risk profile with outcomes in Hispanicpatients referred for PCI: results from the NHLBI Dynamic Registry. Circulation 118(Suppl II) II: 632, 2008- Maree AO, Selzer F, Jneid H, Quiroz R, Marroquin OC, Mulukutla R, Laskey WK,Jacobs AK. Impact of renal insufficiency on prescription of discharge medication afterpercutaneous coronary intervention. J Am Coll Cardiol 35 (Suppl A): A36, 2009- Maree AO, Selzer F, Adams B, Patel N, Jneid H, Marroquin OC, Mulukutla SR,LaskeyWK, Jacobs AK. Impact of renal insufficiency on bleeding events in patients undergoingpercutaneous coronary intervention. J Am Coll Cardiol 35 (Suppl A): A 37, 2009Charlton, Gerald- Loeppky JA, Icenogle MV, Charlton GA, et al. Hypoxemia and AMS: Which comesfirst. High Alt Med Biol: 2008;9(4):271-9.Ricciardi, Mark J.- Cardiogenic Shock- In: Ricciardi MJ, Mukherjee, ER Bates, M Roffi, and DJ Moliterno Eds. CardiacCatheterization, Coronary & Peripheral Angiography, and Interventional Procedures,Chapter 34. 2009.- Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronaryflow reserve and ST-segment resolution during percutaneous coronary intervention foracute myocardial infarction: A benefit of postconditioning. Catheter Cardiovasc Interv2008;72:212-20.Roldan, Carlos- Peralta M, Hayek R, Sharrar J, Qualls C, Sibbitt WL, Roldan CA. Libman-Sacksendocarditis is a cause of stoke/transient ischemic atacks and brain injury in patients withsystemic lupus erythematosus. J Investigative Medicine, January 2009.84

- Joson J, Greene ER, Sharrar J, O’rourke C, Roldan CA. Aortic atherosclerosis occursearlier and more often than carotid atherosclerosis in patients with systemic lupuserythematosus. J Investigative Medicine, January 2009- Johnson CR, Roldan CA, Sharrar JM, Brooks WM, Sibbitt WL Jr, Bankhurst AD:Cardiac lesions and thromboembolic disease a a caues of neuropsychiar systemic lupuserythematosus: Histopathology on brain autopsy paired with valve lesions and MRI.Arthritis Rheum 2008;58:S817(1764).- RoLdan CA, Qualls CR, Sopko KS, Sibbitt WL Jr. Transthoracic versus TransesophagealEchocardiography for Detection of Libman-Sacks Endocarditis: A RandomizedControlled Study. J Rheumatol 2008;35:224-9.- Bains SR, Kedia A, Roldan CA. Pericarditis as initial manifestation of proximal aorticdissection in young patients. Am J Emerg Med 2008;26:379.e3-5.- Johnson CR, Michael AA, Sibbitt WL Jr, Mott FJ, Roldan CA, Bankhurst AD: Theeffect of medical insurance on outcomes in systemic lupus erythematosus. ArthritisRheum 2008;58:S881.- Jung R, Sharrar J, Qualls C, Sibbitt WL, Roldan CA. Libman-Sacks endocarditis as acause of neuropsychiatric motor dysfunction. Stroke. Feb 2009.- Roldan CA. Connective Tissue Diseases and the Heart. Current Diagnosis and Treatmentin Cardiology. Appleton and Lange, Norwalk, CT. Third Edition 2008, Chapter 31.Editor-in-Chief: Michael H. Crawford, MD.- Roldan CA.DisplayText cannot span more than one line! Heart. 2008 Aug;94(8):1089-101.Timm, CraigPublications- Timm C and McNulty E. Cardiogenic Shock. In Current Diagnosis and Treatment:Cardiology. Crawford MH (ed): McGraw-Hill Medical, 3 rd edition 2009 (1 st and 2 ndedition, 1995 and 2003, published by Appleton & Lange)G. OUTSIDE PROFESSIONAL ACTIVITIES OF FACULTY/STAFF MEMBERSAt the faculty level, participation in local and national educational efforts continues.- Dr Robert Taylor presented an update on Heart Failure at the October 27, 12 th AnnualReview and Update of Internal Medicine in Santa, Fe NM.- Dr. Warren Laskey presented an update on “Valvular Heart Disease” at the October 27,12 th Annual Review and Update of Internal Medicine in Santa Fe, NM.- Dr. Warren Laskey - Cardiology Grand Rounds. Rhode Island Hospital/Brown UniversitySchool of Medicine. May 2, 2008. Topic: The Clinical Spectrum of IschemicConditioning- Dr. Warren Laskey’s presented, “Addressing the Quality Chasm in Coronary HeartDisease.” American Heart Association, December 11, 2008- Dr. Warren Laskey - American Heart Association Annual Scientific Sessions. NewOrleans, La. November, 2008. Topic: Risk of Radiation in CV Imaging: How Serious IsIt?85

- Dr. Mark Ricciardi - University HealthSystem Consortium Webcast presentation on theCCL Primary PCI Performance Improvement 2/21/2008- Dr. Mark Ricciardi Cardiology Cath Lab - UHC presentation – PerformanceImprovement – TJC/CMS AMI Care Measures 2/11/2008- Dr. Mark Ricciardi - Medical Grand Rounds - Interventional cardiology in the 21 stcentury 3/27/2008- Dr. Mark Ricciardi - New Mexico Bio Lecture –- Santa Fe, NM 6/10/2008- Dr. Mark Ricciardi - 30 th Annual Advances in Primary Care – Lecture/Expert Panel,UNM – SUB 9/2/2008- Dr. Mark Ricciardi - NMACP Annual Scientific Meeting presentation 9/20/2008- Dr. Mark Ricciardi - 12 th Annual Update/Review of Internal Medicine 2008, Santa Fe,NM 10/23/2008 Kalishman S, Timm C, McGuire P, Jerabek R Szydlowski P, Minton D,Ogburn T. Continuous Quality Improvement Process: Reinforcing professional behaviorwhile developing evaluation skills in medical students. Poster, American EvaluationAssociation, 11/08, Denver, Colorado.- 2008 Kalishman S, Viggiano T, Ogrinc G, Timm C. Quality Improvement Processes—Authentic involvement of students during medical school. Small group discussion,AAMC Annual Meeting, 11/08, San Antonio, Texas.- 2009 Richter D, Timm C, Wilson B, Cosgrove E. Tools for Program Evaluation:Using a Logic Model to identify Desired Program outcomes and Kirkpatrick’s Levels ofEvidence to Measure Them. Workshop, WGEA (Western Group on Educational Affairs,AAMC), 5/09, Santa Fe NM.- 2009 Geppert C, Roesch J, Timm C, Cosgrove E. Fourth-Year Students as Instructorsin a First-Year Ethics and Professionalism Course. Poster, WGEA (Western Group onEducational Affairs, AAMC), 5/09, Santa Fe NM.- 2009 Wayne S, Timm C, Serna L, Kalishman S. Trends in prediction of primary carechoice—are demographic and attitudinal predictors changing? Poster, WGEA (WesternGroup on Educational Affairs, AAMC), 5/09, Santa Fe NM.- Rebecca Mayo RN, Phd, CNP presented poster titled: "Heart Disease in New Mexico:Earlier Presentation for Both Men and Women" at the Western Institute Of NursingResearch Conference in April 2009.- Peralta M, Hayek R, Sharrar J, Qualls C, Sibbitt WL, Roldan CA. Libman-Sacksendocarditis is a cause of stoke/transient ischemic atacks and brain injury in patients withsystemic lupus erythematosus. Abstract presented at the Carmel Western ResearchRegional Meeting- Joson J, Greene ER, Sharrar J, O’rourke C, Roldan CA. Aortic atherosclerosis occursearlier and more often than carotid atherosclerosis in patients with systemic lupuserythematosus. Abstract presented at the Carmel Western Research Regional Meeting- Johnson CR, Roldan CA, Sharrar JM, Brooks WM, Sibbitt WL Jr, Bankhurst AD:Cardiac lesions and thromboembolic disease as a caues of neuropsychiar systemic lupuserythematosus: Histopathology on brain autopsy paired with valve lesions and MRI.Presented at the 2008 American College of Rheumatology.- Johnson CR, Michael AA, Sibbitt WL Jr, Mott FJ, Roldan CA, Bankhurst AD: Theeffect of medical insurance on outcomes in systemic lupus erythematosus. ArthritisRheum 2008;58:S881(1947). Presented at the 2008 American College of Rheumatology.Jung RE, Flores R, Sharrar J, Qualls C, Sibbitt WL, Roldan CA.86

- Libman-Sacks Vegetations Are Associated with Motor Cognitive Dysfunction in Patientswith Systemic Lupus Erythematosus. Internation Stroke Conference. San Diego CA,February 2009.- Roldan CA. Libman-Sacks Endocarditis – A Cardiologist Perspective New MexicoCollege of Rheumatology 5-3-08.- Roldan CA. Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic LupusErythematosus. Clinical Neurosciences Grand Rounds 9-12-08.- Dr. Mark Ricciardi - Co-investigator. IMMEDIATE (Immediate Myocardial MetabolicEnhancement During Initial- Dr. Mark Ricciardi - Assessment and Treatment in Emergency care) Trial. NationalInstitutes of Health (NIH). 2008-present- Dr. Mark Ricciardi - Co-investigator. Roche Protocol – CETP INHIBITOR - A phase III,double-blind, randomized placebo-controlled study, to evaluate the effects of oncardiovascular (CV) risk in stable CHD patients, with a documented recent AcuteCoronary Syndrome (ACS)- Dr. Mark Ricciardi - Site Principal Investigator: “A Randomised, Double-blind, ParallelGroup, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel forPrevention of Vascular Events in Patients with Non-ST or ST elevation Acute CoronarySyndromes (ACS) (PLATO- A Study of PLATelet inhibition and Patient Outcomes.)”AstraZeneca. 2007-09.- Dr. Abinash Achrekar - Prevalence and Impact of Patent Foramen Ovale in Patients withObstructive Sleep Apnea. 2008-presentNIH APPROVED FOR FUNDING FROM 9-1-06 TO 7-30-2010).AWARD $2,340,393 (TOTOAL COSTS)ROLDAN CA- Roldan CA, Sibbitt Jr WL, Gasparovic C, Jung R, Qualls C, Crookston K. Libman-SacksEndocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus.- Roldan CA, Tolstrup K, Crawford MH. Association of Retinal Artery Embolism andAortic Atheromatous Disease by Transesophageal Echocardiography..87

DIVISION OF ENDOCRINOLOGY88

DIVISION OF ENDOCRINOLOGYANNUAL REPORT: JULY 1, 2008- JUNE 30, 2009DAVID S. SCHADE, M.D., PROFESSOR AND CHIEFA. SIGNIFICANT DEVELOPMENTS AND ACHIEVEMENTS- David S. Schade, M.D., Chief, Division of Endocrinology, continues to be principalinvestigator for three NIH-funded grants, the Diabetes Prevention Program OutcomesStudy (DPPOS), the Epidemiology of Diabetes Intervention and Complications (EDIC),and Type 1 Diabetes TrialNet. He is Director, Office of Research, in the Dept of InternalMedicine and director of the CTSC Core Laboratory. Dr. Schade is responsible for theCTSC/ECHO Clinical Investigators Program and oversees this faculty training programin the School of Medicine. He is mentor for two junior faculty in this program. Heserves as a member of the School of Medicine Research Allocation Committee, theSchool of Medicine Space Committee, the CTSC Administrative Committee, and theAdult Inpatient Medicine Committee.- Dr. Richard Dorin is Section Chief of Endocrinology and Metabolism at the VA andProfessor of Medicine & Biochemistry at UNM School of Medicine. Dr. Dorin attends onthe inpatient Endocrine Consult Service at the VA all months of the year, and attends onthe inpatient Medical Service at the VA one month yearly. Dr. Dorin supervises students,residents, and fellows at two outpatient Endocrine Clinics weekly. Dr. Dorin is chairmanof the Animal Studies Research Subcommittee at the VA. He attends and participates inthe weekly Endocrine Division case conference, and in monthly journal club andendocrine-pathology conferences.- Dr. Mark Burge contributes to Endocrinology clinical activities by providing one halfdayclinic and a ttending for 3 months on the endocrine service and two weeks on theMedicine service. He provides exceptional teaching by being a mentor in theCTSC/ECHO Clinical Investigators program, mentoring medical students, giving lecturesin the Endo teaching block, giving fellow didactic conferences, Board Review sessions,and teaching medical residents rotating through endocrinology. He provides researchadministrative duties as Director of the CTSC. He is Program Director for the UNMCTSA grant, which is the competitive replacement for the General Clinical ResearchCenter. He participates in Dr. Schade’s American Diabetes Association grant, “Theimportance of timing of insulin in type 1 diabetes.”- Dr. Kathleen Colleran is a major contributor to the Endo Division’s clinical care. She hastwo one half day clinics, plus Thyroid Ultrasound clinic twice a month, and supervisesthe Endo Fellow’s clinic every Tuesday afternoon. She attended on the Medicine servicefor 2 weeks. She is the Block Chair for the Endo-Renal block. She has initiated severalresearch projects as well as undertaking two pharmaceutical studies. She is Director ofthe Clinical Trials Center, which is important for any faculty member doing clinicalresearch.- Dr. Patti Kapsner has two half day general endocrinology clinics per week, one half daydiabetes clinic per week plus a half day thyroid nodule clinic twice a month whereultrasound guided FNA biopsy of thyroid nodules occur when deemed necessary. Shealso provides endocrine consultative service to her colleagues in other divisions anddepartments. Additionally she provides care to a large and unique transsexual89

population, again frequently providing their primary care as well as endocrine care. Sheattended on the Medicine service for two weeks and attends on the inpatient consultativeservice for endocrinology 3 months per year.- Dr. Kapsner is the program director for our fellowship program in Endocrinology andplays an integral role in the education of medical students and residents. She lectures andfunctions as a tutor in the Phase I Endocrinology-Reproductive Medicine block. Dr.Kapsner facilitates the education of Phase II and Phase III medical students andhousestaff as they rotate through the required Comprehensive Ambulatory Clerkship andEndocrinology elective and she has received much positive feedback from them. She hasalso participated as a speaker in several CME events put on by the Department of InternalMedicine and its divisions.- Dr. Kapsner has been a leader in the Department’s diabetes initiatives. She is co-chair ofthe Diabetes Disease Management Team and is playing a pivotal role in the developmentof UNMs Diabetes Center for Excellence. Dr. Kapsner has also been active in clinicaltrials and will be presenting an abstract related to the effectiveness of technosphereinsulin at the European Association for the Study of Diabetes meeting in September. Shewas also an author on an abstract presented at the American Diabetes Associationmeeting in June 2009.- Our second year fellows, Zhi Qiao, Stephen Mitchell, and David Podolsky, M.D.,provided excellent clinical care as did our first year fellow, Lina Aguirre MD. Dr.Podolsky did research with Dr. Kapsner and all four fellows presented abstracts at theAmerican Federation for Medical Research in Carmel, CA in February 2009. Dr. Qiaoand Aguirre also presented an abstract at Endo 2009, the national meeting of theEndocrine Society with Dr. Aguirre receiving several honors for recognition of her work.All four fellows have published articles related to endocrinology in medical journals.- All of the fellows rotate through three months of Bone Clinic, Pediatric EndocrinologyClinic, Reproductive Endocrinology and Metabolic Clinic.- All of the fellows attend and participate in all monthly meetings of the CTSC/EchoClinical Investigators Meeting.- All of the faculty members of the Endocrinology Division were listed in theAlbuquerque: The Magazine publication for “The ABQ Physicians chosen by fellow docsas the best in their specialties” in March 2009.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE FUTURE- Dr. Schade will continue in all of the roles that he has currently undertaken as describedin the previous year. He continues to be principal investigator for three NIH-fundedgrants. He serves as Chief of Endocrinology and Director of Research in the Dept ofInternal Medicine. Dr. Schade will begin a three year American Diabetes Associationgrant, “The importance of timing in type 1 diabetes.”- Dr. Dorin will continue to direct clinical, teaching, and administrative activities at theVA, and is leading efforts to develop and recruit an additional faculty position in the VAEndocrine Division. He supervises the VA Cooperative Studies Peptide ResourceFacility. He will conduct several pharmaceutical sponsored clinical studies, and continueas Chairman of the VA Animal Studies Research Committee.- Dr. Patti Kapsner will continue patient care and mentor fellows in her Monday morningEndocrinology Clinic and Thyroid Nodule Clinic. She will also continue as the90

fellowship director and playing an active role in the education of medical students andresidents. She will continue to provide direction for diabetes care and education for thedivision and department. Additionally she is pursuing additional industry sponsoredclinical trials.- All of the members of the Endocrinology Division were listed in the Albuquerque: TheMagazine publication for “The ABQ P hysicians chosen by fellow docs as the best intheir specialties” in March 2009.- For the next fiscal year, Dr. Burge will continue many of his activities in education andclinical service, including mentoring one junior faculty through the CTSC/ECHOClinical Investigators Program and one Endocrinology fellow. He is Director of theClinical and Translational Science Center. He has received a $200,000 extension to hisR01 grant.- Dr. Colleran will participate in clinical duties and expand her research activities inProject ECHO and clinical trials. She will oversee the Endocrine Teaching Block and isdirector of the Clinical Trials Center.- Reina Villareal, M.D., will join the endocrine service at the VAMC in 2009.- Our second year fellow, Lina Aguirre, will do both clinical and research rotations.- Our new first year fellows, Matt Bouchonville and Madhavi Garimella, M.D., will begintheir Endocrine fellowships in July 2009. They will obtain clinical and researchexperience.C. APPOINTMENTS TO FACULTY/STAFFFaculty- There were no new appointments to Endocrinology in 2008-2009.Staff- Melissa Green began as the Admin III in March 2009.D. SEPARATIONS FROM FACULTY/STAFFFaculty- There were no separations from faculty in Endocrinology in 2008-2009.Staff- Corinna Saiz resigned her position as Admin III in January 2009.E. PUBLICATIONS OF THE DIVISIONPublications 2008-2009David S. Schade, M.D. Publications1 Sawyer AM, Schade DS. Case Report: Use of a continuous glucose monitor in the managementof inoperable metastatic insulinoma. Endocrine Practice 14:880-883, 2008.2. Duran-Valdez E, Gonzalez de Serna D, Schneider S, et al. incl Schade D. Metabolic effects oftwo days of strict bed rest in man. Endocrine Practice 14(5):564-69, 2008.91

3. The DCCT/EDIC Study Research Group, including Schade DS. Impact of diabetes and itstreatment on cognitive function among adolescents who participated in the Diabetes Control andComplications Trial. Diabetes Care 31:1933-38, 2008.4. Schneider S, Amorim F, Gonzalez de Serna D, Duran-Valdez E, Schade DS, Robergs R.Impaired orthostatic response in patients with type 2 diabetes after 48 hours bed rest. Endocrine Practice15(2):104-110, 2009.5. Gutierrez A et al. incl Schade DS. A dose response of alpha vitamin E to gamma vitamin E intype 2 diabetes. Metabolism 58:469-478, 2009.6. The Diabetes Prevention Program Research Group, including Schade DS. The association ofENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes PreventionProgram. J Clin Endocrinol Metab 94(2):449-455, 2009.7. The Diabetes Prevention Program Research Group, including Schade DS. Evaluating theaccuracy of an aneroid sphygmomanometer in a clinical trial setting. Am J Hypertens 22(3):263-6, 2009.8. The Diabetes Prevention Program Research Group, including Schade DS. Changes in albuminexcretion in the Diabetes Prevention Program. Diabetes Care 32(4):720-5, 2009.9. The Diabetes Prevention Program Research Group, including Schade DS. Effect of progressionfrom impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyleand metformin intervention. Diabetes Care 32(4):726-32, 2009.10. The Diabetes Prevention Program Research Group, including Schade DS. Changes in healthstate utilities with changes in body mass in the Diabetes Prevention Program. Obesity 2009 Apr 23;advance online publication.11. The DCCT/EDIC Study Research Group, including Schade DS. Association of diet withglycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control andComplications Trial. American Journa1 of Clinical Nutrition 89:518-524, 2009.12. The DCCT/EDIC Study Research Group, including Schade DS. Urinary incontinence amongwomen with type 1 diabetes: How common is it? Journal of Urology 181:1224-30, 2009.13. The DCCT/EDIC Study Research Group, including Schade DS. Urinary tract infections inwomen with type 1 diabetes mellitus: Survey of female participants in the Epidemiology of DiabetesInterventions and Complications Study Cohort. Journal of Urology 181:1129-35, 2009.14. The DCCT/EDIC Study Research Group, including Schade DS. Effect of intensive glycemiccontrol and diabetic complications on lower urinary tract symptoms (LUTS) in men with type 1 diabetes.Diabetes Care 32:664-70, 2009.15. The DCCT/EDIC Study Research Group, including Schade DS. Sexual dysfunction in womenwith type 1 diabetes: long-term findings from the DCCT/EDIC study cohort. Diabetes Care 32:780-85,2009.16. The DCCT/EDIC Study Research Group, including Schade DS. Risk factors for urinaryincontinence among women with type 1 diabetes: Findings from the Epidemiology of DiabetesInterventions and Complications (EDIC) study. Urology 73:1203-09, 2009.17. The DCCT/EDIC Study Research Group, including Schade DS. Cardiac autonomic neuropathyin the Diabetes Control and Complications Trial/Epidemiology of Diabetes Inverventions andComplications Study (DCCT/EDIC) Trial. Circulation 119:2886-2893, 2009.18. The DCCT/EDIC Study Research Group, including Schade DS. Sexual dysfunction andsymptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. Journal of SexualMedicine Epublished April 28, 2009.19. The DCCT/EDIC Study Research Group, including Schade DS. Genome-wide association scanfor diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58:1403-10, 2009.20. The DCCT/EDIC Study Research Group, including Schade DS. Effects of prior intensive insulintherapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes controland Complications Trial/Epidemiology of Diabetes Interventions and Complications Study(DCCT/EDIC). Circulation 119:2886-93, 2009.92

Richard Dorin, M.D., Publications- NoneMark R. Burge, M.D., Publications- NoneKathleen Colleran, M.D., Publications1. Podolsky D and Colleran K. Aggressive Pheochromocytoma: A Rare Presentation a RareDisease Secondary to a Rare Genetic Disorder. Is there a Place for Innovative Medical Therapies?Endocrine Trends 10-11, 2008.2. Sanchez L and Colleran K. Endocrine Complications after a Craniopharyngioma. (accepted forpublication in the Journal of Cardiometabolic Syndrome)Patricia Kapsner, M.D., Publications- NoneAbstracts 2008-2009David S. Schade, M.D.1. DCCT/EDIC Research Group, incl Schade DS. A genome-wide association study identifiedvariation near SORCS1 as a major locus for glycemic control in type 1 diabetes, as measured by bothHbA1c and glucose. Diabetes 58(1):A16, 2009.2. DCCT/EDIC Research Group, incl Schade DS. LDL-containing immune complexes in theDCCT/EDIC Cohort: Associations with lipoprotein subclasses. Diabetes 58(1):A172, 2009.3. DCCT/EDIC Research Group, incl Schade DS. Apolipoprotein-defined lipoproteins in theDCCT/EDIC cohort: Associations with diabetic nephropathy in type 1 diabetes. Diabetes 58(1):A243,2009.4. Diabetes Prevention Program Group incl. Schade DS. Effect of metformin on bodyweight and waist circumference in the Diabetes Prevention Program Outcomes Study. ADA69th Scientific Sessions, New Orleans, Diabetes 58(S1):A76.Richard Dorin, M.D.1. Qiao Z, Dorin R, Qualls C, Urban F. Assessment of maximal cortisol secretion rates insecondary adrenal insufficiency (AI) patients and in healthy controls using advanced numericalmodeling methods. Journal of Investigative Medicine 57(1):113.Mark R. Burge, M.D.1. Mitchell S, Eversole M, Hammer T, Burge MR. Oral ethanol before sleep delaysrecovery from overnight hypoglycemia in healthy subjects. J Invest Med 2009;57:123.2. Mitchell S, Burge MR. Exploring the weight neutral eff ects of insulin detemir vs.insulin glargine in type 1 diabetes. J Invest Med 2009;57:242.3. Aguirre LE, Burge MR, Colleran KM. Carvedilol vs Metoprolol: A comparison ofeffects on endothelial function and oxidative stress in response to acute hyperglycemia inpatients with type 2 diabetes and hypertension. J Invest Med 2009;57:124-125.4. Aguirre LE, Burge MR, Colleran KM. Beneficial Vascular Effects of Carvedilol vsMetoprolol during Hyperglycemia in Type 2 Diabetes and Hypertension. Endocrinology2009;XX(Suppl. 1):In Press.93

Kathleen Colleran, M.D.1. Colleran K, Aguirre L, Burge C arvediolol vs Metoprolol: A comparison of Effects onEndothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients withType 2 Diabetes and Hypertension. Journal of Investigative Medicine 57:124-125, 2009.Patricia Kapsner, M.D.1. Bergenstal R, Kapsner P, Rendell M, Boss AH, Howard CP , Chang P-C, Richardson PC.Comparative efficacy and safety of AFRESA and a rapid-acting analog both given with glarginein subjects with T1DM in a 52-week study. American Diabetes Association annual meeting,New Orleans, LA. Diabetes 58(s1):A128.2. Podolsky D, Kapsner P. Diazoxide Induced DKA in a Patient with an Insulinoma.Western Association for Medical Research Western Regional Meeting, Carmel, California.February 2009. Journal of Investigative Medicine 57(1):205.F. OUTSIDE PROFESSIONAL ACTIVITIES OF FACULTY MEMBERS- Dr. Schade is a member of the American Board of Internal Medicine Subspecialty Boardon Endocrinology, Diabetes, and Metabolism.- Dr. Burge spent one week in Diabetes Camp for the American Diabetes Association. Dr.Burge is a Councilor, Western Society for Clinical Investigation, 2008 to present.- Dr. Kapsner is a member of the Board of Directors for Parents of Behaviorally DifferentChildren and a regular blood donor to the Albuquerque United Blood Services.- Dr. Colleran spent one week in Diabetes Camp for the American Diabetes Association.G. OUTSIDE SPONSORED RESEARCHDavid S. Schade, M.D.- “Diabetes Prevention Program Outcomes Study NIH 1U1DK489407-13, NationalInstitutes of Health, $523,500/yr Principal Investigator, 1994-2009- “Epidemiology of Diabetes Intervention & Complications,” NIH U 1 37825-09S1,$165,660/year, Principal Investigator, 1994-2015- -“A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2factorial design study of the efficacy and safety of long term administration of nateglinideand valsartan in the prevention of diabetes and cardiovascular outcomes in subjects withimpaired glucose Tolerance (IGT),” $309,790, Novartis Pharmaceuticals, PrincipalInvestigator, 2001-2009.- “Type 1 Diabetes TrialNet,” $10,000/yr, Univ of South Florida/NIH, PrincipalInvestigator, 2004- present.- “Postprandial Hyperglycemia and oxidative stress,” $7,500, Endocrine FellowsFoundation, Principal Investigator, 11/15/07 - 11/14/08- “The importance of timing in type 1 diabetes,” American Diabetes Association,$600,000, 7/1/08-6/30/2011.Richard Dorin, M.D.- NoneMark R. Burge, M.D.94

- “A 24-week randomized, double-blind study to comp are the efficacy, safety andtolerability of Avandia7 (8mg once daily) in combination with glyburide in AfricanAmerican and Hispanic Patients with type 2 diabetes mellitus who are inadequatelycontrolled on glyburide monotherapy (BRL 049653/RSD 1018TV/1, Study 143).”SmithKline Beecham, Principal Investigator, $48,688.00, 6/00 to present.- “Correlates of home blood glucose monitoring in type 2 diabetes,” Cell Robotics Inc.,Principal Investigator, $2,000.00, 10/00 to present.- “The effect of ethanol on overnight glucose regulation in type 2 diabetes,” R01DK061990-01A2, NIDDK, Principal Investigator, $1,685,750.00, 2/1/04-1/31/09.Kathleen Colleran, M.D.- “A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study ofRosuvastatin (Crestorâ) 20 mg in the Primary Prevention of Cardiovascular EventsAmong Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein.” Principal Investigator, Astra Zeneca, 9/03-9/08, $96,000- “An Open Label Evaluation of the Safety and Efficacy of a Combination of Niacin ERand Simvastatin in Patients with Dyslipidemia,” Principal Investigator, KOSPharmaceuticals, 6/04-present, $50,000- “The Comprehensive Rimonobant Evaluation Study of Cardiovascular ENDpoints andOutcomes (Crescendo)” Principal Investigator, Sanofi Aventis, 2/06-4/09, $180,000- “An interactive program to improve diabetes prevention and outcomes in rural NewMexico, Principal Investigator, Minority Research Infrastructure Support Program (M-RISP), 10/06-9/09, $364,000- “A Phase II, multi-center, randomized, double-blind, placebo-and acative-controlledstudy to determine the efficacy and safety of three doses of TAK-379 in subjects withtype 2 diabetes,” Co-Principal Investigator, Kendle International, Inc., 9/15/08-12/30/09,$17,202Patricia Kapsner, M.D.- “A Multi-Center, randomized, double-blind, active-controlled, clinical trial to evaluatethe safety and tolerability of 24 weeks treatment with Vildagliptin (50mg qd) versussitagliptin (25mg qd) in patients with type 2 diabetes and severe renal insufficiency,”Principal Investigator, Novartis Pharmaceuticals Corporation, 8/10/07-current, $165,145- “A Phase II, multi-center, randomized, double-blind, placebo-and active-controlled studyto determine the efficacy and safety of three doses of TAK-379 in subjects with type 2diabetes,” Principal Investigator, Kendle International, Inc., 9/15/08-12/30/09, $17,202.95

DIVISION OF EPIDEMIOLOGYANDPREVENTIVE MEDICINE96

DIVISION OF EPIDEMIOLOGY AND PREVENTIVE MEDICINEANNUAL REPORT: JULY 1, 2008- JUNE 30, 2009MARIANNE BERWICK, PHD, PROFESSOR AND CHIEFA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARThe following highlights activities of the Division during the 2008 fiscal year.Education- The Division of Epidemiology and Biostatistics has been actively teaching MedicalStudents the basics of epidemiologic study design and basic biostatistics during the year.This program continues to expand and is becoming even more integrated into the coremedical school curriculum and is led by Dr. Charles Wiggins.- Dr. Deirdre Hill has led the epidemiology educational program in the CTSA’s Master’sof Science in Clinical Research while Dr. Huining Kang and Dr. Sang-Joon Lee have ledthe biostatistics educational program in the same venue.Research- Faculty in the Division were involved in a broad array of research endeavors in areas thatinclude cancer, environmental, and occupational health (see faculty grant support).- New faculty include Irena King, Ph.D., formerly of the Fred Hutchinson Cancer ResearchCenter and Linda Cook, Ph.D, formerly of Calgary, Alberta, Canada- The division managed a contracts and grants portfolio totaling approximately 3.25million dollars, excluding those grants managed by contracts and grants personnel in theCancer Center and the New Mexico Tumor Registry.Clinical/Service- Four primary faculty in the Division had clinical responsibilities: Dr. Kesler focused inthe area of Environmental/Occupational Medicine; Richard Hoffman, focused onscreening for colorectal and prostate cancer; Glen Murata, focused on Health ServicesResearch, and Ellen Yee, focused on screening issues. The last three have appointmentsat the VA with their primary home in the Division of Epidemiology and Biostatistics.- One additional, secondary faculty member also had clinical responsibilities: Dr. Herman(Geriatrics).B. SIGNIFICANT PLANS FOR THE FUTUREEducation- Initiatives to instruct and mentor medical students and residents in research methods willbe further refined. The Division will also continue to play an active role in developing aPh.D. program in Epidemiology.Research- Refinement of the organizational structure for cancer prevention and outreach is expectedto take place the hiring of both a faculty Director of Cancer Prevention and a Director for97

Cancer Health Disparities. In addition, we are searching for another molecularepidemiologist. The Division expects to partner with the Cancer Center and others in theUNMHSC community to pursue grant funding in the area of health disparities. Fundingof additional training and mentoring grants (e.g. P20, K99, R25, etc.) is also anticipated.C. FACULTYPrimary AppointmentsEd Bedrick, Ph.D.Marianne Berwick, Ph.D.Linda Cook, Ph.D.Kristina Flores., Ph.D.Melissa Gonzales, Ph.D.Deirdre Hill, Ph.D.Richard Hoffman, M.D., M.P.H.Huining Kang, Ph.D.Denece O. Kesler, M.D., M.P.H.Irena King, Ph.D.Sang-Joon Lee, Ph.D.Glen Murata, M.D.Orrin Myers, Ph.D.Christine Stidley, Ph.D.Phillip Wagner, M.D.Charles Wiggins, Ph.D.Ellen Yee, M.D.Secondary AppointmentsCarla J. Herman, M.D., M.P.H.John Scariano, Ph.D.Voluntary AdjunctBert Davis, PhDSeymour Grufferman, M.D., M.P.H.Sue Kimm, M.D.Janice Yager, Ph.D.Letters of Academic TitleNoell Stone, M.S.Eszter Erdei, Ph.D.D. APPOINTMENTS TO FACULTY/STAFFFaculty- Irena King, Ph.D. (October, 2008)Staff98

- Salina Torres, Ph.D., Post-doctoral Fellow (August, 2008)- Lilik Zakarian, M.S. (April, 2009)E. SEPARATIONS OF FACULTY/STAFFFaculty- Sue Y.S. Kimm, M.D. (July 2008)Staff- Jieru Yu (January 2009)F. PUBLICATIONS OF THE DIVISIONMarianne Berwick, Ph.D., M.P.H.- Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, BainsM, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW. DNAdamage and repair capacity in patients with lung cancer: prediction of multiple primarytumors. J Clin Oncol. 2008 Jul 20;26(21):3560-6.- Berwick M. Are tanning beds "safe"? Human studies of melanoma. Pigment CellMelanoma Res. 2008 Oct;21(5):517-9.- Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, OliveriaSA, Berwick M. Sun protection and skin self-examination in melanoma survivors.Psychooncology. 2009 Jan 13. [Epub ahead of print]- Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W,Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA,Ingvar C, Kanetsky PA, Karagas MR, Le Marchand L, Mackie RM, Olsson H, ØsterlindA, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, ZensMS, Ziegler A, Barrett JH. A pooled analysis of melanocytic nevus phenotype and therisk of cutaneous melanoma at different latitudes. Int J Cancer. 2009 Jan 15;124(2):420-8.- Oliveria SA, Satagopan JM, Gellar AC, Dusza SW, Weinstock MA, Berwick M, BishopM, Heneghan MK, Halpern AC. Study of Nevi in Children (SONIC): Baseline Findingsand Predictors of Nevus Count.. American Journalof Epidemiology. :. 169:41-53, 2009- Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V,Berwick M, Elwood JM, Holly EA, Kirkpatrick C, Mack T, Bishop JN, Osterlind A,Swerdlow AJ, Zanetti R, Green AC, Karagas MR, Whiteman DC. Nevus density andmelanoma risk in women: a pooled analysis to test the divergent pathway hypothesis..International Journal of Cancer. :. 124:937-44, 2009- Sood A, Qualls C, Seagrave J, Stidley CA , Archibeque T, Berwick M, Schuyler M.Effect of specific allergen inhalation on serum adiponectin in human asthma.. Chest. :.135:287-94, 2009.- Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ,Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE,Begg CB. Evaluation of the clonal origin of multiple primary melanomas usingmolecular profiling. J Invest Dermatol. 2009 Aug;129(8):1972-82. Epub 2009 Mar 12.99

- Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M,Bracci PM, Elwood JM, Ernstoff MS, Gallagher RP, Green AC, Gruis NA, Holly EA,Ingvar C, Kanetsky PA, Karagas MR, Lee TK, Le Marchand L, Mackie RM, Olsson H,Østerlind A, Rebbeck TR, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, ZensMS, Newton-Bishop JA. Sun exposure and melanoma risk at different latitudes: a pooledanalysis of 5700 cases and 7216 controls. Int J Epidemiol. 2009 Jun;38(3):814-30. Epub2009 Apr 8.- Lauer FT, Mitchell LA, Bedrick E, McDonald JD, Lee WY, Li WW, H, Amaya MA,Berwick M, Gonzales M, Currey R, Pingitore NE Jr, Burchiel SW. Temporal-spatialanalysis of U.S.-Mexico border environmental fine and coarse PM air sample extractactivity in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2009 Jul1;238(1):1-10. Epub 2009 May 3.- Scope A, Marghoob AA, Chen CS, Lieb JA, Weinstock MA, Halpern AC; SONIC StudyGroup Dermoscopic patterns and subclinical melanocytic nests in normal-appearingskin. Br J Dermatol. 2009 Jun;160(6):1318-21. Epub 2009 Mar 11. Collaborators:Dusza SW, Oliveria SA, Geller AC, Satagopen J, Berwick M, Henegan MK, Bishop M.- Yang J, Guo H, Gallazzi F, Berwick M, Padilla RS, Miao Y. Evaluation of a Novel Arg-Gly-Asp-Conjugated alpha-Melanocyte Stimulating Hormone Hybrid Peptide forPotential Melanoma Therapy. Bioconjug Chem. 2009 Jun 24. [Epub ahead of print]- Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health.. DermatologicalClinicals. :. 27:205-14, 2009Edward Bedrick, Ph.D.- Moorjani GR, Bedrick EJ, Michael AA, P eisajovich A, Sibbitt WL Jr, Bankhurst AD.Integration of safety technologies into rheumatology and orthopedics practices: arandomized, controlled trial. Arthritis Rheum. 2008 Jul;58(7):1907-14.- Nunez SE, Bedrick EJ, Kettwich SC, Kettwich LG, Bankhurst AD, Sibbitt WL Jr. Arandomized, controlled trial of the reciprocating procedure device for local anesthesia. JEmerg Med. 2008 Aug;35(2):119-25. Epub 2008 Feb 20.- Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, HuntWC, Lindsey DE, Gabaldon D, Zager PG; DCI Medical Directors. Age-related bloodpressure patterns and blood pressure variability among hemodialysis patients. Clin J AmSoc Nephrol. 2008 Sep;3(5):1407-14. Epub 2008 Aug 13.- Cao C, Backer JM, Laporte J, Bedrick EJ, Wandinger-Ness A. Sequential actions ofmyotubularin lipid phosphatases regulate endosomal PI(3)P and growth factor receptortrafficking. Mol Biol Cell. 2008 Aug;19(8):3334-46. Epub 2008 Jun 4.- Lauer FT, Mitchell LA, Bedrick E, McDonald JD, Lee WY, Li WW, Olvera H, AmayaMA, Berwick M, Gonzales M, Currey R, Pingitore NE Jr, Burchiel SW. Temporalspatialanalysis of U.S.-Mexico border environmental fine and coarse PM air sampleextract activity in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2009 Jul1;238(1):1-10. Epub 2009 May 3.Linda Cook, Ph.D.- Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends inCanada: analysis by birth cohort and period of diagnosis. Liver Int. 2008Nov;28(9):1272-9. Epub 2008 Apr 1.100

- Adolphe A, Cook LS, Huang X. A cross-sectional study of intima-media thickness,ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. MayoClin Proc. 2009 Mar;84(3):218-20.- Mack LA, Cook LS, Temple WJ, Carlson LE, Hilsden RJ, Paolucci EO. Colorectalcancer screening among first-degree relatives of colorectal cancer patients: benefits andbarriers. Ann Surg Oncol. 2009 Aug;16(8):2092-100. Epub 2009 May 29.Melissa Gonzales, Ph.D.- Lauer FT, Mitchell LA, Bedrick E, McDonald JD, Lee WY, Li WW, Olvera H, AmayaMA, Berwick M, Gonzales M, Currey R, Pingitore NE Jr, Burchiel SW. Temporalspatialanalysis of U.S.-Mexico border environmental fine and coarse PM air sampleextract activity in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2009 Jul1;238(1):1-10. Epub 2009 May 3.Deirdre Hill, Ph.D.- Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, ColtJS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA,Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, WardMH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P. Etiologic heterogeneity amongnon-Hodgkin lymphoma subtypes. Blood. 2008 Dec 15;112(13):5150-60. Epub 2008Sep 16.Richard Hoffman, M.D., MPH- Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM. Prostatecancer incidence among American Indian and Alaska Native men, US, 1999-2004.Cancer. 2008 Sep 1;113(5 Suppl):1203-12.- Carney PA, Hoffman RM, Lieberman DA, Hornbrook MC, Dietrich AJ, Klabunde CN.Data systems to evaluate colorectal cancer screening practices and outcomes at thepopulation level. Med Care. 2008 Sep;46(9 Suppl 1):S132-7.- Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Bloodglucose monitoring is associated with better glycemic control in type 2 diabetes: adatabase study. J Gen Intern Med. 2009 Jan;24(1):48-52. Epub 2008 Oct 31- Hoffman RM. Re: Offering annual fecal occult blood tests at Annual Flu Shot ClinicsIncreases Colorectal Cancer Screening Rates. Annals of Family Medicine. :. 7:17, 2009- Hoffman RM. Re: Selenium and vitamin E, alone or together did not prevent prostatecancer.. Annals of Internal Medicine. :. 150:JC3-10, JC 3-11, 2009.- Othman M, Bradley AG, Hoffman RM, Roy P. Variable stiffness colonoscope versusregular adult colonoscope: a meta-analysis of randomized controlledtrials..Gastrointestinal Endoscopy. :. 41:17-24, 2009.- Hoffman RM. Informed decision making for prostate cancer treatment.. JAMA : 2009http://jama-assn.org/chi/eletters/301/20/2141#447Huning Kang, Ph.D.- Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ, PotterJW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann MA, RellingMV,den Boer ML, Willman CL, Carroll WL; Children's Oncology Group Study; Dutch101

Childhood Oncology Group; German Cooperative Study Group for Childhood AcuteLymphoblastic Leukemia. Gene expression signatures predictive of early response andoutcome in high-risk childhood acute lymphoblastic leukemia: A Children's OncologyGroup Study [corrected]. J Clin Oncol. 2008 Sep 20;26(27):4376-84Irena King, Ph.D.- Shannon J, King IB, Lampe JW, Gao DL, Ray RM, Lin MG, Stalsberg H, Thomas DB.Erythrocyte fatty acids and risk of proliferative and nonproliferative fibrocystic disease inwomen in Shanghai, China. Am J Clin Nutr. 2009 Jan;89(1):265-76. Epub 2008 Dec 3.- Takata Y, King IB, Neuhouser ML, Schaffer S, Barnett M, Thornquist M, Peters U,Goodman GE. Association of serum phospholipid fatty acids with breast cancer riskamong postmenopausal cigarette smokers. Cancer Causes Control. 2009 May;20(4):497-504. Epub 2009 Mar 3.- Lemaitre RN, King IB, Sotoodehnia N, Rea TD, Raghunathan TE, Rice KM, Lumley TS,Knopp RH, Cobb LA, Copass MK, Siscovick DS. Red blood cell membrane alphalinolenicacid and the risk of sudden cardiac arrest. Metabolism. 2009 Apr;58(4):534-40.Sang-Joon Lee, Ph.D.- Verschraegen C, Raftopoulo H, Feit K, De Jager R, Lee SJ, Sweeney C,. A phase I studyof the combination of TZT-1027 and Gemcitabine administered on day 1 and 8 everythree weeks to patients with advanced or metastatic solid tumors.. The Internet Journal ofOncology. :. 5:1, 2008- Pacheco AV, Rasila K, Lee SJ, Verschraegen C, Rabinowitz I, Elias L, Lee FC. Phase IIstudies of antiangiogenic four drug regimens for the treatment of advanced renal cellcarcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.. Urologic Oncology.:. 26:610-615, 2008.- Lee SJ, Gounder M, Rubin EH, Li JM, Gu Z, Thalasila A, Loyer E, Kudelka AP,Verschraegen CF. Optimal modeling for phase I design of a two drug combination-resultsof a phase I study of cisplatin with 9-nitrocamptothecin.. Investigational New Drugs. :.26:541-551, 2008.- Sayar, Z. Shen, S. J. Lee, M. Royce, I. Rabinowitz, F. Lee, H. Smith, S. Eberhardt, A.Maestas, H. Lu and C. Verschraegen. Phase I study of capecitabine in combination withcisplatin and irinotecan in patients with advanced solid malignancies, InvestigationalNew Drugs, Volume 27 (2): 153-158, 2009.- Armien, Anibal; Armien, Blas; Koster, Frederick; Avila, Mario; Gonzalez, Publio;Pascale, Juan; de la Cruz, Manuel; Saldivar, Yamitzel; Mendoza, Yaxelis; Gracia,Fernando; Hjelle, Brian; Lee, Sang-Joon; Yates, Terry; Salazar-Bravo, Jorge. HantavirusInfection and Habitat Associations among Rodent Populations in Agroecosystems ofPanama: Implications for Human Disease Risk: American Journal of Tropical Medicine& Hygiene, 81: 59-66, 2009.Glen Murata, M.D.- Tzamaloukas AH, Ing TS, Siamopoulos KC, Raj DS, Elisaf MS, Rohrscheib M, MurataGH. Pathophysiology and management of fluid and electrolyte disturbances in patientson chronic dialysis with severe hyperglycemia. Semin Dial. 2008 Sep-Oct;21(5):431-9.102

- Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Bloodglucose monitoring is associated with better glycemic control in type 2 diabetes: adatabase study. J Gen Intern Med. 2009 Jan;24(1):48-52. Epub 2008 Oct 31.Orrin Myers, Ph.D.- Breashears DB, Myers OB, Meyer CW, Barnes FJ, Zou CB, Allen CD, McDowell NG,Pockman WT. Tree die-off in response to global-change-type drought: mortality insightsfrom a decade of plant water potential measurements.. Frontiers in Ecology and theEnvironment. :. 7:185-189, 2009- Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, Hunt WC,Lindsey DE, Gabaldon D, Zager PG; DCI Medical Directors. Age-r elated bloodpressure patterns and blood pressure variability among hemodialysis patients. Clin J AmSoc Nephrol. 2008 Sep;3(5):1407-14. Epub 2008 Aug 13.Christine Stidley, Ph.D.- Leng S, Stidley CA, Bernauer AM, Picchi MA, Sheng X, Frasco MA, Van Den Berg D,Gilliland FD, Crowell RE, Belinsky SA. Haplotypes of DNMT1 and DNMT3B areassociated with mutagen sensitivity induced by benzo[a]pyrene diol epoxide amongsmokers. Carcinogenesis. 2008 Jul;29(7):1380-5. Epub 2008 May 21.- Leng S, Bernauer A, Stidley CA, Picchi MA, Sheng X, Frasco MA, Van Den Berg D,Gilliland FD, Crowell RE, Belinsky SA. Association between common genetic variationin Cockayne syndrome A and B genes and nucleotide excision repair capacity amongsmokers. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2062-9.- Belinsky SA, Schiller JH, Stidley CA. DNA methylation biomarkers to assess therapyand chemoprevention for non-small cell lung cancer. Nutr Rev. 2008 Aug;66 Suppl1:S24-6.- Sood A, Stidley CA, Picchi MA, Celedón JC, Gilliland F, Crowell RE, Belinsky SA,Tesfaigzi Y. Difference in airflow obstruction between Hispanic and non-HispanicWhite female smokers. COPD. 2008 Oct;5(5):274-81.- Losa M, Scavini M, Gatti E, Rossini A, Madaschi S, Formenti I, Caumo A, Stidley CA,Lanzi R. Long-term effects of growth hormone replacement therapy on thyroid functionin adults with growth hormone deficiency. Thyroid. 2008 Dec;18(12):1249-54.- Sood A, Qualls C, Seagrave J, Stidley C A, Archibeque T, Berwick M, Schuyler M.Effect of specific allergen inhalation on serum adiponectin in human asthma.. Chest. :.135:287-94, 2009.- Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, Belinsky SA.Concomitant promoter methylation of multiple genes in lung adenocarcinomas fromcurrent, former and never smokers. Carcinogenesis. 2009 Jul;30(7):1132-8. Epub 2009May 12.Charles Wiggins, Ph.D.- Wiggins CL, Perdue DG, Henderson JA, Bruce MG, Lanier AP, Kelley JJ, Seals BF,Espey DK. Gastric cancer among American Indians and Alaska Natives in the UnitedStates, 1999-2004. Cancer. 2008 Sep 1;113(5 Suppl):1225-33.103

- Wiggins CL, Espey DK, Wingo PA, Kaur JS, Wilson RT, Swan J, Miller BA, Jim MA,Kelly JJ, Lanier AP. Cancer among American Indians and Alaska Natives in the UnitedStates, 1999-2004. Cancer. 2008 Sep 1;113(5 Suppl):1142-52.- Espey DK, Wiggins CL, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods forimproving cancer surveillance data in American Indian and Alaska Native populations.Cancer. 2008 Sep 1;113(5 Suppl):1120-30.- Lemrow SM, Perdue DG, Stewart SL, Richardson LC, Jim MA, French HT, Swan J,Edwards BK, Wiggins C, Dickie L, Espey DK. Gallbladder cancer incidence amongAmerican Indians and Alaska Natives, US, 1999-2004. Cancer Epidemiol BiomarkersPrev. 2008 Nov;17(11):3224-32. Epub 2008 Oct 28.- Wayne SJ, Neuhouser ML, Koprowski C, Ulrich CM, Wiggins C, Gilliland F,Baumgartner KB, Baumgartner RN, McTiernan A, Bernstein L, Ballard-Barbash R.Breast cancer survivors who use estrogenic botanical supplements have lower serumestrogen levels than non users. Breast Cancer Res Treat. 2009 Sep;117(1):111-9. Epub2008 Oct 18.- Wayne S, Neuhouser ML, Ulrich CM, Koprowski C, Wiggins C , Baumgartner KB,Bernstein L, Baumgartner RN, Gilliland F, McTiernan A, Ballard-Barbash R.Association between alcohol intake and serum sex hormones and peptides differs bytamoxifen use in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2008Nov;17(11):3224-32. Epub 2008 Oct 28.- Coughlin SS, Richards TB, Nasseri K, Weiss NS, Wiggins CL, Saraiya M, StinchcombDG, Vensor VM, Nielson CM. Cervical cancer incidence in the United States in the US-Mexico border region, 1998-2003. Cancer, 2008 Nov 15;113(10 Suppl):2964-73.G. OUTSIDE SPONSORED RESEARCHMarianne Berwick, Ph.D .(3R28L) Title: Solar Exposure and Melanoma Survival (GEM2)Agency/Sponsor: NCIAmount: $413,130Budget Period: April 1, 2009 – March 31, 2010Project Period: May 6, 2005 – March 31, 2010(3R28L) Title: Solar Exposure and Melanoma Survival (GEM2), Administrative SupplementAgency/Sponsor: NCIAmount: $69,150Budget Period: April 1, 2009 – March 31, 2010Project Period: May 1, 2007 – March 31, 2010(3R22Q) Title: Indoor Tanning Use, DNA Repair and Risk of MelanomaAgency/Sponsor: Subaward, University of MinnesotaAmount: $138,411Budget Period: July 1, 2008 – June 30, 2009Project Period: October 1, 2004 – June 30, 2009(3R34K) Title: Melanoma RAF/BRAF Mutations; Heterogeneity, Risk and Prognosis104

Agency/Sponsor: Subaward, University of North CarolinaAmount: $15,031Budget Period: Apr 1, 2009 – March 31, 2010Project Period: May 13, 2005 – April 30, 2008Kristina Flores, Ph.D.(3R33Q) NARCH – Tribal Community Cancer ControlAgency/Sponsor: Albuquerque Area Indian Health BoardAmount: $166,078Budget Period: September 15, 2008– September 14, 2009Project Period: September 15, 2005 – September 14, 2009(3R58Y) Folate Metabolism & Methylation in Lung CancerAgency/Sponsor: NIH/NCIAmount: $136,894Budget Period: August 1, 2008 – July 31, 2009Project Period: August 20, 2007– July 31, 2012Melissa Gonzales, Ph.D.(3R29Z) Title: Mentored Career Development in Molecular EpidemiologyAgency/Sponsor: NIH/NIEHSAmount: $120,233Budget Period: August 1, 2008 – July 31, 2009Project Period: August 14 2005 – July 31, 2010Deirdre Hill, Ph.D.(3R61M) Title: Cancer Genetics NetworkAgency/Sponsor: Subaward, Massachusetts General HospitalAmount: $76,782Budget Period: May 1, 2008 – April 30, 2009Project Period: May 1, 2007 – April 30, 2010Richard Hoffman, M.D.(3R66G) Title: Race, CoMorbidity and Long Term Prostate Cancer OutcomesAgency/Sponsor: University of Southern CaliforniaAmount: $82,336Budget Period: August 1, 2008 – July 31, 2009Project Period: August 1, 2007 – July 31, 2009(3R65E) Title: Medical EditorAgency/Sponsor: Foundation for Informed Medical Decision-MakingAmount: $23,655Budget Period: July 1, 2008 – June 30, 2009Project Period: November 1, 2007 – June 30, 2010Denece Kesler, M.D.105

(3R65X) Title: New Mexico Occupational Health Surveillance RegistryAgency/Sponsor: NMDOH (Flow Through, CDC, NIOSH)Amount: $5,275Budget Period: July 1, 2008– June 30, 2009Project Period: July 1, 2008 – June 30, 2009(3R68G) Title: New Mexico Radiation Exposure Screening and Education ProgramAgency/Sponsor: HRSAAmount: $231,963Budget Period: September 1, 2008 – August 31, 2009Project Period: September 1, 2003 – August 31, 2009(3R51W) Title: Development of a Medical Surveillance Program for Former Los AlamosNational Laboratory WorkersAgency/Sponsor: DOE, Subaward, Johns HopkinsAmount: $43,434Budget Period: August 10, 2008 – November 30, 2009Project Period: August 10, 2006 – January 31, 2010Orrin Myers, Ph.D.(3R81B) Title: Statistical Support to Valles CalderaAgency/Sponsor: Valles Caldera TrustAmount: $16,917Budget Period: April 14, 2009 – September 30, 2009Project Period: April 14, 2009 – September 30, 2009(3R66V) Title: NM Environmental Public Health Effects TrackingAgency/Sponsor: NMDOHAmount: $50,668Budget Period: January 31, 2009 – June 30, 2009Project Period: July 1, 2008 – June 30, 2009(3R65D) Title: Biostatistical Support to the Jicarilla Apache NationAgency/Sponsor: Jicarilla Apache NationAmount: $9,988Budget Period: December 1, 2007 – November 30, 2008Project Period: December 1, 2007 – November 30, 2008Christine Stidley, Ph.D.(3R78N) Title: Statistical Support for LRRI Lung Cancer ProgramAgency/Sponsor: Lovelace Respiratory Research InstituteAmount: $41,701Budget Period: October 1, 2008 – September 30, 2009Project Period: October 1, 2005 – September 30, 2009(3R76R) Title: Genetic and Epigenetic Biomarkers of Squamous Cell Carcinoma of the Lung106

Agency/Sponsor: Lovelace Biomedical and Environmental Research InstituteAmount: $17,432Budget Period: September 12, 2008 – June 30, 2009Project Period: September 12, 2008 – June 30, 2013(3R79P) Title: Validation of Pan-Species ELISAsAgency/Sponsor: Lovelace Biomedical and Environmental Research InstituteAmount: $31,240Budget Period: September 2, 2008 – July 31, 2009Project Period: September 2, 2008 – July 31, 2009Charles Wiggins, Ph.D.(3R010) Title: SEER – Surveillance, Epidemiology and End Results ProgramAgency/Sponsor: NCIAmount: $15,849,243 (multi-year amount)Budget Period: August 1, 2003 – July 31, 2010Project Period: August 1, 2003 – July 31, 2010(3R37i) Title: Ethnicity, Breast Cancer Recurrence & Long-Term Quality of LifeAgency/Sponsor: University of LouisvilleAmount: $25,000Budget Period: July 1, 2008 – May 31, 2009Project Period: September 09, 2005 – June 30, 2010107

DIVISION OF GASTROENTEROLOGYAND HEPATOLOGY108

DIVISION OF GASTROENTEROLOGY AND HEPATOLOGYANNUAL REPORT: JULY 1, 2008 – JUNE 30, 2009THOMAS Y. MA, MD, PHDPROFESSOR OF MEDICINE, CELL BIOLOGY AND PHYSIOLOGYCHIEF OF GASTROENTEROLOGY AND HEPATOLOGYA. SIGNIFICANT ACCOMPLISHMENTS AND DEVELOPMENTS- During the past academic year (July 1, 2008 – June 30, 2009), Gastroenterology (G.I.)and Hepatology Division has made many important and significant advances in allacademic areas including research, clinical, and educational activities. The G.I.Fellowship Training Program has been greatly upgraded with important changesfurther emphasizing education and training, the research programs have been greatlyenhanced with increases in grant funding and expansion of the basic science researchprogram, and the divisional clinical productivity has remained at a very high levelduring the review period.- The UNM G.I. Division research investigators had an outstanding year as evidencedby over 53 research publications and over $13 million dollars in total researchfunding.Education- For the seventh year in a row, top two percentile of the fellowship applicants werematched into our fellowship program. This emphasizes the highest quality of fellowsin our training program and is further evidence of the excellent progress the Divisionhas made in providing an excellent training program. The G.I. fellowship trainingand education program has been completely overhauled during the past six years tooptimize the training and education experience of the G.I. fellows and rotatingResidents. During the past seven years, the total fellowship positions have beenincreased from 5 to 11 positions. The increase in the number of fellowship positionshas decreased the clinical service burden and increased the training opportunity. Thegastroenterology teaching conferences have been revised and upgraded. Thursdayafternoons (3-4 hours) have been designated strictly for educational conferences. Thecore curriculum conferences are held on a weekly basis and cover the core topics ingastroenterology. The weekly core curriculum module is moderated by a facultymember having an expertise in the selected disease topic. Over the three yearfellowship training program all relevant core topics in G.I. are covered. In addition,Journal Club, Research conferences, monthly clinical case conferences, and biweeklyG.I./Radiology/Surgery combined conferences are held to discuss anyinteresting or difficult clinical cases and relevant clinical topics. For the monthly G.I.Grand Rounds, world-renowned experts in various G.I. diseases are invited to provideinsight into the latest advances in treatment of G.I. diseases. Additionally, six to eightresearch experts are invited throughout the year to discuss the latest advances in G.I.Research. The UNM G.I. Fellowship program is a dynamic program always lookingfor ways to improve the training process. The stated goal of the GastroenterologyDivision is to have the best G.I. Fellowship training program in the country.Clinical109

- The clinical productivity of the G.I. Division remains at a very high level. All of thefaculty continue to have clinical productivity above the top 10th percentile based onclinical RVUs. The total clinical billing for the 2008-2009 academic year was$6,570,601 (compared to $5,603,258 for 2007-2008, $4,658,199 for 2006-2007,$4,287,000 for 2005-2006, $3,899,817 for 2004-2005, $4,013,000 for 2003-2004,$3,516,000 for 2002-2003 and $2,517,000 for 2001-2002). The total G.I. Divisionrevenue generated for the 2008-2009 academic year was $1,941, 960 (compared to$1,659,557 for 2007-2008, $1,379,937 for 2006-2007, $1,048,704 for 2005-2006 and$975,817 for 2004-2005 and $1,139,000 for 2003-2004 and $996,000 for 2002-2003and $640,000 for the 2001-2002). Thus, the overall clinical productivity of the G.I.Division remains outstanding.Research- With the arrival of Dr. Thomas Ma as the Division Chief in January, 2002, there hasbeen a major expansion of basic and clinical research programs. Recent additions ofDr. Henry C. Lin (clinician and lab scientist with expertise in translational research inthe fields of intestinal motility and transit) as the Chief of G.I. Section at the VAMCfurther strengthen the expanding G.I. research program. The total research funding inG.I. Division exceeds $13 million in research funding. As a comparison, the totalresearch funding in 2000-2001 academic year was zero. Thus, the growth in researchfunding has been outstanding. There were over 53 publications from the Divisionduring the academic year. Several faculty have international reputation in researchand serve on key national research grant study sections. Dr. Ma serves as Chair ofVA Merit Review Board and member of NIH study sections, Dr. Boedeker serves asa member of NIH study section and Dr. Lin serves on a NIH study section.- The research program and research opportunity for the G.I. fellows have also beengreatly expanded during the past three and a half years. All G.I. fellows have beenprovided with minimum of 6 months of protected time for research and given anopportunity to pursue both clinical and basic science research. With greater emphasisand opportunity for research involvement, all second and third year G.I. fellows haveparticipated in important research projects and have presented abstracts at a nationalor regional scientific meeting.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURE- A major goal for the G.I. Division in the upcoming year is to expand on theimprovements achieved during the last academic year in education, research, andclinical activities. A top priority of the Division is to continue expansion of G.I.endoscopic procedure area. Additionally new plans have been developed forestablishment of off-site center for G.I. Ambulatory Services.- One of the top priorities of the Division continues to be Faculty recruitment. Sincethe demand for G.I. services remains very high, recruitment of new Faculty remainsan important priority. The goal for the upcoming year is to recruit 2 new faculty atUNMHSC and 1 new faculty at the VAMC.- An important goal for the Division is to continue to increase funding in both clinicaland basic research in the new academic year.110

- During the last three years, a major initiative in the complete re-hauling of theeducation program was undertaken. The new changes have made a huge impact inthe fellowship training program. Full implementation of education activities willcontinue to occur in the 2009-2010 Academic Year and beyond.C. APPOINTMENTS TO FACULTY AND STAFFFaculty:NoneStaff: Shanriqa Bravo, Clinic Coordinator, September 2008Jamie Wier, Fellowship Coordinator, September 2008Shuhong Guo, Associate Scientist, September 2008Wentao Luo, Research Technician II, May 2009Bala Ramadass, Post-doc, July 2009D. SEPARATIONS OF FACULTY AND STAFFFaculty: Tong Jing, Assistant Professor of Medicine, November 2008Jeffrey Dunkelberg, Professor of Medicine, May 2009Staff: Lisa Finley, Fellowship Coordinator, July 2008Jamie Wier, Fellowship Coordinator, November 2008Erin O’Keefe, Research Tech III, May 2009E. PUBLICATIONS OF THE DIVISION’S FACULTYAl-Sadi, Rana M.- Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tightjunction barrier. Review. Frontiers of Bioscience . 2009; 14:2765-78Arora, Sanjeev- Yu S, Douglass JM, Qualls C, Arora S, Dunkelburg JC. “Response to Therapy withPegylated Interferon and Ribavirin for Chronic Hepatitis C In Hispanics Compared toNon-Hispanic Whites,” American Journal of Gastroentrology. Accepted for Publication2008.- Berkley, EM, Leslie, KK, Arora, S, Qualls, C, Dunkelberg, JC. “Chronic Hepatitis C inPregnancy,” Obstet Gynecol. 2008 Aug;112(2 Pt 1):304-10.- Geppert CM, Arora S. “Widening the Door: The Evolution of Hepatitis C Treatment inPatients with Psychiatric Disorders,” Hepatology. 2007 Oct;46(4):957-9.- Arora S, Thornton K, Jenkusky SM, Parish B, Scaletti JV. “Project ECHO: LinkingUniversity Specialists with Rural and Prison-Based Clinicians to Improve Care forPeople with Chronic Hepatitis C in New Mexico,” Public Health Rep. 2007;122 Suppl2:74-7.- Gish RG, Arora S, Rajender Reddy K, Nelson DR, O’Brien C, Xu Y, Murphy B.“Virological Response and Safety Outcomes in Therapy-Naïve Patients Treated for111

Chronic Hepatitis C with Taribavirin or Ribavirin in Combination with PegylatedInterferon alfa-2a: A Randomized, Phase 2 Study,” J Hepatol. 2007 Jul;47(1):51-9. Epub2007 Mar 12.- Sanjeev Arora, M.D., Glen H. Murata, M.D., Karla Thornton, M.D., Brooke Parish,M.D., Steven M. Jenkusky, M.D., Jeffrey C. Dunkelberg, M.D., Richard M. Hoffman,M.D., Miriam Komaromy, M.D.. Abstract. “Project ECHO (Extension for CommunityHealthcare Outcomes): Knowledge Networks Expand Access to Hepatitis C (HCV)Treatment with Pegylated Interferon and Ribavirin in Rural Areas and Prisons. Care is asSafe and Effective as a University HCV Clinic,” Digestive Disease Week AnnualMeeting, San Diego, CA, May 18-21, 2008, abstract published in Gastroenterology, Vol.134, Issue, 4, Supplement 1, A-50-A-51, April 2008.Boedeker, Edgar C.Journal Articles- Malyukova I, Murray KF, Zhu C, Boedeker E, Kane A, Patterson K, Peterson JR,Donowitz M, Kovbasnjuk O. Macropinocytosis in Shiga toxin 1 uptake by humanintestinal epithelial cells and transcellular transcytosis. Am J Physiol Gastrointest LiverPhysiol. 2009 Jan;296(1):G78-92. Epub 2008 OctBook Chapters- Serna, A. and Boedeker EC. Pathogenesis and treatment of Shiga toxin-producingEscherichia coli infections. Curr. Opin. Gastroenterol. 24:38-47. (2008)Editorials- Boedeker EC: Gastrointestinal infections, an overview: from pathogens to metagenomes.Curr. Opin. Gastroenterol. 2008, 24:1-3.Abstracts- Serna A., Zhu, C, Okeefe E, Nugent A, Boedeker E. Ciprofloxacin In Rabbits InfectedWith A Shiga-Toxin (Stx)-Producing E. Coli (STEC) Strain Leads To Worse ClinicalOutcome And Increased Toxin Release Gastroenterology 134: A- 2008.- Kpadeh Z , Frank D, Boedeker E, Harpaz N, Sartor RB, Li E. NOD2 Risk Allele isAssociated with Microbial Community Imbalances in Human Inflammatory BowelDisease. Gastroenterology 136 A- 2009- Irina Malyukova I, Boedeker E, Donowitz M, Kovbasnjuk O. Shiga toxin 1 uptake byintestinal epithelial cells is Cdc-42 mediated and clathrin-independent Gastroenterology136 A- 2009- O'Keefe E, Boedeker E. Clonal Invasive Escherichia coli Isolates from InflammatoryBowel Disease (IBD) Resections. Gastroenterology 136 A- 2009- Othman M, O'Keefe E, Crane J, Boedeker E. Zinc Protects Rabbit Ileal Loops AgainstPathogenic Effects of Shiga-Toxin Producing E.coli. Gastroenterology 136 A- 2009- Ruiz-Perez F, Byrd W, O'Keefe E, Zhu C, Boedeker E. Secretion of the Shiga toxin Bsubunit (Stx 1B) via autotransporter proteins optimizes systemic immune response to theantigen expressed in attenuated Escherichia coli (E. coli) vaccine strains. Abstracts of theOne Hundred and Eighth Gen.Mtng.of the Amer .Soc.for Microbiology , May 2009112

- Byrd W, O'Keefe E, Boedeker E. Toward A Live Attenuated Escherichia coli Vaccinefor Enterotoxigenic Escherichia coli (ETEC) Abstracts of the One Hundred and EighthGen.Mtng.of the Amer .Soc.for Microbiology , May 2009- Byrd W, O'Keefe, Crane J, Boedeker E. Zinc Protects Rabbit Ileal Loops AgainstPathogenic Effects of Shiga-Toxin 1 (Stx1)-Producing E.coli (strain RDEC-H19A)Abstracts of the One Hundred and Eighth Gen. Mtng. of the Amer. Soc. forMicrobiology, May 2009- Kpadeh Z, O'Keefe E, Boedeker E. ATG Risk Alleles Are Associated With InvasiveE.coli with Prolonged Macrophage Survival in Human Inflammatory Bowel DiseaseTissues. Submitted to the Annual Meeting of the Society for Mucosal Immunology,Boston MA July 2009.Dunkelberg, Jeffrey C.- Berkley E, Leslie K, Arora S, Qualls C, Dunkelberg J. 2008. “Chronic hepatitis C inpregnancy.” Obstetrics and Gynecology 112(2):304-310.- Othman M, Dunkelberg J, Arora S. 2008. Hepatitis B and Hepatitis C. In Press.Evidence-Based Internal Medicine Solutions.- Yu S, Douglass J, Qualls C, Arora S, Dunkelberg J. 2008. “Hispanic patients with- Genotype 2 or 3 chronic hepatitis C have lower rates of sustained virologic response totreatment with pegylated interferon and ribavirin.” In Press. American Journal ofGastroenterology- DiLauro S, Dunkelberg J, Kistin MG, Barakat J, Wiggins C. “Trends in hepatocellularcarcinoma in New Mexico, 1973-2004.” In preparation.- Othman M, Dunkelberg J, Roy P. 2008. “A systematic review of ursodeoxycholic acidtreatment for primary sclerosing cholangitis.” 2008. In preparation.- Brandes R, Dunkelberg J. “An unusual cause of liver failure in a 17 year old pregnantwoman.” 2008. In preparation.- Arora S, Murata G, Thornton K, Jenkusky S, Parish B, Dunkelberg J, Deming P. 2008.“Project ECHO (Extension for Community Healthcare Outcomes): Knowledge networksexpand access to hepatitis C (HCV) treatment with pegylated interferon and ribavirin inrural areas and prisons. Care is as safe and effective as a University HCV clinic.” 13 thInternational Symposium on Viral Hepatitis and Liver Disease. Washington, DC.- Arora S, Murata G, Thornton K, Jenkusky S, Parish B, Dunkelberg J, Deming P. 2009.“Project ECHO (Extension for Community Healthcare Outcomes): Knowledge networksexpand access to hepatitis C (HCV) treatment with pegylated interferon and ribavirin inrural areas and prisons. Care is as safe and effective as a University HCV clinic.”Submitted as a late-breaking abstract to AGA/DDW.Shuhong Guo- Guo Shuhong, Miyake Minoru, Liu Ke Jian, Shi Honglian, Specific inhibition ofhypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia throughdeteriorating cellular redox environment, Journal of Neurochemistry 2009, 108 (5): 1309-1321.- Nadjar Agnes, Berton Olivier, Guo Shuhong, Leneuve Patricia, Dovero Sandra, DiguetElsa, Tison Francois, Zhao Baolu, Holzenberger Martin, Bezard Erwan, IGF-1 signaling113

educecs neuron-inflammatory response and sensitivity of neurons to MPTP,Neurobiology of Aging (accepted, Epub ahead of print).- Guo Shuhong, Bragina Olga, XuyYuexian, Cao Zongxian, Chen Hu, Zhou Bo, MorganMarilee, Jiang Binghua, Lin Yong, L iu Kejian, Shi Honglian, Glucose upregulates HIF-1ÿ expression in primary cortical neurons in response to hypoxia through maintainingcellular redox status, Journal of Neurochemistry 2008, 105 (5): 1849-1860Lin, Henry C.- Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW,- Nowak T, Nusynowitz ML, Parkman HP, Shreve P, Szarka LA, Snape WJ Jr, ZiessmanHA; American Neurogastroenterology and Motility Society and the Society of NuclearMedicine. Consensus recommendations for gastric emptying scintigraphy: a jointreport of the American Neurogastroenterology and Motility Society and theSociety of Nuclear Medicine. J Nucl Med Technol 2008;36(1):44-54- Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and humandisease. Current Opinion in Gastroenterology 2008;24(1):11-16.- Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW,Nowak T, Nusynowitz ML, Parkman HP, Shreve P, Szarka LA, Snape WJ Jr, ZiessmanHA; American Neurogastroenterology and Motility Society and the Society of NuclearMedicine. Consensus recommendations for gastric emptying scintigraphy: a jointreport of the American Neurogastroenterology and Motility Society and theSociety of Nuclear Medicine. Am J Gastroenterol 2008;103(3):753-63.- Weinstock LB; Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patientswith interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci 2008;53(5):1246-51- Al-khatib K, Lin HC. Gut Microbes, Immune Activation and IBS. Gut and Liver 2009;3(1): 14-19.- Nakamura M, Lin HC, McSweeney CS, Mackie RI, Gaskins HR. Mechanisms ofhydrogen disposal in the human colon and implications for health and disease. Ann RevFood Science & Technology (in press) 2009Book Chapters- Stone E and Lin HC. Eating Disorders. Chapter in Textbook of Gastroenterology, ed. T.Yamada (in press).Ma, Thomas Y.- Dokladny K, Kennedy J, Ye D, Ma TY. Molecular mechanisms of physiologicallyrelevant heat exposure-induced up-regulation of occludin protein expression: regulatoryrole of heat shock factor-1. Am J Pathol 172(3):659-70, 2008.- Al-Sadi RM, Ye D, Dokladny K, Ma TY. Myosin light chain kinase (MLCK) mediatesthe IL-1ÿ induced increase in intestinal epithelial tight junction permeability. J Immunol15;180(8):5653-61, 2008.- Dokladny K, Walker W, Ma TY, Moseley P. Lack of cross-tolerance following heat andcadmium exposure in functional MDCK monolayers. J Applied Toxicology 7;885-94,2008.114

- Ye D, Ma TY. Cellular and molecular mechanism of myosin light chain kinase (MLCK)promoter activity regulation. J Cell Mol Med 12;1331-46, 2008.- Lynch BC, Lathrop SL, Ye D, Ma TY, Cerilli LA. Expression of the p16(INK4a) geneproduct in premalignant and malignant epithelial lesions of the gallbladder. Ann DiagnPathol 12(3):161-4, 2008.- Boivin M, Roy PK, Bradley A, Kennedy JC, Rihani T, Ma TY. Mechanism of interferongamma-induced increase in T84 intestinal epithelial tight junction. J Interferon andCytokine Res. 2009 Jan;29(1):45-54.- Subramanian V, Marchant J, Boulware M, Ma TY, Said H. Membrane targeting andintracellular trafficking of the human sodium-dependent multivitamin transporter(hSMVT) in polarized epithelial cells. Am J Physiol Cell Physiol. 2009 Apr;296(4):C663-71.- Al-Sadi RM, Boivin M, Ma TY. Mechanism of cytokine modulation of intestinal tightjunction barrier. Frontiers Biological Sciences. (In-Press).- Ma TY, Anderson JM. Tight junctions and intestinal barrier. In Johnson LR ed.Physiology of the Gastrointestinal Tract. 4 th ed. Elsevier Academic Press; Burlington,MA; 2006; 1559-1594. (Book Chapter)McCarthy, Denis M.- McCarthy, DM. Do drugs or bugs cause GERD? J Clin Gastroenterol 41(suppl 2):S59-S63 2007.- McCarthy DM. Gastrointestinal Bleeding: Problems That Persist (Editorial)Gastrointestinal Endoscopy 2009; 70 (2): 225-228.Parasher, Gulshan- Parasher G, Chang KJ. Perspectives and the future of Endoscopic Ultrasound.Endoscopic Ultrasound in Gastroenterology. Ardengh JC and Eds. Rubio Publishers (Inpress) 2008.Ye, Dongmei- Bridget C Lynch, Sarah L Lathrop, Dongmei Ye, Thomas Y Ma, Lisa A Cerilli“Expression of the p16 (INK4a) gene product in premalignant and malignant epitheliallesions of the gallbladder.”, Ann Diagn Pathol., 2008, 12(3):161-4.- Dongmei Ye, Thomas Y Ma, “Cellular and Molecular Mechanisms that Mediate theBasal and Tumor Necrosis Factor-ÿ Induced Regulation of Myosin Light Chain KinaseGene Activity”, J Cell and Mol Med., 2008, Mar 17.- Rana Al-Sadi, Dongmei Ye, Thomas Y Ma, “Mechanism of IL-1{beta}-Induced Increasein Intestinal Epithelial Tight Junction Permeability”, J Immunol., 2008, 180(8): 5653-61.- Karol Dokladny, Dongmei Ye, John C Kennedy, Pope L Moseley, Thomas Y Ma,“Cellular and molecular mechanisms of heat stress-induced up-regulation of occludinprotein expression: Regulatory role of heat shock factor-1”, Am J Pathol., 2008, 172(3):659-70.115

F. OUTSIDE PROFESSIONAL ACTIVITIES OF FACULTY AND STAFFArora, SanjeevMedical Executive CommitteeClinical Operations Group of UNMHSCUncompensated Care Task ForcePatient & Referring Physician Satisfaction Committee, UNMHMember, American Gastroenterology AssociationFellow, American College of Physicians-American Society of Internal MedicineMember, American Association for the Advancement of SciencesFellow, American College of GastroenterologyAmerican society of Gastrointestinal Endoscopy (ASGE)Practice Management Committee of ASGEGreater Albuquerque Medical AssociationProgram Chairman (Dr. Arora)Course Director, Update and Review of Internal Medicine, Annual conference October 19-24,2008Barakat, JehadAmerican Gastroenterology AssociationAmerican Society for Gastrointestinal EndoscopyPeer Journal Reviewer:a. Alimentary Pharmacology & Therapeutics Journalb. American Journal of Gastroenterologyc. Digestive Diseases and Sciencesd. Journal of the American College of SurgeonsBoedeker, Edgar C.1974-present1976-present1976-present1976-present1977-present1982-present1984-present1984-present1985-present2000-presentAmerican College of PhysiciansAmerican Gastroenterological AssociationAmerican Federation for Clinical (Medical) ResearchAmerican Association for the Study of Liver DiseaseAmerican Society for Gastrointestinal EndoscopyAmerican Society for MicrobiologyInfectious Diseases Society of AmericaGastroenterology Research GroupNorth American Society for Pediatric GastroenterologyAmerican College of GastroenterologyNational Service/Peer Review Work1983-present Grants Reviewer, Canadian Foundation for Ileitis and Colitis1990-present NIH Reviewers Reserve2006 Jun-present Permanent Member Member NIDDK/NIH Mucosal Pathobiology (MPB)study section2008 Nov Invited reviewer, NIDDK Digestive Disease Center Applications,116

Washington DCEditorial Tasks1979-present Reviewer, Gastroenterology1981-present Reviewer, J Clin Inv1982-present Reviewer, J Ped Gastro & Nutr1983-present Reviewer, Ann Int Med1985-present Reviewer, Infect Immun1988-present Reviewer, Rev Infect Dis1993-2008 Editor, Gastrointestinal Infections, Current Opinion in GastroenterologyDunkelberg, Jeffrey C.American Gastroenterological AssociationAmerican Association for the Study of Liver DiseasesKistin, Martin G.MembershipAmerican Gastroenterological AssociationAmerican College of Gastroenterology, Past GovernorAmerican Society of Gastrointestinal EndoscopyAmerican College of PhysiciansAssociation of Specialty ProfessorsOther extramural professional activitiesAd hoc reviewing for journal Digestive Diseases and SciencesMember CPI (Clinical Prevention Initiative) for colorectal cancer screening, Albuquerque, NMLin, Henry C.MembershipAmerican College of PhysiciansAmerican Gastroenterological AssociationAmerican Motility SocietyAmerican Physiological SocietyInternational Group for the Study of Neurogastroenterology and MotilityAmerican Microbiology SocietyFederal Government Study SectionsSmall business study section, National Institute of Diabetes and Digestive and Kidney Diseases,March, 2008Program Project Study Section, National Institute of Diabetes and Digestive and KidneyDiseases, November, 2008Editorial BoardsBoard member, Digestive Disease Sciences, 1999-presentEditor, Digestive Disease & Sciences, 2000-presentBoard member, Am J of Physiology: Gastrointestinal and Liver Physiology, 2003-presentJournal Reviews117

American Journal of Clinical NutritionAmerican Journal of GastroenterologyAmerican Journal of MedicineAmerican Journal of Physiology: GI and Liver PhysiologyAmerican Journal of Physiology: Regulatory PhysiologyClinical Gastroenterology and HepatologyDigestionDigestive Diseases and SciencesDigestive and Liver DiseasesEndocrinologyEuropean Journal of Gastroenterology and HepatologyGastroenterologyJournal of Applied PhysiologyJournal of Comparative NeurologyJournal of Clinical GastroenterologyJournal of Endocrinology and MetabolismJournal of Gastroenterology, Hepatology and NutritionJournal of Pediatric Gastroenterology and NutritionJournal of PhysiologyNature Clinical Practice: Gastroenterology and HepatologyNeurogastroenterology and MotilityPeptidesRegulatory PeptidesMa, Thomas Y.Membership:American Association for the Advancement of ScienceAmerican College of Gastroenterology (Fellow)American College of Physicians-American Society of Internal Medicine (Fellow)American Gastroenterological AssociationAmerican Physiological SocietyCrohn’s & Colitis Foundation of AmericaNew York Academy of SciencesWestern Association of PhysiciansAssociation of Subspecialty PhysiciansReviewer, Peer-Reviewed Medical and Scientific Journals:American Journal of Clinical NutritionAmerican Journal of GastroenterologyAmerican Journal of PathologyAmerican Journal of Physiology: Cell PhysiologyAmerican Journal of Physiology: Gastrointestinal PhysiologyCanadian Journal of GastroenterologyDigestionDigestive Disease and ScienceGastroenterology118

GutHepatologyJournal of Bioactive PolymersJournal of Cellular PhysiologyJournal of Clinical InvestigationJournal of Laboratory and Clinical MedicineJournal of Parenteral & Enteral NutritionNutritionProceedings of Society of Experimental Medicine and BiologyProstaglandinsService for National, International Medical Associations and Foundations:Organizer and Chair for the GI Section of annual meeting of Western Society of ClinicalInvestigators in Carmel, CA (2008-2009)Council Member for Western Association of Professors (2006 to Present)National and International Grant Review Board Participation:NIH Study Section: Member, Special Emphasis Panel Challenge grants (5/2009)NIH Study Section: Member, Special Emphasis Panel U34 grants (4/2009)VA Merit Review Study Section: Chairman, Gastroenterology Section (2007-2010)VA Merit Review Study Section: Member, Gastroenterology Section (2006-2009)McCarthy, Denis M.Member Western Society for Clinical Investigation, 1981- PresentMember New York Academy of Sciences, 1983-PresentMember Western Association of Physicians, 1991-PresesntAmerican Gastroenterological Association Fellow, 2006- PresentEditorial & ReviewRegular reviewer for Gastroenterology, Journal of the American Medical Association,Gastrointestinal Endoscopy, Annals of Internal Medicine, GUT, Alimentary Pharmacology &TherapyNew England Journal of Medicine, American Journal of Gastroenterology, Digestive Diseasesand Sciences, Practical Gastroenteorloyg, Hepatology, Pediatric Gastroenterology & Nutrition,Psychomatic MedicineEditorial Board Member: Journal of Clinical GastroenterologyEditorial Board Member: Digestive diseases and SciencesParasher, GulshanAmerican College of Gastroenterology (NM), GovernorAmerican College of Gastroenterology, National Patient Care Committee, MemberAmerican College of Gastroenterology, FellowAmerican College of Physician, FellowAmerican Endosonography Club, MemberAmerican Gastroenterological Association, MemberAmerican Medical Association, Associate Member119

American Society of Gastrointestinal Endoscopy, MemberGlobal Academic Faculty – Gastrohep.comMedical Society of the State of New York, Associate MemberWestern Society of Medical Research, MemberSpector, MonroeAmerican College of Gastroenterology, FellowAmerican College of Physicians-American Society of Internal Medicine, FellowAmerican Medical Association, MemberAmerican Society for Gastrointestinal Endoscopy, MemberStrickland, Robert G.Albuquerque and Bernalillo Medical AssociationAmerican Association for Study of Liver DiseasesAmerican College of Physicians, FellowAmerican Federation for Medical Research FoundationAmerican Gastroenterological AssociationAmerican Society of Gastrointestinal EndoscopyAssociation of Professors of MedicineAustralian Medical AssociationFellow, Royal Australasian College of PhysiciansGastroenterological Society of AustraliaNew Mexico Medical SocietySociety for Experimental Biology and MedicineThe Royal Society of MedicineWestern Association of PhysiciansWestern Society of Clinical InvestigationG. OUTSIDE SPONSORED RESEARCHSanjeev Arora, MD.Grant Awards:- Expansion of Rural Health Care Research Infrastructure through the ECHO Model.Federal funding source: Agency for Healthcare Research and Quality, Minority ResearchInfrastructure Support Program (M-RISP). Start date: 09/21/2007-08/31/10. Amount:$1.5 million over 3 years.- Demonstration and Replication of the ECHO Model: A Robust Paradigm to Expand BestPractice Care for Vulnerable Populations. Funding source: Robert Wood JohnsonFoundation. Date: 02/15/09 – 02-14-12. Amount: $ 5 million over 3 years.Outside sponsored Research- A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with PeginterferonAlfa 2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naïve Subjects withGenotype 1 Chronic Hepatitis C VX950-108. $165,643.00- Vx-950-TiDP24-C216 "A Randomized, Double blind, Placebo-controlled, Phase III Trialof 2 Regimens of Telaprevir (with and without delayed start) Combined with Pegylated120

Interferon alfa-2a (Pegtasys) and Ribavirin (Copegus) in Subjects with Chronic Genotype1 Hepatitis C Infection who Failed Prior Pegylated Interferon Plus Ribavirin Treatment.- MV21371/A (Roche) A Randomized, Open-Label, Multicenter Study Examining theEffects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS®(Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained VirologicalResponse in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve aRapid Viral Response.- VX08-950-111 (Vertex) A Randomized Study of Stopping Treatment at 24 Weeks orContinuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) WhileReceiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®).- A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a(Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (GroupA) of Study VX06-950-106 Who do not Achieve or Maintain an Undetectable HCVRNA Level Through Sustained Viral Response, $150,000.- A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a(Pegasys®), and Ribavirin (Copegus® ) in Subjects with Genotype 1 Hepatitis C WhoHave Not Achieved Sustained Viral Response with a Prior Course of Interferon-BasedTherapy, VX-950-106 and 107 rollover, HRRC 07-041, $162,500. Closed June 4, 2009.Boedeker, Edgar C.Agency: NIDDK Type: RO1DK59012-O1A1Period: 9/1/01 – 6/30/09 $400,000Title: “Intervention Strategies for Hemorrhagic Colitis and Hemolytic Uremic Syndrome(HUS)”.Agency: Department of Veterans Affairs Type: VA/DOD Merit Review AwardPeriod: 4/1/00 - 3/28/10 $700,000Title: “Attaching/Effacing E.coli as Vaccine Vectors”Henry C. Lin- Does small intestinal bacterial overgrowth contribute to functional dyspepsia, NIH R21,Principal Investigator, 2008- 2010 $325,710- Bacterial Overgrowth Associated with Chronic Multisymptom Illness Complex, VAMerit Review, Principal Investigator, 2009- 2012 $450,000- Small Intestinal Microbial Community in Gulf War Illness, Department of Defense,Congressionally Directed Medical Research Program, Principal Investigator, 2009-2012$600,000- Lectin as a dietary toxin, New Mexico Center for Environmental Health Sciences PilotProject Grant, Co-PI (PI:Moseley P), 2008-2009 $10,000Ma, Thomas Y.- 2005-2010 VA Merit Review Grant: Regulation of intestinal paracellularpermeability. Direct cost: $150,000 per year (Total direct cost: $782,000)- (Funded withsecond highest priority score-130).121

- 2003-2009 National Institutes of Health (NIH) RO-1: TNF- modulation of intestinalepithelial permeability. Direct cost: $220,000 per year (Total Direct Cost $1,100,000;Total Cost $1,695,000)- (Priority score 165; 12th Percentile)- 2009-2014 National Institutes of Health (NIH) RO-1: TNF- modulation of intestinalepithelial permeability. Direct cost: $250,000 per year (Total Cost $1,875,000) (Priorityscore 133; 7 th Percentile) (Funding approved)- 2009-2014 National Institutes of Health (NIH) RO-1: IL-1 modulation of intestinalepithelial permeability. Direct cost: $250,000 per year (Total Direct Cost $1,875,000)(Priority score 150; 14 th percentile) (Funding approved)-EDUCATIONAL 2008-2009:Sanjeev Arora, M.D.Roche Pharmaceuticals, Education Grant, $20,000Roche Pharmaceuticals, Education Grant, $25,000Roche Pharmaceuticals, Education Grant, $30,000Astra Merck Pharmaceuticals, Digestive Disease Week Program, $2,000Astra Merck Pharmaceuticals, Educational Grant, $1,500Astra Merck Pharmaceuticals, Dept. of Medicine Speaker Program, $20,000Thomas Ma, M.D., Ph.D.Takeda Pharmaceuticals, Digestive Disease Week Program, $5,000TAP Pharmaceuticals, Education Grant, $1,400Gilead Sciences, Inc, Education Grant, $5,000AstraZeneca Pharmaceuticals, Education Grant $4,000TAP Pharmaceuticals, Educational Grant, $3,631.25122

DIVISION OF GENERAL INTERNAL MEDICINE(UNM)123

DIVISION OF GENERAL INTERNAL MEDICINE (UNM)ANNUAL REPORT: JULY 1, 2008– JUNE 30, 2009ROBERT LEVERENCE, M.D., PROFESSOR AND CHIEFA. SIGNIFICANT ACCOMPLISHMENTS & DEVELOPMENTSThe Division has remained strong in all three areas of the Department's mission: education,clinical service and research.1. Clinical Accomplishments- Primary Care: In 2008 GIM built a foundation for development of the Patient CenteredMedical Home by establishing the first QI committee dedicated to Ambulatory Care –The Primary Care Quality Service Group which served as a review board for potential QIprojects and as an oversight committee for ongoing projects. We also piloted a newchronic care service delivery model – the Nurse Facilitated Diabetes Clinic. These effortswere both lead by Dr Adolphe and both were very successful. In 2009 efforts toward thePCMH became more formalized with the hire of Dr Robert Fritch DO (GIM) asExecutive Director of Primary care. Utilizing his skills in Organizational Leadership, helead a site visit to the Colorado Collaborative which inspired unit and medical directors tounit in a highly organized and robust effort toward developing/implementing PCMHconcepts at UNM. We were pleased to attend the UNMH PCMH Kick-Off Meeting inJuly 2009 lead by Jamie Silva-Steele, Dr Carolyn Voss and Mr Steve McKernan, whoendorsed our vision and mission. Consequently we are optimistic about further progressand success in 2010. Our short and medium range goals are 1) to implement a patientregistry in order to monitor clinical/quality outcomes, 2) enhance interpersonalcommunication, professionalism, and teamwork in clinics through training in leadershipskills, peer/staff reviews, and new staffing models, 3) dissemination of new chroniccare/preventive service delivery models.- There is also a need in the community to expand primary care and so GIM will work withUNMH to help meet that challenge, as well as help develop a primary care base in RioRancho in anticipation for the opening of UNM West Hospital.- Hospitalist Medicine Section: The Hospital Medicine Section has continued to grow insize and function over the last year. We have added 4 additional faculty members (lost 2,1 went part time, 1 on leave) and developed a more robust leadership developmentcurriculum. We have a one day formal orientation and a structured mentorship program.Our hospitalists have continued to take on leadership roles including one becoming themedical director of utilization review, one as the medical student clerkship director, andone as the assistant director of clinical affairs. We have also taken lead roles in CPOEdevelopment and all members are becoming CPOE 'super-users.' We have alsodeveloped many clinical care order sets to enhance protocol driven care to beimplemented with CPOE.- Our quality improvement projects have grown in number, size, and complexity. We havecontinued our VTE prophylaxis improvement projects, we have improved our VTEprophylaxis rate above 90% and are beginning a grant funded project to further increase124

this to >95%. Glycemic control has refined the insulin protocol and begun to focus onnursing processes to improve care. With our participation in the BOOST Project (Societyof Hospital Medicine Discharge Process Improvement,) we have implemented an RNdischarge checklist and developed new discharge paperwork. We have also worked onimproving rates of handwashing, continued our participation in the Sepsis workgroup,and continued to improve our post-discharge clinic.- At the end of the academic year we had our two largest changes, design of a new wardstructure and implementation of all electronic progress notes. We have increased thefaculty to resident ratios and created teams that could function independent of resident.We are now able to handle a larger patient census and have successfully gone to allelectronic documentation of inpatient care. The feedback on both of these initiatives hasbeen overwhelmingly positive.- Our next year will be focused on continued recruitment of quality faculty members aswell as retention of current staff. We will be helping with CPOE implementation andwill explore expansion in consult services and night coverage for the next academic year.Section of Integrative Medicine: Please see supplemental sectionSports Medicine: GIM is also integral to the success of the Sports Medicine Program for theNew Mexico Lobos. Dr. Ann Gateley provides all of the primary care for the teams, and alsoutilizes the training room for teaching residents about both sports and adolescent medicine.Poverty Medicine: Dr. Sierra continued her clinical sessions at Health Care for the Homelesstwice a month, providing post discharge continuity by seeing patients who were recentlyhospitalized at UNMH. She also regularly supervised medical student volunteers at East CentralMinistries, One Hope Centro de Vida Clinic, and the Mexican Consulate.2. Educational Activities- GIMs contribution to Health Equity/Public Health at UNM has been lead by Dr. CynthiaArndell with the dedicated support and help by Dr Ellen Cosgrove.- The development of the Health Equity Curriculum (formerly Poverty MedicineCurriculum) in FY08 was lead by Dr. Arndell and in FY09 it received national exposureby its posting on the National Health Care for the Homeless Clinician Network web site.Through such dissemination Vanderbilt University is using this curriculum to help designits own community health curriculum.- Introduction to Principles of Public Health for Medical Students is a two weekcourse designed to expose first year medical students to the social determinants of healthin a real world setting. The development of this course was lead by Dr Arndell andemphasizes self-reflection and the challenging of one’s own biases. This work wassupported by a Con Alma Grant and piloted in July 2009 among 24 medical students.Evaluations were outstanding. FY10 will be spent reviewing evaluations and conveningmedical student focus groups to prepare the course for its implementation into thecurriculum July 2010. Support will be sought through application for funding from theAssociation for Prevention Teaching and Research as well as application for continuationof the Con Alma Grant.125

- Planning of the IM Clerkship Post Discharge Home Visit Experience was forwardedthis past year by Drs Arndell, Bigney, and Fancovic in collaboration with the College ofPharmacy. Through this experience we look forward to medical and pharmacy studentsgaining enhanced exposure to the greater context of patient care by performing homevisits in FY10.- The Medical Shelter Respite Rounds and Street Outreach is a multidisciplinary effortsupported by a La Tierra Sagrata Society Grant. This experience was developed in FY09to allow 4 th year medical students as well as nursing students more advanced exposure tourban medical care for the homeless.- GIM retains a strong presence in education at all levels and across the institution. GIMmembers are active in clinical skills precepting, Phase I and Phase II tutorials, PIM, PIE,and continuity clinic precepting. GIM met its Phase I tutorial obligation.- The SIM continues to offer a selective for Phase III students in Integrative practice.- GIM continues to provide the core of teachers in the DOIM, with regard to inpatientmedicine and internal medicine ambulatory primary care, both for students and residents.- Division members are providing leadership in education in the following areas: UMEdirectorship (Bronwyn Wilson), Clerkship directorship(Ed Fancovic and DeeptiRao),Clinical Skills (Course director, George Comerci), Competency-based evaluation(Bronwyn Wilson), Communications Skills (Ann Morrison, Bronwyn Wilson),Integrative Medicine (Arti Prasad), Resident Education (Jenny Jern igan and DanaFotieo, Associate Residency Program Directors).3. Research/Scholarly Activities- The Division has continued its growth in this area, with the following notableaccomplishments:o Dr Adolphe has extensive experience in clinical trials and is collaborating withthe Clinical Trials Center to expand its scope to primary care.o As co-investigator, Dr Adolphe applied for two grants (NIH-Challenge Grant andthe International Diabetes Federation Grant) to support study of the NurseAssisted Diabetes Clinic.o Several GIM faculty are members of RIOS Net, New Mexico’s practice-basedresearch network. Dr Leverence is the director of RIOS Net Outreach, member ofthe executive committee and board.4. Administrative Activities- Many members of the Division have been placed in or continue in key leadership roles,not only in the Department, but in the School of Medicine and the Health SciencesCenter, as mentioned above.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE FUTURE- Hospitalist Section and Ambulatory care: As above.- Integrative Medicine: Establish an Integrative Medicine in Residency program at UNMin collaboration with the University of Arizona. Continue to expand services and definecompetencies/credentialing for disciplines new to the institution.- Implement new DoIM promotion criteria.126

- Enhance professional faculty development through implementation of ProfessionalPractice Reviews.- Implement new division-based budgetary authority.- Obtain promotion for eligible faculty- Expand Clinical Trials Program in Primary care.C. APPOINTMENTS TO FACULTY AND STAFFNew Faculty:- Carlos Macias, M.D. (7/1/08)- Peter Barnett, M.D. (7/1/08)- Leonard Noronha, M.D. (7/1/08)- Emily Petersen, M.D. (7/1/08)- Melissa Martinez, M.D. (11/1/08)- John Pierce, M.D. (3/1/09)New Administrative Posts:- Bronwyn Wilson, M.D. (DoIM UME Director)- Parsa Shahinpoor, M.D. (DoIM Clerkship Director)Promotions:- Peggy Beeley, M.D. Professor- Dana Fotieo, M.D. Professor- Wendy Gernstein, M.D. Associate ProfessorNew Staff:- Sandra Kimura – Admin II (11/1/09)D. SEPARATION OF FACULTY AND STAFFFaculty:- Carlos Macias, M.D. (6/30/09)- Parsa Shahinpoor, M.D. (6/30/09)- Melissa Kennedy, M.D. (4/30/09)Staff:- NoneE. PUBLICATIONS OF GIM FACULTYGeorge Comerci, M.D.- Comerci GD, Williams TM, Kellie S, Immune Tolerance after Total LymphoidIrradiation for Heart Transplantation: Immunosuppressant-free Survival for 8 years.Journal of Heart and Lung Transplantation 2009; 28: 743-5- Roesch JJ, Wang S, Comerci GD, Quinonez C, Reddy S, Rogers D, Bugs and BloodCells. Am J of Med 2009; 122: 632-635127

Robert Leverence, M.D.- Philip J. Kroth, MD, MS, Laurie McPherson, MSCIS, Robert Leverence, MD, WilsonPace, MD, Elvan Daniels, MD, Robert Rhyne, MD, and Robert L. Williams, MD, MPHfor the PRIME Net Consortium. User Preferences for Completing Practice-BasedResearch Network Survey: A Case Report from PRIME Net. Annals of Family Medicine(in press) May 2009.Philip Kroth, M.D.- Stewart RS, Edgar HJ, Tatlock C, Peacock F, Kroth PJ. Developing a standardizedcephalometric vocabulary: choices and possible strategies. J Dent Educ. 2008 Sep; Vol72(9) Page 989-97- Kroth PJ, McPherson L, Leverence R, Pace W, Daniels E, Rhyne R, Williams R.Combining Web-Based and Mail Surveys Improves Response Rates: A PBRN Study FromPRIME Net. Ann Fam Med 2009; Vol 7 Page 245-248.John R Pierce, M.D.- Bell TE, Hale TW, Pierce JR Jr. Association of age, hospitalization and cat ownershipwith MRSA nasal colonization of community event attendees [abstract SA09A26].Staphylococcus Symposium 2009, 3/11/09. Honolulu, HI.- Pierce JR Jr, Milton JS. Hantavirus: is it important for practitioners? [editorial]. SouthMed J 2009; 102:563-564.- Urban RS, Pierce JR Jr, Jenkins MR, Berk SL. PreTest Medicine. Self Assessment andReview (12 th ed). New Yourk: McGraw Hill; 2009.Allen Adolphe, M.D.- Allen Adolphe, M.D. PhD, Linda Cook PhD, Xun Huang MS. A Cross-Sectional Studyof Intima-Media Thickness, Ethnicity, Metabolic Syndrome, and Cardiovascular Risk in2268 Study Participants. Mayo Clin Proc. 2009; 84(3):221-228.F. OUTSIDE PROFESSIONAL ACTIVITIESArti Prasad, M.D.- La Tierra Sagrada Society- CAHCIM ~ Consortium of Academic Health Centers for Integrative Medicine- Health Care for the Homeless in Albuquerque, NMKendall Rogers, M.D.- Society of Hospital (SHM) Medicine Quality Improvement Pre-Course. Chicago- Presentor: VTE Prophylaxis Journey at UNMH- Presentor/Facilitator: Glycemic Control Break-out Session- Course Director/Presenter: Society of Hospital Medicine: Expert Series on VTEProphylaxis. St. Louis- Faculty: Society of Hospital Medicine Annual Meeting. Chicago- Presentation: Leveraging IT to Enhance Protocol Driven Care- Panel Member: BOOST Project for improving discharge128

- Committee Chair: SHM Information Technology Task Force- Committee Member: SHM Health Quality/Patient Safety CommitteePhilip Kroth, M.D.- American Medical Informatics Association Academic Forum, charter member- New Mexico Regional Health Information Organization (RHIO) Grande / New MexicoHealth Information Collaborative Joint Steering Committee, member- RIOS Net IS Steering Committee, Chair- UNM Cancer Research and Treatment Center, caBIG Advisory Committee, member- American Medical Informatics Association Academic Forum, Rockville, MD – July 2008- Presenter: 30 th Annual Advances in Primary Care Conference, Albuquerque, NMMelissa Martinez, M.D.- Co Chair of The Clinical Prevention Initiative (CPI) for Immunizations this is acollaboration of the New Mexico Medical Society and the New Mexico Department ofHealth with the goal of improving the quality and enhancing the delivery of clinicalpreventive services in the state.- Alternate Delegate to the Congress of Delegates of the American Academy of FamilyPhysicians- Board of Directions of the New Mexico Chapter of the American Academy of FamilyPhysicians.John Simson, M.D.- Presenter – Workshop (4 day) on Physical Diagnosis in Amsterdam for the DutchAdaptation of the NMSU educational program for clinical psychologists with prescriptiveauthority.Patrick Boyle, M.D.- Presenter: Joint Conference - 49th Cardiovascular Disease Epidemiology and Prevention-and- Nutrition, Physical Activity and Metabolism - March 2009, Palm Harbour, FL,Recent Trials in Type 2 Diabetes and Cardiovascular Implications.- Chairman, Hypoglycemia: Clinical Implications Symposium, American DiabetesAssociation National Scientific Sessions, New Orleans, LA, June 2009.- American College of Cardiology, National Committee, Diabetes Initiative to Formulate aCurriculum in Type 2 Diabetes for Cardiologists. Fall 2008.John Pierce, M.D.- American College of Preventive Medicine (CME Committee)- American Geriatrics Society (Disaster Planning and Preparedness Special Interest Group)- American Public Health Association (Policy Committee, Gerontological Health Section)- Centers for Disease Control and Prevention (Preparedness Competency DevelopmentProject)- Ad hoc reviewer: American Journal of Preventive Medicine, Journal of Public HealthManagement and Practice and Southern Medical JournalRobert Fritch, M.D.129

- BA/MD Program Mentor- Volunteer Medical Consultation for uninsured Albuquerque Asian population.- Member of NM Osteopathic Foundation- PIE Preceptor/Circuit riderAllen Adolphe, M.D.- Lecture: El Paso Pain Society, July 30, 2009. "Diabetic Neuropathic Pain: Diagnosisand Treatment"Julie Sierra, M.D.- Volunteer physician at East Central Ministries One Hope Centro de Vida clinic -supervising medical students and residents in clinic serving primarily undocumentedimmigrants in the SE Heights - one Saturday a month, July 08-June 09- Volunteer physician at Mexican Consulate clinic - supervising medical students in clinicserving Mexican immigrants - once a month, May 09-June 09- Albuquerque Coordinator of Salud Southwest Tour - 14 US students studying at the LatinAmerican School of Medicine travelling through the Southwest United States to learnabout the needs of underserved communities and how they can make an impact - June 09-Aug 09- Twice monthly medical clinics at Healthcare for the Homeless - supported by Dept ofMedicine - July 08-June 09- Medical interpreter for Catholic Charities Refugee Resettlement Program - July 08-June09G. OUTSIDE SPONSORED RESEARCHNameAdolphe,Allen BAdolphe,Allen BAdolphe,Allen BAdolphe,Allen BGarcia,David A.SponsorNameProjectTitleSponsorNumberStartDateStopDatePPD Clinical Trial 100001367 12/14/ 12/13/Developmen Phase II2007 2012tDaiichi Clinical Trial 101125794 2/28/ 2/14/Sankyo Phase II2008 2013Hoffmann- Clinical Trial 100001144 7/1/ 5/13/La Roche2008 2012Hoffmann- Clinical Trial 100001144 1/27/ 7/13/La Roche Phase III2009 2010Bristol Clinical Trial CV185017 04/13/ 4/12/Myers Agreement2007 2011Squibb, Inc.Clinical 5256 1/15/ 1/15/Garcia, D McMasterCEBA TrialPrasad, A Foundations Mindfulness-Based StressReduction2005100000465 2/11/200820092/10/2009FA Direct Total19,879 79,517 99,39726,208 104,834 131,04346,956 187,824 234,780$22,929 68,789 91,71810,565 42,259 52,82432,00010,000130

Prasad, A WeilFoundationVoss, CWilson, B,co-invest,PI isHelitzerCDCHR-AdvancingIntegrativeMedComputerized riskassessment inan employeepopulation101264477 1/1/20079/29200412/31/20089/29/20075,000221,000 900,000 1,121,000Honors/AwardsGeorge Comerci, Jr M.D.- The Arnold P Gold Foundation’s Leonard Tow Humanism in Medicine Award- Phase I Excellence in Teaching Award (awarded by the Class of 2009)- Leonard Tow Humanism in Medicine award, 2009Arti Prasad, M.D.- Top Doctors Albuquerque – 2009 Best Physicians as chosen by their peers, AlbuquerqueMagazine, March 2009- UNM Representative and delegate for the United States Pharmacopeia (USP) convention,April 2010- UNM Primary Research Collaborative Pilot Project Funding application. A Comparisonof- Mind-Body Fitness Practice with a Group Walking Program on Blood Pressure, BodyMass Index, Waist Circumference and sustainability, $4,000Jeff Danska, P.A.- Travel Exam certification, International Society of Travel Medicine, 2009John Simson, M.D.- Masters of Public Health, Medical College of Wisconsin, May 2009131

UNM CENTER FOR LIFE (CFL)PREVENTIVE AND INTEGRATIVE MEDICINE SPECIALTY CLINICJULY 1, 2008 – JUNE 30, 2009ARTI PRASAD, M.D., FACPEXECUTIVE DIRECTOR, UNM CFL ANDSECTION CHIEF, SECTION OF INTEGRATIVE MEDICINEThe Center for Life (CFL) was inaugurated in 2007, as part of the expansion of the Section ofIntegrative Medicine (2001-2007) at the UNM Health Sciences Center. Integrative Medicine ishealing-oriented medicine that takes account of the whole person (mind, body, and spirit),including all aspects of lifestyle. As with most academic units, CFL provides clinical service,medical education, research, and community service. These are described in detail below.MISSION- To provide customer-oriented, preventative services and medical care in a healingenvironment by integrating the highest standards of conventional and complementarymedicine, and by nurturing the intrinsic healing in the whole person – body, mind, andspirit.CLINICAL SERVICE- UNM Center for Life is committed to provide comprehensive and integrative health careconsultations, working collaboratively with medical doctors, traditional healers, anddoctors of oriental medicine, and massage therapist. There has been a change in thegovernance of the clinical operations from the UH to the UNMMG as of April 2009. TheCenter has hired 4 new clinical staff under the UNMMG, and has also grown its providerbase after the departure of Drs. Kennedy and Small. There are 4 part-time MD’s, a midlevelpractitioner, a holistic nurse, a Myofascial Pain and Movement Therapist,Psychologist, Massage therapist, and an Ayurvedic life-style counselor working at thecenter. The center saw an estimated 3,900 patients from July 2008 – June 2009, a 68%increase from the previous year’s patient volume and met the projected target.- We saw a wide variety of patients including cancer, chronic pain, fibromyalgia,myofascial pain, menopause, obesity, anxiety, and other mood disorders. We had a slowstart in seeing patients due to the Department of Health inspection and licensure, staff andprovider turnover, and many part-time providers. The patient satisfaction surveycontinues to be positive with-in the range on the lickard scale of 1 to 5 with an averagerating of 4.- We have developed partnerships with Lovelace Women’s hospital, UNM CRTC, andPediatric Pain clinic. The following services have been provided:o Integrative Medicine Consultationo Acupuncture and Chinese medicineo Comprehensive Chronic Pain Evaluationo Myofascial trigger point needlingo Myofascial trigger point releaseo Massage Therapyo Hypnotherapy132

o Psychological counselingo Ayurvedic Life-Style counselingo Comprehensive Stress Reduction Evaluationo Opportunity to meet with Curanderas and other traditional healersThe key therapeutic modalities from around the world includeo modern medicineo traditional healing (Curanderismo and Native American)o traditional Chinese Medicineo nutrition, Herbs, Supplements, and Botanicalso myofascial therapy for pain managemento mind-body medicineo other complementary medicine modalities such as Healing touch and massagetherapyo movement therapyo natural skin careEDUCATION- Under education, we were involved with undergraduate medical education,undergraduate nursing education, graduate medical educational, post graduatemedical education, and patient education services. The number of students’ graduateand post-graduate, participants during FY ‘09 was approximately 14. The total hoursper year of patient education classes/courses were approximately 5,275 hours.The key educational components are:o ambulatory 4 th year medical student electiveo resident electiveo Mindfulness Based Stress Reduction classes (MBSR)o Mindful Eating and Living classes (MEAL)o Yoga, Qi Gong classeso Movement therapy classes such as NiaRESEARCH- The Section of Integrative Medicine has been awarded a $4,000 pilot project grantfrom PCRC titled “A Comparison of a Mind-Body Fitness Practice with a GroupWalking Program on Blood Pressure, Body Mass Index, Waist Circumference, andSustainability.”133

- The Center was involved with outreach community activities to better serve the needsof many New Mexicans who will benefit from preventive, wellness, and integrativemedicine education. These communities included: city employees, San Filiepcommunity, Lovelace breast cancer patients, Albuquerque Diabetic Educators,Albuquerque district Dietetic association, Cancer Services of New Mexico Families,and local farmersThe key community service components are:- partnerships with non-profit organizations from community outreach seminars onprevention and wellness such as: Cancer Services of NM (Executive Director ofIntegrative Medicine clinic is on the medical advisory board and a speaker for 2cancer retreats per year, Lovelace Women’s Hospital (referrals from Physician’s forcancer patients to be seen at the Integrative Medicine clinic)- media opportunities to reach a wide range of audience- Community outreach activities served over 1500 people totaling around 39 hours ofparticipation from the Center for Life.Honors for Dr. Prasad:Top Doctors Albuquerque2009 Best Physicians as Chosen by Their PeersAlbuquerque Magazine, March 2009Selected as the UNM delegate for the USP convention to be held in April 2010.CFL GIVING CIRCLES- We are very grateful to our state legislature, our Governor, and his Executives and DeanRoth for funding integrative medicine program as it has allowed us to inform ourpotential donor prospects, the commitment of State and the HSC in promoting health andhealing. We were able to create a Center for Life Giving Circles, a donor program whichhas been sponsored by generous donors who believe in our cause, and who know that theCenter’s intentions for the community are four-fold; to provide clinical service, medicaleducation, research, and community service. With continued support, we will be able todemonstrate to our donors, the strength and partnership of State and the HSC in CFL.This continued partnership will assist the Center in expanding our donor support.134

DIVISION OF GENERAL INTERNAL MEDICINE(NMVHCS)135

DIVISION OF GENERAL INTERNAL MEDICINEALBUQUERQUE VA MEDICAL CENTERANNUAL REPORT: JULY 1, 2008-JUNE 30, 2009MARTIN SCHIMMEL, M.D., ASSOCIATE CHIEF OF STAFF,AMBULATORY CAREA. SIGNIFICANT DEVELOPMENTS AND ACHIEVEMENTS DURING THEACADEMIC YEARNon-Teaching Clinical Activities- In AY 2008-2009, our division was comprised of 30 outpatient internal medicinephysicians (Albuquerque and Rural Health Network) and 4 Physician Assistants. TheHospitalist group previously managed by Ambulatory Care Service was transferred toMedicine Specialty Service on 7/1/2008. The outpatient physician providers devote up to100% of their clinical time managing their patient panels. Many of the physicianproviders have departmental assignments involving disease management, performanceimprovement and systems redesign. Several of the female providers spend up to 10% oftheir clinical time attending patients in the Women’s Comprehensive Care Clinic.Supervision of mid-level providers occurs within each clinical team.Teaching Activities Involving Direct Resident Supervision- The outpatient GIM physicians, provide the majority of clinical teaching occurring in theresident continuity and PRIME clinic. Approximately 20-30% of their time is dedicatedto this function. Continuity clinic coverage is provided by long-term assignment ofspecific attending physicians to specific half-day sessions. Supervision and attending inPRIME clinic is assigned on a rotating schedule. Several of the outpatient facultyphysicians have additionally contributed 2-4 weeks as inpatient ward attendings.Non-Clinical Teaching Activities- Faculty contributed approximately 20% of their time to non-clinical, undergraduate,graduate and post-graduate teaching programs of the School of Medicine. The followingis a list of faculty activities:o Implementation of new ambulatory care curriculum for resident outpatient clinicso Facilitating Phase I & Phase II Tutorialso Evaluation of Phase II Capstone presentationso Mentoring Internal Medicine and Primary Care Chief Residentso Development of resident inpatient curriculumo Associate Residency Program DirectorB. SIGNIFICANT PLANS AND GOALS FOR AY2008-2009- The NMVAHCS primary care division achieved and continues to maintain the goal set inprevious years to improve clinical productivity levels. Primary care panel sizes continueto be adjusted along guidelines set by the Department of Veterans Affairs.- Advanced Clinic Access (ACA) was successfully implemented in previous academic yearand continues to be enhanced. The Primary Care Service continues to meet and exceed136

its access targets set by the Department of Veterans Affairs. Further enhancements toACA included the planning phase for acquisition and implementation of additionalmodules to AudioCARE a system which will provide individual patients and providerswith PIN protected HIPPA compliant, e-mail accounts in which their PCP may leavesecure messages related to diagnostic test results and other therapeutic interventions.- Continued implementation of the Chronic Care Model progressed during this academicyear. Individual provider nurse dyads were established on all primary care teams.Registered Nurses have begun training which will allow them to utilize providerdevelopedand initiated standing orders for use of a spectrum of antihypertensivemedications. Upon completion of the hypertension project, they will progress to trainingin lipid and diabetes management utilizing established protocols.- The Hypertension Working Group has been suspended since the NMVAHCS hasconsistently met and exceeded its performance measures for management ofhypertension. The Diabetes Management Group continues to meet regularly. This yearthere were two one-half day education sessions presented by Glen Murata, M.D. and hisgroup addressing the patho-physiology of diabetes mellitus and its pharmacologictreatment. The Diabetes Management Group is robustly supported by physicianchampions and continues to address methodology to enhance diabetic control of ourpopulation. The Colorectal Cancer Group continued to address successful strategies forenhancing colorectal cancer screening and follow up of patients with colorectal cancer.An innovative short term study involving the use of an immunochemical test was pilotedby Dr. Richard Hoffman and has now garnered VA support and will become thedesignated methodology for colorectal cancer screening. A Chronic Pain ManagementGroup was formed during the previous academic year and was responsible forredefinition of the prescribing and delivery of opioid medications. A need was recognizedfor development of a Co-Occurring Disorders Clinic which would provide care for highriskopiod patients. Patricia Pade, M.D., an internist with addiction medicinecertification, was recruited and has implemented this Clinic which is now fullyoperational. A part-time addiction trained psychiatrist is now participating in the care ofthis population. Dr. Pade is in the process of review for UNM faculty appointment and isinterested in participating in resident education in her addiction specialty.C. APPOINTMENTS TO GIM FACULTY/STAFFFACULTY- Mara Sievers Archambault, M.D.- Gregg Fotieo M.D.- Kevin Edwards M.D.- Amad Chadha M.D.- Cynthia Heins M.D.- Mara Sievers-Archambault, M.D.- Glen Murata M.D. - secondary appointment to GIM (primary in Epidemiology)- Richard Hoffman M.D. – secondary appointment to GIM (primary in Epidemiology)- Ellen Yee M.D. – secondary appointment to GIM (primary in Epidemiology)- William Abeyta, M.D. – secondary appointment to GIM (primary in Spinal CordInjury)137

Staff- Curt Kapsner, M.D. – secondary appointment to GIM (primary in MedicineSpecialties)- Oscar Miranda, M.D.- John Link, M.D.- Dennis Walker, M.D.- Khurshid Muhammad, M.D.- Charlene Avery, M.D.- Richard Montminy, M.D.- Patricia Pade, M.D.- Greg Brown, M.D.D. SEPARATIONS FROM THE FACULTY/STAFFFaculty: NoneStaff: NoneE. FACULTY PROMOTION & TENURE DECISIONSNoneF. OUTSIDE SPONSORED RESEARCH- GIM/Epidemiology faculty are reported elsewhere.- Research Presentations: GIM/Epidemiology faculty are reported elsewhere- Research grants: GIM/Epidemiology faculty are reported elsewhereActive grants: GIM/Epidemiology faculty are reported elsewhere.G. PUBLICATIONS OF THE DIVISION- GIM/Epidemiology faculty are reported elsewhere.H. AWARDS AND RECOGNITIONS- GIM/Epidemiology faculty are reported elsewhere.I. GRAND ROUND PRESENTATIONS- GIM/Epidemiology faculty are reported elsewhere.138

DIVISION OF GERIATRICS139

DIVISION OF GERIATRICSANNUAL REPORT: JULY 2008 - JUNE 2009CARLA J. HERMAN, MD, MPH, ASSOCIATE PROFESSOR AND CHIEFA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEAR- Dr. David Bennahum is leading the Ethics Certificate Program in the Ethics Institute.- Dr. Judith Kitzes was appointed Director of Special Projects including preparation forLCME accreditation, Medical Educators Scholars Program (MES) and Academic Supportin undergraduate medical education and continues as Curriculum Director for the UNMSOM BA/MD Program.- Dr. Janice Knoefel continued to supervise all fellows and residents in training in thegeriatric.- Out-patient clinics at the NM Veterans Healthcare System. She is a co-investigator on anew NIH-funded grant which will expand her previous research into healthy populationsin different age groups with and without hypertension and diabetes.- Dr. Robert Lindeman is a member of the HRSA-funded Geriatric Education CenterExecutive Committee and Chairs the Executive Committee.- Dr. Lisa Marr joined the Division in October 2008 as Section Chief for PalliativeMedicine. She has developed an active inpatient consult service with Advanced NursePractitioner, Carolyn Klotz. Ms. Klotz serves on the MICU End-of-Life Committee.- Dr. Denise Minton participated in the MERC program through the AAMC. She wasidentified as a master tutor and taught tutor training in the School of Medicine.- Dr. Devon Neale joined the faculty in September 2008 and is leading the geriatric andpalliative care education for Internal Medicine and Family Medicine residents.- Dr Donna Jean Parker joined the faculty in March 2009 and is Director of the HomeBased Primary Care Program as well as trains all of our residents and fellows in homecare at the NM Veterans Healthcare System.- Dr. Sandra Qaseem serves as the Program Director for the geriatric fellowship andcontinues to lead the Home Visit Program. She also serves as Medical Director forGentiva Home Health Services and Alliance Home Health.- Dr. Mohammad Siddiqui serves as co-medical director for Manzano del Sol Care Centerand continues to teach in the Foundations of Clinical Practice.- Dr. Anne Simpson serves as Rust Professor and Director, University of New MexicoHealth Sciences Center for Ethics.- Dr. April Volk was appointed to the faculty of medicine and will lead the Palliative CareProgram at the NM Veterans Health Care System.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURE- The Palliative Medicine Section will begin the process of accreditation for a palliativemedicine fellowship.- The Geriatrics/Extended Care Section at the VA is planning and has funding for a majorexpansion of palliative care activities, to include a multi-disciplinary consult team,remodeling of 10 existing extended care beds into a separate palliative care unit and140

adding an additional physician faculty member in the next year. Our first faculty member,Dr. April Volk, was appointed to direct the program. Another faculty member is beingrecruited to assume the duties on the Extended Care Unit, as well as to further expand thehome care program. In addition, we anticipate the new ACOS for Geriatrics/ExtendedCare, Dr. Dennis Villareal, to join our faculty in September 2009.C. APPOINTMENTS TO THE FACULTY/STAFFFaculty- Lisa Marr, M.D.- Devon Neale, M.D.- Donna Jean Parker, M.D.- April Volk, M.D.Staff- Carolyn Klotz, ANPD. SEPARATION OF FACULTY/STAFFFaculty- Denise Zwhalen-Minton, M.D.Staff- NoneE. PUBLICATIONS OF THE DIVISIONCarla Herman, M.D., MPH- Eleazer GP, Stewart TJ, Weidland GD, Anderson MB, Simpson D, Herman CH (SteeringCommittee). The National evaluation of Senior Mentor Programs: Older Adults in MedicalEducation. JAGS 2009; 57:321-326.Judith Kitzes, M.D., MPH- Kitzes JA, Kalishman S, Mines J, Kingsley D, Lawerence E, “Palliative medicine deathrounds: small group learning on a vital subject” Am J Hosp Palliat Care 2008-2009;25:483-91.Janice Knoefel, M.D., MPH- Hope OA, Zeber JE, Kressin NR, Bokhour BG, Vancott AC, Cramer JA, Amuan ME,Knoefel JE, Pugh MJ. New-onset geriatric epilepsy care: Race, setting of diagnosis, andchoice of antiepileptic drug. Epilepsia 2009;50:1085-93.- Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. Newonsetepilepsy risk factors in older veterans. J Am Geriatr Soc 2009;57:237-42.Robert Lindeman, M.D.- Lindeman RD: Chapter 8. Hydration, electrolyte, and mineral needs. In: Handbook ofClinical Nutrition and Aging, 2nd edition, Bales CW, and Ritchie CS, editors, HumanaPress, New York, New York, 2009, pp. 137-155.141

Lisa Marr, M.D.- Back AL, Anderson WG, Bunch L, Marr LA, Wallace JA, Yang HB, Arnold RM.“Communication about cancer near the end of life”. Cancer 2008;113:1897-1910.- Siddiqui F, Marr L, Weissman DE. “Neoplastic meningitis #135 ”. J Palliat Med2009;12:88-89.Devon Neale, M.D.- Neale D, Herman C. A systematic approach to geriatric curriculum evaluation andenhancement. JAGS 2009:S36.F. OUTSIDE PROFESSIONAL ACTIVITIES OF FACULTY/STAFFCarla Herman, M.D., MPH- 2009- Advisory Board Member, Public Health and Health Services Block Grant, NMDepartment of Health- 2009- Board Member, Great West Division, American Cancer Society, Seattle WA- 2007-2009-Board Member, Area Agency on Aging Advisory Council, City ofAlbuquerque- 2006-2009- Member, NIH Study Section, Community Level Health Promotion, Healthof the Population- Fellow, American College of Physicians- Member, American Geriatrics Society- Medical Writer, Healthwise (non-profit consumer health education company), Boise,IdahoJournal Reviewer:- Annals of Internal Medicine, 1992 – ongoing- Journal of the American Geriatrics Society, 1995- ongoingJudith Kitzes, M.D., MPH- Member, American Association of Hospice and Palliative MedicineJanice Knoefel, M.D., MPH- Member, American Academy of Neurology- Member, American Medical Association- Member, American Geriatric Society- Member, Gerontological Society of America- Member, American Society of Neurorehabilitation- Member, Alzheimer Association- Member, American Board of Psychiatry and Neurology- Examiner: American Board of Psychiatry and Neurology- Reviewer: American Academy of Neurology- American Geriatric Society- New England Journal of Medicine’s Journal Watch NeurologyRobert Lindeman, M.D.142

- Member, Editorial Boards and frequent reviewer for Journal of the American College ofNutrition; International Urology and Nephrology Journal (Nephrology section); andCurrent Nutrition and Food Science Journal.- Ad hoc reviewer for the Kidney, Nutrition, Obesity, and Diabetes (KNOD) EpidemiologyStudy Section, NIH.- Master and Fellow, American College of Nutrition;- Fellow, American Geriatric Society;- Fellow, American College of Physicians- Member, Gerontological Society of America- Member, Western Association of PhysiciansLisa Marr, M.D.Presentations- 17 th International Congress on Palliative Care. Workshop: Delivering Prognosis WhileMaintaining Hope and Trust. Marr, L and Rosielle, D. September 2008- American Academy of Hospice and Palliative Medicine. Workshop: CommunicationSkills for Transitions in Goals of Care. Back A, Arnold, R, Tulsky, J, Marr, L, Yang, H,Bunch, L and Anderson WG. March 2009- International Telehealth Palliative Care Symposium, May 2009. Presentation:Prognostication in Serious Illness- Cultural Considerations.National Committees:- Academic Palliative Medicine Task Force, American Academy of Hospice and PalliativeMedicineDevon Neale, M.D.- Member, American Medical Association- Member, American Geriatrics Society- Member, American College of Physicians- Member, American Academy of Hospice and Palliative MedicineDonna Jean Parker, M.D.- Member, American Academy of Family Practice- Member, American Geriatrics Society-Sandra Qaseem, M.D.- Member, American Geriatric Society- Member, American Association of Home Care PhysiciansMohammad Sayeed Siddiqui, M.D.- Member, American Medical Directors Association- Member, American Association of Family PracticeAnne Simpson, M.D.- National Council of Negro Women “Living Portrait of African-American Women”Award 2009- David Thomasma International Bioethics Group143

- American Medical Directors Association, Ethics Committee and House of Delegates- Co-Chair R.A.C.E. Affinity Group, American Society for Bioethics and Humanities- Good Samaritan National Board of Medical DirectorsMemberships:- 2006-Present National Medical Association- 2005-Present Association of Clinicians for the Underserved- 2004-Present Association for Practical and Professional Ethics- 2003-Present American Society for Bioethics and Humanities- 2002-Present American Medical Association- 2002-Present National Citizen’s Coalition for Nursing Home Reform- 2002-Present American Society for Bioethics and Humanities- 1996-Present American Geriatric Society (AGS)• (AGS) Ethno-geriatrics special interest group• (AGS) Elder mistreatment special interest groupApril Volk, M.D.- Member, Academy of Hospice and Palliative Medicine- Member, American Academy of Pain Management- Member, American College of Physicians- Member, American Medical AssociationDenise Zhwalen-Minton, M.D.- Member, American Association of Medical CollegesH. OUTSIDE SPONSORED RESEARCHCarla Herman, M.D., MPH- “The UNM Center on Aging Comprehensive Program to Strengthen Physicians’ Trainingin Geriatrics”- Principal Investigator- Donald W. Reynolds Foundation- 9/03-8/08Janice Knoefel, M.D., MPH- R01 AG029495-01 Aine (PI)- Imaging the Development of Memory Strategies in Aging” 9/15/08-8/31/13- 5R01 AG020302-04 Aine (PI)- NIH/NIA- “Functional Imaging of Aging and Alzheimer’s Disease” 6/1/04 – 4/30/10- Pilot Project Awards in CTSC Research Aine (PI)- UNM Health Sciences Center (UNM HSC)- “Neuroimaging Successful vs. Normal Aging.” 1/1/07-12/31/08Anne Simpson, M.D.- Expansion of Rural Health Care Research Infrastructure through the ECHO Model144

- Title: AHRQ: Minority Research Infrastructure Support Program (M-RISP)- Dr. Simpson is CO-PI for the Medical Ethics 9/1/07 - 8/31/10145

DIVISION OF HEMATOLOGY/ONCOLOGY146

DIVISION OF HEMATOLOGY/ONCOLOGYANNUAL REPORT: JULY 1, 2008 - JUNE 30, 2009ROBERT HROMAS, M.D., PROFESSOR AND CHIEFClinical FacultyAroop Mangalik, M.D.Jack Saiki, M.D.Melanie Royce, M.D.Dennie Jones, M.D.Yehuda Patt, M.D.Claire Verschraegen, M.D.Fa Chyi Lee, M.D.Ian Rabinowitz, M.D.Ed Libby, M.D.Amy Tarnower, M.D.Elizabeth McGuire, M.D.Thomas Downs, M.D.Richard Lauer, M.D.Katie Rasila, M.D.Warren Alexander, M.D.David Garcia, M.D.Robert Weiler, M.D.Katub Khan, M.D.Thomas Schroeder, M.D.Gene Wong, M.D.William Thompson, M.D.Benjamin Liem, M.D.Lisa Berle, D.O.Paul Anthony, M.D.Montaser Shaheen, M.D.Houman Fekrazad, M.D.Robert Hromas, M.D., ChiefResearch FacultyJohn Rushton, Ph.D.Julie Lovchik, Ph.D.Terry Wu, Ph.D.Richard Dahl, Ph.D.Hugo Arias, Ph.D.Sudha Singh, Ph.D.Elizabeth Williamson, Ph.D.A. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARResearch147

- The Division organizes and supervises all clinical oncology research for the UNM HealthScience Center. In FY2008/9, the Division administrated 327 UNMCC protocols, ofwhich 114 studies were therapeutic/interventional trials. These therapeutic trials are alsoopen within the New Mexico Cancer Care Alliance, and thus accrue not only at UNM butalso at numerous affiliated community sites. At the UNM outpatient oncology clinics,2640 new cancer patients (shown in Summary 3) were treated in FY2008/9, and theDivision supervised 443 accruals on therapeutic trials (17% of all new treated patients),with an additional 101 therapeutic accruals supervised by the Division at the communityaffiliate sites. Oncology accruals to all types of trials supervised by the Division were1241 in fiscal year 2008/9, 2724 in CY2008, 1036 in CY2007, 633 in CY2005, 577 inCY2004, 230 in CY 2002, and 385 in CY2003. Of patients accrued to therapeutic clinicaltrials in FY 2008/9, 83% were women, 7% were Native Americans, and 44% wereHispanics.- The Division published 41 peer-reviewed papers last year, in high quality journals suchas the Journal of Clinical Oncology (2007 citation impact 15.4), or Blood (2007 c itationimpact 10.9).- The Division held $XXX M in total extra-mural research grants in FY2008/9 academicyear. Dr. Lyons contributed the bulk of this extra-mural funding. He continues to obtainan extraordinary amount of funding for his investigation into the infectious organismsthat could be used as bio-terrorism agents, and into the genetic determinants of infection.Dr. Dahl and Dr. Hromas also hold extra-mural peer-reviewed grants in hematopoiesis.Dr. Hromas obtained two new RO1 grants in DNA repair. Dr. Verschraegen holds anMB-CCOP grant from the NCI. Drs. Verschraegen, Patt, Jon es, Bauman, and Roycehold multiple extra-mural pharmaceutical grants listed below.- The Division continues to play a key leadership role in developing the flow oftranslational science from laboratory to clinic and back again that is essential for the NCIP30 CCSG to the UNM Cancer Center.Clinical Service- The UNM CRTC is one of 61 NCI-designated cancer centers in the US. The Divisionsupervises all cancer care at the UNM Cancer Center, with Division faculty chairing theUNM HSC Oncology Committee, the policy setting body of the HSC, and serving asOncology Physician in Chief for the UNM Hospital.- The Division supervised seeing 4549 total new cancer patients were seen (as opposed totreated) at the UNM Cancer Center in CY2008, compared to 3622 new cancer patientsseen in CY2006, up from 2589 new cancer patients in 2004, and 1200 in 2000. Thus, in 8years the number of new cancer patients seen at UNM has gone up significantly. Thisrepresents 44% of the total number of new cancer patients in the state of New Mexico.The Division supervised 96,000 out-patient visits in FY2008/9, up from 20,000 in 2000.Dr. Rabinowitz serves as the UNM Cancer Center’s Out-Patient Clinic Director, and Dr.Lauer is the overall Executive Medical Director for oncology efforts at the CancerCenter. He also is on the UNM Hospital Executive Medical Board, and serves as theChair of the Oncology Committee for the UNM HSC.- The Division in 2008/9 had responsibility for directing Hematology and MedicalOncology care in the Lovelace Sandia Health Care System, which comprises four areahospitals, Lovelace Gibson, Lovelace Downtown, Lovelace West Mesa, and Women’s148

Hospital. This effort continues currently. There is an average of 40 new Hematology orOncology patients seen a month in this system, for a total of 480 new patients per year.This system’s out-patient Hematology-Oncology clinic was re-organized, key personnelretained and others recruited. A new in-patient Hematology-Oncology service wascreated for Lovelace, and a system-wide call schedule initiated.- There are 8 multi-disciplinary clinics at the UNM Cancer Center, which is directed by Dr.Rabinowitz. These are in breast (led by Dr. Royce), lung (led by Dr. Jones), GI (led byDr. Lee), hematologic malignancies (led by Dr. Libby), gynecologic malignancies (led byDr. Muller of Ob-Gyn), GU (led by Dr. Rabinowitz), Radiation Oncology (led by Dr.Khan), and Phase I trials (led by Dr. Verschraegen). These continue to function at a highlevel in the Cancer Center. Such clinics routinely include medical oncology, clinical trialscoordinators, surgical oncology, radiology, and radiation oncology. The Divisionprovides the leadership for these multi-disciplinary clinics. These multi-disciplinaryclinics also have cognate clinical working groups that prioritize clinical trials andstimulate translational research in collaboration with the basic scientists of the CancerCenter.- The Division continues to supervise the Hematology-Oncology in-patient service atUNM Hospital, with Dr. Lee serving as the Medical Director of 5 East, the OncologyFloor, and Dr. Jones serving as Medical Director of 3 East, the Hematology Floor.- Drs. Libby, Hromas, and Rabinowitz were all named one of the Top Docs forHematology in Albuquerque again in 2008, and Drs. Lee and Rabinowitz were namedone of the Albuquerque Top Docs in Oncology. One of the major clinicalaccomplishments this year was the successful integration of the exclusive oncology carecontract with Lovelace Health plan into the Division. This ensures this stability of patientreferrals into the UNM Cancer Center. Another major clinical accomplishment of thisfiscal year was the successful opening of the UNM Cancer Center clinic in Santa Fe at St.Vincent’s hospital. This included the hiring of 2 new faculty to staff those clinics in SantaFe. It also includes negotiating and integrating community oncologists into this clinic,and opening a clinical trials operation there.- The Division is organized into 7 Sections, Hematology/Stem Cell Transplantation led byDr. Libby, Gastrointestinal Malignancies led by Dr. Lee, Aerodigestive Tumors, led byDr. Jones, Breast Cancer led by Dr. Royce, Radiation Oncology led by Dr. Khan,Experimental Therapeutic led by Dr. Verschraegen, and Genitourinary Cancer led by Dr.Rabinowitz.Education- There are currently 4 Hematology-Oncology Fellows in the training program. Thefellowship is now a mandatory three total years, with a required basic or laboratoryresearch component, with board eligibility in both Hematology and Oncology. This pastyear we had the fellowship reviewed by the ACGME,a nd it was given a full 5 yearaccreditation. We requested a fifth position for FY2009/10 from the ACGME, and thisrequest was granted. So we anticipate that there will be a fifth fellow in 2009 /10. Giventhe enormous growth of the oncology program at UNM, both in clinical care and inresearch, there should be an increased educational opportunity for Hematology-OncologyFellows here at UNM.149

- The Division continues to organize the Thursday noon Clinic Clinical OncologyResearch Conference (led by Dr. Verschraegen), the Wednesday morning OncologyJournal club (led by Dr. Rabinowitz) , the Wednesday morning didactic fellow/residentlecture series, the Tuesday afternoon UNM-wide ACOS-required Tumor Board (led byDrs. Mangalik and Lee), and the monthly City-Wide Hematology Meetings (led by Dr.Libby).- The Division continued to distribute to all Residents, Medical Students, and Fellows thatrotate through any oncology clinic or ward the “Pocket Hematology-Oncology:Everything You Need to Know at Your Fingertips.” This has been updated, and a newprinting took place in Fall, 2007. The Division holds two didactic educations lectures perweek for residents and fellows on topics in Hematology-Oncology, one Mondayafternoon at 4 PM, and the other Wednesday morning at 7:00 AM.Administration- Dr. Ian Rabinowitz continues to serve as UNM Cancer Center Out-Patient ClinicalDirector, and Dr. Libby is the Director of Stem Cell Transplantation for UNM hospitaland the Cancer Center. Dr. Lee is Medical Director of 5E in UNMH, the oncology inpatientward. Dr. Lee also serves on the Pharmacy and Therapeutics Committee of UNMHospital. Dr. Jones is Medical Director of 3E of UNM Hospital, and both he and Dr. Leesit on the UNMH Medical Directors Committee.- Dr. Hromas completed his service as Chair of the NIH Hematopoiesis Study Section. Hecontinues as Deputy Director of the UNM Cancer Center, and as Director of the ClinicalResearch Committee, which supervises all clinical oncology research at the HSC. He isalso on the American Society of Hematology Program Committee, and will be ScientificProgram Chair in 2010. He chaired NIH Review Panels for a Program Project grant, forthe Stem Cell Niche RFA from the NHLBI, and for the Special Emphasis Panel on theHematopoietic Stem Cell.- Drs. Verschraegen and Jones served on the NIH Loan Repayment Study Section. Dr.Verschraegen is the Director of Experimental Therapeutics, the Phase I trials arm of theCancer Center. She is also Director of the Minority-Based Community Clinical OncologyProgram.- Dr. Jones is the Director of the Clinical Trials Office, the administrative office thatorganizes clinical oncology research. Dr. Royce chairs of the Protocol ReviewCommittee of the UNM Cancer Center, which reviews all UNM oncology clinicalprotocols for scientific merit and feasibility. Dr. Verschraegen is the Director ofExperimental Therapeutics, which is the Phase I Trials effort, which will be responsiblefor building an early phase cancer drug development program program at the CancerCenter.- Dr. Jones is the Medical Director of the New Mexico Cancer Care Alliance, which bringscutting edge clinical trials to the community. Dr. Verschragen is Chair of the EducationCommittee of the Alliance. Dr. Lyons continued his directorship of the SignatureProgram in Infectious Disease of the UNM HSC.- Dr. Lauer is the Executive Medical Director of the Cancer Center, and has replaced Dr.Hromas as Oncology Physician-in-Chief for the UNM Hospital. He also now Chairs theOncology Committee for the UNM HSC, and serves on the Executive MedicalCommittee of the UNM Hospital.150

B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTUREResearch- Last year clinical research was designated as an area for improvement. That area has beenmarkedly expanded, as described above. With the institution of the Clinical ResearchCommittee to streamline and prioritize all clinical oncology research, and the recruitmentof new clinical investigators, there has been a marked increase in accruals to protocols,and in clinical publications. Even in Phase I/II therapeutic trials, an area that most centershave difficulty even initiating, we have reached the goal of 50 patients annually.However, the number of patients placed on therapeutic clinical research protocols needsto continue to increase to reach the goal of 20% of all new cancer patients placed ontherapeutic trials. Specifically, new clinical protocols will be opened that will easilyaccrue large numbers of enrollees.- However, translating novel drugs discovered at UNM to clinical trials remains a complexgoal. This clinical trial effort is coordinated by Dr. Verschraegen in ExperimentalTherapeutics. The challenge for this year is to define 2-3 specific agents that have comefrom the UNM Cancer Center laboratories that can be translated into Phase I-II clinicaltrials. Several key targets have been identified, Metnase and Gypsy Integrase (from Dr.Hromas’ lab) and GPR30 (from Drs. Royce and Prossnitz). There are small moleculeinhibitors of these targets in hand, and the goal will be to develop these into clinical trials.Interestingly, Metnase and Intnase are also inhibited by two known HIV drugs, and thesecan be used to reduce the ability of Metnase and Intnase to repair the DNA damagecaused by cancer drugs. A major goal of the Division this year is to initiate a clinical trialtesting the re-purposing of these HIV drugs when added to cancer chemotherapy.- Another major goal of the Divisional research this year is to increase the number of extramuralpeer-reviewed basic or translational research grants. While Dr. Hromas was able toobtain funding for the two new RO1 grants on DNA repair that he had submitted, as aDivision there are really only a few extra-mural funded investigators. The goal will be tomentor some of the junior faculty towards peer-reviewed funding. Dr. Dahl will submitan RO1 to NIH on the role of Oct4 in embryonic hematopoiesis. He will also submit anR21 on the role of microRNAs in hematopoiesis. Dr. Garcia will submit an R21 oncancer-induced thrombosis, and Dr. Williamson will submit an R21 on preventing DNArepair in cancer cells after chemotherapy. Dr. Singh will submit a grant on the leukocytespecificGTPase IRGM.Clinical Service- The goal for last academic year was to fully incorporate the Lovelace Health plan patientsinto the Division’s oncology practice. This required recruitment of 2 new medicaloncologists with clinical trials expertise to help increase the number of patients placed onto clinical trials. These faculty were recruited (Dayao and Bauman), and the increase inpatient load was accommodated. In addition, a clinical trials program was initiated there,and more than 30 patients were accrued to therapeutic clinical trials.- This year there are three major goals for the Division’s clinical service. First, we wereawarded the contract for oncology service at the St. Vincent’s Hospital in Santa Fe, andtwo new oncologists were hired to provide that service (Shaheen and Fekrazad). The goal151

for this year is to incorporate that practice into the overall UNM Cancer Center clinicalservices. This will include generating a clinical research program there.- The next major goal for the Division for this year is to stabilize the Las Cruces outreachclinic. This will entail recruiting one or two new oncologists there, and a new nursepractioner. The third major goal for this year is to move into the new Cancer Center clinicbuilding, and to make this move as smooth for patients as possible. This new clinicbuilding has a complex and powerful electronic medical record that staff and faculty mustrapidly become adept with.- We will expand the Cancer Center oncology outreach clinics in Farmington, and the westside of Albuquerque. This will entail recruitment of additional clinical faculty. The goalof this expansion is the creation a state-wide cancer care network. We will continue themarketing plan for cancer care at UNM to take advantage of the major accomplishmentsrecently. We will continue to carefully negotiate strategic partnerships with otherhospitals and insurance plans in the state. The Division has in the past and will in thefuture take on additional clinical work load in efforts to expand market share. Oncemarket share is increased additional faculty will be hired to continue this additionalclinical care. The Division now supervises cancer care for nearly 40% of all cancerpatients in the state.- The split of the UNM Hospital clinical service into separate Hematology and Oncologyservices was successfully implemented. The difficulty of doubling the attendingrequirements of the Division without significant external support was overcome by theextraordinary efforts of the faculty. Redefining partnerships with the internal Medicineresidency program and with the UNM hospital in terms of personnel support will berequired. This separation will be required in order to build the stem cell transplantationprogram.Education- We will seek to increase the clinical trials research training for the Hematology-Oncologyfellows. A new rotation will be established that is devoted to formal training in clinicalresearch. We will strengthen and formalize the education efforts for residents and fellowson the UNMH Hematology-Oncology in-patient service. We will continue the significantefforts in didactic lectures for Fellows in Hematology-Oncology and Internal Medicineresidents for board review.Administration- The major goal for this next year is to completely integrate the new UN Cancer Centerclinic building with the outreach clinics at Lovelace downtown, Las Cruces, Santa Fe,and Farmington, and the new faculty and electronic medical record. The new CancerCenter out-patient clinic building will restructure and maximize patient flow, in order tomaintain the disease-specific clinics of the Division. The new building has increasedcheck-in and check-out stations, and increased chemotherapy capacity. Finally, fullyintegrating the new section of Radiation Oncology into the Division is an administrativepriority for the Division. Fully integrating the Division, with its multiple complexSections into a functional organism is imperative in order to achieve the above aims.C. APPOINTMENTS TO FACULTY152

Faculty- Montaser Shaheen, M.D.- Houman Fekrazad, M.D.- Zoneddy Dayao, M.D.- Julie Bauman, M.D.- Sudha Singh, Ph.D.D. SEPARATION OF FACULTY- Meera Ravindranathan, MD, moved to San Diego for a community practice.E. PUBLICATIONS FOR THE DIVISION OF HEMATOLOGY/ONCOLOGY- There were 41 papers published by members of the Division in the 2008/9 academic year.This is up from 30 in 2007/8. Some publications are listed twice below to provide creditto distinct faculty members who are co-authors, but are not counted twice in this total. Ofnote, two articles from Dr. Hromas’ group were featured on the cover of their respectivejournals, Blood and Nucleic Acids Research.Hromas, Robert- Nickoloff JA, De Haro LP, Wray J, Hromas R. Mechanisms of leukemia translocations.Curr Opin Hematol. 2008 Jul;15(4):338-45.- Williamson EA, Farrington J, Martinez L, Ness S. O’Rourke J, Lee SH, Nicholoff J,Hromas R. Expression levels of the human DNA repair protein metnase influencelentiviral genomic integration. Biochimie. 2008 Sep;90(9):1422-6.- Hromas R, Wray J, Lee SH, Martinez L, Farrington J, Corwin LK, Ramsey H, NickoloffJA, Williamson EA.Metnase interacts with DNA Ligase IV and increases the accuracy ofNHEJ repair. DNA Repair (Amst). 2008 Dec 1;7(12):1927-37.- Williamson EA, Rasila KK. Corwin LK, Wray J, Beck BD, Severns V, Mobarak C,Nickoloff JA, Hromas R. The SET and transposase domain protein Metnase enhanceschromosome decatenation: Regulation by automethylation. Nucleic Acids Res. 2008;36(18):5822-31 (Cover).- Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, Nickoloff JA,Hromas R.Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoSONE. 2009;4(4):e5323.- Kong KY, Williamson EA, Rogers JH, Tran T, Hromas R, Dahl R.Expression of SCL in mesoderm rescues hematopoiesis in the absence of Oct-4. Blood.2009; 114(1):60-3 (Cover).- Wray J, Williamson EA, Lee S-H, Libby E, Willman CL, Nickoloff JA, Hromas R.Metnase mediates chromosome decatenation in acute leukemia cells. Blood, 2009, May15. [epub ahead of print] (Cover).153

Schroeder, Thomas- South M, Chiu JK, Teh BS, Bloch C, Schroeder TM, Paulino AC. Supine craniospinalirradiation using intrafractional junction shifts and field-in-field dose shaping: earlyexperience at Methodist Hospital. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):477-83.Verschraegen, Claire- Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P,Allievi C, Eisenfeld A, Verschraegen CF. Phase I study of paclitaxel poligulumexadministrated weekly for patients with advanced solidl malignancies. Cancer ChemotherPharmacol. 20008 Nov 25 [pub ahead of print]- Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, MaestasA, Lu H, Verachraegen C. Phase I study of capecitabine in combination with cirplatinand irinotecan in patients with advanced solid malignancies. Invest New Drugs. 2008 Sep5. [Epub ahead of print]- Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, EisenfeldA, Singer JW, Oldham FB. A Phase I and pharmacokinetic study of paclitaxelpoliglymex and cisplatin in patients with advanced solid tumors. Cancer ChemotherPharmacol. 2008 Aug 6. [Epub ahead of print]- Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K,Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexedplus gemcitabine as first-time chemotherapy for patients with peritoneal mesothelioma:final report of a Phase II Trail. J Clin Oncol. 2008 Jul 20;26(21):3567-72.- Lee SJ, Gounder M, Rubin EH, Li JM, Gu Z, Thalasila A, Loyer E, Kudelka AP,Verschraegen CF. Optimal modeling for Phase I desgin of a two drug combinationresultsof a Phase I study of cisplatin with 9-nitrocamptothecin. Invest New Drugs. 2008Dec;26(6):541-51. Epub 2008 Jul 4.- Mills DA, Fekrazad HM, Verschraegen CF. SNS-595, a naphthyridine cell cycleinhibitor and stimulator of apoptosis for the treatment of cancers. Curr Opin InvestigDrugs. 2008 Jun;9(6):647-57. Review.- Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF. PhaseII studies of antiangiogenic four drug regimens for the treatment of advanced renal cellcarcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol. 2008Nov-Dec;26(6):610-5. Epub 2008 Mar 4.- Nguyen D, Lee SJ, Libby E, Verschraegen C. Rate of thromboembolic events inmesothelioma. Ann Thorac Surg. 2008 Mar;85(3):1032-8.Royce, Melanie- Stefan Glück, Michael Andria, Melanie Royce. XeNA: Xeloda plus docetaxel, with orwithout trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci.2008;5(6):341-6.- Angela Meisner, M. Houman Fekrazad and Melanie Royce. Breast Disease: Benign andMalignant. Med Clin N Am 2008 (92):1115–1141.- H Sayar, Z Shen, S-J Lee, M Royce, I Rabinowitz, F Lee, H Smith, S Eberhardt, AMaestas, H Lu and C Vershraegen. Phase I study of capecitabine in combination withcisplatin and irinotecan in patients with advanced solid malignancies. Invest New Drugs.Epub September 5, 2008.154

Lyons, C. Richard- Rollins, S.M., A. Peppercorn, J.S. Young, M. Drysdale, A. Baresch, M.V. Bikowski,D.A.- Ashford, C.P. Quinn, M. Handfield, J.D. Hillman, C.R. Lyons, T.M. Koehler, S.B.- Calderwood and E.T. Ryan. 2008. Application of in vivo induced antigen technology- (IVIAT) to Bacillus anthracis. PLoS ONE. 3:e1824.- Chand HS, Drysdale M, Lovchik J, Koehler TM, Lipscomb MF, Lyons CR. InfectImmun.Discriminating virulence mechanisms among Bacillus anthracis strains by using amurine subcutaneous infection model. 2009 Jan;77(1):429-35. Epub 2008 Nov 3Infection and Immunity.Libby, Edward- Libby E. Pregnancy and Thromboembolic Disease.Thromb Research.2008;123 Suppl1:S55-7. Epub 2008 Oct 8.- Libby E and Lee A, Anticoagulants in Cancer. Freedman and Loscalzo: NewTherapeutic Agents in Thrombosis and Thrombolysis. 2008. Informa Healthcare, 52Vandefiilt Avenue, New York, NY 10017. (in press).- Derrick Nguyen MD, Sang-Joon Lee PhD, Edward Libby MD and Claire VerschraegenMD. Rate of Thromboembolic Events in Mesothelioma. Ann Thorac Surg. 2008Mar;85(3):1032-8.Rabinowitz, Ian- Pacheco AP, Rasila, K, Lee SJ, Verschraegen C, Rabinowitz I, Elias L, Lee FC (2008)Phase II Studies of Antiangiogenic Four Drug Regimens for the Treatment of AdvancedRenal Cell Carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. UrologicOncology 26(6):610-5- Larson RA, Druker BJ, Guihot F, O’Brien SG, Riviere GJ, Krahnke F, Gathmann I,Wang Y; IRIS (International Randomized Interferon vs ST1771) Study Group(Rabinowitz I). (2008) Imatinib pharmacokinetics and its correlation with response andsafety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.Blood. 111(8):4022-8.- Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, EisenfeldA, Singer JW, Oldham FB.(2008) A phase I and pharmacokinetic study of paclitaxelpoliglumex and cisplatin in patients with advanced solid tumors. Cancer ChemotherPharmacol. Epub ahead of print- Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F,Smith H, Eberhardt S, MaestasA, Lu H, Verschraegen C. (2008). Phase I study of capecitabine in combination withcisplatin and irinotecan in patients with advanced solid malignancies. Invest New Drugs.Epub ahead of print.- Rabinowitz I. (2008) Interaction Between Statins and Rituximab in Non-Hodgkin'sLymphoma. J Clin Oncol.26(33):5486.Patt, Yehuda- Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Ngyuen NT, Chan W,Kaseb A, Curley SA, Vauthey J-N, Ellis LM, Abdalla E, Lozano RD, Patt YZ, BrownJL, Abbruzzese JL and Li D. Effect of different types of smoking and synergism with155

Hepatitis C virus on risk of hepatocellular carcinoma in American men and women: ACase-Control study. Int. J. Cancer 2008; 123: 1883-1891- Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey J-N, Glover KY,Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, andLi D. The association of family history liver cancer with hepatocellular carcinoma: ACase-Control study in the United States. Journal of Hepatology 2008; In Press.- Hassan MM, Li D, Patt YZ, Vauthey J-N, Thomas MB, Curley SA, Spitz MR, AbdallaEK, Davila M, Lozano RD, Hassan DM, Chan W, Kaseb A, Brown TD and AbbruzzeseJL. Association between Hypothyroidism and Hepatocellular Carcinoma: USA Case-Control Trial. Hepatology 2008; In Press.Garcia, David- Neal M, Crowther M, Douketis J, Verhovsek M, Stidley C, Garcia D. Reversal ofvitamin k antagonist-associated Coagulopathy: A survey of current practice. ThrombRes. 2008;122(6):864-6.- Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA.Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized onwarfarin therapy: the low INR study. Pharmacotherapy. 2008 Aug;28(8):960-7.- Garcia D, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, MerliGJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE. Delivery of OptimizedAnticoagulant Therapy: Consensus Statement from the Anticoagulation Forum Annals ofPharmacotherapy. 2008 42(7):979-88.- Garcia D, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk ofThromboembolism With Short-term Interruption of Warfarin Therapy. Archives ofInternal Medicine. 168(1):63-9; 2008.- Garcia D. Warfarin and pharmacogenomic testing: the case for restraint. ClinPharmacol Ther. 2008 Sep; 84(3):303-5.- Garcia D. Duration of anticoagulant therapy for patients with venousthromboembolism. Thromb Res. 2008;123 Suppl 1:S62-4.- Garcia D, Hylek E. Reducing the Risk for Stroke in Patients Who Have AtrialFibrillation. Cardiology Clinics. 2008; 26:267-275.- Garcia D, Spyropoulos A. Update in the Treatment of Venous Thromboembolism.Seminars in Respiratory and Critical Care Medicine. 2008; 29:40-46.Lee, Fa Chyi- Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF. PhaseII studies of anti-angiogenic four drug regimens for the treatment of advanced renal cellcarcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol. 2008Nov-Dec;26(6):610-5.Jones, Dennie- Sagar B, Estaphan F, Spell DW, Klementich F, Jones, Jr. DV. A Pilot Phase II Study OfCapecitabine With Carboplatin In Patients With Advanced Nonsmall Cell Lung Cancer.In Press—Int J Oncology, 2009.156

Dahl, Richard- Kong KY, Williamson EA, Rogers JH, Tran T, Hromas R, Dahl R.Expression of SCL in mesoderm rescues hematopoiesis in the absence of Oct-4. Blood.2009; 114(1):60-3 (Cover).- Dahl R (2009) Development of Monocytes and Granulocytes. In: Molecular Basis ofHematopoiesis that (Ed. B. Kee and A. Wickrema) Springer PressF. OUTSIDE PROFESSIONAL ACTIVITIESHromas, Robert- State of New Mexico Cancer Council, 2004-present- American Society of Hematology Scholars Study Section, 2003-present- American Society of Hematology Program Committee, 2008-present- NIH Hematopoiesis Study Section, Chair 2007-8- Chair, NHLBI RFA Review Panel, Blood Stem Cell Niche, 2009- Chair, NHLBI SEP Hematopoietic Stem Cell Regulation, 2009- Chair, NHLBI P01 AG033564 Review Panel, 2009- Invited Speaker, NCI APRC Workshop on Innovative Cancer Research Collaborations,2008Verschraegen, Claire- IGCS Education Committee, 2002-present- Loan Repayment Program – NIH Study Section, 2006-present- GOG Rare Tumor Committee, 2005-present- Chair, Education Committee, New Mexico Cancer Care Alliance, 2008-presentTarnower, Amy- New Mexico Cancer Alliance: Board Member, 2005-present- Lovelace Clinic Clinical Trials PIRabinowitz, Ian- Southwest Oncology Group Clinical Trials AuditorLyons, C. Richard- NIH study section member: Biodefense, 2005-present- Tularemia Vaccine Development National CoordinatorLibby, Edward- Organizer, 5th Annual Southwest Symposium on Thrombosis and Hemostasis- Member, Southwest Oncology Group Leukemia CommitteeRoyce, Melanie- NCI Study Section: Community Clinical Oncology Programs, 2005- present- Southwest Oncology Group (SWOG) Breast Committee member, 2004-present.- New Mexico State Cancer Council Member, August 2005 – present.157

- St. Joseph’s Community Health Breast Cancer Resource Task Force, Albuquerque, NM,August 2005 – present.- Editorial Advisory Board for ONCOLOGY, 2005 - Present- Editor, Internet Journal of Oncology, 2002 – Present- New Mexico Department of Health Medical Advisory Board member, Breast andCervical Cancer Program, September 2004 – present.- New Mexico Cancer Council Member and member of the Communications Workgroup,August 2005 – present.Jones, Dennie- Loan Repayment Program – NIH Study Section, 2006-present- State of Kentucky Lung Cancer Review Committee, 2006-8- Southwest Oncology Group Lung Cancer Committee MemberDahl, Richard- American Cancer Society Leukemia and Immunology Review Panel, 2007-present.- ACS IRG Review Panel at UNM, 2007-present.Mangalik, Aroop- National Surgical Adjuvant Breast Program Site CoordinatorBauman, Julie- PI, Eastern Cooperative Oncology Group at UNM Cancer Center, 2008-present.- Member, ECOG national Head and Neck Committee, 2008-presentDayao, Zoneddy- UNM Cancer Center Representative to the NCCTG- Member, UNM Human Research Review CommitteeG. OUTSIDE SPONSORED RESEARCH- The Division held a total of $12.5 M in peer-reviewed extra-mural research diect supportin 2008/9. This includes multiple grants from the NIH. All listed financial amounts arefor direct costs coming to UNM for the total duration of the grant. There are severalgrants for which a Division member is a co-investigator, and these are also counted here.The PI is listed under that grant. The Division also holds a large amount of extra-murallyfunded clinical research grants, which are not peer-reviewed, but still constituteexternally sponsored. These are also listed below.Hromas, Robert- Leukemia and Lymphoma Society SCOR “Comprehensive Molecular Technologies forImproved Risk Classification and Therapy,” PI- C. Willman, LLS 7388-06, Project 3-“Biological Models for Novel Outcome Genes in ALL,” PI- R. Hromas, Total DirectCosts per Annum $210,000, 10-1-05 to 9-30-10- NIH T35 HL076595, “Institutional National Research Service Award Hispanic,” TotalDirect Costs per annum $75,000, 10-1-03 to 9-31-08. PI- R. Hromas.158

- Novartis Myeloid Development Workshop Educational Grant, Total Costs- $20,000, 7-1-08 to 6-30-09.- NIH RO1 CA140442 “Transposases in Etoposide Resistance,” Total Direct Costs perAnnum $233,000, 6-15-09 to 6-14-12, PI- R. Hromas.- NIH RO1 HL093606 “The Transposase Metnase in Leukemic Decatenation,” TotalDirect Costs per annum- $250,000, 7-1-08 to 6-30-12, PI- R. Hromas- NIH PA11959 “Metnase in replication stress,” supports Leyma De Haro in her PhDstudies. Total Direct costs per annum, $26,839. 7-1-08 to 6-30-10.Bauman, Julie12/31/08 9/30/10 INST CSTI571BUS240: A Phase II Study ofIntermittent Gleevec® (Imatinib mesylate) andWeekly Paclitaxel in Patients Aged 70 or Olderwith Advanced Non-small Cell Lung Cancer1/29/09 1/28/14 INST OSI3602s: Multicenter Randomized Phase IIStudy of Erlotinib, Cisplatin and Radiotherapyversus Cisplatin and Radiotherapy in Patients withStage III and IV Squamous Cell Carcinoma of theHead and Neck7/15/09 7/15/14 ImClone IMCL CP13-0811 (CP02-0860):Randomized, Open-Label, Stratified Phase 2 Trialof Gemcitabine, Carboplatin, and Cetuximab withvs. without IMC-A12 in Chemotherapy-NaïvePatients with Advanced/Metastatic Non-Small CellLung Cancer$ 13,32832,500111,976Lyons, C. RichardNIH HHSN266200500040C/ABD N01-AI-5PI: Lyons 9/30/05-9/29/10$25,000,000Tularemia vaccine development TeamNIH/NIAID PO1 AI 56295-01A1 Pulmonary defenses to biothreatsPI ;Lyons 37/1/05-6/30/10$13,900,000NIH/NIAID U19-AI57234-01-05 Dendritic Cell Response to Category A BiothreatsPI-J. Banchereau (I Lyons Project PI)U19 AI057234 9/03-8/09$1,100,0001 U54 AI057156-01 Regional Center of Excellence: Biodefense and Emerging Infections,Region 6PI-T. Koehler (Lyons Project PI) 9/03 – 3/09$600,000159

1 U54 AI057156-01 Regional Center of Excellence: Biodefense and Emerging Infections,Region 6Small Animal Core PI: Lyons 9/03- -3/09$3,500,000NIH/NIAID UO1 AI061200-01 ( Polypeptide antigenemia for early diagnosis of anthraxPI: Kozel 2/05-12/10$1,300,000NIH/NIAID HHSN266200400044C N01-AI-40044 Discovery and development of novel tlr7,tlr8, and/or tlr9 ligands for bioterror defensePI Krieg 7/05-6/09$860,000NIH/NIAID HHS200400064C/AB N01-AI-40064to infectious diseasesPI; Gulcher 9/15/04-9/14/094,500,000DeCode Population genetics of resistanceRabinowitz, IanPA-02-125 (PI: Flynn) 07/01/2005-06/30/2007NIHBioengineering Nanotechnology Initiative. Improving Biopsies using Magnetic Nanoparticles$400,000Goals: Develop novel diagnostic tools using magnetic nanoparticlesPA06-009 (PI: Flynn) 01/01/2008-01/31/2010NIHBioengineering Nanotechnology Initiative Improving Biopsies using Magnetic Nanoparticles$1,034,351Goals: Develop novel diagnostic tools using magnetic nanoparticles.FIGS Proposal (PI: Rabinowitz) 07/01/2008-06/30/2009Internal UNM AwardFIGS proposal: A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients with LocallyTreatable Prostate Cancer Prior to Prostatectomy or Brachytherapy.$31,000Goals: Correlate the level of oxidative product (ATQ) of vitamin E and its effect on prostatecancerVerschraegen, Claire160

2401C 8/16/02 8/15/08 A Multi-center, Randomized Phase IIIStudy of Adjuvant Oncophage VersusObservation in Patients with High RiskRecurrence after Surgical Treatment forRenal Cell Carcinoma.3604P 5/1/05 1/29/10 A PHASE 1 SAFETY ANDPHARMACOKINETIC STUDY OFSU011248 AND CAPECITABINE INPATIENTS WITH ADVANCEDPharm 2458-04-01Pharm 0530PSOLID TUMORS (Pfizer A6181044)11/3/05 11/3/10 PRAECIS 2458-04-01: A Phase I DoseEscalation Safety/Tolerance Study ofPPI-2458 in Subjects with Non-Hodgkin¿s Lymphoma or Solid Tumor10/24/05 10/24/10 Pharm 0530P, An open label, phase Istudy to evaluate the safety, tolerability,and pharmacokinetics of patupilone inpatients with advanced solid tumors andvarying degrees of hepatic function(CEPO906A2121; Novartis 2121)Pharm 0518P 9/1/05 9/1/10 Pharm 0518P, A Treatment Protocol forPatients Continuing from a PriorSU011248 Protocol (ProtocolA6181030)3704P 5/1/05 2/28/103704P, MULTICENTERRANDOMIZED COMPARATIVEPHASE III TRIAL OF ONCONASE®+ DOXORUBICIN VSDOXORUBICIN IN PATIENTSWITH MALIGNANTMESOTHELIOMAPharm 307979TPU S111111/17/06 11/31/11 Bayer #307979, Phase 1/2 study of ZK-Epothilone (ZK-Epo; ZK 219477) incombination with carboplatin inpatients with platinum-sensitive,recurrent ovarian cancer3/28/06 11/15/08 A PHASE 1, OPEN-LABEL STUDYEVALUATING THEPHARMACOKINETICS OFCOMPONENTS OF S-1 INPATIENTS WITH VARYINGDEGREES OF RENAL FUNCTION.S1111$72,337105,336136,30460,00032,00038,15070,00040,000161

0544P 8/1/06 8/1/10 A Multi-Center Single Arm Phase IIStudy of MDX-010(BMS-734016)Monotherapy in Patients withPreviously Treated Unresectable StageIII or IV MelanomaPharmCA184024PharmCA1840253/6/07 3/5/12 Bristol Myers Squibb CA184024: AMulti-Center, Randomized, Double-Blind, Two-Arm, Phase III Study inPatients with Untreated Stage III(Unresectable) or IV MelanomaReceiving Dacarbazine Plus 10 mg/kgof Ipilimumab (MDX-010) vs.Dacarbazine With Placebo7/1706 7/16/11 BMS CA184025: A Multi-Center,Open-Label, Phase II Study ofIpilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-upfor Patients Previously Enrolled inIpilimumab (MDX-010) ProtocolsPharm 0505P 6/1/05 6/1/11 ImClone Study 0505P, CP02-0452:Randomized Phase III Study ofDocetaxel or Pemetrexed with orwithout Cetuximab in Patients withRecurrent or Progressive Non-SmallCell Lung Cancer (NSCLC)afterPlatinum-Based TherapyPharm A6181065 4/13/07 4/30/12 Pfizer A6181065: A RANDOMIZEDPHASE II STUDY OF THEEFFICACY AND SAFETY OFSUNITINIB MALATE SCHEDULE4/2 VS. SUNITINIB MALATECONTINUOUS DOSING AS FIRST-LINE THERAPY FOR METASTATICRENAL CELL CANCER (RENALEFFECT TRIAL)Pharm I1Y-MC-JFBA5/24/07 5/23/12 Eli Lilly I1Y-MC-JFBA: A phase 1study of LY2523355 in patients withadvanced cancerPharm SPO-0011 6/1/07 9/30/09 Phase 1 Open Label, Multicenter, DoseEscalating, Clinical Study of Safety,Tolerability and Pharmacokinetic andPharmacodynamic Profiles of SNS-314,a Novel Aurora Kinase Inhibitor,Administered to Patients withAdvanced Solid Tumors24,93151,42718,29154,4329,686147,922115,233162

Pharm H8K-MC-JZADINST 0509CPharm NV06-0039PharmEGF110557PharmNKV103444PharmEGF190608/7/07 8/6/12 Eli Lilly H8K-MC-JZAD: A Phase 2Study of LY573636-SodiumAdministered as Second-Line or Third-Line Treatment in Patients withUnresectable or Metastatic Soft TissueSarcoma11/28/05 11/27/08 INST 0509C: Phase I/II Study of theCombination of Docetaxel,Gemcitabine, and Bevacizumab, inPatients with Advanced or RecurrentSoft Tissue Sarcoma10/23/07 10/23/10 Marshall Edwards Pty Ltd/Covance:Multi-Center, Randomized, Double-Blind, Phase III Efficacy StudyComparing Phenoxodiol (Oral DosageForm) in Combination with Carboplatinversus Carboplatin with Placebo inPatients with Platinum-Resistant ofPlatinum-Refractory Late-StageEpithelial Ovarian, Fallopian orPrimary Peritoneal Cancer Following atLeast Second Line Platinum Therapy(OVATURE study)12/5/07 12/4/12 (STUDY COMPLETE) GSKEGF110557: An Open-Label, Two-Part, Single Sequence Study toExamine the Effects of Lapatinib on thePharmacokinetics of OrallyAdministered Digoxin in Subjects withMetastatic ErbB2+ Positive BreastCancer11/4/08 11/13/13 GSK NKV103444: An Open Label,Repeat Dose , Randomized, TwoPeriod, Crossover Study to Investigatethe Potential PharmacokineticInteractions between Oral GW679769and Intravenous Cyclophosphamide inCancer Patients1/29/08 1/28/13 GSK EGF19060: An Open-Label,Phase 1b Roll-over Study to Assess theLong-Term Safety Profile of Lapatinibin Cancer Patients25,37114,10017,79417,3146,76310,025163

Pharm 4783-08 7/29/08 7/28/13 Synta 4783-08: A Randomized,Double-blind, Phase 3 Trial of STA-4783 in Combination with Paclitaxelversus Paclitaxel Alone for Treatmentof Chemotherapy-Naïve Subjects withStage IV Metastatic MelanomaNSTAVF3911s/3910sPharm Poniard07012/22/07 2/1/10 INST/Genentech AVF3911s: Phase IIand Pharmacokinetic Study ofBevacizumab and Doxil in theTreatment of Platinum-Resistant orRefractory Ovarian Cancer8/14/08 8/13/13 Poniard 0701: A Phase 1 Study ofPicoplatin in Subjects with AdvancedNon-Hematological Malignancies withEmphasis on Cardiac RepolarizationINST CZ48-01 9/15/08 9/14/13 INST CZ48-01: Phase I andPharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) inPatients with Solid Tumors orLymphomaPharm AP-23573-07-302PharmCA184045Pharm CBP 08-01Pharm IPM20021/23/08 1/22/13 ARIAD AP-23573-07-302: A PivotalTrial to Determine the Efficacy andSafety of AP23573 when Administeredas Maintenance Therapy to Patientswith Metastatic Soft-Tissue or BoneSarcomas1/30/08 1/29/13 BMS CA184045: A MulticenterTreatment Protocol for CompassionateUse of Ipilimumab (BMS-734016)Monotherapy in Subjects withUnresectable Stage III or Stage IVMelanoma11/3/08/ 12/2/13 CanBas CBP 08-01: Phase I/II Study ofa Triplet Combination of CBP501,Pemetrexed and Cisplatin in Patientswith Advanced Solid Tumors and inChemotherapy-Naïve Patients withMalignant Pleural Mesothelioma10/22/08 10/21/13 Ziopharm IPM2002: A Phase IIMulticenter, Parallel Group,Randomized Study of PalifosfamideTris Plus Doxorubicin versusDoxorubicin in Subjects withUnresectable or Metastatic Soft-TissueSarcoma7,98374,16620,66165,23979,9004,00078,46091,186164

Pharm CA184-029PharmEGF111767Pharm LX01-315-02Pharm TH-CR-3051/12/09 1/11/14 Bristol-Myers Squibb CA184-029:Adjuvant Immunotherapy with Anti-CTLA-4 Monoclonal Antibody(Ipilimumab) Versus Placebo AfterComplete Resection of High-Risk StageIII Melanoma: A Randomiz ed,Double-Blind Phase 3 Trial of theEORTC Melanoma Group1/12/09 1/11/14 (STUDY COMPLETE) GSKEGF111767: An Open-Label, Phase IbContinuation Study of LapatinibMonotherapy or Lapatinib inCombination with other Anti-cancerTreatment in Patients with SolidTumors1/12/09 1/11/14 Vical LX01-315-02: A Phase 3 ClinicalTrial to Evaluate the Safety andEfficacy of Treatment with 2 mgIntralesional Allovectin-7 Compared toDacarbazine (DTIC) or Temozolomide(TMZ) in Subjects with RecurrentMetastatic Melanoma3/12/07 3/12/12 Threshold Pharmaceuticals TH-CR-305: An Open Label Phase 2 Study ofthe Efficacy and Safety ofGlufosfamide in Previously TreatedAdvanced Soft Tissue Sarcoma66,26021,34373,06446,337RTOG Trials 2/17/04 2/16/04 RTOG Supplemental Funds 16,000PI: Verschraegen. NCI U10 CA 086780, New Mexico Minority Based Community ClinicalOncology Program, 6-20-08 to 5-31-13, Direct costs $435,153 per annum.Royce, MelaniePharm 0546P 4/1/06 4/1/10 (STUDY COMPLETE)GlaxoSmithKline EGF105084: A PhaseII Study of Lapatinib for BrainMetastases in Subjects with ErbB2-Positive Breast Cancer FollowingTrastuzumab-based Systemic Therapyand Cranial Radiotherapy (EGF105084)$26,872165

INST 0514CPharmAVF3693gPharmAVF3694g12/28/05 12/27/10 INST 0514C- A Neoadjuvant Phase IITrial of GW572016 in HER2Overexpressing Breast Cancer Patients:Biologic Correlative Study8/1/06 8/1/10 Genentech AVF3693g: A phase III,multicenter, randomized, placebocontrolledtrial evaluating the efficacyand safety of bevacizumab incombination with chemotherapyregimens in subjects with previouslytreated metastatic breast cancer8/1/06 8/1/10 Genentech AVF3694g: A multicenter,phase III, randomized, placebocontrolledtrial evaluating the efficacyand safety of bevacizumab incombination with chemotherapyregimens in subjects with previouslyuntreated metastatic breast cancerPharm 20050136 7/17/06 9/1/11 Amgen 20050136: A randomized,double-blind, multicenter study ofdenosumab compared with zoledronicacid (Zometa) in the treatment of bonemetastases in advanced breast cancer.Pharm A6181094 2/27/08 2/26/13 Pfizer A6181094: A Phase 3 Study ofSUO11248 in Combination withPaclitaxel versus Bevacizumab withPaclitaxel in the First-Line AdvancedDisease Setting in Patients HavingBreast CancerPharm BMSCA163131COMIRB 02-8244/1/08 3/31/13 BMS CA163131, IXTEND: ARandomized Phase 2 Study to Evaluatethe Combinations of Ixabepilone plusCapecitTabine or CapEcitabiNeDocetaxel plus Capecitabine Docetaxelin the Treatment of Metastatic BreastCancer12/6/07 12/31/09 COMIRB 02-824: Differential generegulation during neoadjuvant therapytrial of epirubicin/Cyclophosphamide(EC) vs Docetaxel/Capecitabine (DX)regimens in patients with large ERpositiveand ER-Negative breastcancer: A randomized Phase II Trial16,0009,0059,00539,12042,28056,00020,678166

Pharm A6181099 5/16/08 5/15/09 Pfizer A6181099: A Randomized,Phase 3 Study of Sunitinib inCombination with CapecitabineCompared with Capecitabine inPatients with Previously Treated BreastCancerPharmCA163100PharmEGF108916NCCTG /N063D8/6/08 8/5/13 Bristol-Meyers Squibb CA163100: ARandomized Phase II BiomarkerNeoadjuvant Study of Sequential ACFollowed by Ixabepilone Compared toSequential AC Followed by Paclitaxelin Women with Early Stage BreastCancer Not Overexpressing HER-2 andEstrogen Receptors9/10/07 9/9/12 GSK EGF108916: An Open-Label ,Multi-Centre Study of Lapatinib inCombination with Chemotherapy inPatients with ErbB2 OverexpressingBreast Cancer after TrastuzumabFailure in the Neoadjuvant or AdjuvantSetting4/11/08 4/11/13 NCCTG N063D/ALTTO: AdjuvantLapatinib and/or TrastuzumabTreatment Optimisation Study. ARandomised, Multi-Centre, Open-Label, Phase III Study of AdjuvantLapatinib, Trastuzumab, TheirSequence and Their Combination inPatients with HER2/ErbB2 PositivePrimary Breast CancerINST A&G 7 3/1/09 2/28/14 INST/A&G 7: Prognostic Significanceof GP88 Expression in Correlation withDisease Free Survival and OverallSurvival in Breast Cancer Patients withEstrogen Receptor Positive TumorsPharm 20062042 7/8/09 7/8/14 Amgen 20062042: An Open-LabelStudy of AMG 386 in Combinationwith Either Paclitaxel and Trastuzumabor Capecitabine and Lapatinib inSubjects with HER2-positive LocallyRecurrent or Metastatic Breast Cancer52,03437,56031,94479,9857,04055,600Dahl, RichardTranscription factor ratios directing hematopoietic differentiationP.I. Richard Dahl, 50% effortAmerican Cancer Society167

07/2006-06/2010Total Direct costs: $600,000: Indirect costs $120,000Biologic Models for Dissection of Novel Outcome Genes in ALLP.I. Robert Hromas, Co-I Richard Dahl (25% effort), Co-I Larry SklarLeukemia and Lymphoma Society, SCOR grant10/ 2005-09/ 2010Direct costs: $1,050,000; Indirect costs: $210,000Patt, YehudaPharm 0515P7/1/05 6/30/10 Pharm 0515P, ML18491 Roche: XELOX-ADVS (Dense Vs. Standard). A RandomizedStudy of Intermittent Capecitabine inCombination with Oxaliplatin (XELOXQ3W) and Bevacizumab versus Intermittentin Combination with Oxaliplatin (XELOSQ2W) and Bevacizumab as First-lineTreatment for Patients with MetastaticColorectal CancerINST OX-05-024 12/6/06 12/5/11 INST OX-05-024: Phase II Trial ofGemcitabine and Oxaliplatin (Gem-Ox)with Erlotinib (Tarceva) in the Treatm ent ofHepatocellular Carcinoma (HCC) andBiliary Tree Cancer (BTC) (intra- and extrahepaticcholangiocarcinoma, bile ductcancer, adenocarcinoma of the Ampulla ofVater and gallbladder carcinoma) Patientswith Adequate Platelet Counts(>100,000/uL)Pharm NAP-0601 4/13/07 4/12/12 Nuvelo NAP-0601: Multicenter, Two-StageStudy to Evaluate the Safety and Efficacy ofSecond-Line Metastatic ColorectalCarcinoma Treatment with RecombinantNAPc2Pharm H8Z-MC-JACS4/18/08 4/17/13 Eli Lilly H8Z-MC-JACS: An open label,single arm, phase 2 study withpharmacokinetic sampling to evaluateLY2181308 in patients with advancedhepatocelluar carcinomaPharm AMP-004 9/14/06 9/13/11 Amplimed AMP-004: A Phase I Trial ofImexon, Injection (Amplimexon) plusGemicitabine in Advanced, PreviouslyUntreated Pancreatic Adenocarcinoma$19,63190,85552,50028,31344,207168

Garcia, DavidPharm ATI-5923-CLN-505Pharm EFC6521 11/13/08BRIDGE(1U01HL08675501A1)11/1/07 12/31/09 ARYx ATI-5923-CLN-505: ARandomized, Double-Blind Comparisonof ATI-5923, a Novel Vitamin KAntagonist, with Warfarin in PatientsRequiring Chronic Anticoagulation11/13/13 Sanofi-Aventis EFC6521: AMultinational, Randomized, DoubleBlind, Placebo-Controlled Study toEvaluate the Efficacy and Safety ofAVE5026 in the Prevention of VenousThromboembolism (VTE) in CancerPatients at High Risk for VTE and WhoAre Undergoing Chemotherapy (SAVE-ONCO)6/12/09 6/12/14 NHLBI/Duke CRI BRIDGE(1U01HL08675501A1): BridgingAnticoagulation in Patients who RequireTemporary Interruption of WarfarinTherapy for an Elective InvasiveProcedure or SurgeryJones, Dennie V. Jr.Pharm AVF3752g 10/2/07 1/31/09 STUDY COMPLETE) GenentechAVF3752g: A phase II trial ofBevacizumab in combination with first orsecond-line therapy in subjects with treatedbrain metastases due to non-squamous nonsmallcell lung cancerPharm 0501P 6/1/05 5/31/08 Taiho Pharma USA,(0501P)TPU S1202-An Open-Label, Non-Randomized,Multicenter, Three Stage, Phase 2 Study ofS-1 in Combination with Cisplatin as 1stLine Therapy for Patients with AdvancedNon-Small Cell Lung Cancer ( StageIIIB/Stage 1V)INST J0658 5/11/07 4/30/09 NCI/Johns Hopkins J0658: A Phase I/IIStudy of Entinostat in Combination with 5-Azacytidine in Patients with RecurrentAdvanced Non-Small Cell Lung Cancer60,59737,840160,000$24,60712,78223,520169

Pharm AVF3991n 4/19/07 4/30/12 PPD/Genentech AVF3991n: Anobservational study of Avastin(bevacizumab) in combination withchemotherapy for treatment of metastatic orlocally advanced and unresectablecolorectal cancer, locally advanced ormetastatic non-small cell lung (excludingpredominant squamous cell histology), orlocally recurrent or metastatic breast cancer(ARIES)UMGCC 0822GCCPharm VGFT-ST-07086/1/09 12/31/1UMGCC 0822 GCC: A Randomized,0 Double-Blind, Placebo-ControlledMulticenter Phase 2 Study of the Efficacyand Safety of Apricoxib in Combinationwith Either Docetaxel or Pemetrexed inNon-Small Cell Lung Cancer Patients5/15/09 5/15/14 Regeneron VGFT-ST-0708: A Phase 1/2Study of Aflibercept Administered inCombination with Pemetrexed andCisplatin in Patients with AdvancedCarcinomaLee, Fa-Chyi0100C 1/2/01 1/1/12 Phase I Dose Finding Clinical Trial ofCombination Paclitaxel, Carboplatin andTemozolomide for Subjects with SolidTumor MalignanciesPharm 0502P 6/1/05 5/31/11 TAIHO TPU-S1201 (0502P): An Open-Label, Non-Randomized, Multicenter,Two-Stage, Phase II Study of S-1 as 2ndLine Therapy for Patients with MetastaticPancreatic Cancer3304C 7/1/05 7/1/11 INST 3304C: A Phase II trial using acombination of Oxaliplatin, Capecitabine,and Celecoxib with Concurrent Radiationfor Patients with Newly DiagnosedResectable Rectal CancerPharm 0507P 4/1/05 4/1/08 TAIHO Pharma USA TPU-S1301(0507P)- An Open-Label, Multicenter,Randomized, Phase 3 Study of S-1 inCombination with Cisplatin ComparedAgainst 5-FU in Combination withCisplatin in Patients with AdvancedGastric Cancer4,4806,00059,378$17,40016,150100,41214,616170

Pharm 20050181 8/3/06 8/2/11 Amgen 20050181: A randomized,multicenter phase 3 study to compare theefficacy of panitumumab in combinationwith chemotherapy to the efficacy ofchemotherapy alone in patients withpreviously treated metastatic colorectalcancerPharm GSKMET11164310/18/07 10/17/10 GSK MET111643: A phase 2 study ofXL880 Administered Orally on anIntermittent Schedule to Subjects withPoorly Differentiated Diffuse MetastaticGastric Cancer (formerly Exelixis XL880-204)Pharm AMP-019 2/7/08 2/6/13 Amplimed AMP-019: A Phase 2bRandomized, Double-Blind, MulticenterTrial of Amplimexon plus Gemcitabineversus Gemcitabine plus AmplimexonPlacebo in Patients With MetastaticChemotherapy Naive PancreaticAdenocarcinomaPharm EFC102621/1/09 7/31/11 NSABP/Sanofi EFC10262: AMultinational, Randomized, Double-BlindStudy, Comparing the Efficacy ofAflibercept Once Every 2 Weeks versusPlacebo in Patients with MetastaticColorectal Cancer (MCRC) Treated withIrinotecan / 5-FU Combination (FOLFIRI)After Failure of an Oxaliplatin BasedRegimen (VELOUR)0100C 1/2/01 1/1/12 Phase I Dose Finding Clinical Trial ofCombination Paclitaxel, Carboplatin andTemozolomide for Subjects with SolidTumor MalignanciesPharm 0502P6/1/05 5/31/11 TAIHO TPU-S1201 (0502P): An Open-Label, Non-Randomized, Multicenter,Two-Stage, Phase II Study of S-1 as 2ndLine Therapy for Patients with MetastaticPancreatic Cancer3304C 7/1/05 7/1/11 INST 3304C: A Phase II trial using acombination of Oxaliplatin, Capecitabine,and Celecoxib with Concurrent Radiationfor Patients with Newly DiagnosedResectable Rectal Cancer48,00038,04622,961142,00017,40016,150100,412171

Pharm 0507P 4/1/05 4/1/08 TAIHO Pharma USA TPU-S130114616(0507P)- An Open-Label, Multicenter,Randomized, Phase 3 Study of S-1 inCombination with Cisplatin ComparedAgainst 5-FU in Combination withCisplatin in Patients with AdvancedGastric CancerPharm 20050181 8/3/06 8/2/11 Amgen 20050181: A randomized,48,000multicenter phase 3 study to compare theefficacy of panitumumab in combinationwith chemotherapy to the efficacy ofchemotherapy alone in patients withpreviously treated metastatic colorectalcancerPharm EFC10262 1/1/09 7/30/11 NSABP/Sanofi EFC10262: A142,000Multinational, Randomized, Double-BlindStudy, Comparing the Efficacy ofAflibercept Once Every 2 Weeks versusPlacebo in Patients with MetastaticColorectal Cancer (MCRC) Treated withIrinotecan / 5-FU Combination (FOLFIRI)After Failure of an Oxaliplatin BasedRegimen (VELOUR)ECOG Trials 9/1/03 9/1/11 ECOG Trials Supplemental Funds 82,312Pharm 20070509 7/8/09 7/8/14 Amgen 20070509: A Randomized,Multicenter, Phase 2 Study to Compare theEfficacy of Panitumumab in Combinationwith mFOLFOX6 to the Efficacy ofBevacizumab in Combination WithmFOLFOX6 in Patients With PreviouslyUntreated, KRAS Wild-Type,Unresectable, Metastatic ColorectalCancerPharmAPO4565g5/7/09 5/7/13 Genentech APO4565g: A Phase Ib Studyof the Safety and Pharmacokinetics ofApo2L/TRAIL Administered inCombination with the Folfox Regimen andBevacizumab in Patients with PreviouslyUntreated, Locally Advanced, Recurrent,or Metastatic Colorectal Cancer96,33023,005172

Pharm 20070509 7/8/09 7/8/14 Amgen 20070509: A Randomized,Multicenter, Phase 2 Study to Compare theEfficacy of Panitumumab in Combinationwith mFOLFOX6 to the Efficacy ofBevacizumab in Combination WithmFOLFOX6 in Patients With PreviouslyUntreated, KRAS Wild-Type,Unresectable, Metastatic ColorectalCancerLibby, EdwardPharmCAMN107A2109Pharm C307001PharmC18083/3064/NL/MN4/3/06 9/1/08 Novartis AMN107: An open-label,multi-center, expanded access study oforal AMN107 in adult patients withimatinib (Glivec®/Gleevec®)- resistantor- intolerant chronic myeloid leukemiain blast crisis, accelerated phase orchronic phase10/18/07 10/17/12 (STUDY COMPLETE) Cylene C3-07-001: A Phase 2 Multi-Center, OpenLabel Study Evaluating ClinicalEfficacy, Safety and PharmacodynamicEffects of CX-3543 in Patients withRelapsed or Refractory B-Cell ChronicLymphocytic Leukemia (B-CLL)5/14/09 3/1/14 Cephalon C18083/3064/NL/MN: AnOpen-Label, Randomized, Multi-CenterTrial of Bendamustine HCL andRituximab (BR) Compared toRituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) orRituximab, Cyclophosphamide,Doxorubicin, Vincristine andPrednisone (R-CHOP) Chemotherapyin First Line Treatment of Subjects withIndolent Non-Hodgkins Lymphoma(NHL)96,330$24,50021,97521,156173

DIVISION OF INFECTIOUS DISEASES174

DIVISION OF INFECTIOUS DISEASESANNUAL REPORT: JULY 1, 2008-JUNE 30, 2009GREGORY J. MERTZ, M.D., PROFESSOR AND CHIEFA. SIGNIFICANT DEVELOPMENTS AND ACHIEVEMENTSADMINISTRATIVEMarcos Burgos- Renewed contract with New Mexico Department of Health for his position as MedicalDirector of the Tuberculosis program (50% salary support).Tom Byrd- Promoted to Professor of Medicine and Molecular Genetics and Microbiology withtenure.- Became member of UNM Promotion and Tenure CommitteeSusan Kellie- Developed the MRSA initiative at University Hospital with Infection Control team; theMRSA Team received “Journey to Excellence” award from the Committee onExcellence, July 24, 2008Sam Lee- Assisted recruitments of VA ID-Antimicrobial Stewardship pharmacist, ID-OP AT nurse,ID-MRSA coordinatorGreg Mertz- Designed an audit of billing for inpatient consults that revealed low billing capture andled to reorganization of inpatient billing for DoIM- Obtained approval from the UNM Hospital for hiring of a midlevel practitioner to assistwith OPAT clinic and inpatient consultations tied to OPAT and hired Vincent Zummo,PA to fill the new positionRobert Munk- Worked with outside vendor to develop AIDS InfoNet web site capability to displayNepali and Indian educational materials- Developed a new collaboration with Solidarity and Action Against the HIV Virus inIndia (SAATHII). SAATHII conducts various HIV/AIDS educational and trainingactivities in several cities in India. They are providing translations of InfoNet fact sheetsinto Bengali, Hindi, Oriya, Tamil and Telugu.Douglas J. Perkins- Awarded NIH Fogarty Framework Global Health grant.- Hired new post-doctoral fellow research scientist (Prakash Kempaiah, PhD).- Hired new Program Coordinator (Beth Kaimowitz).- Developed web site for Global and Geographic Medicine Program.175

- Travelled to India with Dr. Ravi Durvasula to establish clinical and research sites forUNM medical students, residents, and fellows.- Travelled to Kenya to establish clinical and research sites for UNM medical students,residents, and fellows.Elaine Thomas- Secured continued funding for STD provider education from NM DOH- Secured continued funding AIDS Education and Training Center for statewide providereducation on HIV.- Restructured AETC staff mix to improve programKarla Thornton- Coordinated ID Division’s curriculum for resident Thursday school- Served as mentor, HIV Continuity Clinic- Mentor, Bernadette Johnson, Pharm D, “Immunologic response to Hepatitis B vaccine inHIV patients”- Completed curriculum and obtained support to begin a HCV Peer Education project inthe NM Department of Corrections.Bruce Williams- Supervised completion of transfer of TSC from UH to UNMMG- Began service on UNMMG Physician Advisory Group (PAG)- Elected as PAG representative (non-voting) to UNMMG Executive Committee.EDUCATIONMarcos Burgos- Research mentor to Bonnie Young & PhD thesis advisor committee co-chair,Anthropology Department UNM Main Campus. “Genetic and environmental componentsof susceptibility to tuberculosis in Latin America”- Research mentor for Almea Matanock UNM SOM IV year medical student,“Tuberculosis and Diabetes.” August 2008 to May 2009.- Lectures to UNM DoIM house staff (1), and UNM ID fellows on tuberculosis (2) andTuberculosis and HIV co-infection.- Clinical teaching of students, residents and fellows at the Stanford tuberculosis clinic,DOH. In 2008 to 2009 academic year approximately 3 infectious diseases fellows, 8medical students, 3 residents and 4 other UNM students rotated through the TB clinic.- Infectious disease block leader with Susan Kelly of the Internal Medicine Grand Roundslectures on “Bad Bugs, no drugs: facing the challenge of antimicrobial resistance”.DR/XDR-TB: A Global Challenge with Local Implications" by Dr. Charles Daley,Professor of Medicine, National Jewish Medical and Research Center and CommunityMRSA: What’s UP with That? Dr. Henry Chambers, Professor of Medicine, Chief,Division of Infectious Diseases, SFGH, University of California San Francisco,September 2008.- Organizer of the Southwest TB controllers’ meeting in Flagstaff Arizona, October 2008.- Attended the 39 th International Union Against Tuberculosis and Lung Diseases WorldConference, October 2008, Paris France.176

- Attended the Four Corners Infectious Disease Meeting, October 2008.- Attended the CDC tuberculosis controllers meeting June 2009.Tom Byrd- Medical Student Lecture in the Infection and Immunity Block 12/08 – “Fulminant andDeadly Infections”.- Graduate Student Lecture in Biomed 652 Global ID block 5/09– “TuberculosisImmunopathogenesis”.-Susan Kellie- Developed 18.5 hours of CME/CEUs for New Mexico Methicillin-ResistantStaphylococcus aureus Collaborative workshops in conjunction with collaborativesteering committee.- Delivered CME lectures at two UNM CME events: “The New MRSA”, lecture at UNMCME “Current Concepts in General Surgery 2008” 9/5/08:, and: “Vaccines for adults”,lecture for the joint UNMSOM and Beth Israel/Harvard Medical School CME course,“Update and review of internal medicine 2007”, also presented the “Infectious DiseasesQ &A session”, 10/23/08, Santa Fe, New Mexico.- Co-coordinated with Dr. Marcos Burgos: Infectious Diseases Department of InternalMedicine rand Rounds Block, “Bad bugs, no drugs: facing the challenge of antimicrobialresistance”, for a total of 4 CME hours.Sam Lee- Continues as Research mentor to Marisa Miceli, MD, ID Fellow. “Combinationtherapies against Candida albicans biofilms in vitro.” 2007 – June 2008.- Research mentor to Neil Ku, MD, ID Fellow “Combination therapies against Candidaalbicans biofilms in vitro.” July 2008 – June 2009.- Continues as Research mentor to Stella Bernardo, Ph.D, Post-doctoral Fellow. “Secretedvirulence proteins and biofilm formation in Candida albicans.” 2007 – present. Assistedwriting and submission of VA Career Development Award, Level 2 (pending).- Continues as Research mentor to Suresh Kumar, Ph.D, Post-doctoral Fellow. “Secretedvirulence proteins and biofilm formation in Candida albicans.” 2007 – present.- Continues as Member, dissertation committee, Bobban Subhadra, Ph.D student,Biomedical Sciences Graduate Program, UNM School of Medicine.- Lectures to UNM DoIM housestaff (1), and UNM ID Fellows (1) on fungal infections.- VA HIV clinic preceptor for Marisa Miceli, MD and Nicole Klein, MD- Continues as Member, Infectious Diseases and Inflammation Program traini ng faculty.Douglas J. Perkins- Mentored two junior faculty, four postdoctoral fellows, one ID fellow, four PhD students,one medical student, three MSc students, and two undergraduates.- Tutor for phase 1 undergraduate medical education (Infection and Immu nity)- Two lectures to first year undergraduate medical students.- Two lectures in the MPH program.- One lecture in the BMSB program to MSc and PhD students.177

Karla Thornton- Designed outcomes database and began collection of data for Health care for theHomeless Re-entry CollaborativeRESEARCHSusan Kellie- Mentored two medicine residents in prize-winning posters at American College ofPhysicians New Mexico meeting, October 18, 2008: “Q fever in New Mexico”, Brown Gand Kellie S, second prize for associate member posters, and “Vancomycin-intermediateS. aureus comes to New Mexico”, White T and Kellie S, third prize for associate memberposters.- Mentored Timothy Muller, graduate student in Health Education Program, on practicumproject required for degree completion, July-Dec 2008 (development of a knowledge,attitudes and practice questionnaire of health care workers regarding MRSA).- Mentored Eugene Fayerberg and Jacques Bouchard, medical students in research projecton C. difficile 4/7/09-presentSam Lee- Candida molecular pathogenesis: secreted virulence proteins and biofilm formation.- Antifungal strategies and combinations against Candida biofilms.- High-throughput antifungal drug target screening (in collaboration with Dr. Larry Sklar,UNM Cancer Center)DJ Perkins- “UNM Framework Program for Global Health” 1 R25TW008099-01, 5/6/2009-4/30/2011, $269,966 (DJ Perkins, PI, grant awarded 5/6/09).- “Uncovering the Biological Pathways Responsible for Suppression of Erythropoiesis inChildren with Severe Malarial Anemia”, in response to NIH RFA-OD-09-003, (DJPerkins, PI, submitted 4/27/09).- “Genetic Basis of Severe Malarial Anemia” Supplement, in response to NIH NOT-OD-09-056, (DJ Perkins, PI, submitted 4/17/09).- “Impact of Surface Receptors and FC Gamma Receptors in Severe Malarial Anemia”,NIH/GRIP, 1 R01 TW008306-01, 9/20/2009 to 09/20/2012. Ouma PI (DJ Perkins, Co-Investigator).CLINICAL/SERVICEDiane Hanfelt-Goade- Added Cystic Fibrosis clinic halftime, .15 clinical FTE- Doubled the number of clinic days of Outpatient ID Clinic, shared with Susan Kellie, toaverage 6 clinics per monthMichelle Iandiorio- Attended for ID outpatient rotation for medical students and medicine residents- Phase I MS Clinical Skills preceptor for pulmonary178

Elaine Thomas- Took training course on colposcopy- Took training course on buprenorphine administrationB. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE FUTUREADMINISTRATIONMarcos Burgos- Continue to renew yearly funding for Medical Director of the Tuberculosis Program NMDOH and tuberculosis educationTom Byrd- Invited to submitted proposals to the Department of Defense dealing with Gulf WarIllness and to the Cystic Fibrosis Foundation for competitive renewal of current funding.Diane Hanfelt-Goade- Acting Director of the Cystic Fibrosis Clinic as of August 1 st with responsibility for CFclinic and CF Foundation grant.Susan Kellie- Establish antimicrobial stewardship program at VA staffed by Tiffany Goolsby,Pharm.D, Antimicrobial Pharmacist in ID service- Establish distance learning program for Infection Control/Hospital Epidemiology withinECHO program under direction of New Mexico Department of Health through ARRAfundedHealthcare-Associated Infection reduction program for states.- Develop curriculum to offer ID fellowship with Infection Control/Hospital Epidemiologyfocus based at VA- Develop projects on role of IT in interinstitutional aspects of infection control inconjunction with Tricore and UNM investigatorsSam Lee- Assist in establishment of antimicrobial stewardship program at VA Albuqerque MedicalCenter with Dr. Susan Kellie and Dr. Tiffany Goolsby (VA ID pharmacist).Greg Mertz- Work with HSC clinical affairs to plan and recruit for hospital epidemiology andantibiotic stewardship programs- Perform needs assessment and feasibility evaluation for expanded travel clinicRobert Munk- Develop collaboration with Project ECHO for development of patient-orientededucational materials on Hepatitis CDJ Perkins- Continue development of the Global and Geographic Medicine Program.179

- Hire new administrative assistant for UNM Framework Program in Glob al Health.EDUCATIONMarcos Burgos- Plan an ECHO pilot study for management of MDR-TB patients in Lima Peru.- Develop lecture on Interferon Gamma release assays for the diagnosis of latenttuberculosis infection.Sam Lee- Continue precepting ID Fellows, Dr. Nicole Klein and Dr. Neil Ku in HIV clinic.- Continue precepting post-doctoral fellows Dr. Stella Bernardo, Dr. Suresh Kumar, and IDFellow Dr. Neil Ku in fungal pathogenesis and biofilm research.Greg Mertz- Publish chapters on acyclovir and valacyclovir in Kucer’s The Use of Antibiotics, 6 th Ed.Douglas J. Perkins- With Ravi Durvasula, develop two new courses in Global Health with distance learningoptions, sponsor a Southwest Regional Workshop in Global Health, and develop acomprehensive overseas curriculum for research in global health at UNM.- Develop a new MSc and Certificate Program in Global Health in HSC.Karla Thornton- Complete pilot training of prison peer educators for HCV peer education Program,“Prisoner Health is Community Health.”RESEARCHMarcos Burgos- Revise and Resubmit molecular epidemiology of tuberculosis in New Mexico paper toCID.- Submit for publication “Burden of tuberculosis in a public health hospital in Lima Peru”to Emerging Infections.Diane Hanfelt-Goade- Will resubmit IGERT and two NIH grantsSam Lee- Present 1-2 original research abstracts at national ID meetings on Candida molecularpathogenesis and/or in vitro studies of C. albicans biofilms per year.- Publish 1-2 original research papers on Candida molecular pathogenesis and/or in vitrostudies of C. albicans biofilms per year.- Produce data for NIH R21 or R01 grant submission in 1-2 years.- Participate in 1 industry sponsored clinical trialGreg Mertz180

- Submit competitive renewal for ICIDR research grant in July 2009- Submit manuscript describing the clinical course 104 cases of hantaviruscardiopulmonary syndrome in Chile- Submit two additional research papersDouglas J. Perkins- Prepare and publish manuscripts in top-ranked, peer-review journals, and providepresentations at American Society of Tropical Medicine and Hygiene and MultilateralInitiative on Malaria conferences.- Continue malaria research and training of NIH Fogarty trainees in Kenya and at UNM.Karla Thornton- Analyze and submit for publication the results of the ECHO HCV Outcomes study.- Complete data collection, Comparison of treatment outcomes between empiric andtargeted therapy for osteomyelitis (with Michelle Iandiorio)CLINICAL/SERVICEMarcos Burgos- Continue clinical teleconferences reviewing cases as part of the tuberculosis program toall 5 regions of the state and pilot an ECHO like approach for these teleconferences.Sam Lee- Continue to expand HIV clinic enrollment at VA Albuquerque Medical CenterC. APPOINTMENTS TO FACULTY/STAFFFACULTY- NoneStaff/trainees- Vincent Zummo, PA, September 2008- Tara Smith, ID Health Educator, AIDS Education and Training Center, October 29, 2008- Beth Kaimowitz, Global and Geographic Medicine Program, Program Coordinator, Sept.1, 2008- Irene Estrada, ID Division Administrator, April 14, 2009- Neil Ku, MD, ID Fellow, July 1, 2008- Nicole Klein, MD, ID Fellow, July 1, 2008- Prakash Kempaiah, PhD, Post-doctoral Fellow, 12/1/08; HS Associate Scientist 2, 6/1/09.D. SEPARATIONS FROM FACULTY/STAFFFaculty- NoneSEPARATIONS FROM STAFF- Hollie Medina, Administrative Assistant III, February 2009- Cynthia Wootton, Division Administrator, February 2009181

- Doug Carpenter, Administrative Assistant II, December 2008- Marisa Miceli, M.D., ID Fellow, June 30, 2009- Linda Jeffcoat, Administrative Assistant III, June 17, 2009- Marlies Sichler, Administrative Assistant III, August 2008- Cole Sprague, Research Coordinator, March 6, 2009- Sara Koster, Research Coordinator, July 2008- John B. Brown, Health Educator, AIDS Education and Training Center, July 31, 2008- Patricia Carter, Program Manager, AIDS Education and Training Center, June 5, 2009E. PUBLICATIONS OF THE DIVISIONBOOKS, CHAPTERS AND ARTICLES- Bernardo SM, Jones JK, Kot J, Khalique ZK, Hardison S, Lee SA. Candida albicansVPS1 contributes to protease secretion, filamentation, and biofilm formation. FungalGenet Biol 2008; 45: 861–877.- Comerci G, Williams T, Kellie S. Immune Tolerance after Total Lymphoid Irradiationfor Heart Transplantation: Immunosuppressant-free survival for 8 years. Journal of Heartand Lung Transplantation 2009; 28 (7): 743-8.- Goade DE. Genital Herpes. In: Armstrong D and Cohen J, eds. Infectious Diseases.Mosby, London 2008- Greendyke, R., and T.F. Byrd. 2008. Differential antibiotic susceptibility ofMycobacterium abscessus variants in biofilms and macrophages compared to that ofplanktonic bacteria. Antimicrobial Agents and Chemotherapy 52:2019-2026.- Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the UnitedStates. Arch Neurol 2009;66:523-7.- Lee SA, Jones JK, Hardison S, Kot J, Khalique ZK, Bernardo SM, Lazzell A, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and invivo virulence. Mycopathologia 2009;167:55-63.- Mertz GJ. Bunyaviridae: Bunyaviruses, Phleboviruses, Nairoviruses and Hantaviruses.In Clinical Virology, Third Edition. Richman DD, Whitley RJ, Hayden FG, editors,ASM Press, Washington, DC, 2009;977-1008- Mertz G and Iandiorio MJ. Hantavirus Cardiopulmonary Syndrome in the Americas.In Clinical Infectious Disease. Schlossberg D, editor. Cambridge University Press, NewYork, NY. 2008; 1271-3.- Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications forprevention of transmission. J Infect Dis 2008; 198:1098-100.- Keller CC, Ouma C, Ouma Y, Awandare GA, Davenport GC, Were T, Hittner JB, VululeJM, Ong'echa JM, Perkins DJ.Suppression of a Novel Hematopoietic Mediator in Children with Severe Malarial Anemia.Infection and Immunity. 2009 Jun 15. [Epub ahead of print]- Ouma C, Davenport GC, Awandare GA, Keller CC, Were T, Otieno MF, Vulule JM,Martinson J, Ong'echa JM, Ferrell RE, Perkins DJ. Polymorphic variability in theinterleukin (IL)-1beta promoter conditions susceptibility to severe malarial anemia andfunctional changes in IL-1beta production. Journal of Infectious Diseases. 2008 Oct15;198(8):1219-26.182

- Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J,Ong'echa JM, Ferrell RE, Perkins DJ. Haplotypes of IL-10 promoter variants areassociated with susceptibility to severe malarial anemia and functional changes in IL-10production. Human Genetics. 2008 Dec;124(5):515-24. Epub 2008 Oct 30.- Pergam SA, Schmidt D, Nofchissey RA, Hunt WC, Harford AH and Goade DE.Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am JTrop Med Hyg. 2009 Feb;80(2):279-85.- Sadek JR, Pergam SA, Harrington JA, Echevarria LA, Davis LE, Goade D, Harnar J,Nofchissey RA, Sewell CM, Ettestad P, Haaland KY. Persistent neurological impairmentassociated with West Nile virus infection. J Clin Exp neuropsychol. 2009 Jun 8:1-8.- Were T, Davenport GC, Yamo EO, Hittner JB, Awandare GA, Otieno MF, Ouma C,Orago AS, Vulule JM, Ong'echa JM, Perkins DJ. Naturally acquired hemozoin bymonocytes promotes suppression of RANTES in children with malarial anemia throughtan IL-10 dependent mechanism. Microbes and Infection. 2009 Jul-Aug;11(8-9):811-9.Epub 2009 May 7.- Wiederhold NP, Grabinski JL, Garcia-Effron G, Perlin DS, Lee SA. Pyrosequencing todetect mutations in FKS1 that confer reduced echinocandin susceptibility in Candidaalbicans. Antimicrob Agents Chemother 2008 52:4145-8.PRESENTATIONSMarcos Burgos- Abstract and poster presentation “fitness of drug resistant strains of tuberculosis.” 39 thUnion World Conference on Lung Health Controversial Topics in MDR-TBManagement, October 2008, Paris France.- Abstract and Poster presentation on “Use of Interferon- Release Assay in a contactinvestigation among dyalisis and immunocompromise patients in Albuquerque NewMexico.” 2009 National TB Conference, Atlanta, GA, June 2009- Abstract and poster presentation on “the Fitness of clinical trains of tuberculosis” at theInternational Union Against Tuberculosis and Lung Disease North American Region13thAnnual Conference, Vancouver, Canada, February, 2009.- Clinical management of a Child with X-DR-TB in Santa Cruz, Bolivia, Four CornersConference, Flagstaff, Arizona, October, 2008.- Lecture at the annual Outbreak Response in the 4 Corners seminar, Farmington, NM.“The epidemiology of MDR-TB and X-DR tuberculosis and management implications”,April 2009.- Presentation on “Virulence of Drug Resistant Tuberculosis”, Congreso Nacional DeNeumologia, Veracruz, Mexico, April 2009.- Up date of Tuberculosis treatment and management, Grand Rounds lecture Los AlamosMedical Center, April, 2009Susan Kellie- 7/31/08-“Epidemiology-an overview”, seminar to third-year nursing students, UNM.- 8/11/08-“MRSA in ESRD patients”, lecture to Nephrology Division and dialysispersonnel- 1/22/09-“Multidrug-resistant organisms in long-term care”, lecture to Geriatrics Division.183

- 3/13/09-“A patient undergoing paracentesis”, M&M discussion, Department of InternalMedicine- 3/19/09-“Environmental aspects of infection control”, core curriculum lecture to IDfellows and division.- 4/9/09-“Antibiotics”, core curriculum talk for DOIM residents.- 4/30/09-“Antibiotics in the ICU”, core curriculum for surgical, ED, and anesthesiaresidents- 4/30/09-“Vaccines, diarrhea, and travel medicine”, core curriculum lecture for internalmedicine residents.- 5/8/09-“H1N1 influenza: what you should know”-Morbidity/Mortality lecture for internalmedicine residents.- 6/18/09-“Selected infections in pregnancy”-lecture to Materno-fetal medicine fellows- 11/7/08-“Multidrug-resistant organisms in urologic infections” , Grand Rounds, Divisionof Urology- 5/8/09-“H1N1 influenza, 2009-what you need to know”, Grand Rounds, Department ofSurgeryGreg Mertz- Glass GE, Marquet PA, Palma ER, Barria I, Yates TL, Vial PA, Ferres M, Mertz GJ.Predicting hantavirus risk in Chile. (Abstract 713) Am J Trop Med Hygiene2008;79(supplement) p. 210.- Vial PA, Mertz GJ, Ferres M, et al. Andes viral RNA load in Chilean patients withhantavirus cardiopulmonary syndrome. (Abstract 1103) Am J Trop Med Hygiene2008;79(supplement) p. 323.- Vial PA, Ferres M, Valdivieso F, Delgado I, Calvo M, Castillo C, Donoso S, Navarro E,Hernandez Y, Diaz R, Riquelme R, Scholtz L, Noriega M, Tomicic V, Belmar E, CuizaA, Tapia M, Arriagada JJ, Tassara E, Hjelle B, Mertz GJ. Clinical course of hantaviruscardiopulmonary syndrome in Chilean patients. (Abstract 1127) Am J Trop Med Hygiene2008;79(supplement) p. 330.Douglas J. Perkins- “Role of Childhood Pathogens in sub-Saharan Africa”, Global Health for MedicalProfessionals Conference, Albuquerque, NM, 10/18/09.- “Genetic Basis of Childhood Malaria and Epidemiological Perspectives”, TropicalMedicine and Telehealth Conference, Rajkot, India, 2/09.- “Unraveling the Complex Genetics of Severe Childhood Malaria,” Rajendra MemorialResearch Institute (RMRI), Patna, India, 2/09Karla Thornton- 10/08, “The Potential Role of Project ECHO in Detention Facilities,” Annual Conference,Bernalillo County Detention Facilitators. Ruidoso, New Mexico.- 7/08, “Approach to the Newly Diagnosed HIV Patient,” HIV Curriculum. Albuquerque,New Mexico, Sponsor: NM AIDS Education and Training Center- S. Arora, G. Murata, K. A. Thornton, S. Jenkusky, B. Parish, J.C. Dunkelberg, P.Deming. Project ECHO (Extension for Community Health Outcomes): KnowledgeNetworks Expand Access to Hepatitis C (HCV) Treatment with Pegylated Interferon and184

Ribavirin in Rural Areas and Prisons. Care is as safe and effective as a University Clinic.Annual Meeting of the American Association for the Study of Liver Diseases, SanFrancisco, California, October 2008, #1221F. OUTSIDE PROFESSIONAL ACTIVITIESMarcos Burgos- Member, Steering Committee, Clinical Trials Division, International Union AgainstTuberculosis and Lung Disease- Reviewer, Journal of Infectious diseases, 2005-present- Reviewer Journal of Clinical Infectious Diseases, 2005 – present- Reviewer Journal International Union Against Tuberculosis and lung Disease 2000-present.Susan Kellie- Contributed to the final report from the House Joint Memorial 67 Committee to the NewMexico Secretary of Health on the public reporting of healthcare-associated infections inNew Mexico and participated monthly in this committee, which is chaired by Departmentof Health and monitors the progress of 6 hospitals reporting data on healthcare-associatedinfections and healthcare worker influenza immunization rates through the NationalHealthcare Safety Network of CDC.- Delivered the following invited lectures:- 7/10/08: “Overview of the NM MRSA Collaborative”, and “MRSA Risk Assessment”,talks at New Mexico MRSA Collaborative Learning Session I, Albuquerque- 9/16/08: “The new MRSA”, talk to medical staff at Los Alamos Medical Center- 9/18/08: “The new MRSA: biology, epidemiology, treatment and prevention”, talk toAmerican Academy of Physician Assistants, New Mexico Regional Conference.- 9/27/08: “MRSA in the Operating Room”, talk to Association of Surgical TechnologistsAnnual Meeting.- 10/16/08: “Overview of the MRSA Collaborative”, “Decolonization-to scrub or not toscrub”, “MRSA in long term care”, talks at New Mexico MRSA Collaborative LearningSession 2, Albuquerque.- 2/5/09: “MRSA in correctional settings: epidemiology, recognition, and control”, talk toOffice of Justice Services Management Staff, Bureau of Indian Affairs Western Office,Albuquerque- 2/12/09: “New Mexico MRSA Collaborative Update”, and “Extending the collaborativework across the spectrum of care”, talks at New Mexico Collaborative Learning Session3 and Summit, Albuquerque.- 2/13/09: “New Mexico MRSA Collaborative Update”, talk at New Mexico Annual APICconference, Albuquerque- 3/5/09: “MRSA in the Healthcare Workplace”, talk via telehealth ECHO OccupationalHealth Clinic network.- 5/15/09: “Emerging infections in the healthcare workplace”, talk at regional Workers’Compensation Association conference, Albuquerque.- 5/22/09: “The new MRSA: epidemiology, infection control and treatment”, two talks atLovelace Westside Hospital, Albuquerque.185

- 6/1/09: “MRSA skin and soft tissue infections”, talk to ECHO clinic detention HCVgroup- 6/3/09: “MRSA skin and soft tissue infections”, talk to ECHO clinic community HCVgroup- 6/26/09: “The new MRSA: epidemiology, clinical syndromes, and treatment”, talk toECHO community pulmonary medicine group.Sam Lee- Ad hoc reviewer: BMC Informatics, Medical MycologyGreg Mertz- Member, VA Merit Review Subcommittee, Infectious Diseases A- Hantavirus Cardiopulmonary Syndrome in the Americas, Internal Medicine GrandRounds, Sanford School of Medicine of the University of South Dakota, Sioux Falls, SD,August 27- Editorial Board of Journal of Infectious Diseases- Editorial Board of Sexually Transmitted Diseases- Reviewer for American Journal of Tropical Medicine and Hygiene, Annals of InternalMedicine, Antiviral Research, Emerging Infectious Diseases, Journal of InfectiousDiseasesRobert Munk- Member, Scientific Committee, International Congress on Drug Therapy in HIVInfection, Glasgow, UK- Member, Scientific Committee, International Workshop on Adverse Drug Reactions andCo-morbidities in HIVDouglas J. Perkins- NIH Center for Scientific Review, Immunity and Host Defense Study Section,- 6/4/09-6/5/09.- NIH Center for Scientific Review, Clinical Research and Field Studies of InfectiousDiseases Study Section, 10/3/08.Elaine Thomas- Organized one-day CME conference on HIV 5/1/09 with about 80 health care attendees- Ongoing lectures, CME and other education statewide, e.g. lectures in Taos, Los Alamos,Las Cruces, multiple Albuquerque facilities, Navajo Nation, NM Pharmacy Association,etc.Karla Thornton- Accepted as member, American Association for the Study of Liver DiseasesG. OUTSIDE SPONSORED RESEARCH186

Project TitleFunding SourceDollarAmountDatesMycobacterium abscessusglycopeptidolipid and thepathogenesis of lung diseasein cystic fibrosis T Byrd: PIInnate Immunity in severeinfectious diseases ascontracted by:Population Genetics AnalysisProgram: Immunity toVaccines/Infections. D.Hanfelt- GoadeRole: co-investigatorCystic FibrosisFoundationNIH/NIAID/DAIT/BAA-04-18 (CR Lyons –PI)$180,000.00 July 1, 2008 – June30, 201010% salary October 01, 2004 –September 30, 2009CASG NIH/NIAID/CASGLong term therapy ofherpes encephalitis. DHanfelt-Goade Role: regionalinvestigatorUniversity of Alabama $25,000 pt subcontractDouble-Blind, Multicenter,Randomized, Placebo-Controlled Trial EvaluatingFosfomycin/Tobramycin forInhalationin Patients with CysticFibrosis and Pseudomonasaeruginosa D. Hanfelt-GoadeRole: regional investigatorA trial of intravenousperamavir for moderate tosevere influenza inhospitalized patients. D.Hanfelt-Goade Role:Regional investigatorGilead PharmaceuticalsBiocrystPharmaceuticalsPhase IIPhase III187

A statewide collaborative toreduce methicillin-resistantStaphylococcus aureusbacteremias in New Mexico.S. KellieCardinal HealthFoundation, PatientSafety Grants 2008$50,000; S Kellie,PI, 10% effort6/1/08-7/31/09Active S. LeeActive - “Secreted virulenceproteins and biofilmformation in Candidaalbicans” S LeeCompleted. S LeeCompleted. S LeeDepartment of VeteransAffairs MERITSupplemental Funding,Department of VeteransAffairs MERIT ReviewGrantAstellas CharitableGrants and DonationsProgram, UnrestrictedEducational GrantDepartment of VeteransAffairs InstitutionalEquipment Grant$60,000. July 1, 2008 – June30, 2010. $405,000 April 1 2008 –March 31, 2011$3500 June 2009$250,000 June 2009Hantavirus Ecology andDisease in Chile and Panama,NIH/NIAID G Mertz, PI,25% effort; D Hanfelt-Goade, Co-Investigator 10%effortInternationalCollaborations inInfectious DiseasesResearch (ICIDR) , 2U19 AI045452$4,166,102 8/31/2005-4/30/2010Training in HantavirusEcology, Virology, andClinical Investigation in theAmericas; (G Mertz, PI, 5%effort)Fogarty InternationalCenter GlobalInfectious DiseaseTraining Program,National Institutes ofHealth5D43TW001133$656,752 July 1, 2006-June30, 2011188

A double-blind, randomized,controlled Phase III study toassess the prophylacticefficacy and safety of gD-Alum/MPL vaccine in theprevention of genital herpesdisease in young women whoare HSV-1 and -2seronegative, (G Mertz,UNM Site PI, 5% effort)NIAID subcontractthrough St. LouisUniversity VaccineEvaluation Unit$738,994 July 15, 2004-August 31, 2011“UNM Framework Program “” DHHS/NIHfor Global Health” DJ 1R25TW008099-01Perkins, PI; R Durvasula andG Mertz, Co-Investigators$269,966 5/6/09-4/30/11“Biology of InfectiousDisease and Inflammation,”(B Hjelle, PI; T Byrd, RDurvasula, S Lee, G Mertz &DJ Perkins – Mentors)A Phase 2 Dose FindingStudy with ASP2151 inSubjects with RecurrentEpisodes of Genital Herpes,G Mertz, UNM site PI, 5%effortDHHS/NIH/NIAIDT32 AI007538ISN 15L-CL-101Astellas Pharma US,Inc.$1,515,081 9/1/08 – 08/31/13$100,875 6/27/07-10/31/08Vaccine EvaluationTreatment Units (VTEUs):Evaluation of controlMeasures Against DiseasesOther Than AIDS K KotloffPI; G Mertz, UNM site PINIAIDHHSN272200800001Cproject-specificfundingNov 1, 2007 - Oct31, 2014AIDS Education andTraining Center ElaineThomas, PI, 25% effortSTD Faculty ExpansionProgram contract from, ,Elaine Thomas, PI, 25%effortHRSA throughUniversity of ColoradoNew MexicoDepartment of Health$226,618 7/1/08-6/30/09$49,347189

Albuquerque Healthcare forthe Homeless Inc, EvaluationServices and Treatment forthe Homeless (.05 FTE) Dr.Thornton.HSC-11508 $69,876.00UNM Framework Program inGlobal Health, DJ Perkins,PI, 10% effortNIH, FogartyInternational Center, 1R25TW008099-01Genetic Basis of Severe NIH, 7 R01 AI051305-Malarial Anemia, DJ Perkins, 06PI, 50% effort$269,966 5/6/2000-4/30/2011$2,261,342 4/1/2008-3/31/2012Training and Research onSevere Malarial Anemia, DJPerkins, PI, 5% effortEcology of AfricanHighlands Malaria, Yan, PI,UC-Irvine, DJ Perkins, PI,UNM sub-award, 5% effortFogarty/Framework Programfor Global Health, Ong’echa(PI), DJ Perkins, Co-InvestigatorImpact of Surface Receptorsand FC Gamma Receptors inSevere Malarial Anemia,Ouma PI, DJ Perkins, Co-InvestigatorNIH, FogartyInternational Center, 7D43TW005884-06NIH, sub-award withUC-Irvine, 2 R01AI50243-07NIH, 1 R01TW007631-02 A1NIH/GRIP, 1 R01TW008306-01$517,368 4/1/2008-3/31/2012$15,807 5/1/2008-2/28/201008/01/07-7/31/119/20/2009 to09/20/2012T. cruzi molecular targets forvector paratransgenesisR Durvasula, PINIH $1,367,926 2/15/07-1/31/2011190

DIVISION OF NEPHROLOGY191

DIVISION OF NEPHROLOGYANNUAL REPORT: JULY 1, 2008 - JUNE 30, 2009MARK ROHRSCHEIB, M.D., ASSISTANT PROFESSOR AND INTERIM CHIEFA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEAREducation- C. Adams, M.D. and M. Adeniyi, M.D. successfully completed their fellowshipprogram.- Alas, M.D., G. Elia, M.D., B. Horowitz, M.D., J. Owen, M.D., and P. Singh, M.D.successfully completed their first year of the fellowship program.- Alas, M.D., G. Elia, M.D., B. Horowitz, M.D., J. Owen, M.D., and P. Singh, M.D.entered the nephrology fellowship as first year fellows July 2008.- Gupta, M.D. successfully completed his fellowship program in December 2008.- The division continued to participate in CME activities throughout NM, including theAdvances in Internal Medicine Lecture series.- Nephrology faculty mentor students, residents, and Ph.D. candidates.Research- The Zuni Kidney Project’s NIH award entitled “Genetics of Kidney Disease in ZuniIndians” completed its fifth year in January 2009. This project is an ongoingcollaboration with Jean MacCluer’s genetics group at the Southwest Foundation forBiomedical Research.- Dominic Raj, M.D. continued his research on the R-01 grant from the NIH on the“Cytokine gene polymorphism in CRIC cohort”.- Dominic Raj, M.D. continued a 2 year grant from Satellite Research on “Cytokinesactivation and protein catabolism in ESRD”.- Karen Servilla, MD was awarded a grant from Dialysis Clinic, Inc. on “The impact ofblood pressure on left ventricular mass among hemodialysis patients”.- Philip Zager, M.D. will be representing UNM HSC and DCI in a study of Dialysis Policyand Procedures influencing clinical outcomes to be conducted in collaboration with theCenter for Outcomes Comes Research and Education at UCLA.- Philip Zager, M.D .continued a grant from Genzyme to study the impact of intravenousvitamin K analogues on clinical outcomes among hemodialysis patients.- Philip Zager, M.D., continues his work as the Director of the DCI Clinical Research Unit.This unit will focus on outcomes research in ESRD.Clinical- The division continues to fulfill its clinical obligations at UNMHSC and at DCI facilitiesthroughout NM.- We continue to perform living donor renal transplants, resulting in an increase in theoverall transplant activity.- David Buchwald, M.D., shares responsibility for division’s clinical program atUNMHSC. Dr. Buchwald also has responsibility for medical coverage for thehemodialysis patients at DCI in Acoma-Canoncito-Laguna Pueblo and Grants.192

- James Gibb, M.D. participates in the division’s clinical program at UNMHSC and hasresponsibility for medical coverage for the hemodialysis patients at DCI in Silver Cityand Carlsbad.- Ambreen Gul, M.D. shares responsibility for the division’s consults and clinical programat UNMHSC. Dr. Gul also shares responsibility for the nephrology fellowship program.- Antonia M. Harford, M.D., is the Medical Director of the UNMH Renal Transplant andthe Acute Dialysis Programs. She has responsibility for medical coverage for thehemodialysis patients at DCI in Rio Rancho.- Charles T. Spalding, M.D., shares responsibility for the division’s consults at UNMHSC.- Aideloje Onime, M.D., shares responsibility for the division’s consults and clinicalprogram at UNMHSC. Dr. Onime also shares responsibility for the inpatient program atthe VAMC.- Dominic Raj, M.D., shares responsibility for the divisions’ clinical care and consults atUNMHSC.- Mark Rohrscheib, M.D., shares responsibility for the divisions’ consults and clinical careat UNMHSC and has responsibility for medical coverage for the hemodialysis patients atDCI centers in Taos and Raton.- Karen Servilla, M.D., shares responsibility for the inpatient and outpatient programs atthe VAMC. Dr. Servilla also serves as Program Director for the nephrology fellowshipprogram.- Antonios Tzamaloukas, M.D., is responsible for coverage on the inpatient and outpatientservices at the VAMC. Dr. Tzamaloukas runs the peritoneal dialysis program at theVAMC.- Philip Zager, M.D., serves as the Medical Director of UNMHSC’s Dialysis Program. Inthis capacity, he provides administrative oversight for DCI facilities in NM.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTUREEducation- Require fellow’s participation in research activities that will lend to either publication ora formal presentation at a national or regional meeting. Research proposals will berequired on problems identified in both basic and clinical investigations includingmolecular epidemiology, outcomes research, and clinical trials.Research- Expand efforts to identify the genetic and environmental factors that modulate the risk forand the progression of renal disease, diabetes and cardiovascular disease in minoritypopulations in the Southwest. Will work closely with the NIEHS Center to accomplishthis goal.- Develop mechanisms for utilizing the Powerchart database to improve the care and theoutcomes of patients with renal disease and hypertension and expand outcomes trackingin transplant patients.- Develop a clinical trials unit to test new therapies for renal disease, hypertension, andrenal transplantation.- Expand the research funding within the division. Sources will include the NIH, variousfoundations, DCI’s Paul Teschan Research Fund, and industry.193

- Recruit faculty with expertise in molecular epidemiology and biomedical engineering.- Write an NIH grant on increasing minority access to transplantation.Clinical- Expand renal replacement therapy to patients in underserved areas throughout the state ofNM.- A new outpatient dialysis facility is being built in Santa Domingo.- Develop innovative mechanisms for providing quality renal care in an environment ofdecreasing resources and increasing demand.- Increase clinical productivity by increasing clinical space. UNMH Medical Specialtiesclinics do not provide the division with enough clinical rooms to see all our patients in atimely manner, nor for all our fellows to run their continuity clinics. We will continue toactively explore the possibility of moving the division’s office and clinic space to theDCI facility at 1500 Indian School Road in Albuquerque.- Expand pre-ESRD screening and treatment.- Initiate outpatient programs for renal biopsy and treatment of transplant rejection.- -Expand clinical outreach program if adequate faculty and support services are availableand if a significant proportion of the revenue generated is made available to supportdivision activities.C. APPOINTMENTS TO FACULTY/STAFFFaculty- David Buchwald, M.D.- Ambreen Gul, M.D.- Charles T. Spalding, M.D.Staff- NoneD. SEPARATION FROM FACULTY/STAFFFaculty- Farid Osman, M.D., Assistant Professor- Aideloje Onime, M.D., Assistant Professer- Dominic Raj, M.D., ProfessorStaff- Chris AquinoE. PUBLICATIONS OF THE DIVISION- MR, Tzamaloukas AH, Johnson HK, Zager PG Servilla KS, Singh AK, Hunt WC,Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib- Anemia Management and Association of Race with Mortality and Hospitalization in aLarge Not-for-Profit Dialysis Organization. Am J Kidney Dis. 2009 July 21.194

- Zager PG, Rohrscheib MR- Blood pressure and mortality risk in patients treated by peritoneal dialysis. Am J KidneyDis. 2009 Jan; 53(1):9-11- Gupta A, Rohrscheib M, Tzamaloukas AH- Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronichemodialysis. Hemodial Int. 2008 Oct; 12 Suppl 2;S43-7.- Tzamaloukas AH, Ing TS, Siamopoulos KC, Raj DS, Elisaf MS, Rohrscheib M, MurataGH- Pathophysiology and management of fluid and electrolyte disturbances in patients onchronic dialysis with sever hyperglycemia. Semin Dial. Sept-Oct; 21(5):431-9.- Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, Hunt WC,Lindsey DE, Gabaldon D, Zager PG; DCI Medical Directors- Age-related blood pressure patterns and blood pressure variability among hemodialysispatients. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1407-14- Nunez S, Konstantinov KN, Servilla KS, Harthshorne MF, Williams WL, Gibel LJ,Tzamaloukas AH- Association between scleroderma, renal carcinoma and membranous nephropathy. ClinNephrol. 2009 Jan; 71(1):63-8- Gupta A, Sun Y, Konstantinov KN, Servilla KS, Harthshorne MF, Tzamaloukas AH- Tumoral calcinosis without hyperparathyroidism in a patient on continuous ambulatoryperitoneal dialysis. Adv Perit Dial. 2008; 24:132-6- Agaba EI, Mamven MH, Agaba PA, Tzamaloukas AH- Self-reported screening of nephrologists for chronic kidney disease: a nationwide survey.Int Urol Nephrol. 2009 Mar 6- Agaba EI, Wigwe CM, Agaba PA, Tzamaloukas AH- Performance of the Cockcroft-Gault and MDRD equations in adult Nigerians withchronic kidney disease. Int Urol Nephrol. 2009; 41(3);635-42Raj DS, Sun Y, Tzamaloukas AH- Hypercatabolism in dialysis patients. Curr Opin Nephrol Hype rtens. 2008 Nove;17(6)589-94.Gibel LJ, Hartshorne MF, Tzamaloukas AH- Rapidly developing lower abdominal mass with pronounced azotemia: the importance ofimaging. South Med J. 2008; 101(7):767-8.Tzamaloukas AH, Raj DS- Referral of patients with chronic kidney disease to the nephrologist: why and when. PeriDial Int. 2008 Jul-Aug; 28(4):343-6.Oreopoulos DG, Tzamaloukas AH- Our war against bacteria in peritoneal dialysis, the last 40 years! Int Urol Nephrol. 2008;40(3):709-14Waters DL, Mullins PG, Qualls CR, Raj DS, Gasparovic C, Baumgartner RN- Mitochondrial function in physically active elders with sarcopenia. Mech Ageing Dev.2009 May; 130(5):315-9.195

- Shah VO, Scariano J, Waters D, Qualls C, Morgan M, Pickett G, Gaparovic C, DokladnyK, Moseley P, Raj DS- Mitochondrial DNA deletion and sarcopenia. Genet Med. 2009 Mar: 11(3):147-52.Raj DS- Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2009Apr; 38(5):382-8- Raj DS, Moseley P, Dominic EA, Onime A, Tzamalou kas AH, Boyd A, Shah VO, GlewR, Wolfe R, Ferrando A- Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis.Kidney Int. 2008 May; 73(9):1054-61- Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, Satko SG, BowdenDW, Guggirala R, Elston RC, Guo X, Hanson RL, Igo RP Jr, Ipp E, Kimmel PL,Knowler WC, Molineros J, Nelson RG, Pahl MV, Quade SR, Rasooly RS, Rotter JI, SaadMF, Scavini M, Schelling JR, Sedor JR, Shah VO, Zager PG, Abboud HE, FamilyInvestigation of Nephropathy and Diabetes Research Group- Hereitability of the severity of diabetic retinopathy: the FIND-Eye study. InvestOphthalmol Vis Sci. 2008 Sep; 49(9):3839-45.F. OUTSIDE PROFESSIONAL ACTIVITIES- Dominic Raj, M.D. is on the abstract committee for International Society of Nephrology.- Division faculty members serve as reviewers for the following journals: KidneyInternational; American Journal of Kidney Disease; American Journal of CardiovascularDrugs; Peritoneal Dialysis International; Nephrology, Dialysis and Transplantation; Postgraduatemedical journals; Hemodialysis International; Journal of the American Societyof Nephrology; Peritoneal Dialysis Bulletin; Western Journal of Medicine; Alcohol andAlcoholism; Clinical Chemistry; Peritoneal Dialysis International; Geriatric Nephrologyand Urology; American Society of Artificial Organs Journal; Journal of Diabetes and itsComplications; Hellenic Nephrology; Clinical Nephrology; European Journal of ClinicalInvestigation; Journal of Renal Nutrition.- Antonios Tzamaloukas, M.D., serves as member of the Editorial Board for KidneyInternational.- Philip Zager, M.D., and Vallabh Shah, Ph.D., serve on the Strong Heart Study - Studygroup.- Philip Zager, M.D., serves as the DCI Corporate Medical Director for QualityManagement and is a member of the DCI MIS Steering Committee and the NIDDKFIND Steering Committee.G. OUTSIDE SPONSORED RESEARCH- NIH NIDDK Genetics of Kidney Disease in Zuni Indians, Jan 2004 to Dec 2009.- Amgen, A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety andEfficacy of a Calcimimetic Agent (AMG 073) in subjects with SecondaryHyperparathyroidism of Chronic Renal Insufficiency Amgen, A Placebo-controlled,Double-blind, Multi-center Study to Assess the Efficacy and Safety of an Oral196

Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic KidneyDisease (Hemodialysis and Peritoneal Dialysis)197

DIVISION OF PULMONARY, CRITICAL CAREAND SLEEP MEDICINE198

DIVISION OF PULMONARY, CRITICAL CARE, AND SLEEP MEDICINEANNUAL REPORT: JULY 1, 2008-JUNE 30, 2009RICHARD CROWELL, M.D., PROFESSOR AND CHIEFFACULTYRichard E. Crowell, M.D. (Chief, Division of Pulmonary, Critical Care, and Sleep Medicine; Co-Director, CRTC and VA Multidisciplinary Chest Clinics; Chairman, Sepsis MortalityImprovement Team)Amanda Beck, M.D., Ph.D. (Medical Director, Adult Sleep Services; Program Director, SleepMedicine Program)Michel Boivin, M.D.CMLee K. Brown, M.D. (Executive Medical Director, Sleep Medicine; Medical Director, 5ACCClinics)H. Katrina Busby, M.D. (Program Director, Pulmonary / Critical Care and Critical CareFellowship Programs; Medical Director, MICU, New Mexico VA Health Care System)Betty Chang, M.D. CM, Ph.D. (Director, Residency Education Programs; Assistant Dean,Graduate Medical Education)Karol Dokladny, Ph.D.Michelle Harkins, M.D. (Medical Director, MICU, UNMH; Medical Director, PulmonaryOutpatient Services; Director, Pulmonary Clinic; Co-Director, Asthma Program; MedicalDirector, Pulmonary Function Laboratory)Gary K. Iwamoto, M.D. (CMIO; Co-Director, Asthma Program)Diane Klepper, M.D. (Medical Director, Raton Miners Hospital Outreach Services; MedicalDirector, CNM Respiratory Therapy Program)Pope L. Moseley, M.D. (Regents’ Professor and Chair, Internal Medicine)Akshay Sood, M.D., M.P.H., F.C.C.P.Jennifer L. Taylor-Cousar, M.D. Adult Cystic Fibrosis ProgramDona Upson, M.D. (Medical Director, Pulmonary Function Laboratory, New Mexico VA HealthCare System)Eleana M. Zamora, M.D.MID-LEVEL PROVIDERSBarbara Krygier, RN, CFNP (Sleep Medicine)ADMINISTRATIVE STAFFAmanda Dronet (Office Administrator: Pulmonary, Critical Care, and Sleep Medicine)Diogina Colapietro – Administrative Assistant IINoemi Gutierrez- Administrative Assistant IIJocelyn Gilsdorf- Student Employee, Administrative Assistant IIA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEARPulmonary Medicine199

- In collaboration with the UNM Cancer Research and Treatment Center and RespiratoryTherapy, continued development of an Endobronchial Ultrasound system, or EBUS, withpatient procedures starting Fall 2008 (Crowell).- Development and continued progress of the Sepsis Mortality Improvement Team(SMITe) to address hospital morbidity and mortality of patients with sepsis. RichardCrowell, M.D., was named as the chairman of this team, which also includes MichelleHarkins, M.D., and Michel Boivin, M.D.- Initiation of the Computerized Patient Order Entry (CPOE) program by UniversityHospital to develop and implement electronic order entry for UH patients. GaryIwamoto, M.D., is the CMIO over the expansion of the EMR/CPOE.- Addition of an Asthma program to Project ECHO, which utilizes a novel telemedicineapproach to subspecialty care of patients in rural areas of the state. Michelle Harkins,M.D., was named to lead this program.- Institution of novel patient tracking system for MICU resulting in significantimprovements in billing and collection.- Continued increase in overall patient visits, addition of clinic days, and development oftranslational research projects.- Continued development of faculty practice in Pulmonary and Occupational Medicinestaffed by Akshay Sood, M.D., MPH, located at the Sleep Center.- Maintained control of the Raton Outreach Programs for Miners (Crowell, PI; Klepper,Clinical Director).Critical Care Medicine- Development of ongoing training program in ICU-based ultrasound for faculty andfellows.- Continued development of a MICU Nurse Practitioner Team to provide extended ICUcoverage.- Ongoing revision of the documentation practices that optimize collections usingelectronic and progress notes the MICU has converted to electronic providerdocumentation.- Continued development and initiation of standardized protocols for the ICU (Harkins)- Continued development and initiation of standardized protocols for the ICU (Iwamoto,Harkins, Boivin)Sleep Medicine- Continued implementation of the marketing plan through attendance at 9 health fairs and3 lectures at a variety of public and professional venues including UNM School ofBusiness, PIMA and a CEU class for UNMH nursing and respiratory therapists.- Dr. Amanda Beck, as Program Director of the Sleep Medicine fellowship, guided theprogram through a successful ACGME site visit that resulted in a full 5-yearaccreditation with absolutely no provisons. Continued to train 2 fellows per year in sleepmedicine.- Continued Senior Sleep Clinic (a year-long continuity clinic) for patients over 75 years ofage utilizing geriatric residents and sleep fellows working with Dr. Beck.Numerous rotations by Neurology, Psychiatry, Internal Medicine, and Family Practiceresidents, Pulmonary fellows, and medical students throughout the year.200

- Election of Dr. Lee Brown as Chair, Polysomnographic Practice Advisory Committee ofthe New Mexico Medical Board.- New computerized polysomnograph equipment for outpatient and inpatient laboratoriesutilized throughout the academic year. Processes developed for computerized orderentry, database management, and records tracking.- New system initiated for informing patients of sleep laboratory results, shortening thewait between the time of the study and the next step in their management.- Recruited new faculty member, Dr. Frank Ralls, who has primary board certification inFamily Practice, subspecialty certification in Geriatrics, and completed our 1-yearACGME-accredited sleep medicine fellowship. Dr. Ralls start date is set for August 1,2009 and he will practice the full gamut of sleep medicine in age groups from pediatric togeriatric.- Business Development- Continued development of a business plan for a west side Sleep Disorders Center.- Planning is now specifically to add sleep laboratory bedrooms to the UNMMG SandovalRegional Medical Center. Review was not obtained due to the adverse financial analysis,a result of the requirement for global professional, rather than facility-based, billing. Ameeting was subsequently held with UNMH senior leadership to consider collaborationbetween UNMMG and UNMH so that facility-based billing could be employed. UNMHsenior leadership indicated they would consider the plan. There has been no additionalfeedback to date, and at least two private sleep laboratories have subsequently begunoperation on the Westside, thus negatively impacting this business opportunity.- A business plan was initiated for expansion of the sleep laboratory and clinic operationsinto the OmniSleep location near the current sleep disorders center, when this privateoperation vacates.- Negotiations continue with the Albuquerque VA Medical Center with respect toassuming the sleep disorders care of their patients.Education/Training- Betty Chang, MDCM, PhD continued as Assistant Dean of the Graduate MedicalEducation program.- Betty Chang, MDCM PhD, Assumed the position of Program Director, Internal Medicine- Michelle Harkins, M.D., Assumed Directorship of UNMH-MICU- Michelle Harkins, M.D., Project ECHO Pulmonary Clinic/Grand Rounds: CMEpresentations: Funded under Robert Wood Johnson Foundation at .25 FTE- Dona J. Upson, M.D., Co-Chair, Workshop on The Pharmaco-Economics of RespiratoryMedications, 2008 American Thoracic Society International ConferenceB. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTUREPulmonary- Continued development of the Multidisciplinary Chest Clinic referral system (Crowell).- Continue to nurture referrals to Adult Asthma, Exercise Testing, and Vocal cordDysfunction programs from non-UNM patient resources.- Recruit additional faculty201

Critical Care- Development of a Pulmonary/ICU training program for Ultrasound use. This includesresident training in the placement of central lines and fellow training for emergency andprocedural use of ultrasound in Pulmonary/Critical Care settings (Boivin, Iwamoto)- Continue development of the “MICU Nurses Practioner’s Program (Iwamoto, Harkins,Boivin).- Recruitment of new VA-based Pulmonary/Critical Care faculty member: Hired- JennyMao, August 2009- Recruit additional facultySleep Medicine- Continued development and implementation of expansion plans for the sleep disorderscenter on the Eastside.- Continued development of a sleep laboratory component at the Sandoval RegionalMedical Center.- Conclude agreements with the Albuquerque VA Medical Center.Recruit additional faculty and one additional fellow as necessary for newfacilities/contracts.- Increase the amount of research activity by faculty, sleep fellows, and pulmonary/criticalcare fellows, including continuing or new research on: 1) restless legs syndrome (Drs.Brown and Ralls); 2) oculopharyngeal muscular dystrophy and sleep apnea (Drs. Grigg-Damberger and Brown); 3) complex sleep apnea (Dr. Brown); 4) sleep apnea and patentforamen ovale (Drs. Ricciardi and Brown); 5) testing of new sleep scoring montages (Dr.Grigg-Damberger); osteopontin levels in patients with obstructive sleep apnea (Drs.Wells and Beck), open lung ventilation with spontaneous breathing and sleep quality inthe ICU (Drs. Brown and Marinaro).Education- Continued to update resident and student rotation curriculum.- Continue to improve research opportunities for fellows in training.Research- Continue development of research activity in areas of focus, including lung cancer(Crowell), asthma (Sood, Iwamoto, Harkins), epithelial leakage during sepsis and criticalillness (Boivin), heat shock proteins (Moseley), and sleep (Brown).C. APPOINTMENT TO FACULTY/STAFFFaculty- Frank Ralls, M.D. – July 14, 2009- Amanda A. Beck, M.D., PhD.- promoted to Professor of Internal MedicineStaff- Liz Seaburg (Student) - September 2, 2008- Diogina (Denise) Colapietro - October 6, 2008- Amanda Dronet - January 5, 2009202

- Jocelyn Gilsdorf (Student) - February 5, 2009- Noemi Gutierrez - April 13, 2009- Stephanie Ramirez – Clinic SupervisorFellows- Hassan Abouhouli, MD- 2008-2009D. SEPARATION OF FACULTY/STAFFFaculty- Ken Casey, MD, MPH – January 23, 2009Staff- April Finkenhoefer- November 30, 2008- Liz Seaburg (Student) – January 16, 2009Fellows- Frank Ralls, MD- June 30, 2009- Completed Sleep Fellowship Program- Ziad Ismael, MD- June 30, 2009- Completed CC/Pulmonary Fellowship Program- Bhagat Aulakh, MD- June 30, 2009- Completed CC/Pulmonary Fellowship ProgramE. PUBLICATIONS OF THE DIVISIONRichard E. Crowell, M.D.- Sood, A., Stidley, C.A., Picchi, M.A., Celedon, J.C., Gilliland, F., Belinsky, S.A.,Crowell, R.E., and Tesfaigzi, Y. Differences in airflow obstruction between Hispanic andnon-Hispanic white female smokers. COPD: J Chronic Obst Pulm Dis 5:274-81, 2008.- Boivin MA, Roy PK, Bradley A, Rihani T, Kennedy J, Ma TY. Pl-3 Kinase regulation ofintestinal barrier disruption by Interferon-Gamma. Journal of Interferon and CytokineResearch. :29:45-54, 2009- Al-Sadi RA, Boivin MA, Ma TY, Mechanisms of Cytokine Regulation of the TightJunction Barrier. Frontiers in Bioscience. :14:2765-2778, 2009.- Battah S, Ma TY, Boivin MA, IL-6 increases intestinal epithelial Tight JunctionPermeability. Journal of Investigative Medicine. :57:157, 2009.- Braude D, Ronan D, Weiss S, Boivin MA, Gerstein N. Comparison of Available Gum-Elastic Bougles. Am J Emerg Med : 27:267-270, 2009.- Boivin MA, Battah S I, Al-Sadi R, Ma T. The Effect of Interleukin-6 On IntestinalPermeability. Gastroenterology: 136: A-411, 2009.- Patel Y, Aguero T, Ho W S, Boivin MA, Lin HC. Exposure to Crude Red Kidney BeansIncreases Intestinal Permeability. Gastroenterology: 136: A-729, 2009.- Ho WS, Aguero R, Boivin MA, Patel Y, Lin HC. Efffect of Red Kidney Beans OnIntestinal Permeability May Be Due to Direct Toxicity. Gastroenterology. :136:A-576,2009.203

Lee K. Brown, M.D.- Casey KR, Brown LK. Sleep-Disordered Breathing and Renal Failure: A Search forFundamental Mechanisms. Sleep Med 2009; 10:15-18.Brown LK. Physicians and Sleep Deprivation [editorial]. Curr Opin Pulm Med 2008;14:507-511.- Brown LK. The Harvard Medical School’s Guide to a Good Night’s Sleep. [bookreview] J Clin Sleep Med 2008; 4:381-2.- Brown LK. President’s Column: Of this and that…. [editorial] GAMA Reports 2008; 30(October): 1,7.- Brown LK. President’s Column: GAMA Annual Membership Fee Could Increase.[editorial] GAMA Reports 2008; 30 (November): 1-2.- Brown LK. President’s Column: Caley, We Hardly Knew Ye. [editorial] GAMA Reports2008; 30 (December): 1,3.- Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, Parthasarathy S, QuanSF, Rowley JA. Response to Marcus CL. Letter to the Editor: Concerns regarding thepediatric component of the AASM clinical guidelines for the manual titration of positiveairway pressure in patients with obstructive sleep apnea. J Clin Sleep Med 2008; 4:607.Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, Parthasarathy S, QuanSF, Rowley JA. Response to Johnson K, Johnson D. Letter to the Editor: In reference toclinical guidelines for the manual titration of positive airway pressure in patients withobstructive sleep apnea. J Clin Sleep Med 2008; 4:610.- Brown LK, Lee-Chong T. Hypoventilation Syndromes [preface]. Semin Respir Crit CareMed 2009; 30:249-251.- Madeleine M. Grigg-Damberger, MDGrigg-Damberger M, Wells A. Central Congenital Hypoventilation Syndrome: ChangingFace of a Less Mysterious but More Complex Genetic Disorder. Semin Respir Crit CareMed 2009;30:262-274.- Audrey Wells, MDGrigg-Damberger M, Wells A. Central Congenital Hypoventilation Syndrome: ChangingFace of a Less Mysterious but More Complex Genetic Disorder. Semin Respir Crit CareMed 2009;30:262-274.- Whit W. Brown RPSGT, CRTBrown WW. Sleep studies and home ventilation: a new partnership? Sleep Review,April 2009.- Betty Chang, MDCM, PhD- ACGME Annual Educational Conference, March 2009 Promoting Good Learning andSafe, Effective Care: A Five-Year Review of the ACGME ’s Common Duty HourStandards Panel Discussion – Panel MemberKarol Dokladny, Ph.D.- Dokladny K, Ye D, Kennedy J, Moseley P, Ma T. (2008). Cellular and molecularmechanisms of heat stress-induced up-regulation of occludin protein expression:Regulatory role of HSF-1. American J of Pathology, 172:659-670.- Dokladny K, Wharton W, Ma T, Moseley P. (2008). Lack of cross-tolerance followingheat and cadmium exposure in functional MDCK monolayers. J Appl Tox.204

Michelle S. Harkins, M.D.- Harkins MS, Kelly HW: Asthma Management. In: O’Keefe L, Linn WD, Posey et aleditors. Primary Care Pharmacotherapy, 1st ed. New York, McGraw-Hill; August 1,2008, Chapter 8.- Harkins, MS. Invited Review: Exercise regulates heat shock proteins and nitric oxide.Exercise Sport Sciences Reviews, Vol. 37 (2): 73-77, April 2009Pope L. Moseley, M.D.- Amorim FT, Yamada PM, Robergs RA, Schneider SM, Moseley PL. The effect of therate of heat storage on serum heat shock protein 72 in humans. Eur J Appl Physiol.104(6):965-72, 2008.- Yamada P, Amorim FA, Moseley PL, Schneider SS: Heat shock protein 72 response toexercise in humans. Sports Medicine 38:715-33, 2008- Shah VO, Scariano J, Waters D, Qualls C, Morgan M, Pickett G, Gasparovic C,Dokladny K, Moseley PL, Raj DSC. Mitochondrial Deletion and Sarcopenia. Genetics inMedicine 11(3)147-152. March 2009- Dokladny K, Ye D, Kennedy J, Moseley PL, and Ma TY. Cellular and Molecular Mechanisms ofHeat Stress Induced Upregulation of Occludin Protein Expression: Regulatory Role of HSF-1Am. J. Path 172:659-70, 2008.- van Hall G, Steensberg A, Fischer C, Keller C, Hiscock N ,Møller K, Saltin B, Moseley PL, andPedersen B: Interleukin-6 Markedly Decreases Skeletal Muscle Protein Turnover and IncreasesNon-muscle Amino Acid Utilization in Healthy Individuals. J. Clin Endo Met. 93:2851-8, 2008- Doklodny K, Wharton W, Ma TY, Moseley PL: Lack of Cross-Tolerance Following Heat andCadmium Exposure in Functional MDCK Monolayers J. Appl. Tox. 28(7):885-94- Raj DSC, Moseley P, Dominic EA, Onime A, Tzamaloukas AH, Boyd A, Shah VH, Glew R,Ferrando A: Interleukin-6 Modulates Hepatic and Muscle Protein Synthesis during Hemodialysis.Kidney Int’l. 73(9):1054-61, 2008- van Hall G, Steensberg A, Fischer C, Keller C, Møller K, Moseley P, Pedersen BK. Interleukin-6markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acidutilization in healthy individuals. J Clin Endocrinol Metab. 93(7):2851-8, 2008.- Amorim FT, Yamada PM, Robergs RA, Schneider SM, Moseley PL. The effect of the rate ofheat storage on serum heat shock protein 72 in humans. Eur J Appl Physiol. 104(6):965-72,2008.- Yamada P, Amorim FA, Moseley PL, Schneider SS: Heat shock protein 72 response to exercisein humans. Sports Medicine 38:715-33, 2008- Shah VO, Scariano J, Waters D, Qualls C, Morgan M, Pickett G, Gasparovic C, Dokladny K,Moseley P, Raj DSC. Mitochondrial Deletion and Sarcopenia. Genetics in Medicine 11(3)147-152. March 2009- Andreasen AS, Pedersen-Skovsgarrd T, Mortensen OH, van Hall G, Moseley PL, Pedersen BK.The effect of glutamine infusion on the inflammatory response and HSP7- during humanexperimental endotoxemia. Critical Care 12:1R7 2009- Moseley PL: Nitric oxide and the stress response – two 2-edged swords swing together(commentary). Exerc Sport Sci rev. 2009 Apr: 37(2):57Akshay Sood, M.D.- Sood, A; Petersen, H; Blanchette, C; Meek, P; Belinsky, S; Picchi, M; Tesfaigzi, Y(2009) Wood Smoke-Associated Chronic Obstructive Pulmonary Disease (COPD) -Underappreciated in the United States? Am J Resp Crit Care Med, 179 (Abstracts Issue),2009; A4742. Andoh, J; Verhulst, S; Edson, B; Ganesh, M; Hopkins-Price, P; Sood, A205

(2009) Predictors for Abstinence from Smoking among Reactive Telephone HelplineCallers Am J Resp Crit Care Med, 179 (Abstracts Issue), 2009; A3963.- Sood, A; Qualls, C; Arynchyn, A; Beckett, W; Smith, L; Thyagarajan, B; Sidney, S;Jacobs, D. (2009) Asthma Is Associated with Both Fat and Lean Mass in Women. Am JResp Crit Care Med, 179 (Abstracts Issue), 2009; A5510.- Dominic, E; Qualls, C; Beckett, W; Jacobs, D; Smith, L; Gross, B; Thyagarajan, B;Steffes, M; Sood, A (2009) Sex-Specific Effects of Serum Adiponectin Concentration onAsthma Severity Am J Resp Crit Care Med, 179 (Abstracts Issue), 2009;, A5516.- Hopkins-Price, P; Henkle, S; Henkle, L; Verhulst, SJ; Sood, A (2009) Associationbetween Body Mass Index and ‘ Perceptiveness’ of Dyspnea during Bronchoconstrictionin Asthma, Am J Resp Crit Care Med, 179 (Abstracts Issue), 2009; A5511.- Sood, A; Cui, X; Qualls, C; Beckett, WS, Gross, MD, Steffes, MW, Smith, LJ; JacobsDR (2008). Association between Asthma and Serum Adiponectin Concentration inWomen. Thorax. 2008 Dec: 63:877-882.- Sood, A; Stidley, C; Picchi, M; Celedon, J; Gilliland, F; Crowell, R; Belinsky, S;Tesfaigzi, Y. (2008) Difference in airflow obstruction between Hispanic and non-Hispanic white female smokers” COPD: J of Chr Obstructive Pulm Dis.2008 Oct Vol. 5,Issue 5, 274-81.- Sood, A; Qualls, C; Seagrave, J; Stidley, C; Berwick, M; Archibeque, T; Schuyler, M. Effect ofSpecific Allergen Inhalation on Serum Adiponectin in Human Asthma. CHEST. 2008 Sep 23.[Epub ahead of print]).- Sood, A; Qualls, C; Seagrave, J; Stidley, C; Berwick, M; Archibeque, T; Schuyler, M. Effect ofSpecific Allergen Inhalation on Serum Adiponectin in Human Asthma. CHEST. 2009; 135(2):287-294. Epub 2008 Sep 23. PMID: 18812451.- Thyagarajan, B; Smith, LJ; Barr, G; Gross, MD; Sood, A; Kalhan, R; Jacobs, DR. Association ofCirculating Adhesion Molecules with Lung Function: The CARDIA Study. CHEST. 2009;135(6): 1481-1487. Epub 2009 Feb 18. PMID: 19225066.- Sood, A; Andoh, J; Verhulst, S; Ganesh, M; Edson, B; Hopkines-Price, P. Real-World’Effectiveness of Reactive Telephone Counseling for Smoking Cessation: A RandomizedControlled Trial. CHEST. 2009 Feb 18. [Epub ahead of print]. PMID: 19225061.Jennifer Taylor-Cousar, M.D.- Taylor-Cousar JL, Hypoventilation in Cystic Fibrosis, Seminar Respiratory and CriticalCare Medicine; 30 (3): 293-302, 2009- Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H,Weston BW, Wright FA, Knowles MR. Histo-blood Group Gene Polymorphisms asPotential Genetic Modifiers of Infection and Cystic Fibrosis Lung Disease Severity.PLoSOne;2009http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0004270Dona J. Upson, M.D.- Upson D, Padilla J. Exploring factors that influence tobacco use and cessation amonglesbian, gay, bisexual transgender and queer youth in New Mexico. American Journal ofRespiratory and Critical Care Medicine: Volume 179, Abstracts Issue: 2009.F. OUTSIDE PROFESSIONAL ACTIVITIES206

Richard E. Crowell, M.D.- Member, Executive Committee- Member, American Association for Cancer Research- Member, Lung Cancer Guidelines Committee, Chapter in Stage IV Chemotherapy(ACCP)- Member, Program Committee (ACCP)- Member, CRTC Scientific Leadership Committee- Chair, Sepsis Mortality Improvement Team (SMITe)- Member, Rapid Response Team Committee- Member, UNM Cancer Research and Treatment Center, Lung Cancer Program- Co-Director, CRTC, Lung Cancer Clinical Working Group- Abstract reviewer, Annual Meeting of the American College of Chest Physicians- Abstract reviewer, Annual Western Regional Meeting of the American Federation forMedical Research, Carmel, CA- Member, American College of Chest Physicians (ACCP)- Member, Thoracic Oncology Network Steering Committee (ACCP)- Member, American Thoracic Society, Clinical Problems Assembly- International Association for the Study of Lung CancerAd Hoc Reviewer:- American Journal of Respiratory and Critical Care Medicine- American Journal of Respiratory Cell and Molecular BiologyCHEST- American Journal of Pathology- Journal of Leukocyte Biology- European Respiratory Journal- Cancer Epidemiology, Biomarkers, and Prevention- Journal of EpidemiologyAmanda Beck, M.D, Ph.D.- Ad Hoc Reviewer for: Sleep- Medical Director, Adult Sleep Services- Program Director, Sleep Medicine Fellowship- American Academy of Sleep Medicine Fellowship Training Committee- Vice President, New Mexico State Sleep SocietyMichel A. Boivin, M.D.- Member, Sepsis Mortality Improvement Team (SMITe)- Fellow of the American College of Chest Physicians- Fellow of the Royal College of Physicians and Surgeons of Canada- American Federation of Medical Research Councilor for New Mexico (2005-present)- Co-Chair, CPR Committee at University of New Mexico Hospital- Chair, Nutrition Committee at University of New Mexico Hospital- Chair of the Western branch of the American Federation for Medical Research- Planning Committee member for Carmel Tri-Societies Meeting207

- Lead Reviewer - Pulmonary / Critical Care section- Carmel Tri Societies Meeting- Reviewer - Experimental Biology and Medicine- Reviewer Nutrition in Clinical Practice- Reviewer American Journal of Physiology- Planning Committee - Annual meeting of the Albuquerque chapter of the AmericanAssociation of Critical Care NursesLee K. Brown, M.D.- American Thoracic Society: Health Policy Committee (2004-present; Chair, 2006-2009)New Mexico Thoracic Society: Planning Committee, 29th - 37th Annual New MexicoThoracic Society Lung Disease Symposia (2000-present)Outstanding Clinician Award, 2009American College of Chest Physicians: Sleep Issues in Healthcare Workers Task Force(2008 – present)- CHEST- Editorial Board (2001-present)- Abstract Reviewer for Annual Scientific Assemblies (1995 - 2009).- American Academy of Sleep Medicine (formerly, American Sleep DisordersAssociation): Board of Directors (2006 – 2009)- Chair, Ad Hoc Guidelines Task Force (2008 – 2009)- Documents Committee (2009 – present)- Ad Hoc NPPV Titration Protocol Task Force (2008 – present)- Ad Hoc Institute of Medicine Task Force (2009)- Ad Hoc ACGME Sleep Fellowship Task Force (2007 – 2009)- Ad Hoc PAP Titration Protocol Task Force (2007 – 2009)- Ad Hoc Course Review Task Force (2008 – 2009)- Associate Editor, Journal of Clinical Sleep Medicine (2006-present)- Book Review Editor, Journal of Clinical Sleep Medicine (2006-present)- American Sleep Medicine Foundation- Board of Directors (2006-2009)- American Board of Sleep Medicine- Board of Directors (2006-2009)- Associated Professional Sleep Societies LLC- Board of Directors (2007 – 2009)- Greater Albuquerque Medical Association- Immediate Past President and Member, Boardof Trustees (2009) President and Member, Board of Trustees (2008)- Physician Recruitment and Retention Committee (2002-2003, 2009-present)- Delegate to the New Mexico Medical Society Annual Meeting (2000-2009)- New Mexico Medical Society: Liaison Committee to the UNM School of Medicine(2001-present)- State of New Mexico Medical Board: Polysomnographic Practice Advisory Committee(2008-present; Chair, 2009-present)- Editor, Sleep and Respiratory Neurobiology Section, Current Opinion in PulmonaryMedicine, 2007 – 2009).- Brown LK, Lee-chiong T. Guest Editors, Seminars in Respiratory and Critical CareMedicine, Hypoventilation Syndromes Issue (2009)Ad Hoc ReviewerCHEST- Clinical Pulmonary Medicine;208

SLEEP- Clinical Sleep Medicine- American Journal of Medicine- Respiration- Nephron- Mayo Clinic Proceedings- Clinical Infectious Disease- MetabolismHelen K. Busby, M.D.- Acting Section Chief, New Mexico VA Health Care System- Medical Director, MICU New Mexico VA Health Care System- Director, Critical Care Fellowship Program- Director, Pulmonary and Critical Care Fellowship Program- Chair, Code Blue Committee, New Mexico VA Health Care System- Chair, Ventilator Associated Pneumonia Prevention Committee, New Mexico VA- Environmental Control CommitteeBetty Chang, M.D., CM, Ph.D.- Program Director Internal Medicine- Assistant Dean for Graduate Medical Education- Member, University of New Mexico Graduate Medical Education Committee- Chair, University of New Mexico GME Program Review Committee- Member - New Mexico VA Healthcare System - Respiratory Care Committee- Member - UNM Internal Medicine Post Graduate Committee- Member – UNM Internal Medicine Executive Committee- Member – UNM Duty Hour Task Force- Member – UNM Internal Medicine Ward Redesign Task Force- Member – American College of Chest Physicians- Member – American College of Physicians- Member – American Thoracic Society- Member – NM American College of Physicians Governing Council- Ad Hoc Reviewer:- CHEST- American Journal of RheumatologyMadeleine Grigg-Damberger, M.D.- Ad hoc Reviewer: Sleep, Journal of Sleep Medicine, Pediatric Pulmonology.- Neurology Resident Concerns Committee, University of New Mexico (2000-present)- Neurology Education Committee, University of New Mexico (2000-present)- Neurology Library Committee, University of New Mexico (1999-present)- American Board of Internal Medicine Sleep Medicine Test Committee, member, 2005-present.- American Academy of Sleep Medicine Special Interest Section in Neurology, 1995-present, Chair (1998-present).209

- American Clinical Neurophysiology Society Sleep Medicine Committee Chair (October1996-present).- Editorial Board, Journal of Clinical Sleep Medicine, July 2007-present- Council of the American Clinical Neurophysiology Society, Board Member(electedposition), February 2008-present.- Consortium of Clinical Neurophysiology Fellowship Directors, member, 2008-present.- Amelia Island Annual Pediatric Sleep Medicine Conference, Program CommitteeMember, 2006-present.- Annual Annenberg Sleep Apnea in Infancy and Childhood Conference Program- Committee, April 2006-present; Co-chair January 2007-present.- Michelle Harkins, M.D.- Assistant Program Director for Internal Medicine Residency Program- Medical Director, Medical Intensive Care Unit, UNMH 2009- Present- Medical Director, Pulmonary Services and PFT lab 2008- Present- Pulmonary Clinic Director- Adult Inpatient Medicine Committee, March 2009- Present- Inpatient Leadership team, March 2009- Present- Member, Sepsis Mortality Improvement Team (SMITe)- Critical Care ad hoc Medical Staff Committee, March 2004-Present- NM Chapter of the American Thoracic Society, Board MemberPharmacy andTherapeutics Committee – Member, October 2005- Present- American Thoracic Society - Member- American College of Physicians - Member- American College of Chest Physicians - Fellow- Society of Critical Care Medicine – Member- SOM Post-Graduate Education Committee member- SOM Committee for House Officer Scholarly Activity- Chair 2006- Present- Post-Graduate Medical Education Committee, IM- Member 2006- Present- NM ATS Annual Conference- Program Chair for 2009- Ad Hoc Reviewer- Scholarly Activities: Manuscript Reviewer for Therapy: 2009- Abstract Reviewer for ACCP CHEST meetings- May 2009- Manuscript Reviewer for CHEST- Reviewer, Journal of the National Medical AssociationGary Iwamoto, M.D.- American Thoracic Society - Member- American College of Physicians - Member- American College of Chest Physicians - Fellow- Society of Critical Care Medicine – Member- CMIO- Chair SynergE3 Oversight Committee- CoChair SynergE3 Outpatient Advisory Committee- CoChair SynergE3 Inpatient Advisory Committee- Member HSC IT Security Council210

Diane Klepper, M.D.- Cardiovascular, Pulmonary and Renal Curriculum Planning Committee - Member- Medical Director, Raton Miner’s Colfax Medical Center Outreach Clinics- Medical Director, CNM Respiratory Therapy and Training Program- Ombuds-Person, University of New Mexico School of Medicine Accreditation SiteVisitor- Committee on Accreditation for Respiratory Care- Member- Khatali Alumni Association - Board Member- La Tierra Segrada - Board MemberPope Moseley, M.D.- American Federation for Clinical Research, Midwest Region, Councilor- National Cancer Institute Advisory Panel on the Biochemical Effects of PesticideExposures.- Consultant on Workers’ Safety, Iowa Department of Transportation- Abstract Review Committee, Midwest Section, American Federation for ClinicalResearch, Pulmonary Subspecialty Section- Consultant, American Board of Preventive Medicine, Board Review Course.- Membership Committee, American Thoracic Society- NIH/APS/ACSM, Working Group on Integrative Biology in Cardiac and VascularDiseases- State of New Mexico Governors Advisory Board on Respiratory Care- Advisory Board, National Environmental Respiratory Center, Environmental ProtectionAgency.- Consultant on Agricultural & Environmental Health, Texas Tech University, Lubbock,TX.- Western Society of Clinical Investigation, Councilor- American Thoracic Society, Health Care Policy Committee- Western Association of Physicians, Councilor- American Thoracic Society Public Policy Committee 2002 – Present- Biomedical Research Institute of New Mexico (BRINM), April 2005-present- American College of Chest Physicians, Fellow- American College of Sports Medicine, Fellow- American College of Occupational Medicine, Member- American Physiological Society, Member- American College of Forensic Examiners, Member- American College of Physicians-American Society of Internal Medicine (ACP-ASIM)Fellow- Reviewing for National Funding Organizations- 2006-present Special emphasis study section, National Institute of Arthritis,- Musculoskeletal, and Skin Diseases- 2006-present American Thoracic Society Career Development Award Grant Review- 2007-present NIEHS P30 Center Review Committee- 2007-present NIH/ NIEHS Environmental Health Sciences Review Committee211

Editorial Positions- Editorial Advisory Board, Journal of Laboratory and Clinical Medicine, 1993-1998.- Editorial Board, American Journal of Respiratory and Critical Care Medicine, 1993-1996.- Associate Editor, Exercise and Sport Sciences Review (ESSR), 2005-present.- Editorial Board, The American Journal of Medicine, 2005-presentAD HOC Editorial ConsultantAmerican Journal of Physiology- American Journal of Respiratory Cell and Molecular Biology- American Review of Respiratory Disease- Biochemistry- Cancer Research- Chest- Comparative Biochemistry and Physiology- Cytokine- Journal of Applied Physiology- Journal of Biological Chemistry- Journal of Clinical Investigation- Journal of Laboratory and Clinical Medicine- Medicine and Science in Sports and ExerciseAkshay Sood, M.D, MPH- Member, American Thoracic Society- American Thoracic Society, Environment and Occupational Health Assembly- Fellow, American College of Chest Physicians- Member, American College of Occupational and Environmental Medicine- Associate Director, Adult Cystic Fibrosis Program, University of New Mexico- Member, UNM Environmental Health Sciences Signature Program- Leader, Integrated Environmental Health Sciences Cluster Group- Medical Director, Cardiopulmonary Exercise Test Program, UNM Department ofExercise and- Sports Sciences- President, American Thoracic Society, New Mexico ChapterDirector of Program, 37th Annual New Mexico Thoracic Society Symposium- Member, National Pulmonary Subcommittee on Obesity and Diabetes, Coronary ArteryRisk Factors and Disease in Young Adults (CARDIA) study- Member American Medical Association Advisory Committee for Guides to the- Evaluation of Permanent Impairment- Member, Planning Committee, ATS, Environment and Occupational Health Assembly- Member, National Junior Investigators Subcommittee, Coronary Artery Risk Factors andDisease in Young Adults (CARDIA) study212

- Member, (and representative of the American College of Chest Physicians) AmericanMedical Association Advisory Committee for Guides to the Evaluation of PermanentImpairment- Ad Hoc Reviewer:o Respirology- November 2008- University of New Mexico Cardiovascular and Metabolic Disease Pilot Project Program-December 2008- Thorax- March 2009- Research Protocols- National Institutes of Health, Special Emphasis Panel/Scientific Review group ZRG1PSE-C for review of Challenge Grants- June 2009- National Institutes of Health, Infectious Diseases, Reproductive Health, Asthma andPulmonary Conditions (IRAP) Study Section- June 2009- American Journal of Respiratory and Critical Care Medicine- Clinical Medicine: Circulatory, Respiratory and Pulmonary Medicine- Research Protocols University of New Mexico Health Sciences Center’s Human- Research Review Committee – Institutional Review Board- Research Protocols University of New Mexico Health Sciences Center ’s Clinical- Translational Research Center (CTSC) Scholars’ ProgramJennifer Taylor-Cousar, M.D.- American Thoracic Society – Member- American Thoracic Society, 2010 Clinical Problems Program Committee- Member- Mountain West Cystic Fibrosis Consortium Conference, Santa Fe, NM; 2009- Chair- Cystic Fibrosis Foundation, New Mexico Chapter- Board Member- American Academy of Pediatrics- Fellow- American College of Chest Physicians- CTSC Scholar’s Program- Health Policies Committee, American Thoracic SocietyAd Hoc Reviewer:- American Journal of Respiratory Cell and Molecular Biology- MemberDona J. Upson, M.D.- Search Committee, Division of Pulmonary & Critical Care- Member- American Lung Association, Arizona/New Mexico - Member- American Lung Association, Arizona/New Mexico, Advocacy Committee- Member- American Lung Association, Arizona/New Mexico, Research Committee- Member- American Lung Association- NMCAT Advisory Council- American Lung Association, Arizona/New Mexico, Executive Committee, Board ofDirectors- Member- American Lung Association, Nationwide Assembly, Tobacco/Advocacy Committee-Member- American Lung Association, New Mexico Board of Directors- Member- American Lung Association, Diversity Caucus- member- American Thoracic Society, Health Policy Committee- Member213

- American Thoracic Society, Environmental Health Committee- Member- American Thoracic Society, International Lung health Committee- Member- American Thoracic Society, Government Relations Committee – Member- American Thoracic Society, Council of Chapter Representatives, National- Secrectary- New Mexico Thoracic Society, Program Committee - Member- NM Thoracic Society, Representative to American Thoracic Society- Member- NM Thoracic Society, Annual Conference Planning Committee- Member- NM ACP Health & Public Policy Committee- Chair- Advisory Council, New Mexico DOH, Tobacco Settlement Fund – Member- Advisory Council, New Mexico DOH, Stop Tobacco on My People- Member- Advisory Council, New Mexicans Concerned About Tobacco- Member- Veteran’s Administration, Home Respiratory Care Team- Chair- Veteran’s Administration, Medication Reconciliation Committee- Member- Veteran’s Administration, Peer Review Committee- Member- Veteran’s Administration, Respiratory Therapy Quality Assurance Committee- Member- Clinical Prevention Initiative Steering Committee – Member- Working Group-Decreasing Tobacco Use in the LGBT Community – Member- Health & Public Policy Committee – Member- Nominations Committee – Member- Program Committee – Member- Advocate for Tobacco Control (including testifying at NM Legislature, Albuquerque CityCouncil, press conferences regarding Tobacco Settlement funds, Tobacco Tax, CleanIndoor Air) Co-Chair, Workshop on The Pharmaco-Economics of RespiratoryMedications, 2008 American Thoracic Society International ConferenceAd Hoc Reviewer- American College of Physicians, PIER, Annals of Internal Medicine- Association of American Medical College, MEDPortal, Annual Meeting, EducationalAffairs- Lovelace Clinic FoundationEleana M.Zamora, M.D.- Critical Care Committee NMVAHCS – Member- NMVAHCS Pharmacy and Therapeutics Committee – Member- NMVAHCS Transfusion Committee – Member- American Thoracic Society – Member- American College of Physicians – Member- American College of Chest Physicians – member- Society of Critical Care Medicine – Member- Infectious Disease Society of America—Member- NMVAHCS Antibiotic Subcommitee -- Member- Combined ICU Committee member,NMVAHCS- Clerkship director NMVAHCS214

G. OUTSIDE SPONSORED RESEARCHRichard Crowell, M.D.Project Title:“Risk Factors for Epigenetic Silencing of Lung Cancer Genes.”Principal Investigators: Steven Belinsky, Ph.D., Richard E. Crowell, M.D. (UNMSubcontract)Percent Effort: 20%Funding Organization:National Institutes of Health / National Cancer InstituteStart and Stopping Dates: 09/01/2004 – 08/31/2009Total Award: $ 5,000,000UNM Subcontract total: $ 1,265,473Project Title:“Cognitive Function and Symptom Self-Management in COPD”Principal Investigators: Paula Meek, R.N., Ph.D., Principal InvestigatorRichard E. Crowell, M.D., Co-InvestigatorPercent Effort: 5%Funding Organization: NIHDates: 12/01/04 – 11/30/08Project Title:“Advanced Aerosol Delivery System for Lung Cancer Treatment”Principal Investigator: Hugh Smyth, D. Pharm, Ph.D., Richard E. Crowell, M.D., MentorPercent Effort: 5%Funding Organization: Oxnard FoundationStart and Stopping Dates: 12/01/2006 – 11/30/2008Project Title:“Patient and Provider Views on Lung Cancer Treatment”Principal Investigator: Richard E. Crowell, M.D.Percent Effort: 10%Funding Organization: Research Allocation Committee (UNM)Start and Stopping Dates: 02/01/2007 – 01/31/2009Total Award: $20,000Project Title:Principal Investigator:Pulmonary Services of Miner’sRichard E. Crowell, M.D.Diane Klepper, MD – Clinical DirectorMiner’s Colfax Medical CenterFunding Organization:Start and Stopping Dates: 7/1/2008 – 6/30/2009Total Award: $400,900Project Title:Veteran’s Administration Medical CenterPrincipal Investigator: Richard E. Crowell, M.D., IPA Christopher ZimaPercent Effort:Funding Organization: Veteran’s AdministrationStart and Stopping Dates: 09/01/08 – 09/02/09Total Award: $38, 603215

Lee Brown, M.D.Project Title: An Equivalency Study to Evaluate the AutoSet CS 2 vs. VP AP III-A FlowGenerator for the treatment of Central, Mixed Sleep Apnea or Periodic Breathing. (CA-07-04).Principal Investigators: Lee Brown, M.D.Percent Effort: 5%Dates:12/8/2004-presentTotal Award: $61,800Project Title: The Effects of Ethanol on Overnight Glucose Regulation in Type 2Diabetes Mellitus (R01 DK061990-01A1)Principle Investigator: Mark R. Burge M.D.Co-Investigator:Lee Brown, M.D.Dates:01/01/06-PresentGary Iwamoto, M.D.Project Title:Clinical Trial Agreement-Phase IVPrincipal Investigators: Gary Iwamoto, M.D.Funding Organization: Sanofi-AventisDates: 11/21/2006 - 11/20/2010Award: $202,800Project Title:Clinical Trial Agreement-Phase IVPrincipal Investigators: Gary Iwamoto, M.D.Funding Organization: Sanofi-AventisDates: 11/21/2008 - 11/20/2009Award: $50,700Diane Klepper, M.D.Project Title:Medical Director, Respiratory Therapy ProgramPrincipal Investigators: Diane Klepper, M.D.Percent Effort: 10%Funding Organization: Central New Mexico Community College (formerly TVI)Dates: 09/01/07-09/02/09Award: $70,040Project Title:Pulmonary Services of Miner’sPrincipal Investigator: Richard E. Crowell, MDDiane Klepper, M.D. – Clinical DirectorPercent Effort: 50%Funding Organization: Miner’s Colfax Medical CenterStart and Stopping Dates: 7/1/2008 – 6/30/2009Total Award: $400,900Pope Moseley, M.D.Project Title:Principal Investigator:Biology of Infectious Diseases and Inflammation Training GrantMary Lipscomb, M.D.216

Funding Organization: National Institute of Health/NIAID, 1 T32 AI07538Duration of Award 10/01/2003 - 09/30/2008Project Title:Clinical Translational Science Center Planning GrantPrincipal Investigator: Mark Burge, M.D.Pope L. Moseley, M.D., Co-director, Career Development CoreFunding Organization: National Institute of Health, P20 RR023493Percent Effort 10%Duration of Award 10/01/2006 – 09/30/2008Project Title:Clinical Translational Science Center Planning GrantPrincipal Investigator: Mark Burge, M.D.Pope L. Moseley, M.D., Deputy Director, Participant and Clinical Interactions ResourcesFunding Organization: National Institute of Health, P20 RR023493PercentEffort 10 %Duration of Award 10/01/ 2006 – 09/30/2008Pending:Project Title:University of New Mexico Clinical Translational Science CenterPrincipal Investigator: Mark Burge, M.D.Pope L. Moseley, M.D., Co-director, Participant and Clinical Interactions Core (PCIR)Funding Organization: National Institute of Health, RM-07-007Percent Effort 10%Akshay Sood, M.D., MPHProject Title:Adiposity, Activity and Asthma – a clinical translational studyPrincipal Investigators: Akshay Sood, MDPercent Effort: 75%Funding Organization: UNM Clinical Translational Science Center Career DevelopmentProgramDates: 11/1/2006 – 10/31/2009Award: $402,759Project Title:Respiratory Impairment and DisabilityPrincipal Investigators: Harber, P. – Sood, A.- Co-investigatorPercent Effort: 50%Funding Organization: American Thoracic Society Project AwardDates: 01/01/2009 – 12/31/2010Award: $10,000Jennifer Taylor-Cousar, M.D.Project Title:Genetic Modifiers in Cystic Fibrosis Lung DiseasePrincipal Investigators: Jennifer Taylor-Cousar, M.D.Funding Organization: University of North CarolinaDates: 12/15/2001 – 12/31/2008Award: $7,025217

Project Title:Trial- Phase IIIPrincipal Investigators: Jennifer Taylor-Cousar, M.D.Funding Organization: Quintiles LaboratoriesDates: 11/20/2008-11/21/2010Award: $32,732Project Title:Trial- Phase IIIPrincipal Investigators: Jennifer Taylor-Cousar, M.D.Funding Organization: Quintiles LaboratoriesDates: 06/13/08-2006/14/2009Award: $27, 300Project Title:Genetic Modifiers in Cystic Fibrosis: Twin-Sibling StudyPrincipal Investigators: Jennifer Taylor-Cousar, M.D.Funding Organization: John Hopkins UniversityDates: 07/17/2007-04/02/2012Award: $5,000Project Title:Facilitation Initiative ProgramPrincipal Investigators: Jennifer Taylor-Cousar, M.D.Funding Organization: Cystic Fibrosis FoundationDates: 12/01/2007-12/02/2008Award: $64,800Dona Upson, M.D.Project Title:Principal Investigators:Funding Organization:Dates: 11/1/2008 – 7/31/2008Award: $15,000Exploring factors that influence tobacco use and cessation amonglesbian, gay, bisexual, transgender, lesbian, gay, and queer peoplein New MexicoDona J Upson, M.D.UNM Center for Respiratory ResearchProject Title:The Pharmaco-Economics of Medications for Respiratory DiseasesProject RenewalPrincipal Investigators: Dona J Upson, M.D.Funding Organization: American Thoracic SocietyDates: 01/01/200-12/31/2008Award: $4,000RESEARCHPulmonary Medicine Active Research Projects- Subcontract to LRRI/RAC Project. PI: Crowell, R.; PI: Sood, A.- Project ECHO. PI: Harkins, M.218

Sleep Medicine Active Research Projects- HRRC 09-156. Cardiovascular and Metabolic Disease Signature Program. Osteopontin:a molecular marker of inflammation associated with sleep-disordered breathing. PI: Dr.Beck. CoI: Drs. Wells, Brown, Ralls, Laura V. Gonzalez Bosc, Ms. Krygier, Steve LopezRPSGT.HRRC 07-381. Prevalence and impact of patent foramen ovale in patients withobstructive sleep apnea. PI: Dr. Mark J. Ricciardi. CoI: Drs. Brown, Beck, Ralls, Grigg-Damberger, Abinash Achrekar, Ms. Krygier, Ms. Anderson, Megan Rauch RRT, RPSGT,John Glasser RPSGT, Steve Lopez RPSGT.HRRC 08-242. Restless legs syndrome and antidepressant medications: a prospectiveobservational study. PI: Dr. Brown. CoI: Drs. Ralls, Beck, Grigg-Damberger, Ms.Krygier.HRRC 09-322. UNM Research Allocation Committee. Can open lung ventilation withspontaneous breathing lead to better sleep patterns: a pilot study. PI: Dr. JonathanMarinaro. CoI: Dr. Brown, Ms. Rauch, Mr. Lopez.219

DIVISION OF RHEUMATOLOGY220

DIVISION OF CLINICAL IMMUNOLOGY AND RHEUMATIC DISEASESANNUAL REPORT: JULY 1, 2008-JUNE 2009ARTHUR D. BANKHURST, M.D.PROFESSOR OF MEDICINECHIEF, DIVISION OF RHEUMATOLOGYA. SIGNIFICANT ACHIEVEMENTS DURING THE ACADEMIC YEAR- We continue to run the Division of Rheumatology with two full time UNM physiciansand two full time VA physicians who constitute the divisional attending staff at UNM,VAMC, IHS-PHS (Albuquerque), Carrie Tingley Juvenile Arthritis. This staff is anattempt to respond favorably to the new managed care initiatives and accommodatepromptly any consultations from the General Medicine staff or elsewhere at theUniversity. Unfortunately, we will need further resources to meet these goals. Asidefrom its extensive educational and clinical program, the Division continues to have theresearch activities supported by in excess of $1,000,000 of external funding from thefederal government and the pharmaceutical industry. The Division published 15abstractsand manuscripts.- Clyde Sanchez, Ph.D., CNP has joined the Department and has been training as arheumatology subspecialty NP for the past 8 months. Mr. Sanchez is providing follow uptreatment to the Clinic’s established patients who present with uncomplicated, non-urgentrheumatologic complaint.- The Fellowship Curriculum was updated to provide an updated reflection of the trainingprovided per ACGME standards.- The Fellowship Coordinator is now working with the Fellows in the development ofindividual portfolios.B. SIGNIFICANT PLANS AND RECOMMENDATIONS- The overall objective for the Division in 2009 -10 is to incorporate the physician –extender (NP) and plan to provide more timely service to patients with rheumaticconditions. We have worked extensively with the Advanced Access team to accomplishthis goal. In addition, we will strive to continue the level of excellence in teaching,clinical care, and research. We have achieved a level of excellence over the years inteaching, clinical care and research.- The Division is seeking to establish an Endowed Chair to not only supervise and train a4 th fellow, the Chair would dedicate research in a large part to Native Americanrheumatic conditions.- The rheumatology portion (RAP, Rheumatology Access Program) of the ECHO projectcontinues to grow with an expansion of cooperative sites to 12.- Accordingly, the specific goals are as follows:Education- To continue to expand the state-wide RAP program- To continue to seek funding for the Endowed Chair.Research221

- Continue to expand our external support for the research activities of the Division.- Dr. Wilmer Sibbitt was a Co-PI on an NIH RO1 research grant to study the effects ofinflammation (lupus) on the heart. The PI was Dr. Carlos Roldan.- Dr. Bankhurst continues his clinical research on RA with 2 pharmaceutical companies.Clinical/Service- The staff is poised to respond promptly to the clinical needs of managed care systems inthe milieu of change in the health delivery system.- Dr. Bankhurst has initiated a telemedicine clinic with First Choice, Bernalillo County’slow cost health care provider. This model of subspecialty service can potentially beextended to rural areas throughout the state.C. APPOINTMENTS TO FACULTY/STAFFFaculty- NoneStaff- Clyde Sanchez, Ph.D., CNP joined the department- Traci Jastrzemski joined the department as Unit Administrator, June 29, 2009.D. OUTSIDE SPONSORED RESEARCHArthur D. Bankhurst, M.D.- Tap Pharmaceuticals, ending 2010, $33,115.00.- La-Roche, ending 2012. 1,007,406.00E. OUTSIDE PROFESSIONAL ACTIVITIES- Bankhurst, AD: National Arthritis Foundation, Regional Chairman, Education Councilfor MIT, Western Society for Clinical Investigation, American College of Rheumatology.- Sibbitt, WL, National Arthritis Foundation, American College of Rheumatology,American Foundation for Clinical Research, American Society for Clinical Investigation,Society of Physicians, Society for Magnetic Resonance in Medicine.- DuClos, TW, National Arthritis Foundation, The Kunkel Society, Western Society forClinical Investigation Councilor, American College of Rheumatology- Konstantinov, Konstantine: American Association of Chronic Fatigue Syndrome,Bulgarian Dermatological Society.F. PUBLICATIONS OF THE DIVISION- Gerstein NS, Martin HB, Toma, G MD; Sibbitt RR, Sibbitt WL Jr. Central venous accesswith the new safety technology the reciprocating procedure device. J Clin Anesth. 2009Aug 21. [Epub ahead of print]- Johnson CR, Michael AA, Sibbitt WL Jr, Mott FJ, Roldan CR, Bankhurst AD: Theeffect of medical insurance on outcomes in systemic lupus erythematosus. ArthritisRheum 2008;58:S881(1947).222

- Johnson CR, Roldan CR, Sharrar JM, Brooks WM, Sibbitt WL Jr., Bankhurst AD.Cardiac lesions and thromboembolic disease as a cause of neuropsychiatric systemiclupus erythematosus: Histophatology on brain autopsy paired with valve lesions andMRI. Arthritis Rheum. 2008; 58:S817 (1764).- Konstantinov KN, Sitdikov RA, Lopez GP, Atanassov PB, Rubin RL. Rapid detection ofanti-chromatin autoantibodies in human serum using a portable electrochemicalbiosensor. BIOSENSORS AND BIOELECTRONICS 2009, 24:1949-1954.- Lu J, Marnell LL, Mold C, Duclos TW and Sun PD. 2008. Structural recognition andfunctional activation of FcgR by innate pentraxins. Nature 456:989-992.- Marjon, KD, Marnell LL, Mold C, DuClos TW, 2009. Macrophages activated by C-reactive protein through FCgRI transfer suppression of immune thrombocytopenia. J.Immunol. 182:1397-1403.- Michael AA, Bank PA, Peisajovich A, Park KS, Sibbitt WL Jr., Bankhurst AD. Devicebasedapproaches to improve the safety and effectiveness of local injection therapy forosteoarthritis: A randomized controlled trial. Arthritis Rheum 2008;58:S485(862).- Michael AA, Peisajovich A, Moorjani GR, Park KS, Sibbitt WL Jr., Bankhurst AD. Arandomized controlled trial of anatomic approach and syringe device for intraarticularinjection of the knee. Arthritis Rheum 2008;58:S732(1532).- Michael AA, Schellinger E, Moorjani GR, Peisajovich A, Sibbitt WL Jr., Bankhurst AD.Corticosteroid injection of the carpal tunnel using safety technologies: A randomizedcontrolled trial. Arthritis Rheum 2008;58:S732(1533).- Park KS, Peisajovich A, Michael AA, Sibbitt WL Jr., Bankhurst AD. Should localanesthesia be used for arthrocentesis and joint injections? Rheumatol Int. Rheumatol Int.2009 Apr; 29(6):721-3.- Park KS, Sibbitt WL Jr., Peisajovich A, Michael AA, Bankhurst AD. Improving theoutcomes of intraarticular procedures: The synergy of direct ultrasound guidance and thereceiprocating procedure device (RPD). J Investigative Med 2009; 57:212(409).- Park KS, Sibbitt WL Jr, Peisajovich A, Michael AA, Bankhurst AD: Improving theoutcomes of intraarticular procedures: The synergy of direct ultrasound guidance and thereciprocating procedure device (RPD). J Investigative Med 2009;57:212(409).- Peisajovich A, Michael AA, Sibbitt RR, Band PA, Sibbitt WL Jr, Bankhurst AD:Improving the outcomes of intraarticular procedures: The synergey of direct ultrasoundguidance and the reciprocating procedure device. Arthritis Rheum 2008;58:S629(1238).- Peisajovich A, Park KS, Michael AA, Sibbitt WL Jr., Bankhurst AD. A randomizedcontrolled trial of local anesthesia for arthrocentesis and joint injections. Arthritis Rheum2008;58:S732-S733(1534).- Sibbitt WL Jr, Peisajovich A, Michael AA, Park KS, Sibbitt RR, Band PA, BankhurstAD. Does sonographic needle guidance affect the clinical outcome of intraarticularinjections? J Rheumatol. 2009 Jul 31. [Epub ahead of print]223

CENTER FOR OCCUPATIONAL AND ENVIRONMENTAL HEALTH PROMOTION(COEHP)224

CENTER FOR OCCUPATIONAL AND ENVIRONMENTAL HEALTH PROMOTION(COEHP) ANNUAL REPORT: JULY 1, 2008 - JUNE 30, 2009DENECE O. KESLER, M.D., MPH, MEDICAL DIRECTORA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEAR- The Center for Occupational and Environmental Health Promotion (COEHP) continuesto provide services in three vital areas to UNM and to community partners, with Dr.Denece Kesler as the Director of the Center and Patricia Shuman as the ProgramManager. The three service areas are outlined as follows:o Clinical Services: The Employee Occupational Health Services (EOHS) cliniccontinues to provide occupational health clinical services.o Database and Compliance Services: Databases required for departmental orregulatory purposes are developed and maintained, with Joseph Shealy serving asthe manager.o Consultative Services: Services are provided to a variety of departments in suchareas as development of policies and procedures involving occupational andenvironmental health. Patricia Shuman is the manager of the ConsultativeServices. The research and education programs in occupational and environmentalmedicine are components of COEHP under the Program in Occupational andEnvironmental Health (POEH).Administrative- Dr. Kesler was appointed Chief Risk Officer for UNM.- Dr. Kesler was appointed as chair, UNM Loss Control Program Task Force- Dr. Kesler was appointed as program director for a proposed new UNM preventivemedicine residency program.Education- Dr. Kesler directed the elective rotation in occupational and environmental medicine(oem) for UNM internal medicine and family medicine residents.- COEHP staff participated in providing education to residents completing the oemrotation.- Deborah Anaya participated as a tutor for the UNM School of Medicine.Clinical/Service- EOHS continues to provide clinical services for the approximately 16,500 UNMemployees. These services include pre-placement evaluations, medical surveillanceevaluations, immunizations, evaluation and treatment of work-related injury and illness,and return to work assessments.Research- Dr. Kesler became the UNM PI for the John Hopkins University Former Los AlamosWorker’s Surveillance program. Sue Boggio, RN, and Deborah Anaya, CNP participatedin this project.225

- Dr. Kesler became the PI for the RESEP project. Dr. Kesler became the PI for theRadiation Exposure Screening and Education Program (RESEP) this year. ElizabethKocher, Program Manager, Peggy Leslie, Outreach clinic Coordinator and Ameenah Fox,Administrative Assistant participate in this program. The RESEP program screens formeruranium industry workers and test site participants for malignant and non-malignantpulmonary and renal diseases. RESEP has just been funded for the 8th year.- Dr. Kesler continued as the Co-PI for the New Mexico Occupational Health SurveillanceRegistry NIOSH funded Department of Health grant.B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTUREEducation- Dr. Kesler is overseeing the completion of the development of the preventive medicineresidency program.- COEHP will continue as a site for elective occupational and environmental medicinerotations for students and residents. Continuing medical education sessions will continueto be provided for local and national conferences. COEHP will provide outreacheducation in worker’s compensation issues.Clinical Services- EOHS will continue to expand the clinical services provided to ensure compliance withregulatory and University requirements.Consultative Services- COEHP will continue to expand the services provided to UNM as well as to communitypartners, especially in the area of addressing the occupational and environmentalmedicine needs of researchers.C. CURRENT FACULTY/STAFFFaculty- Denece O. Kesler, M.D., M.P.H.- Open PositionStaff- Deborah Anaya, Nurse Practitioner, 1.0- Patricia Shuman, Nurse Practitioner, 0.5- David Giroux, Physician Assistant, 0.8- Sue Boggio, Registered Nurse, 1.0- Donna Reynolds, Radiologic Technologist, 1.0- Melanie Valdez, Registered Nurse, 1.0- Joe Shealy, Program Manager, 1.0- Norma Jean Bojorquez, Administrative Assistant III, 1.0- Sheila McKisson, Administrative Assistant II, 1.0- Zoila Matamorez, Medical Assistant, 1.0- Elizabeth Kocher, RESEP Program Manager, 1.0- Ameenah Fox, RESEP Administrative 11, 1.0226

D. APPOINTMENTS TO FACULTY/STAFFFaculty- NoneStaff- NoneE. SEPARATION OF FACULTY/STAFFFauculty- Phil Wagner, Assistant Professor, 1.0Staff- Mary Montoya, Supervisor Administrative Support, 1.0- Monica Lara, Administrative Assistant II, 1.0- Ani Barreras, Administrative Assistant I, 1.0F. PUBLICATIONS OF THE DIVISION- NoneG. OUTSIDE PROFESSIONAL ACTIVITIESNational Educational Activities:Dr. Kesler participated in education nationally:- Speaker: "ACOEM's Program for Completion of the Maintenance of Certification Part IVRequirements” presented 4/27/09 at the American Occupational Health Conferencesponsored by the American College of Occupational and Environmental Medicine, SanDiego, CA- Course Director/Moderator, “Applying Clinical Preventive Medicine Principles to YourOccupational Medicine Practice” presented 4/27/09 sponsored by the American Collegeof Occupational and Environmental Medicine, in San Diego, CA- Conference Planning Committee Member, American Occupational Health Conference tobe presented 4/26/09 through 4/29/09 sponsored by the American College ofOccupational and Environmental Medicine, in San Diego, CADr. Kesler:- 2009-Present, Appointed Member, ABMS Committee on Certification, Subcertification,Recertification, and Maintenance of Certification (COCERT)- 2009-Present, Appointed Chair, Certification Committee, American Board of PreventiveMedicine- 2008-Present, Member, American Board of Medical Specialties Assembly- 2008-Present, Member, Leadership Committee, American College of Occupational andEnvironmental Medicine- 2007-Present, Member, Board of Trustees, American Board of Preventive Medicine- 2004-Present, Member, Board of Directors, Rocky Mountain Academy of Occupationaland Environmental Medicine227

- 2004-Present, Chair, Maintenance of Certification Committee, American College ofOccupational and Environmental Medicine- 2006-Present, Representative for the Academic Medicine Section to the House Delegates,American College of Occupational and Environmental Medicine228

ALLERGY SERVICE229

ALLERGY SERVICEANNUAL REPORT: JULY 1, 2008-JUNE 30, 2009MARK SCHUYLER, M.D., PROFESSOR AND CHIEFA. SIGNIFICANT DEVELOPMENTS DURING THE ACADEMIC YEAR- Institution of an Allergy Clinic on the West Side. Eleven extra clinic sessions in theperiod January-June 2008 to maintain access time of 2 weeks or less.- Lecture to ‘Prime’ Residents on Allergy.- Tutor in the Infection and Immunity Block of Phase I of the Medical School Curriculum.- Allergy also assisted Pulmonary in coverage of the UNM Pulmonary ConsultationService (2 weeks plus 6 weekends).B. SIGNIFICANT PLANS AND RECOMMENDATIONS FOR THE NEAR FUTURE- Allergy will continue to expand its clinical services at the Westside clinic.C. APPOINTMENT TO FACULTY/STAFFFaculty- NoneStaff- NoneD. SEPARATION OF FACULTY/STAFFFaculty- NoneStaff- NoneE. PUBLICATIONS OF THE DIVISION- Gilmartin L, Tarleton C, Schuyler M, Wilson B, Oliver J. A Comparison ofInflammatory Mediators Released by Basophils of Asthmatic and Control Subjects inResponse to High-Affinity IgE Receptor Aggregation. Int Arch Allergy Immunology145:182-192, 2008.- Schwalm K, Stevens, J, Jiang, Z, Schuyler M, Schrader R, Randell S, Green F, TesfaigziY. Expression of the Pro-apoptotic Protein Bax is Reduced in Bronchial Mucous Cells ofAsthmatics. Am J Physiology 294:L1102-9, 2008.- Sood A, Qualls C, Seagrave J, Stidley C, Berwick, M, Archibeque T, Schuyler M.Effectof specific Allergen inhalation on serum adiponectin in Human Asthma. Chest. 135:287-294 2009.Abstracts230

- Sood A, Qualls C, Seagrave J,.Stidley C, Berwick, M, Archibeque T, M. Schuyler.Adipokine-Asthma Association: Does Lung 'Talk' to Adipose Tissue? Am J Resp CritCare Med 177: A832, 2008.- Sood A, Qualls C, Seagrave J, Palucki D, McDonald J, Archibeque T, M. Schuyler.Adipokine-Asthma Association: Effect of Allergen Inhalation on Airway Oxidant Stress,Using Exhaled Breath Condensate 8-Isoprostane in Asthma. Am J Resp Crit Care Med177: A976, 2008.- Mizzell JP, Qualls C, M. Schuyler, Sood A. Comparison of Ecoscreen and RTubeDevices of Exhaled Breath Condensate Collection - A Meta-Analysis. Am J Resp CritCare Med 177: A354, 2008.- Chand, H, Schuyler M, Lipscomb M.F. Localization and Enumeration of Human LungDendritic Cells from Asthmatic Patients Undergoing Anti-IgE Therapy: A MultispectralConfocal Microscopy Study. Am J Resp Crit Care Med 179: A3926, 2009.F. OUTSIDE PROFESSIONAL ACTIVITIESEditorial Reviewer- American Review of Respiratory Disease- American Journal of Respiratory Cell and Molecular Biology- Journal of Allergy and Clinical Immunology- Journal of Immunology- Chest- European Respiratory Journal- Journal of Laboratory and Clinical Medicine- Archives of Internal Medicine- Clinical Immunology and Immunopathology- Journal of Applied Physiology- Journal of Leukocyte Biology- Toxicology and Applied Pharmacology- Laboratory Animal Science- American Journal of Respiratory and Critical Care Medicine- American Journal of Medicine- Experimental Lung Research- Clinical Science- Sarcoidosis- Pediatrics- American Journal of Physiology, Lung Cellular and Molecular Physiology- Journal of Respiratory Diseases- Clinical Experimental Immunology- Mayo Clinic Proceedings- Review draft of official ATS statement, 2001- American Journal of Pediatric Drugs- Clinical and Experimental Allergy- Journal of Toxicology and Environmental HealthProfessional Affiliations231

- American College of Physicians (Fellow)- American Thoracic Society- Member, Allergy and Immunology Section (1976-present)- American College of Chest Physicians (Fellow)- Ohio Thoracic Society- American Federation for Clinical Research- American Academy of Allergy, Asthma and Immunology- Western Society for Clinical Investigation- New Mexico Thoracic Society- American Association of Immunologists- Western Association of PhysiciansGrant Reviewer- VA Merit Review Respiration panel- American Heart Association, Region IIIG. OUTSIDE SPONSORED RESEARCH- NIAID. Tularemia Vaccine Development. 9/06-8/10. UNM PI: Rick Lyons MD, PhD.5% effort.- NIAID. Regional Center of Excellence for Biodefenses and Emerging Infections, Region6. 4/04 – 4/10. UNM PI: Rick Lyons MD, PhD. $11,000,000/year for entire center. 5%effort. ~$50,000.DoIM Annual Report 2008-09232